Handbook of Probiotics and Prebiotics, 2nd edition

HANDBOOK OF PROBIOTICS AND PREBIOTICS HANDBOOK OF PROBIOTICS AND PREBIOTICS Second Edition Edited by YUAN KUN LEE N...

Author: Yuan Kun Lee | Seppo Salminen

282 downloads 4969 Views 4MB Size Report

This content was uploaded by our users and we assume good faith they have the permission to share this book. If you own the copyright to this book and it is wrongfully on our website, we offer a simple DMCA procedure to remove your content from our site. Start by pressing the button below!
Report copyright / DMCA form

DOWNLOAD PDF

HANDBOOK OF PROBIOTICS AND PREBIOTICS

HANDBOOK OF PROBIOTICS AND PREBIOTICS Second Edition

Edited by

YUAN KUN LEE National University of Singapore, Singapore

SEPPO SALMINEN University of Turku, Turku, Finland

Copyright Ó 2009 by John Wiley & Sons, Inc. All rights reserved Published by John Wiley & Sons, Inc., Hoboken, New Jersey Published simultaneously in Canada No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, recording, scanning, or otherwise, except as permitted under Section 107 or 108 of the 1976 United States Copyright Act, without either the prior written permission of the Publisher, or authorization through payment of the appropriate per-copy fee to the Copyright Clearance Center, Inc., 222 Rosewood Drive, Danvers, MA 01923, (978) 750-8400, fax (978) 750-4470, or on the web at www.copyright.com. Requests to the Publisher for permission should be addressed to the Permissions Department, John Wiley & Sons, Inc., 111 River Street, Hoboken, NJ 07030, (201) 748-6011, fax (201) 748-6008, or online at http://www.wiley.com/go/permission. Limit of Liability/Disclaimer of Warranty: While the publisher and author have used their best efforts in preparing this book, they make no representations or warranties with respect to the accuracy or completeness of the contents of this book and specifically disclaim any implied warranties of merchantability or fitness for a particular purpose. No warranty may be created or extended by sales representatives or written sales materials. The advice and strategies contained herein may not be suitable for your situation. You should consult with a professional where appropriate. Neither the publisher nor author shall be liable for any loss of profit or any other commercial damages, including but not limited to special, incidental, consequential, or other damages. For general information on our other products and services or for technical support, please contact our Customer Care Department within the United States at (800) 762-2974, outside the United States at (317) 572-3993 or fax (317) 572-4002. Wiley also publishes its books in a variety of electronic formats. Some content that appears in print may not be available in electronic formats. For more information about Wiley products, visit our web site at www.wiley.com. Library of Congress Cataloging-in-Publication Data: Lee, Y. K. (Yuan Kun) Handbook of probiotics and prebiotics / Yuan Kun Lee, Seppo Salminen. – 2nd ed. p. ; cm. Rev. ed. of: Handbook of probiotics / Yuan-Kun Lee ... [et al.]. Includes bibliographical references and index. ISBN 978-0-470-13544-0 (cloth) 1. Probiotics–Handbooks, manuals, etc. 2. Intestines–Microbiology–Handbooks, manuals, etc. 3. Food–Microbiology–Handbooks, manuals, etc. 4. Microorganisms–Therapeutic use–Handbooks, manuals, etc. I. Salminen, Seppo. II. Handbook of probiotics. III. Title. [DNLM: 1. Bacterial Physiology. 2. Food, Formulated. 3. Probiotics–pharmacology. 4. Probiotics–therapeutic use. QW 52 L482 2009] QR171.I6H36 2009 664.001’579–dc22 2008033278 Printed in the United States of America 10 9 8 7 6 5 4 3 2 1

CONTENTS

PREFACE CONTRIBUTORS PART I 1

PROBIOTICS

Probiotic Microorganisms

xv xvii 1 3

1.1 Definitions, 3 1.2 Screening, Identification, and Characterization of Lactobacillus and Bifidobacterium Strains, 4 1.2.1 Sources of Screening for Probiotic Strains, 5 1.2.2 Identification, Classification, and Typing of Bifidobacterium Strains, 7 1.2.2.1 Taxonomy, 7 1.2.2.2 Identification and Typing, 8 1.2.3 Identification, Classification, and Typing of Lactobacillus Strains, 14 1.2.3.1 Taxonomy, 14 1.2.3.2 Identification and Typing, 15 1.2.4 Characterization of Probiotic Properties in Bifidobacterium and Lactobacillus Strains, 19 1.2.4.1 Survival to GIT Stressing Conditions, 19 1.2.4.2 Adhesion/Colonization to/of GIT, 23 1.2.4.3 Antimicrobial Activity, 24 1.2.4.4 Other Probiotic Properties, 24 v

vi

CONTENTS

1.2.5 Conclusion, 24 1.3 Detection and Enumeration of Gastrointestinal Microorganisms, 25 1.3.1 Methods for Intestinal Microbiota Assessment, 25 1.3.1.1 Culture-Dependent Methods, 25 1.3.1.2 Culture-Independent Methods, 30 1.3.2 Detection and Enumeration in Dairy Products, 37 1.3.3 Detection and Enumeration of Specific Probiotics in the Gut, 38 1.3.4 The Problem of the Viability and Physiological State of Intestinal Bacteria, 41 1.3.5 Conclusions, 42 1.4 Enteric Microbial Community Profiling in Gastrointestinal Tract by Terminal-Restriction Fragment Length Polymorphism (T-RFLP), 43 1.4.1 T-RFLP, 43 1.4.2 Universal and Group-Specific Primers, 44 1.4.3 Fluorescent Dyes, 44 1.4.4 DNA Extraction, 46 1.4.5 PCR Amplification, 46 1.4.6 Generation of Terminal Restriction Fragments (TRF) by Digestion of Amplicons with Restriction Enzymes, 46 1.4.7 Software and Data Processing, 47 1.4.8 Microbial Diversity in Different Intestinal Compartments of Pigs, 47 1.4.9 Tracking the Fate of Orally Delivered Probiotics in Feces, 48 1.4.10 Conclusion, 51 1.5 Effective Dosage for Probiotic Effects, 52 1.5.1 Acute (Rotavirus) Diarrhea in Children, 53 1.5.2 Antibiotic-Associated Diarrhea, 54 1.5.2.1 Combination of L. acidophilus þ bifidobacteria or Streptococcus thermophilus, 54 1.5.2.2 L. rhamnosus GG or Saccharomyces boulardii Applied Singly, 57 1.5.3 Helicobacter pyroli, 58 1.6 Incorporating Probiotics into Foods, 58 1.6.1 Probiotic Ingredients, 60 1.6.2 Factors Affecting the Viability of Probiotics in Foods, 60 1.6.2.1 Choice of Probiotic Organism/Food Combinations, 61 1.6.2.2 Physiologic State of the Probiotic, 63 1.6.2.3 Temperature, 63 1.6.2.4 pH, 64 1.6.2.5 Water Activity, 64 1.6.2.6 Oxygen, 65 1.6.2.7 Toxicity of Ingredients, 66

CONTENTS

vii

1.6.2.8 Growth Factors, Protective, and Synergistic Ingredients, 67 1.6.2.9 Freeze–Thawing, 67 1.6.2.10 Sheer Forces, 67 1.6.3 Synbiotics, 67 1.6.4 Delivery Systems, 68 1.6.4.1 Microencapsulation, 68 1.6.4.2 Delivery Devices, 69 1.6.5 Probiotic Foods, 69 1.6.6 Conclusions, 69 1.7 Safety of Probiotic Organisms, 75 1.7.1 Current Proposals for Probiotic Safety, 77 1.7.2 Taxonomic Identification, 79 1.7.3 Pathogenicity, 81 1.7.4 Antibiotic Resistance and Susceptibility, 83 1.7.5 Immune Modulation, 87 1.7.6 Clinical Studies, 90 1.7.7 Postmarket Surveillance, 92 1.7.8 GMO Probiotics, 93 1.7.9 Conclusion, 94 1.8 Legal Status and Regulatory Issues, 95 1.8.1 Human Probiotics, 95 1.8.1.1 Asia, 95 1.8.1.2 Europe, 106 1.8.1.3 The United States of America, 111 1.8.2 Animal Probiotics, 123 1.8.2.1 United States, 123 1.8.2.2 European Union, 123 1.8.2.3 China, 125 1.8.2.4 Japan, 125 1.8.2.5 Korea, 125 1.8.2.6 Thailand, 125 1.8.2.7 Australia, 125 1.8.2.8 New Zealand, 135 1.8.2.9 Indonesia, Malaysia, Philippines, and Vietnam, 139 References, 139 2

Selection and Maintenance of Probiotic Microorganisms 2.1 Isolation of Probiotic Microorganisms, 177 2.2 Selection of Probiotic Microorganisms, 178 2.2.1 Manufacturing Criteria (General Criteria), 179 2.2.2 Shelf Life and Gut Transit (General Criteria), 179 2.2.2.1 Shelf Life of Viable Probiotics Under Different Storage Conditions, 179

177

viii

CONTENTS

2.2.2.2 2.2.2.3

Tolerance to Digestive Juices, 180 Adhesion and Colonization onto Specific Site of Body Surface, 181 2.2.3 Health Properties (Specific Criteria), 181 2.2.4 Safety, 182 2.2.5 Identification, 182 2.3 Maintenance of Probiotic Microorganisms, 184 References, 187 3

Genetic Modification of Probiotic Microorganisms

189

3.1 Mutants Obtained from Probiotic Microorganisms by Random Mutagenesis, 189 3.2 Plasmids, 202 3.3 Vectors for Lactobacilli and Bifidobacteria, 212 3.4 Genetic Recombination, 222 References, 229 4

Role of Probiotics in Health and Diseases 4.1 Cell Line Models in Research, 259 4.2 Laboratory Animal Models in Research, 263 4.3 Effects on Human Health and Diseases, 267 4.3.1 Nutritional Effects, 267 4.3.1.1 Lactose Maldigestion, 268 4.3.1.2 b-Galactosidase in Fermented Milk Products, 269 4.3.2 Prevention and Treatment of Oral Infection and Dental Caries, 270 4.3.3 Prevention and Treatment of Diarrhea, 272 4.3.3.1 Acute (Rotavirus) Diarrhea in Children, 272 4.3.3.2 Antibiotic-Associated Diarrhea, 276 4.3.3.3 Clostridium difficile Associated Diarrhea, 279 4.3.3.4 Radiation-Induced Diarrhea, 279 4.3.3.5 Traveler’s Diarrhea, 280 4.3.3.6 Diarrhea in Tube-Fed Patients, 281 4.3.4 Treatment of Irritable Bowel Syndrome, 282 4.3.5 Prevention and Treatment of Inflammatory Bowel Diseases, 287 4.3.6 Treatment of H. pylori Infection, 292 4.3.7 Prevention of Postoperative Infections, 295 4.3.8 Prevention and Treatment of Respiratory Tract Infections, 299 4.3.9 Prevention and Treatment of Allergic Diseases, 302 4.3.10 Antitumor Effects, 310 4.3.11 Reduction of Serum Cholesterol, 313 4.3.12 Enhancement of Vaccine Responses, 318

257

CONTENTS

ix

4.4 Effects on Farm Animals, 321 4.4.1 Poultry, 322 4.4.2 Swine, 323 4.4.3 Ruminants, 331 4.4.4 Rabbits, 339 4.4.5 Pets, 339 References, 350 5

Mechanisms of Probiotics 5.1 Adhesion to Intestinal Mucus and Epithelium by Probiotics, 377 5.1.1 Adhesion to Gastrointestinal Epithelial Cell Lines, 378 5.1.2 Adhesion to Intestinal Mucus, 378 5.1.3 Colonization of Probiotics in Human Intestine as Assessed by Biopsies, 379 5.1.4 Comparisons Between In Vitro and In Vivo Results, 379 5.1.5 Adhesins, 379 5.1.6 Factors Affecting the Adhesion Properties of Probiotics, 379 5.1.7 Adhesive and Inhibitory Properties of Nonviable Probiotics, 380 5.1.8 Role of Age and Diseases on Adhesion, 383 5.2 Combined Probiotics and Pathogen Adhesion and Aggregation, 384 5.2.1 Aggregation, 385 5.2.2 Adhesion, 385 5.2.3 Assay for Adhesion, 386 5.2.4 Assay for Aggregation, 386 5.2.5 Factors that Determine Adhesion, 389 5.2.6 In Vitro Models, 389 5.2.7 Probiotics in Combination, 390 5.2.8 Conclusion, 391 5.3 Production of Antimicrobial Substances, 391 5.3.1 Organic Acids, 392 5.3.2 Hydrogen Peroxide, 392 5.3.3 Carbon Dioxide, 393 5.3.4 Bacteriocins, 393 5.3.5 Low Molecular Weight Antimicrobial Compounds, 394 5.3.6 Other Antimicrobial Agents, 394 5.4 Immune Effects of Probiotic Bacteria, 395 5.4.1 The Neonatal Intestinal Microbiota, 395 5.4.2 The Importance of the Intestinal Microbiota in Immune Development, 395 5.4.3 Interaction of Commensal and Pathogenic Bacteria with the Intestinal Immune System, 396 5.4.4 Probiotic Effects on Immune Responses, 396

377

x

CONTENTS

5.4.5 5.4.6 5.4.7

Probiotic Effects on Epithelial Cells, 397 Probiotic Effects on DCs, 397 Probiotic Effects on Adaptive Immune Responses: T Helper Cells and T Regulatory Cells, 397 5.4.8 Delivery of Probiotic Bacteria, 398 5.4.9 The Specificity of Probiotic Effects, 399 5.4.10 Summary, 399 5.5 Alteration of Microecology in Human Intestine, 399 5.5.1 Impact on Human Health: in Infants and the Elderly, 399 5.5.1.1 Stepwise Establishment of Microbiota, 400 5.5.1.2 Methodological Improvements in Microbiota Assessment, 401 5.5.1.3 Microbiota After Infancy, 403 5.5.1.4 Host–Microbe Cross Talk, 403 5.5.1.5 Microbiota in the Elderly, 404 5.5.1.6 Maintenance of Healthy Microbiota, 405 5.5.1.7 Conclusion, 405 5.5.2 Impact on Animal Health: Designer Probiotics for the Management of Intestinal Health and Colibacillosis in Weaner Pigs, 406 5.5.2.1 The Farrowing Environment, 406 5.5.2.2 The Weaning Environment, 406 5.5.2.3 Colibacillosis in Pigs, 407 5.5.2.4 Control of Colibacillosis, 408 5.5.2.5 Mechanism of Action, 408 5.5.2.6 Pathogenic and Commensal E. coli—the Concept of Gene Signatures, 409 5.5.2.7 Mosaicism and Genome Plasticity in Porcine E. coli (Clone Gene Signatures), 410 5.5.2.8 Population Gene Signatures in Epidemiological Study, 412 5.5.2.9 Designer Lactic Acid Bacteria as Probiotics, 415 5.5.2.10 Population Gene Signatures as a Measure of Probiotic Bioefficacy, 417 5.5.2.11 Creation of Enteric Microbial Communities for Sustainable Intestinal Health (Probiosis), 419 References, 421 6

Commercially Available Human Probiotic Microorganisms 6.1 Lactobacillus acidophilus, LA-5 , 441 6.1.1 Gastrointestinal Effects, 441 6.1.1.1 Intestinal Microbial Balance, 441 6.1.1.2 Diarrhea, 442 6.1.1.3 Other Gastrointestinal Effects, 442

441

CONTENTS

6.1.2

6.2

6.3

6.4

6.5

6.6

6.7

Immunomodulatory Effects, 443 6.1.2.1 Nonspecific Immune Responses, 443 6.1.2.2 Specific Immune Responses, 443 6.1.3 Other Health Effects, 443 6.1.4 Safety, 444 Lactobacillus acidophilus NCDO 1748, 444 6.2.1 Origin and Safety, 445 6.2.2 In Vitro and Animal Studies, 445 6.2.3 Human Studies, 446 Lactobacillus acidophilus NCFM , 447 6.3.1 L. acidophilus NFCM Basic Properties, 447 6.3.2 Survival of Intestinal Transit and Change in Intestinal Microbiota Composition and Activity, 447 6.3.3 Lactose Intolerance, 448 6.3.4 Relief of Intestinal Pain, 448 6.3.5 Prevention of Common Respiratory Infections and Effects on Immunity, 449 6.3.6 Application, 449 6.3.7 Conclusion, 449 Lactobacillus casei Shirota, 449 6.4.1 Effects on Intestinal Environment, 450 6.4.2 Adhesive Property, 450 6.4.3 Intestinal Physiology, 451 6.4.4 Immunomodulation, 452 6.4.5 Effects on Cancer, 453 6.4.6 Prevention of Infectious Diseases, 454 6.4.7 Prevention of Life Style Diseases, 454 6.4.8 Clinical Application, 455 6.4.9 Safety Assessment, 456 Lactobacillus gasseri OLL2716 (LG21), 457 6.5.1 Helicobacter pylori, 458 6.5.2 Selection of a Probiotic for H. pylori Infection, 458 6.5.3 Effects of LG21 on H. pylori Infection in Humans, 458 6.5.4 Mechanisms of Therapeutic Effects of LG21 on H. pylori Infection, 461 6.5.5 Conclusion, 462 Lactobacillus paracasei ssp. paracasei, F19 , 462 6.6.1 Identification and Safety, 462 6.6.2 In Vitro Studies, 463 6.6.3 Global Gene Expression, 463 6.6.4 Human Studies, 464 Lactobacillus paracasei ssp paracasei, L. casei 431 , 466 6.7.1 Adhesion and Survival Through the GI Tract, 466 6.7.2 Gastrointestinal Effects, 466

xi

xii

CONTENTS

6.8

6.9

6.10

6.11

6.12

6.7.2.1 Intestinal Microbial Balance, 466 6.7.2.2 Diarrhea, 466 6.7.3 Immunomodulatory Effects, 468 6.7.4 Other Health Effects, 468 6.7.5 Safety, 468 Lactobacillus rhamnosus GG, LGG , 469 6.8.1 Storage Stability, 469 6.8.2 Gastrointestinal Persistence and Colonization, 469 6.8.3 Health Benefits, 469 6.8.4 Source of LGG , 470 Lactobacillus rhamnosus, GR-1 and Lactobacillus reuteri RC- 14 , 470 6.9.1 The Strains, 471 6.9.2 In Vitro Properties, 471 6.9.3 Animal Safety, Toxicity, and Effectiveness Studies, 471 6.9.4 Clinical Evidence, 472 6.9.4.1 Safety, Effectiveness, and Efficacy, 472 6.9.5 Summary, 473 Lactobacillus rhamnosus HN001 and Bifidobacterium lactis HN019, 473 6.10.1 Basic Properties of L. rhamnosus HN001 and B. lactis HN019, 473 6.10.2 Survival During the Intestinal Transit and Modulation of the Intestinal Microbiota, 474 6.10.3 Modulation of the Immune System, 474 6.10.4 Reduction of Disease Risk, 477 6.10.5 Application, 477 6.10.6 Conclusions, 477 LGG Extra, A Multispecies Probiotic Combination, 477 6.11.1 Strain Selection for the Combination, 477 6.11.2 Adhesion and Gastrointestinal Survival, 478 6.11.3 Health Benefits, 478 6.11.4 Technological Characteristics, 479 6.11.5 Source of LGG Extra, 480 Bifidobacterium animalis ssp. lactis, BB-12 , 480 6.12.1 Adhesion and Survival Through the GI Tract, 480 6.12.2 Gastrointestinal Effects, 480 6.12.2.1 Intestinal Microbial Balance, 480 6.12.2.2 Diarrheas, 481 6.12.2.3 Gastrointestinal Health of Infants, 482 6.12.2.4 Other Gastrointestinal Effects, 482 6.12.3 Immunomodulatory Effects, 483 6.12.3.1 Nonspecific Immune Responses, 483 6.12.3.2 Specific Immune Responses, 483 6.12.3.3 Other Immunomodulatory Effects, 484

CONTENTS

xiii

6.12.4 Other Health Effects, 484 6.12.5 Safety, 485 6.13 Bifidobacterium breve Strain Yakult, 485 6.13.1 Effects on Intestinal Environment, 485 6.13.2 Intestinal Physiology, 485 6.13.3 Effects on Cancer, 486 6.13.4 Prevention of Infectious Diseases, 486 6.13.5 Prevention of Life Style Diseases, 486 6.13.6 Clinical Application, 487 6.14 Bifidobacterium longum BB536, 488 6.14.1 Evaluation of Safety of BB536, 488 6.14.2 Physiological Effects of BB536, 489 6.14.2.1 Improvement of Intestinal Environment, 489 6.14.2.2 Effects on Immunity and Cancer, 490 6.14.2.3 Antiallergic Activity, 490 6.14.3 Technologies in BB536 Applications, 491 6.15 Bifidobacterium longum Strains BL46 and BL2C—Probiotics for Adults and Ageing Consumers, 492 6.15.1 Safety of BL2C and BL46, 492 6.15.2 The Health Effects of BL2C and BL46, 493 6.15.2.1 BL2C and BL46 Stabilize the Gut Function in the Elderly, 493 6.15.2.2 Modulation of Gut Microbiota by BL2C and BL46, 493 6.15.2.3 BL46 is Effective Against Harmful Bacteria, 493 6.15.2.4 Effects of BL2C and BL46 on the Immune System and Infections, 493 6.15.2.5 BL2C and BL46 Can Bind Toxic Compounds, 493 6.15.3 Technical Properties and Sensory Qualities of BL2C and BL46, 494 6.15.4 Conclusions, 494 References, 494 PART II 7

PREBIOTICS

Prebiotics 7.1 7.2 7.3 7.4 7.5 7.6

The Prebiotic Concept, 535 A Brief History of Prebiotics, 536 Advantages and Disadvantages of the Prebiotic Strategy, 536 Types of Prebiotics, 537 Production of Prebiotics, 540 Prebiotic Mechanisms, 546

533 535

xiv

CONTENTS

7.7 Modulating the Intestinal Microbiota in Infants, 546 7.7.1 Breast Milk, 546 7.7.2 Infant Milk Formulas, 547 7.8 Modulating the Intestinal Microbiota in Adults, 548 7.8.1 Effects at the Genus Level, 548 7.8.2 Effects at the Species Level, 548 7.8.3 Altering the Physiology of the Microbiota, 549 7.9 Modifying the Intestinal Microbiota in the Elderly, 549 7.10 Health Effects and Applications of Prebiotics, 549 7.10.1 Laxatives, 550 7.10.2 Hepatic Encephalopathy, 550 7.10.3 Primary Prevention of Allergy in Infants, 551 7.10.4 Amelioration of Inflammatory Bowel Disease, 551 7.10.5 Prevention of Infections, 555 7.10.6 Mineral Absorption, 556 7.10.7 Prevention of Colorectal Cancer, 556 7.10.8 Reduction in Serum Lipid Concentrations, 559 7.10.9 Use in Weight Management and Improving Insulin Sensitivity, 559 7.11 Functional Foods for Animals, 559 7.12 Safety of Prebiotics, 560 7.13 Regulation of Prebiotics, 560 7.14 Conclusion, 561 References, 562 AUTHOR INDEX

583

SUBJECT INDEX

585

PREFACE

The first edition of the Handbook of Probiotics was published in 1999 when probiotics was still a relatively new scientific discipline. The idea of compiling a handbook came from our review article, “The coming of age of probiotics,” published in the Trends in Food Science and Technology (61: 241–245, 1995), confirming probiotics to be a scientific discipline. The handbook was meant to serve as a source book for aspiring scientists, and it was the first handbook of its kind. Probiotics have since developed into a major research focus area. Product applications include several commercially successful functional foods, health supplements, and therapeutic components and preparations. Cutting-edge methodologies, such as molecular approaches for the identification and quantification of intestinal probiotics, viability of probiotics under processing and storage conditions, and markers for host immune modulation, have been developed. Therefore, it is timely to update the scientific research and clinical trial data and to review and compile advances in methodology for easy reference. At the time of publication of the first edition of the handbook, prebiotics were only at a concept level. Substantial research and clinical interventions on specific prebiotics have since been published to provide scientific basis for their reported effects. It is timely to include prebiotics in this updated handbook. The aim of this updated handbook is to put together information and technology required in the development of a successful probiotic and prebiotic product from the laboratory to the marketplace. The book would continue to serve as a resource material for students, researchers, and company product development technologists.

xv

xvi

PREFACE

This second edition of the Handbook of Probiotics and Prebiotics includes the following changes: 1. New chapters on methods for the analysis (enumeration, identification) of gastrointestinal microbiota. 2. The safety issue in novel probiotic bacteria is expanded, in view of the new regulation requirements for novel food products in Asia, Europe, and North America. 3. Understanding on probiotic mechanisms is incorporated in a new chapter. 4. A new chapter on commercially available human probiotic microorganisms covers in detail most of the early and new strains and preparations as well as the scientific information. 5. The chapter on “Enhancement of Indigenous Probiotic Organisms” is renamed as “Prebiotics” and expanded to accommodate the most recent findings. YUAN KUN LEE SEPPO SALMINEN

CONTRIBUTORS

Andrew W. Bruce, Canadian Research and Development Centre for Probiotics, Lawson Health Research Institute, Canada Toni Chapman, Immunology and Molecular Diagnostic Research Unit (IMDRU), Elizabeth Macarthur Agricultural Institute, Australia James J.C. Chin, Immunology and Molecular Diagnostic Research Unit (IMDRU), Elizabeth Macarthur Agricultural Institute, NSW Department of Primary Industries, Australia. Immunology, John Curtin School of Medical Research, Australian National University, Canberra, Australia. School of Veterinary Science, University of Queensland, Brisbane, Australia M. Carmen Collado, Functional Foods Forum, University of Turku, Finland Ross Crittenden, Food Science Australia, Australia Fred H. Degnan, King & Spalding LLP, Washington, DC, USA Clara G. de los Reyes-Gavil an, Instituto de Productos Lacteos de Asturias (CSIC), Spain Diana Donohue, Toxicology Centre, School of Medical Sciences, RMIT University, Australia Dorte Eskesen, Chr. Hansen A/S, Health & Nutrition Division, Denmark Rangne Fonden, Finnboda Kajv€ag 15, Sweden. Rafael Frias, Central Animal Laboratory, University of Turku, Finland xvii

xviii

CONTRIBUTORS

Miguel Gueimonde, Instituto de Productos Lacteos de Asturias (CSIC), Spain Camilla Hoppe, Chr. Hansen A/S, Health & Nutrition Division, Denmark Kajsa Kajander, Valio Ltd, R&D, Helsinki, Finland Katsunori Kimura, Food Science Institute, Division of Research and Development, Meiji Dairies Corporation, Japan Mayumi Kiwaki, Yakult Central Institute for Microbiology Research, Tokyo, Japan Riitta Korpela, Valio Ltd, R&D, Helsinki, Finland Sampo Lahtinen, Health & Nutrition, Danisco, Finland. Functional Foods Forum, University of Turku, Finland J.M. Laparra, Department of Food Science, Cornell University, Ithaca, NY, USA Charlotte Nexmann Larsen, Chr. Hansen A/S, Health & Nutrition Division, Business Unit, Denmark Yuan Kun Lee, Department of Microbiology, National University of Singapore, Singapore Allan Lim, Kemin Industires (Asia) Pte Ltd, Singapore Abelardo Margolles, Instituto de Productos Lacteos de Asturias (CSIC), Spain Baltasar Mayo, Instituto de Productos Lacteos de Asturias (CSIC), Spain Koji Nomoto, Yakult Central Institute for Microbiology Research, Tokyo, Japan P€aivi Nurminen, Health & Nutrition, Danisco, Finland Arthur Ouwehand, Health & Nutrition, Danisco, Finland Martin J. Playne, Melbourne Biotechnology, Australia Gregor Reid, Canadian Research and Development Centre for Probiotics, Lawson Health Research Institute, Canada Patricia Ruas-Madiedo, Instituto de Productos Lacteos de Asturias (CSIC), Spain Jose M. Saavedra, Johns Hopkins University School of Medicine, Baltimore, MD, USA Seppo Salminen, Functional Foods Forum, University of Turku, Finland Reetta Satokari, Functional Foods Forum, University of Turku, Finland Maija Saxelin, Valio Ltd, R&D, Helsinki, Finland Ulla Svensson, Arla Foods, Sweden Hai-Meng Tan, Kemin Industires (Asia) Pte Ltd, Singapore

CONTRIBUTORS

xix

Mimi Tang, Department of Allergy and Immunology, Royal Children’s Hospital, Australia William Hung Chang Tien, Lytone Enterprise Inc., Taiwan Hirokazu Tsuji, Yakult Central Institute for Microbiology Research, Japan Satu Vesterlund, Functional Foods Forum, University of Turku, Finland Jin-Zhong Xiao, Food Science and Technology Institute, Morinaga Milk Industry Co., Ltd, Japan

PART I PROBIOTICS

1 PROBIOTIC MICROORGANISMS

1.1 DEFINITIONS

Yuan Kun Lee Department of Microbiology, National University of Singapore, Singapore

“Probiotics” is derived from Greek and means “prolife.” It has been redefined throughout the years as more scientific knowledge and better understanding on its relationship between intestinal health and general well-being has been gained. The following are definitions of “probiotics” derived through times. Lilly and Stillwell in 1965 (5) defined probiotics as “Growth promoting factors produced by microorganisms.” Parker in 1974 (7) suggested an interaction between microorganisms with the host: “Organisms and substances with beneficial effects for animals by influencing the intestinal microflora.” Fuller in 1989 (3) defined it as “A live microbial feed supplement which beneficially affects the host animal by improving its intestinal microbial balance.” Havenaar and Huis Int Veld in 1992 (4) said probiotics are “A mono- or mixed culture of live microorganisms which, applied to animal or man, affect beneficially the host by improving the properties of the indigenous microflora.” ILSI (International Life Sciences Institute) Europe Working Group (1998) (9): “A viable microbial food supplement which beneficially influences the health of the host.”

Handbook of Probiotics and Prebiotics, Second Edition Edited by Yuan Kun Lee and Seppo Salminen Copyright 2009 John Wiley & Sons, Inc.

3

4

PROBIOTIC MICROORGANISMS

Diplock et al. in 1999 (1) puts it as “Probiotic food is functional if they have been satisfactorily demonstrated to beneficially affect one or more target functions in the body beyond adequate nutritional effects, in a way that is relevant to either an improved state of health and well-being and/or reduction in the risk of diseases.” Naidu et al. in 1999 (6) said “A microbial dietary adjuvant that beneficially affects the host physiology by modulating mucosal and systemic immunity, as well as improving nutritional and microbial balance in the intestinal tract.” Tannock in 2000 (11) observed that long-term consumption of probiotics was not associated with any drastic change in the intestinal microbiota composition, and thus proposed an alternative definition: “Microbial cells which transit the GI tract and which, in doing so, benefit the health of consumer.” Schrezenmeir and de Vrese in 2001 (10) defined probiotics as “A preparation of a product containing viable, defined microorganisms in sufficient numbers, which alter the microflora (by implantation or colonization) in a compartment of the host and by that exert beneficial health effects in this host.” FAO/WHO (Food and Agriculture Organization and World Health Organization) (2001)(2) and Reidetal.(2003)(8)concentratedexclusively onitshealthpurpose:“Live microorganisms which when administered in adequate amounts confer a health benefit on the host.” 1.2 SCREENING, IDENTIFICATION, AND CHARACTERIZATION OF Lactobacillus AND Bifidobacterium STRAINS

Abelardo Margolles, Baltasar Mayo, and Patricia Ruas-Madiedo Instituto de Productos L acteos de Asturias (CSIC), Villaviciosa, Asturias, Spain

Several genera of bacteria (and yeast) have been proposed as probiotic cultures, the most commonly used are Lactobacillus and Bifidobacterium species. However, the selection of a strain to be used as an effective probiotic is a complex process (Fig. 1.1). The work begins with the source of screening of strains, the most suitable approach being the natural intestinal environment. According to FAO/WHO guidelines it is necessary to identify the microorganism to species/strain level given that the evidence suggests that the probiotic effects are strain specific (60). It is recommended to employ a combination of phenotypic and genetic techniques to accomplish the identification, classification, and typing. For the nomenclature of bacteria, scientifically recognized names must be employed and it is recommended to deposit the strains in an internationally recognized culture collection. Further characterization of strains must be undertaken taking into account the “functional” or probiotic aspects and safety assessment. In vitro tests, some of them summarized in Fig. 1.1, are useful to gain knowledge of both strains and mechanisms of the probiotic effect. In addition, even if these genera have a long history of safe consumption in traditionally fermented products and several species have been awarded a

SCREENING, IDENTIFICATION, AND CHARACTERIZATION

5

FIGURE 1.1 Procedure for the isolation and characterization of novel strains with putative probiotic status.

“General Recognised As Safe” (GRAS) status by the American Food and Drug Association (63) or a qualified presumption of safety (QPS) consideration by the European Food Safety Authority (EFSA) (59), some characteristics (Fig. 1.1) must be studied to ensure the safety of the novel lactobacilli and bifidobacteria strains. Several of the in vitro tests can be correlated with in vivo studies with animal models, but probiotics for human use must be validated with human studies covering both safety (phase 1 trials) and efficacy (phase 2 trials) aspects. Phase 2 studies should be designed as double-blind, randomized, and placebo-controlled to measure the efficacy of the probiotic strain compared with a placebo and also to determine possible adverse effects (60). This chapter focuses on the current techniques for bacterial identification, taxonomic classification, and typing of Lactobacillus and Bifidobacterium strains, and also reviews the in vitro probiotic characterization of strains based on their functional aspects. 1.2.1

Sources of Screening for Probiotic Strains

Even though essentially all animals contain strains of both Lactobacillus and Bifidobacterium genera, it is well accepted that an effective human probiotic should

6


be of human origin. The underlying reason for this is that human intestines are sufficiently different from those of animals, such that the isolates suited to those environments would not necessarily be suited to the human intestine (121). The human gastrointestinal tract (GIT) is a very complex ecological niche and its bacteria inhabitants can achieve the highest cell densities recorded for any ecosystem. Nonetheless, diversity at a division level is among the lowest (19) and the lactobacilli and bifidobacteria comprise less than 5% of the total microbiota (92). A number of articles have been published in the last few years studying the diversity of the GIT ecosystem employing several culture-independent genetic tools. But, for the isolation of novel strains, classical cultivation techniques must be employed. Enrichment, selective media, and specific culture conditions are employed for the isolation of strains from human samples that are initially identified by morphological characterization under the microscope. Molecular tools, mainly based on the sequencing of the 16S rRNA gene, allow identification down to the species level. Using this basic scheme several collections of strains have been isolated from human (and other animal) samples. Commonly, fecal samples are donated by healthy adult or infant volunteers (49, 156). But other GIT sections obtained from healthy individuals and patients submitted to biopsies such as the terminal ileum (56) or colonic mucosa (49) can be screened. Also the oral cavity seems to be the origin of some allochthonous lactobacilli of the intestine (44). Recently, it has been indicated that the infant fecal microbiota reflects the bacterial composition of the breast milk (79, 101). Therefore, the natural microbiota of human milk could be proposed as a source for the isolation of novel probiotic bacteria. Another approach to search for improved probiotic strains (Fig. 1.1) is the adaptation of wild types to the intestinal stressful conditions. After ingestion, the probiotic bacteria must survive the passage through the GIT and reach the colon in order to exert their beneficial effect. The low pH in the stomach and the high concentration of bile salts in the small intestine, which act as biological detergents disrupting the cell membrane, are the principal challenges that probitics must overcome (21). Margolles and coworkers (100) obtained sodium-cholate-resistant Bifidobacterium derivatives by exposure to gradually increasing concentrations of this compound. The resistant phenotype remained stable and promoted some physiological changes that improved the survival of the adapted bacteria into the colon environment (52). Similarly, Collado and Sanz (39) developed a method for direct selection of acid-resistant Bifidobacterium strains by prolonged exposure of human feces to stressful conditions. The recovered strains were intrinsically resistant to acid gastric conditions (pH 2.0) and also showed good tolerance to high concentrations of bile salts and NaCl. This cross-resistance between low pH and bile salts was previously described in bile-adapted strains (118). Several strains with improved tolerance to these and other stressful factors have been described in literature (34, 111, 130, 146) as a method of selecting lactobacilli and bifidobacteria strains with improved viability to GIT and technological conditions. Finally, taking advantage of the genome sequences, novel strains with improved or “designed” probiotic characteristics can be constructed toward specific therapies (157, 165). However, the use of recombinant strains is still far from being applied in


7

functional foods, at least in the European legal frame. Some Bifidobacterium strains have been genetically engineered for therapy against tumors after oral administration (74) and to fight against intestinal pathogens (114, 168). Recombinant Lactobacillus strains are currently under study for the enhancement of the immune system (77, 78), treatment against Helicobacter pylori (41) and improvement of inflammatory colitis (76). Although the species Lactococcus lactis is generally not considered as a probiotic, recombinant strains have been constructed for the oral delivery of therapeutic molecules (87) for the treatment or alleviation of diverse diseases such as allergies (12) and colitis (164). 1.2.2

Identification, Classification, and Typing of Bifidobacterium Strains

1.2.2.1 Taxonomy Microorganisms of the genus Bifidobacterium are nonsporeforming, nonmotile, and nonfilamentous rods, which can display various shapes, with slight bends or with a large variety of branchings, from which the most typical ones are slightly bifurcated club-shaped or spatulated extremities. They can be found singularly, in chains, in aggregates, in “V,” or palisade arrangements when grown under laboratory conditions. They are strictly anaerobic, although some species can tolerate low oxygen concentrations, and they have a fermentative metabolism (151). Tissier described these bacteria at the beginning of the twentieth century (173). They were first included among the family Lactobacillaceae, but in 1924 Orla-Jensen proposed the reclassification of the species Lactobacillus bifidum into the new genus Bifidobacterium (151). The species of the genus Bifidobacterium form a coherent phylogenetic group and show over 93% similarity to the 16S rRNA sequences among them (150). This genus is clustered in the subdivision of high G þ C Gram-positive bacteria, and it is included in the phylum Actinobacteria, class Actinobacteria, subclass Actinobacteridae, order Bifidobacteriales, and family Bifidobacteriaceae. According to the DSMZ Bacterial Nomenclature database (http://www.dsmz.de/microorganisms/bacterial_nomenclature), the species included in the genus Bifidobacterium are 29: B. adolescentis, B. angulatum, B. animalis, B. asteroides, B. bifidum, B. boum, B. breve, B. catenulatum, B. choerinum, B. coryneforme, B. cuniculi, B. dentium, B. gallicum, B. gallinarum, B. indicum, B. longum, B. magnum, B. merycicum, B. minimum, B. pseudocatenulatum, B. pseudolongum, B. psychraerophilum, B. pullorum, B. ruminantium, B. saeculare, B. scardovii, B. subtile, B. thermacidophilum, and B. thermophilum. In turn two subspecies constitute the species B. animalis (subsp. animalis and lactis), B. pseudolongum (subsp. globosum and pseudolongum), and B. thermacidophilum (subsp. thermoacidophilum and porcinum), and the species B. longum is subdivided in three different biotypes (longum, infantis, and suis). All the currently known Bifidobacterium isolates are from a very limited number of habitats, that is human and animal GITs, food, insect intestine, and sewage (65, 196). Among the strains most commonly found in human intestines and feces are those belonging to the species catenulatum, pseudocatenolatum, adolescentis, longum, breve, angulatum, bifidum, and dentium, and the typical species isolated from functional foods is B. animalis subsp. lactis (104); therefore, strains belonging to these species are the first target for health-promoting studies.

8


FIGURE 1.2 Evolutionary relationships of Bifidobacterium strains obtained using 16S rDNA sequences. The evolutionary distances were inferred using the neighbor-joining method and were computed using the maximum composite likelihood method. Units indicate the number of base substitutions per site. All positions containing gaps and missing data were eliminated from the dataset.

A number of phylogenetic studies carried out during the last few years (108, 148, 196, 200), mainly based on sequence comparison of total or partial sequences of the 16S rRNA genes and other housekeeping genes, have grouped the bifidobacterial species in six groups, B. boum group, B. asteroides group, B. adolescentis group, B. pullarum group, B. longum group, and B. pseudologum group (Fig. 1.2). 1.2.2.2 Identification and Typing Currently, there is great concern that the correct identification of a probiotic strain is the first prerequisite to be able to state its microbiological safety. Many studies have revealed deep deficiencies in the microbiological quality and labeling of currently marketed probiotic products for human and animal use. The incorporation of incorrectly identified probiotic bacteria in functional


9

food products clearly has public health implications, by undermining the efficiency of probiotics and by affecting public confidence in functional foods (83). Thus, the use of adequate tools to provide proper strain identification for legal and good manufacturing practices, and to track probiotics during food production, as well as during their intestinal transit, are strictly necessary. Traditionally, bifidobacteria have been identified on the basis of phenotype investigations. The host from which the bifidobacteria was isolated (e.g. animalis, adolescentis, pullorum, dentium, etc.) often represented the first identification criteria for many of these bacteria. Cell morphology, determination of metabolites, enzyme activities, and the ability to utilize sugars are the most commonly analyzed phenotypic characteristics for this genus, and until the 1960s the only identification criteria used. Specifically, the association of a branched shape with the presence of fructose-6-phosphate phosphoketolase (F6PPK) activity in a strain indicates that it belongs to the genus Bifidobacterium (20, 170, 196). However, several problems become apparent when the identification is carried out at species level, and the classical phenotyping, such as sugar fermentation profiles, transaldolase serotyping, cell-wall composition, and the study of the F6PPK isoforms, is clearly not discriminative enough to reach species, subspecies, and biotype level identification with confidence. Furthermore, these phenotypic methods suffer from a certain lack of reproducibility due to the culture conditions, metabolic status of the cells, and sometimes the lack of stability of the genetic determinants responsible for such phenotypes. As a matter of fact, most cases of probiotic misidentifications stem from the use of inappropriate phenotypic methods (83). Mainly in the last decade molecular tools have been developed for identifying probiotics, based on the analysis of nucleic acids and other macromolecules because of the high potential provided by using polymerase chain reaction (PCR) amplification and hybridization with DNA and RNA (22). A summary of the molecular techniques used for identification and typing of potential probiotic bacteria is presented in Table 1.1. The study of ribosomal rRNA genes (rDNA) is the most common methodology for bifidobacteria identification up to date. Bacterial ribosomes are formed from proteins and three ribonucleic acids: 5S RNA, 16S RNA, and 23S RNA. The rRNA genes are organized in rrn operons, bifidobacteria harboring from two to six depending on the species (152, 196). The 16S rDNA has nine variable regions (V1 to V9), and the three genes are separated by variable spacer regions. The detailed analysis of the 16S rDNA, as well as the 16S–23S spacer region (intergenic transcribed sequence, ITS), showed nucleotide fingerprints with different discriminatory levels. The 16S sequencing is being employed to discriminate all bifidobacterial species and their respective subspecies and biotypes (67, 106– 108, 200), whereas the 16S-23S rRNA ITS sequence is much more variable than the 16S rRNA structural gene both in size and sequence, even within closely related taxonomic groups, which makes it a suitable target for both identification and typing by using species-specific primers (72); its analysis has a higher discriminatory capacity and allows the differentiation of different Bifidobacterium strains among the same species (94).

10

rRNA genes, end intergenic regions, other genes

rRNA operons

rRNA genes

ARDRA

rRNA 16S sequencing

Identification, phylogenetic relationships

Identification, typing

Identification of single/ multiple strains, detection of microbial species/strains

Identification

Fatty acids

Species-specific PCR/ multiplex PCR

Identification

Whole-cell proteins

Protein profiles of whole cells FAME profiles

Identification and biotyping

Outcome

Cell metabolism

Target

Simple, highly reproducible, fast and sensitive, availability of primer sequences for most species, possibility of sequencing Simple, digestion with many restriction enzymes Simple, sequencing of PCR fragments and sequence comparison, availability of many “universal” and groupspecific primers

Easy to perform, high repeatability Cheap

Special equipment not required

Advantages

Main Methods for Identification and Typing of Bifidobacterium and Lactobacillus Species

Phenotyping

Methods

a

TABLE 1.1

Absence of a clear definition of genetic species

Phenotypic variability, standardization of culturing and reading conditions Laborious, need of reference strains Special equipment and technical skill needed, mathematical treatment of the results Only few species can be detected at a time; unknown members are not identified; requires sequence data for specific primer design Availability of rRNA gene sequences

Limitations

11

Whole genome

Whole genome

Whole genome

Whole genome

Whole genome

PFGE

AFLP

AP-PCR, RAPD

ERIC-PCR

REP-PCR

Typing

Typing

Typing and identification

Typing

Typing

Identification of bacteria, typing of microbial communities

Typing and identification

rRNA genes

16S rRNA gene, other genes

Identification and typing

recA, groESL, dnaK, hsp60, tuf, etc.

DGGE, TGGE

PCR amplification and sequencing of housekeeping genes Ribotyping

Simple, easy to perform, many primers, cheap Sensitivity and specificity, simple, simultaneous comparison of many samples Simple, PCR-based technique

Large numbers of samples can be analyzed simultaneously; superior taxonomic information regarding unknown bands High resolution and reproducibility, use of many restriction enzymes High reproducibility

More resolution for closely related bacteria than the 16S rRNA sequences Automated (Riboprinter, Qualicon, DuPont)

PCR biases (continued)

Laborious except automated, high conservation of rRNA operons, expensive equipment PCR biases; co-migration of different species; dominant species; heterogeneous copies of rDNA operons; lysis and extraction efficiency Laborious, timeconsuming, analysis of small number of samples Laborious, timeconsuming, technical skill and high standardization needed, expensive Low repeatability, small number of bands PCR biases, careful standardization of the technique

Availability of sequences

12

Whole genome

rRNA intergenic spacer region

16S rRNA genes, whole genome, specific genes

TAP-PCR

RISA, ARISA

Microarray hybridisation

Typing of bacteria, fingerprinting of microbial community structure Bacterial detection and community analysis in complex environments

Typing

Outcome

High power of identification; thousands of genes can be analyzed, automated analysis

RADP variant, 18 mer oligonucleotide with a degenerated position at the 30 end, more reproducibility Highly reproducible; automated

Advantages

Laborious; expensive; in early stage of development

PCR biases; requires large quantities of DNA

PCR biases

Limitations

a FAME: fatty acids methyl esther; ARDRA: amplified ribosomal DNA restriction analysis; DGGE, TGGE: denaturing gradient gel electrophoresis, termal gradient gel electrophoresis; PFGE: pulsed field gel electrophoresis; AFLP: amplified fragment length polymorphism; AP-PCR, RAPD: arbitrarily primed PCR, also know as random amplification of polymorphic DNA; ERIC: enterobacterial repetitive intergenic consencus sequence; REP-PCR: repetitive extragenic palindromic elements-PCR; TAPPCR: triple arbitrary primed-PCR; RISA, ARISA: ribosomal intergenic spacer analysis, automated ribosomal intergenic spacer analysis.

Target

Methodsa

TABLE 1.1 (Continued)


13

Recently, more robust and powerful typing methods have been applied to Bifidobacterium species and strains, such as the multilocus sequence typing (MLST) scheme. The MLST method was first utilized for bacteria in 1998, and it made use of an automated DNA sequencing procedure to characterize the alleles present at different housekeeping gene loci (95). As it is based on nucleotide sequences, it is highly discriminatory and provides unambiguous results that are directly compared between laboratories. Several authors (103, 191, 192, 194, 195, 197–200, 208, 211), analyzed several gene sequences for detailed identification and classification purposes (tuf, recA, xfp, atpD, groEL, groES, dnaK, hsp60, clpC, dnaB, dnaG, dnaJ1, purF, rpoC). Other gene sequences (pyk, tal) have also been studied proving to be valuable for species and subspecies identification (137, 183). Methods based on the PCR are widely used and allow the differentiation between strains of the same species and to some extent, also between species. By examining fingerprint patterns generated by amplification of DNA fragments these methods offer considerable potential for probiotic strain typing. The random amplification of polymorphic DNA (RAPD) technique uses short random sequence primers that are able to bind under low stringency to partially or perfectly complementary sequences of unknown location along the genome. Fingerprint patterns generated with this technique were useful to differentiate Bifidobacterium strains from human and food origin (50, 110, 201). Amplified ribosomal DNA restriction analysis (ARDRA) consists of the amplification of rDNA genes (totally or partially) and subsequent digestion with restriction enzymes, thus the choice of the enzyme(s) is critical for the discriminatory power. Species-specific identification is usually achieved with this technique (89, 143, 185, 188, 190), although B. animalis subsp. lactis and B. animalis subsp. animalis can also be distinguished (191). ERIC (enterobacterial repetitive intergenic consensus sequence)-PCR, and REP (repetitive extrogenic palindromic)-PCR examine specific patterns of repetitive DNA elements. ERIC sequences are 126-bp inverted repeats and REP sequences are short DNA fragments (between 21 and 65 bases) detected in the extragenic space; both are dispersed throughout the bacterial genomes (193, 174). The application of ERIC-PCR for bifidobacterial identification at species and subspecies level has been reported (158, 189), and REP-PCR can be considered as a promising genotypic tool for the identification of bifidobacteria potentially up to strain level (102, 103). Although the aforementioned PCR techniques are the most common methods for identification and typing Bifidobacterium strains, other PCR-based approaches include TGGE/DGGE (temperature gradient gel electrophoresis/denaturing gradient gel electrophoresis) (62, 99, 172), Amplified fragment length polymorphism (AFLP), PCR coupled to enzyme-linked immunosorbent assay (ELISA), triplicate arbitrarily primer (TAP)-PCR, restriction fragment length polymorphism (RFLP)-PCR (48, 147), and multiplex PCR (26, 55, 91, 116, 187) to some extent have been utilized to type bifidobacteria to species, subspecies or strain level (Table 1.1). Some methods for bifidobacteria identification and typing using total (or partial) DNA profiles, including plasmid analysis and RFLP of total DNA, have been used (14, 27, 142). However, pulsed-field gel electrophoresis (PFGE), which involves the digestion of genomic DNA with rare-cutting restriction enzymes and

14


the subsequent separation of the macrofragments through a continuously reorienting electric field, is often considered by microbiologists the best technique for strain-specific typification. PFGE protocols have been established for different Bifidobacterium species (29, 110, 159, 207) and have shown a high discriminatory power to differentiate, for example, B. animalis subsp. lactis strains, which are often not discriminated using other methodologies due to the close genetic background among strains (66). The ribotyping is the most popular and widespread hybridization method for bacterial typing. It combines southern hybridization of genomic DNA restriction patterns with rDNA probes. Furthermore, the availability of commercial systems allows the analysis of a wide range of bacteria in an automated manner. Although it is generally believed that ribotyping has a lower discriminatory power than the PFGE analysis (150), it has been extensively used for bifidobacterial typing (88, 97, 98, 110, 148). Among these techniques, southern blot and microplate blot have also been used to type Bifidobacterium strains (97, 205), and microarray hybridization has arisen during the recent years as a valid alternative to discriminate between Bifidobacterium species (203), although the need for specific equipment and specialized personnel for the analyses severely limits its current applicability as an ordinary method of probiotic identification. Finally, it is worthwhile pointing out that other methods have also been applied to the identification and typing of Bifidobacterium. The chromatographic analysis of organic acids (93) appears to be a useful tool for rapid identification of Bifidobacterium spp. at the genus level. Also, the analysis of the intrinsic fluorescence of aromatic amino acids (16) was shown to be an inexpensive and convenient means of rapidly identifying intestinal bifidobacteria, which could be of help for large probiotic surveys. 1.2.3

Identification, Classification, and Typing of Lactobacillus Strains

1.2.3.1 Taxonomy The genus Lactobacillus is the largest group among the lactic acid bacteria (LAB) containing, at present, more than 120 species and 20 subspecies (http://www.dsmz.de/microorganisms/bacterial_nomenclature_info.php?genus¼ LACTOBACILLUS (65, 150)); though its number increases every year (13 new species have been proposed in 2005, 9 in 2006, and 7 in 2007 up to the time of writing; http://www.ncbi.nlm.nih.go/sites/entrez). The lactobacilli are a broad, morphologically defined group of Gram-positives, nonspore-forming rods or coccobacilli with a GþC content usually below 50 mol% (86). Lactobacilli are clustered in the subdivision of low GþC Gram-positive bacteria, and are included in the phylum Firmicutes, class Bacilli, order Lactobacillales, and family Lactobacillaceae. They are strictly fermentative (either homo- or heterofermenters), aerotolerant or anaerobic, aciduric or acidophilic having complex nutritional requirements (carbohydrates, amino acids, peptides, fatty acid esters, salts, nucleic acid derivatives, vitamins) (86). They are naturally associated with a large variety of nutritive-rich plant- and animal-derived environments, and many species are involved in the manufacture and preservation of fermented foods and feed from raw agricultural materials (such as milk,


15

meat, vegetables, and cereals) in which they are present as contaminants (166). Moreover, some species and strains are broadly used as starters and adjunct cultures to drive food and feed fermentations; notably dairy products (yogurt and cheese), fermented vegetables (olives, pickles, and sauerkraut), fermented meats (salami, sausages), and sourdough bread and other cereal-based food commodities. Although less numerous than bifidobacteria, lactobacilli are natural inhabitants of the GIT and genitourinary (GUrT) tracts of animals and humans, where they are thought to play pivotal roles in the maintenance and recovery of a healthy state (136, 182). Not surprisingly, a number of strains have been used as probiotics for more than 70 years (138). Beneficial effects attributed to indigenous and probiotic lactobacilli include colonization of intestinal and genital mucosa (85), inhibition of pathogens (36, 81), immunomodulation (88), and cholesterol assimilation (132). 1.2.3.2 Identification and Typing Reliable identification of bacterial species and strains and correct naming are primary aims of taxonomic studies, but it also has important consequences for industrial application of bacteria. Morphology, Gram staining, and biochemical tests (fermentation of carbohydrates, growth at different temperatures, salt concentration, etc.) have traditionally been used as the primary methods for classifying Lactobacillus species; these methods are still in use. Based on phenotypic and biochemical characteristics, lactobacilli were divided into three groups according to the type of sugar fermentation (86). Obligate homofermentative lactobacilli ferment hexose sugars by glycolysis and produce mainly lactic acid, while obligatory heterofermentative species use the 6-phospho-gluconate/phosphoketolase (6PG/PK) pathway and produce other end products (CO2, ethanol) in addition to lactic acid (18). A third group includes the facultative heterofermentative lactobacilli that ferment hexoses via the glycolysis and pentoses via the 6PG/PK pathways, respectively. Phenotypic analyses are time consuming and require technical skill and standardized assays and reading conditions, in order to avoid subjective results. Furthermore, it has been widely recognized that Lactobacillus species and strains display an inherent high level of phenotypic variability (86). Thus, phenotypic heterogeneity makes classical microbiological methods ambiguous and unreliable. In fact, many studies emphasize that the phenotypic classification of lactobacilli is unsatisfactory (13, 40, 113, 133, 162). As a recent example, Boyd et al. (28) have reported that the API 50 CH identification system failed to identify the seven Lactobacillus reference strains utilized in their study, and 86 out of 90 vaginal isolates, as compared to the identification obtained by hybridization using wholechromosomal DNA probes. Of particular complexity are the phenotypically and genetically closely related species belonging, among others, to the Lactobacillus casei group (115) or to the Lactobacillus acidophilus complex (131, 144). Moreover, the phenotypic identification does not reflect the phylogenetic relation of the different species (51). The taxonomy of the Lactobacillus species has changed considerably with the increasing knowledge of their genomic structure and phylogenetic relationships gathered with molecular methods (65). The DNA–DNA hybridization technique is still of reference, although this technique is labor intensive and time consuming. Fatty

16


acid methyl ester (FAME) analysis has also been applied to the identification of lactobacilli from dairy and probiotic sources (68, 206). This is an inexpensive procedure that is also of help to study diversity, composition and dynamics of microbial communities, but FAME profiles are rather difficult to interpret and have to be subjected to mathematical treatments. Identification and classification of Lactobacillus species has also been accomplished by analysis of whole-cell protein patterns (133, 204). Highly standardized SDS-PAGE conditions allow a rapid and precise identification of a large number of strains. Profiles of unknown strains are compared to a pattern database of known species. In spite of all these techniques, at present, a majority of the molecular identification methods of Lactobacillus strains rely on the analysis of rRNA genes, mostly after their partial or complete amplification by the PCR technique (Table 1.1). rRNA genes have been generally accepted as the potential target for identification and phylogenetic analysis of bacteria (15). Consequently, PCR amplification and sequencing of 16S rDNA- or 23S rDNA-targeted primers have successfully been used for the detection and identification of Lactobacillus species (115, 171, 186). Amplicons are usually digested with restriction enzymes for some techniques (such as ARDRA), and, more frequently, subjected to double-stranded sequencing. It has been experimentally determined that species having 70% or greater DNA similarity (at the DNA–DNA hybridization or re-association level) share, in fact, more than 97% of 16S rDNA sequence identity (127, 161). Isolates having such a percentage of identity belong to what has been called an operational taxonomic unit (OTU). Comparison of the rRNA gene sequences (mainly 16S rRNA) allows a precise identification and, at the same time, tracking of the evolutionary relationships among the distinct species. The analysis of 16S rDNA sequences has shown that the division of lactobacilli species in three groups is not in accordance with their natural relationships (18). In fact, Lactobacillus species branch into several groups and do not form a coherent phylogenetic unit (65, 150) (Fig. 1.3). At present, specific primers are available for targeting most Lactobacillus species (24, 90, 150, 154). Besides genes of both rRNA molecules, the analysis of ITS has also been utilized for identification purposes (24, 75, 119). Based on either the genes or the ITS regions, some authors have developed multiplex PCR of species-specific primer pairs for the detection of up to eleven different LAB species (90, 154, 160). In the same way as oligonucleotide primers, oligonucleotide probes can also be used in hybridization experiments for specific detection, identification, and quantification of Lactobacillus species (80, 128, 133, 155). Nucleotide differences in the 16S rRNA genes can also be exploited for the electrophoresis separation of PCR-derived amplicons by DGGE technique or its relative temporal temperature gradient electrophoresis (TTGE). These techniques can either be used for the identification of individual strains (61, 184) or for the analysis of the diversity and evolution of whole populations in complex bacterial mixtures (80, 120, 135). Coding genes of highly conserved proteins such as RecA (64, 175), GroESL (202), and the elongation factor (EF) Tu (33, 192) have all been used to identify lactobacilli species and to determine their phylogenetic relationships. These gene sequences provide phylogenetic resolutions comparable to that of the 16S rRNA gene at all


17

FIGURE 1.3 Phylogenetic tree showing the relationships of the 16S rDNA sequences of type strains of selected Lactobacillus species. Sequences were obtained from the Ribosomal Database Project (http://rdp.cme.msu.edu/) and the phylogenetic tree was constructed by an online tree builder resource that uses the Weighbor-weighted neighbor-joining algorithm. The 16S rDNA sequence from the Bacillus subtilis type strain was selected as an outgroup.

taxonomic levels, and better resolution between closely related organisms, as rates of evolutionary substitution in protein-coding genes are one order of magnitude higher than those for 16S rRNA genes. The use of protein-coding sequences further avoids the biases due to multicopy and intragenomic heterogeneity associated to rRNA sequences The comparison of the sequences of the fructose-1,6-bifosphatase (fbp) gene

18


has been recently used for identifying and typing food borne and clinical strains of Lactobacillus rhamnosus (145). Beyond sequence data, the polyphasic approach, which integrates phenotypic, genotypic, and phylogenetic information, has been recognized by the International Committee on Systematic Bacteriology as a new tool for the description of species and for the revision of the present nomenclature of some bacterial groups (181). Intraspecific differentiation of bacteria is highly relevant for the selection of starter and probiotic cultures, because technological, sensorial, antimicrobial, and probiotic attributes are strain specific. Typing methods are very helpful in distinguishing patent protected strains, as well as the distinction of starter, adjunct, and probiotic cultures (strain tracking) from natural isolates. As for the safety aspects, it is crucial to be able to compare clinical (pathogenic) isolates with biotechnological strains in use. Besides phenotypic methods, many PCR-based typing methods have been used for the typing of lactobacilli strains, such as ribotyping (141, 210), RAPD (46, 58, 117, 153, 175), PFGE (144, 179, 190), TAP-PCR (43), AFLP (176), REP elements PRC amplification (REP-PCR), ERIC-PCR (190), etc. PCR-RFLP of intragenic DNA fragments of protein-coding genes involved in primary metabolism (b-galactosidase, lactose permease, and proline dipeptidase) has also been used as a typing method for dairy Lactobacillus delbrueckii strains (69). Chromosome typing (restriction endonuclease fingerprinting of chromosomal DNA, chromotyping) has been applied to the discrimination of strains of lactobacilli and found to be specific and highly reproducible (163, 210); although the large number of bands requires careful standardized electrophoretic conditions. The powerful MLST technique has recently been applied for species identification and phylogenetic studies of Lactobacillus strains. A MSLT method based on the analysis of six loci (pgm, ddl, gyrB, purK1, gdh, and mutS) has been developed for the analysis of L. plantarum strains (47). Even more recently, Diancourt et al. (54) developed and applied a MLST variant, called multilocus variable-number tandem repeats (VNTR) analysis (MLVA), for the fine subtyping of L. casei/L. paracasei strains. A high concordance between the profiles obtained by MLVA and those obtained by AFLP and MLST was observed. Whole-genome sequencing and comparative genomics providing insights on bacterial evolution will surely influence bacterial taxonomy in the near future. In fact, gene and genomic sequence information has recently been proposed as a tool for defining a new genomic–phylogenetic species concept for prokaryotes (163). Comparative genomics has further strengthened the idea that the lactobacilli as a whole do not form a coherent phylogenetic group, supporting the recognition of new subgeneric divisions (32, 96). In fact, it seems that some species (L. salivarius, L. plantarum) are more closely related to Enterococcus faecalis than they are to other lactobacilli (32), and other non-lactobacilli such as Pediococcus pentosaceus will likely cluster within or close to some species of the genus (32, 96). Genome techniques such as comparative genome hybridization (CGH) can quickly be used to determine the genome content of a bacterial strain whose genome sequence is not known (112). CGH has also been found to be valuable for clarifying controversial taxonomical issues. It has already been used for comparison of members within the L. acidophilus group, addressing


19

both intra- and interspecies diversity (23). Microarrays based on the L. johnsonii NCC533 genome were hybridized with total DNA from strains of this and other species of the L. acidophilus complex. A clear stepwise decrease in similarity between members of the complex was found, suggesting that these species belong to a natural phylogenetic unit. Exhaustive phylogenetic analyses based on genome data will be performed when more genome sequences are completed and analyzed. To date, 10 Lactobacillus genomes have been published, and at least 11 more sequencing projects are ongoing (35, 96). 1.2.4 Characterization of Probiotic Properties in Bifidobacterium and Lactobacillus Strains Several criteria have been used for the selection of probiotic strains (Fig. 1.1), the most commonly employed being the survival of the stressful GIT conditions (low pH and high bile salts concentrations), the ability to transitory colonize the GIT, which is related with the adhesion to mucus and/or intestinal epithelium and the antimicrobial activity through the production of antimicrobial molecules or the ability to inhibit/displace the adhesion of pathogens. Several in vitro and in vivo tests are employed for the screening of these characteristics (45, 57, 178, 209), although there is a lack of standardized or unified methodology for the assessment of probiotic functionality. Table 1.2 summarizes some works that report the screening of the most common probiotic characteristics within collections of Lactobacillus, Bifidobacterium, and other LAB strains, mainly isolated from human samples but also from other sources. 1.2.4.1 Survival to GIT Stressing Conditions The transit of probiotics included in foods through different sections of the GIT takes variable times and is submitted to different stressful conditions. After mastication, the first barrier that bacteria must overcome is the low pH values of the stomach with values ranging from 1 to 3 and mean exposure times of 90 min. Into the duodenum the pH value rises to 6–6.5, but bile salts are poured from the gallbladder to reach concentrations ranging from 1.5 to 2% during the first hour of digestion and decreasing afterwards to 0.3% w/v or lower (118). The residence period in the small intestine until 50% emptying oscillate between 2.5 and 3 h and the transit through the colon could take up to 40 h (31). In this location pH values are close to neutral (from 5.5 to 7) and the physiological concentration of bile salts is lower. For the screening of putative probiotic bacteria most works (Table 1.2) simulate in vitro these GIT conditions. Several pH values and bile concentrations are tested for variable times in order to determine the survival of the strain(s) under test. Bacteria are enumerated by culture dependent and/or independent techniques, such as those employing fluorescent probes that allow knowledge of the population of dead and live bacteria. The results of viability obtained are strain dependent and, in general, bifidobacteria strains are less tolerant to acidic conditions than lactobacilli, whereas the first seems to be more tolerant to bile challenge. Few studies have been carried out employing human samples of gastric juice and bile and interestingly, the source of bile (bovine, porcine, or human) modifies the tolerance pattern (56). Therefore, it would be

20

Strain Origin

Infant feces

Human, dairy

Human feces

Human, animals

Human, culture collection

(70) Human, culture collection

Culture collections

Human, fermented foods, unknown

Bifidobacterium (25)





Bifidobacterium (8)

Lactobacillus (12)

Lactobacillus (47)

Adhesion/colonization GIT Survival GIT conditions Adhesion/colonization GIT Antimicrobial activity

Adhesion/colonization GIT

Adhesion/colonization GIT

Adhesion/colonization GIT Antimicrobial activity

Antimicrobial activity

Survival GIT conditions

Survival GIT conditions Adhesion/colonization GIT Antimicrobial activity

Probiotic Character Studied

The survival of three strains seemed to be linked to adhesion ability and tolerance to pH 2.5.

Adhesion is strain-dependent and is modified by pH and pathogens presence Adhesion was strain-dependent

The acquisition of bile resistance modify the adhesion ability of strains

One strain (B. lactis), survive the simulated GIT conditions Inhibition ability varied according to pathogen tested Adhesion and antimicrobial ability varied according to strain and its origin

Not all desirable characteristics were present in a single strain; most adherent and inhibitory were less resistant

Observations

(84)

(177)

(139)

(70)

(38)

(25)

(42)

(209)

References

Screening of Probiotic Characteristics within Collections of Lactobacillus and Bifidobacterium Isolated from Different Sources

Strains Tested (number)

TABLE 1.2

21

Human, animals, dairy

Culture collection

Infant feces

Dairy

Dairy

Culture collection

Dairy

Human oral cavity

Animals, dairy, fermented foods

L. acidophilus group (35)

Lactobacillus (7)

Lactobacillus (35)

Lactobacillus (88)

Lactobacillus (65)

Lactobacillus (4)

Lactobacillus (22)

Lactobacillus (26)

L. plantarum (31)

Survival GIT conditions Antimicrobial activity Adhesion/colonization GIT

Survival GIT conditions Antimicrobial activity Bile salt deconjugation

Adhesion/colonization GIT Antimicrobial activity

Survival GIT conditions Adhesion/colonization GIT Antimicrobial activity In vitro and in vivo safety assessment Antigenotoxic properties

Adhesion/colonization GIT Adhesion/colonization GIT Antimicrobial activity Antimicrobial activity

Two strains (L. salivarius and L. gasseri) as putative probiotics Adhesion depends on both the adhesion model employed and the strain tested

Most strains were resistant to biological barriers. Only 3 strains were able to deconjugate bile salts.

High number of strains showed antigenotoxic and antimutagenic properties High specificity in the inhibition/ displacement of pathogens by lactobacilli

More effective against Gram- and inhibitory activity was straindependent One strain (L. plantarum) showed probiotic characteristic and survive incorporated in cheese

The adhesion to rat colonic mucin ability was strain dependent The growth media and the food matrix affect de adhesion properties

(continued)

(169)

(167)

(180)

(71)

(30)

(37)

(17)

(125)

(109)

22 Survival GIT conditions Antimicrobial activity Survival GIT conditions Antimicrobial activity Bile salt hydrolase activity (BSH) In vivo cholesterol reduction

Human, dairy

Culture collections

Human feces

Lactobacillus and Bifidobacterium (200) Lactobacillus and Bifidobacterium (7) LAB (120)

Probiotic Character Studied

Strain Origin

Strains Tested (number)


Three lactobacilli and 1 bifidobacteria strains survive to GIT conditions Antagonistic activity variable according to strain tested One strain (L. plantarum) showed high in vitro BSH activity and after oral administration was able to reduce cholesterol levels

Observations

(73)

(82)

(134)

References


23

recommendable that probiotic strains intended for human consumption are tested in the presence of human intestinal fluids. 1.2.4.2 Adhesion/Colonization to/of GIT Some of the health effects attributed to probiotics are related to their capability to adhere to the intestinal mucosa. Adhesion is a prerequisite for intestinal colonization, stimulation of the immune system, and for antagonistic activity against enteropathogens through competitive exclusion (57). The intestinal mucosa is covered by a layer of different types of epithelial cells, which are distinctly different in the different regions of GIT, and is in contact with the lumen, the outside of the body. In addition to secretory and absorption cells, an important part of the immune system is placed in this location and it is collectively referee to the GALT (gut-associated lymphoid tissue). The intestinal epithelium is almost completely covered by a protective mucus gel composed predominantly of mucin, glycoproteins acting as the anatomical GIT site in which the host first encounters gut bacteria (53). Genomic information of some probiotic strains revealed the presence of several molecules able to adhere to different components of the intestinal mucosa and to exchange signals with the intestinal immune system (149), which indicate a good adaptation of probiotics to the gut environment. Several models have been employed to study the ability of putative probiotic strains to adhere to the intestinal epithelium. Studies have often been carried out with cellular lines obtained from human colon adenocarcinomas such as Caco-2 (ATCC HTB-37) and HT-29 (ATCC HTB-38) the last one being able to produce mucin (37, 84, 139, 169, 177). Frequently, the adhesion ability of putative probiotics from different collections has been extensively tested against mucus obtained from human (38, 70, 123, 125) or animal origin (109). Interestingly, some strains of Bifidobacterium adhere better to human mucus than to porcine mucus indicating that adhesion is property strain dependent (124), because mucus from different origins (human, canine, possum, bird, and fish) did not modify the adhesion of probiotic strains (140). In addition, bacterial adhesion to human mucus decreased with the age of the donor of the mucus sample, which could be one of the reasons for low bifidobacteria colonization in elderly subjects (122). A good correlation between the human mucus model and the adhesion to Caco-2 has been demonstrated by Gueimonde and collaborators (71) employing three Lactobacillus strains. Both methods are adequate for in vitro adhesion studies but some ex vivo models employing resected tissue of the intestinal mucosa from human or animals have also been shown to be useful (105, 126). In the human intestinal mucus model proposed by Ouwehand and coworkers (126) the material is obtained from patients with colon cancer submitted to surgery. The healthy sections of resected tissue obtained from different sites of the colon are employed in these studies. In general, the strains tested showed higher adhesion to mucus than to colonic tissue and, depending on the strain, the location of the colonic tissue but not that of mucus, also influenced the adhesion properties of the probiotics tested. This is a good model for the assessment of the adhesion of LAB to GIT epithelium and to mucus.

24


1.2.4.3 Antimicrobial Activity In the complex GIT ecosystem probiotics have developed mechanisms to survive in competition with other microorganisms. Essentially, the antagonism is exerted by competition for nutrients and for physical location, but also through the production of antimicrobial substances. In connection with the previous paragraph, the ability of probiotics to produce antimicrobials is one mechanism to inhibit, exclude or compete with adherent enteropathogens for the ecological niche. Several works (Table 1.2) have been carried out to test invitro the interference on adhesion between probiotics and pathogens such as Salmonella enterica serovar Typhimurium, Escherichia coli, Clostridium difficile, Enterobacter sakazakii, and Listeria monocytogenes. Using human intestinal mucus it has been demonstrated that the adhesion antagonism is clearly both, probiotic- and pathogen-strain dependent (38, 71). This specific interaction indicates the need for a case-by-case assessment in order to select probiotics with the ability to inhibit or displace certain pathogens. Most often, cocultures probiotic/enteropathogen are carried out to test the antimicrobial ability of probiotic strains (17, 25, 37, 82, 84, 167). Viability of both types of bacteria is determined and in some cases the antimicrobial activity is tentatively assigned to the production of substances such as organic acids, ethanol, H2O2, or proteinaceus components bacteriocin-like. The general conclusion that arises from these in vitro studies suggests again that the inhibition ability is strain- and culture-condition- dependent and that several molecules and mechanisms are involved in the interrelationship between probiotics and pathogens. 1.2.4.4 Other Probiotic Properties In addition to the previously reviewed properties, other characteristics could be tested to consider a strain as putative probiotic. From these screenings it has been reported that some strains are able to modulate the immune system (129), to produce antigenotoxic compounds (30), to deconjugate bile salts (73, 180), and to decrease cholesterol levels (73). 1.2.5

Conclusion

The selection of a strain to be used as an effective probiotic is a complex process. For human consumption, it is widely accepted that an effective human probiotic should be of human origin the most suitable source being the human GIT. A vast array of specific and reproducible molecular techniques is now available for identification and typing of lactobacilli and bifidobacteria. Molecular techniques have allowed the precise and rapid identification and typing of novel probiotic stains, providing new ways to check for their presence and monitor their development. Nevertheless, for microbial characterization, a polyphasic combination of phenotypic assays and molecular techniques is preferred, since these approaches may provide complementary results. On the other hand, several in vitro and in vivo tests have been found to be useful for the screening of novel strains with putative probiotic properties. In general, the probiotic characteristics are strain-dependent and properties are not all simultaneously present in a single strain. Of note is the realization that the efficacy and safety of a probiotic should be validated in phase 2 clinical trials, a pending subject for most current-in-use probiotic strains.

DETECTION AND ENUMERATION OF GASTROINTESTINAL MICROORGANISMS

25

1.3 DETECTION AND ENUMERATION OF GASTROINTESTINAL MICROORGANISMS

n Miguel Gueimonde and Clara de los Reyes-Gavila Instituto de Productos L acteos de Asturias (CSIC), Villaviciosa, Asturias, Spain

1.3.1

Methods for Intestinal Microbiota Assessment

Understanding the cross talk that occurs between intestinal microbiota and its host promises to expand our views about the relationship between intestinal microbiota and well-being. Unfortunately, we are still far from knowing the qualitative and quantitative composition of the intestinal microbiota and the factors governing its composition in an individual. Several different methodologies, culture dependent and culture independent, have been used for intestinal microbiota assessment (Table 1.3). The aim of this chapter is to review these methodologies, which are divided into two main groups: the culture-dependent and culture-independent methods. 1.3.1.1

Culture-Dependent Methods

1. Nonselective and selective culture media for intestinal microorganisms. The study of intestinal microbiota composition, both qualitatively and quantitatively, has been traditionally carried out by cultivation of feces. In some cases it has also been considered that there are mucosa-associated intestinal microbiota in biopsies of healthy individuals (229, 293) or patients (225, 252, 347). The classical method has been culturing fecal samples on suitable growth media, the sample generally being handled in anaerobic cabinets and processed immediately or within a few hours after collection. The bacterial counts of a given microbial group are determined after incubation in the appropriate conditions. Both nonselective- and selective-differential media have been used for growth and counting and the choice for one or the other was dependent on the microbial group being screened and on the method used for subsequent identification. Some of the more widely used media in recent years includes Wilkins-Chalgren (257, 330, 331, 341) and Columbia blood agar (225, 296) as general media for total anaerobic bacteria. The same media were also employed as selective and/or differential after the addition of the appropriate antibiotics and selective agents for the enumeration of Gram-positives including Clostridium, as well as Bacteroides, Prevotella, and other Gramnegatives (257, 341). MRS, Rogosa, and trypticase phytone yeast extract (TPY) agar were frequently used as base media for counting Bifidobacterium with or without the addition of selective agents (231, 257, 322, 323, 330, 331, 341), and MRS and Rogosa agar were also employed for the enumeration of Lactobacillus (212, 231, 269, 293, 322, 323, 330, 331). Bile–Esculin agar and derived supplemented media were among the most frequently employed for the isolation and enumeration of enterococci (225, 269, 323) and Bacteroides (229, 231, 296, 323). Enterococci have been also counted and isolated

26

Widely used

All

Culture-Dependent Techniques

Detection by PCR

All

Avoids the use of selective and/or inhibitory agents in the media

Culture in nonselective media followed by specific counting

Provides information on both culturable and non-culturable microorganisms High throughput, rapid, and sensitive Possibility to use frozen samples Fast and easy to perform Versatile (primers with different specificities can be used) Different degrees of specificity possible (from group to strain specific)

Culture-Independent Techniques

Direct quantification of the microorganisms of interest

Culture in selective or differential media

Quantitative Possibility to isolate strains for further study and as source of potential probiotics

Advantages

Not quantitative Previous knowledge required on the target microorganisms (to design specific primers instead of using universal primers)

Difficult standardization

Bias due to the different methodologies

Provides information only on culturable microorganisms Time consuming Complicated sample manipulation (e.g. anaerobes) Sublethally injured or dormant cells not detected The presence of selective and/or inhibitory agents may inhibit the growth of part of the population (e.g. injured cells) Requires an extra step for specific counting

Disadvantages

Advantages and Disadvantages of Some Techniques Widely Used for Intestinal Microbiota Research

Techniques

TABLE 1.3

27

Very high throughput. Allows detection of thousands of sequences in a single assay

Quantitative Possibility to observe bacteria in situ (e.g. position in the mucosa) Possibility to couple with automatic image analysis or flow cytometry

Quantitative

FISH

Quantitative PCR

Bias due to different cell lysis/PCR/Cloning efficiencies Methodologically difficult

No previous knowledge of the microbiota present is needed (when using universal primers) Provides important information at population level (e.g. diversity) Versatile (primers with different specificities can be used) No previous knowledge of the microbiota present is needed (when using universal primers) Provides information at population level (if using appropriate primers) Versatile (primers with different specificities can be used) Provides information at population level (if using appropriate primers)

Bias due to number of target gene copy number (continued)

Previous knowledge of the target microorganisms required for probe design (if not universal)

Bias due to different cell permeability to probe Difficult visual counting (e.g. cell aggregates)

Not quantitative Bias due to different cell lysis/PCR efficiencies Methodologically difficult and expensive

Not quantitative Bias due to different cell lysis/PCR efficiencies Methodologically difficult and expensive

Methodologically difficult.

Not quantitative Bias due to different cell lysis/PCR efficiencies

Not quantitative

Provides information on previously unknown bacteria

DNA-Arrays

T-RFLP

TGGE/DGGE

Sequence analyses of randomly amplified 16S rRNA genes

28

No previous knowledge on the microbiota present is needed Allows identification of novel genetic features in the ecosystem Provides important information at population level (e.g. diversity)

No previous knowledge on the microbiota present is needed Provides information on protein coding genes that are being expressed in the ecosystem

Metagenomics

Metaproteomics

Time consuming Methodologically difficult

Previous knowledge of the target microorganisms required for primer design (if not universal) Previous knowledge of the target genes required for primer design Does not provide information on cell numbers Not quantitative Time consuming Bias due to different cell lysis/PCR/cloning efficiencies Methodologically difficult and expensive

Fast and easy to perform

Allows to determine in situ metabolic activity or specific gene expression

Disadvantages

Advantages

RT quantitative PCR

Techniques



29

frequently in Slanetz-Bartley (230, 330) and KF media (296). It is also worthy to note the extensive use of the selective and differential McConkey agar for counting coliforms and enterobacteria (225, 293, 231, 232). Finally, for heterogeneous and complex groups of intestinal bacteria such as clostridia, a great diversity of culture media has been used provided that a unique medium is not appropriate for cultivation of all microbial clusters (257, 269, 296, 322, 331). 2. Identification and typing of intestinal strains. Traditionally, intestinal strains isolated from solid media were identified by means of some general phenotypic characteristics such as carbohydrate fermentation profiles, enzymatic tests, cell morphology, and colony appearance, which have lead to numerous misidentifications. The development of new and different phenotypic methods contributed to the improvement of the accuracy of identification and it is currently possible to identify not only colonies isolated from solid culture media but also nonisolated bacteria present in mucosa and feces. The genus Bifidobacterium is the only intestinal Gram-positive displaying fructose-6-phospate phosphoketolase (F6PPK) activity and its determination constitutes a reliable test for this genus among bacteria from the intestinal environment (255, 330). Vlkova and coworkers (330) used F6PPK, a-galactosidase, and a-glucosidase as enzymatic methods for detection of the abundance of bifidobacteria directly in infant feces. Determination of catabolic end products was also useful for the identification of some particular and characteristic groups of microorganisms (257). One of the most accurate phenotypic methods currently used for identification at the species level is based on the determination of the cellular fatty acid composition (234) with the help of the chromatographic MIDI system (http://www.midi-inc.com/pages/literature.html) both directly in feces (269, 324) and in previously isolated cultures (263, 341). The development of genetic methods for the identification and typification of the bacterial isolates greatly contributed to the improvement our knowledge of intestinal microbiota, although its level of sensitivity is obviously limited by the accuracy and sensitivity of the previous culture media on which microorganisms were isolated. Partial amplification and sequencing of the 16S rRNA gene from previously isolated colonies has been extensively used for identification at the genus and species level (212, 228, 323, 330, 331). Monoclonal antibodies have been used for selective enumeration of Bacteroides vulgatus and Bacteroides distasonis on fecal samples after dilution and plating in a nonselective medium, avoiding the use of selective agents to which part of the Bacteroides population could be sensitive (226). Oligonucleotide probes have also been used for the identification and the quantification of intestinal microbiota by means of colony hybridization (232, 271). Typing of the strains from a given species of intestinal microorganism has often been carried out by pulsed field gel electrophoresis (PFGE) (322, 323) or RAPD by PCR (212, 228) among other genotypic techniques. Several different culture-dependent techniques have been used for quantitative and qualitative characterization of human intestinal microbiota although large differences

30


in species composition and quantitative contents can be found among the results obtained by different authors. These differences could be attributed to the different culture media employed, different methodologies used for the subsequent identification, etc. The high variability of the intestinal microbiota among individuals and the analysis of a low number of individuals in some studies, could also have contributed to the different results observed. 1.3.1.2 Culture-Independent Methods It is estimated that less than 25% of the intestinal bacteria have been cultivated so far, suggesting that many bacteria in the human gut have not been cultured yet and that classical culture based methods have not provided an accurate representation of this community (233, 259, 319). Consequently, the study of intestinal microorganisms has been restricted to the cultivable species and from these, only to the cultivable fraction of each population. These facts led to the overestimation of some species and the underestimation of others, limiting our understanding of intestinal microbiota composition and function. By using different bifidobacterial selective culture media it has been shown that they differ in their selectivity and some media even fail in the recovery of certain species, which could lead to a biased representation of the population (213). These results clearly show the limitations of the culture-based approaches for the study of complex communities. Therefore, more rapid, accurate and specific methods of detection and quantification have been developed. During the last few years, developments in molecular biology have led to alternative culture-independent methods in addition to the traditional culture. One of the most widely applied approaches deals with the use of 16S rRNA and its encoding genes as target molecules. The 16S rDNA gene contains highly conserved regions, present in all bacteria, and highly variable ones that are specific for certain microbes. Specific PCR primers and probes can thus be designed based on these variable regions to detect certain species or groups of bacteria. These culture-independent approaches include 16S rRNA measurements, PCR amplification with specific primers of 16S rDNA extracted from fecal or mucosal samples, universal or group 16S rDNA PCR amplification followed by cloning and sequencing, TGGE, DGGE, terminal restriction fragment length polymorphism (T-RFLP) analysis, fluorescence in situ hybridization (FISH), real-time quantitative PCR, and oligonucleotide-microarrays. In more recent years metagenomic and metaproteomic approaches have also been applied to the intestinal microbiota assessment. 1. Design of PCR Primers for DNA Amplification. Several authors have developed species or group-specific primers for the detection of different microorganisms in the GIT including members of the genera Bacteroides, Clostridium, Fusobacterium, Peptostreptococcus, Eubacterium, Bacteroides, Prevotella, Lactobacillus, and Bifidobacterium (251, 254, 289, 291, 335). Nowadays, rDNA-targeted PCR primers enable a rapid and specific detection of a wide range of bacterial species. Therefore, procedures in which these primers are used have a widespread use in intestinal microbiota assessment. By means of PCR amplification with species-specific primers Wang and


31

collaborators (335) analyzed the fecal microbiota, showing that Fusobacterium prausnitzii, Peptostreptococcus productus, and Clostridium clostridiforme had the highest PCR titters followed by Bacteroides thetaiotaomicron, Bac. vulgatus and Eubacterium limosum. Matsuki et al. (292) studied the bifidobacterial microbiota in adults’ fecal samples and found that Bifidobacterium catenulatum group Bifidobacterium longum and Bifidobacterium adolescentis were the most common species whereas Bifidobacterium breve, Bifidobacterium infantis, and B. longum were the predominant species in infants. Other DNA sequences, such as ERIC sequences, have also been used as targets of PCR primers to fingerprint the microbial community of the human gut (337). 2. Design of Hybridization Probes. Several probes have been developed for the assessment of intestinal microbiota. There are probes for specific detection of Bifidobacterium (271, 280), some Clostridium groups (241, 338), Bacteroides/Porphyromonas/Prevotella group (232), Bacteroides fragilis group, Bac. distasonis or Streptococcus/Lactococcus group (241). Also probes for some species of Bifidobacterium (343) and Eubacterium (313) have been developed. Some other probes for specific intestinal groups such as Phascolarctobacterium group, Veillonella, Eubacterium hallii and relatives, Lachnospira group, Eubacterium cylindroides and relatives and Ruminococcus and relatives are also available (258). These probes have been used for specific culture-independent detection and quantification of different intestinal microorganisms by means of FISH (241, 258, 280, 313, 338) or dot blot hybridization (264, 287, 314). Combinations of PCR amplification and hybridization have also been reported. In a study by Wei and coworkers (337) ERIC-PCR amplicons from a sample were labeled and used to hybridized against other samples in order to identify those amplicons common to different fecal samples. This approach may be helpful for the identification of specific microbiota aberrancies related to different diseases by comparing healthy and ill individuals. 3. Polymerase Chain Reaction – Enzyme-Linked Immunosorbent Assay (PCR-ELISA). This technique combines PCR amplification of DNA and ELISA. The amplified DNA is labeled, commonly with digoxigenin, and hybridized with the specific detection probe that is immobilized in microtiter plate wells. The presence of hybridized DNA is determined by using digoxigenin-targeted antibodies. This methodology has not been extensively used, but it has been applied to the analysis of Bifidobacterium species composition in human feces during a feeding trial (285). 4. Sequence Analysis of Randomly Amplified 16S RNA Genes. Another procedure that has been used in intestinal microbiota research is the PCR amplification of 16S rRNA genes in a sample, using universal or group-specific primers followed by cloning and sequencing of the amplified DNAs. By using universal primers different studies (259, 261, 319) have shown that the predominantly cloned sequences from fecal samples belonged to

32


Clostridium coccoides group (Clostridium rRNA cluster XIVa), Clostridium leptum group (Clostridium rRNA cluster IV), and Bacteroides, which is in agreement with the results recently reported by Eckburg and coworkers (233). By using this approach it was found that, according to the results obtained by culture, even though clostridia tends to increase with age, the Clostridium rRNA cluster XIVa tends to decrease in elderly individuals. This is probably due to a decrease in the number of Ruminococcus obeum and related phylotypes, indicating a possible relation between R. obeum and aging (261). Regarding the species composition, it was found that the predominant fecal species in the Bacteroides group are Bacteroides uniformis and Bac. vulgatus (319). In the Clostridium coccoides group, Eubacterium eligens, Eubacterium rectale, and Eubacterium hadrum were the predominant species. Ruminococcus bromii, Eubacterium siraeum, and F. praustnizii were the unique species detected in the C. leptum group, being F. praustnizii one of the most frequent and numerous species detected by 16S rDNA analysis of human fecal samples (259, 261, 319). Sequencing of amplified 16S rRNA genes has also been used to characterize the differences between the fecal and mucosal microbiota. Eckburg and coworkers (233) analyzed over 11,800 bacterial 16S rDNA sequences from different intestinal locations of three subjects and found that 62% of the phylotypes were novel (244 out of 395) and 80% represented noncultivable species. On the other hand, the same authors indicated that different phylotypes were present in fecal and mucosal samples. Surprisingly, in some studies carried out using this methodology (261, 319) no sequences belonging to the genus Bifidobacterium were detected, probably indicating some problems during the amplification. In this regard, the number of PCR cycles can significantly distort the representation of some organisms in the ecosystem due to preferential amplification of some rDNAs (339). 5. Temperature Gradient Gel Electrophoresis (TGGE) or Denaturing Gradient Gel Electrophoresis (DGGE) Analyses of 16S rRNA Genes. This technique has been one of the most widely used for intestinal microbiota assessment. It consists of the PCR amplification of the 16S rRNA genes with universal or group-specific primer pairs, one of which has a GC clamp attached to the 50 end in order to avoid a complete dissociation of the two DNA strands of the amplified product. Then, amplification products are separated by denaturing gel electrophoresis, through a gradient of temperature (TGGE) or denaturant agent (DGGE), in which the double-stranded DNAwill migrate until it reaches its denaturing conditions in the gradient. This method has been shown to be a powerful tool for monitoring bacterial succession phenomena. In addition, the predominant bands obtained can be sequenced in order to know the identity of the most abundant microorganisms. Using PCR-TGGE, Zoetendal et al. (348) studied the diversity of predominant bacteria in fecal samples from adults. A remarkable stability of the profiles over time was observed and E. hallii,


33

R. obeum, and F. prausnitzii were the most commonly encountered species. In spite of the stability of the predominant fecal microbiota, it was possible to detect variations in some subpopulations over time by using these techniques (327). Satokari and collaborators (311) studied the bifidobacteria microbiota in fecal samples from adults by means of PCR amplification with genus-specific primers and DGGE. Their results highlighted B. adolescentis as the most common species in feces from adults. Other species also found were B. catenulatum, Bifidobacterium pseudocatenulatum, Bifidobacterium dentium, and Bifidobacterium ruminatum. By using these techniques Bifidobacterium and Ruminococcus were reported to be the dominant groups in the intestinal microbiota of babies (236). Favier and coworkers (237) studied the establishment and development of gut microbiota in babies during the first 4 months of life, finding that Escherichia coli and Clostridium spp. were the initial colonizers followed by the appearance of other microorganisms, such as Bifidobacterium and Bacteroides after 2–5 days. On the other hand, comparison of the babies PCR-DGGE profiles with those of their parents suggested a vertical transmission of some microorganisms. With regard to the lactobacilli population, PCR-DGGE results showed that there is a relatively stable Lactobacillus population in each individual (262). Lactobacillus ruminis and Lactobacillus salivarius have been reported to be the true autochthonous lactobacilli whereas other species frequently used in food manufacture can be also detected in feces of individuals (332). In addition, by using PCR-DGGE Zoetendal and coworkers (350) showed that the mucosa-associated bacteria in the colon differ from those recovered from feces, and found host-specific profiles of the mucosa-associated microorganisms. This suggests that the intestinal microbiota composition is influenced by some host factors. Most of the studies carried out using these techniques are aimed at the assessment of microbiota composition by targeting the rDNA genes. However, the rRNA (RT-PCR DGGE/TGGE) has also been used instead of rDNA allowing the identification of the metabolically active microorganisms in the gastrointestinal ecosystem (294, 348). 6. Denaturing High-Performance Liquid Chromatography. This recently developed technique (342) has also been applied to the study of the intestinal microbiota (246). It consists of the PCR amplification of the 16S rRNA genes followed by the separation of the amplification products by means of denaturing high-performance liquid chromatography. Separated PCR products are fluorescent dyed and detected using a fluorescence detector. 7. Terminal-Restriction Fragment Length Polymorphism (T-RFLP) Analysis. The 16S rDNA T-RFLP analysis consists of the amplification of the 16S rDNA with a primer fluorescent labeled and an unlabeled primer so that the PCR product is labeled at only one end. After digestion of the PCR

34


products with one or more endonucleases the length of the labeled terminal restriction fragments is determined by capillary electrophoresis. A rapid assessment and identification of predominant human intestinal bacteria can be accomplished with this method using the appropriate restriction enzymes (160, 260, 272, 289). Sakamoto and coworkers (289) assessed the fecal microbiota in adults using T-RFLP analysis showing that the patterns are host specific. These results are in agreement with previous results obtained by DGGE. This technique has also been used for assessment of fecal microbiota in elderly people (261) and to study the effect of a vegetarian diet on intestinal microbiota (50). Interestingly, differences have been found between the results obtained by T-RFLP and cloned 16S rDNA analysis, indicating a possible bias related with a large number of cycles in PCR amplification (260, 261). 8. Oligonucleotide Arrays. Wang and coworkers (333, 334) developed an oligonucleotide-microarray using species-specific probes for the detection of the predominant human intestinal bacteria in fecal samples. Microarray technology can be used for simultaneous detection of thousands of target DNA sequences at one time. Thus, its use could permit the detection of many bacterial species in a sample in a rapid and accurate manner. In order to avoid the use of the expensive microarray equipment needed for this technique, a membrane-array procedure has also been reported (336). Recently, Palmer and coworkers (303) developed a microarray containing over 10,000 16S rDNA probes and applied it to the assessment of the colonic mucosa, which allowed the detection and the determination of the relative abundance of species present at levels of 0.03% or greater. In the next few years, with the increasing availability of genome sequences from intestinal bacteria, microarrays analysis will become a powerful and valuable tool to assess microbial composition of the human intestinal tract and to study how different members of the intestinal microbiota modulate the expression of genes from both intestinal cells and other intestinal bacteria. The culture-independent approaches discussed earlier has led to a better understanding of the qualitative content and the predominant species of the intestinal microbiota. Unfortunately, they have failed to provide reliable data on its quantitative content or on the less abundant groups or species that are also present in the GIT. Thus, some quantitative culture-independent methods have been recently developed and are discussed next. 9. Relative Amount of Group or Specie-rRNA. One approach for the quantitative study of the intestinal microbiota is the quantification of the relative amounts of 16S rRNA of each group or species with regard to the total amount of 16S rRNA in the sample by using specific probes and, for example, dot blot hybridization. The amount of 16S rRNA provides not so much a measure of cell numbers as a measure of the metabolic status of each microbial group. By using this procedure it was shown that six bacterial groups represented up to 70% of the total fecal rRNA, Bacteroides-Prevotella being the dominant


35

group with 37% of the total 16S rRNA (314). In addition, by means of this procedure Marteau et al. (287) showed that the human cecal and fecal microbiota differs quantitatively and qualitatively. 10. Fluorescence In Situ Hybridization (FISH). Using FISH with different groupspecific probes around 90% of the total fecal bacteria can be detected; Bacteriodes/Prevotella and the Clostridium coccoides/E. rectale groups being the microorganisms present at higher numbers (1010) (241, 258), followed by Eubacterium low GþC group (258). Other bacterial groups present at high levels (over 109 cells/g feces) included Ruminococcus (258) and Bifidobacterium (241, 258, 280). Enterobacteriaceae, Veillonella, and the group Lactobacillus/Enterococcus showed counts under 108 cells/g feces. FISH has also been used for the assessment of changes in levels of the predominant groups of intestinal bacteria as a result of the consumption of prebiotics or probiotics (273, 325) or to assess the influence of the mode of delivery on intestinal microbiota (309). Also the effect of breast-feeding was studied by means of FISH, and it has been shown to be related to the predominance of bifidobacteria, whereas formula-fed infants showed similar amounts of Bacteroides and Bifidobacterium. In addition, changes in the minor components of the fecal microbiota were also observed (256). By means of FISH it has also been shown that there are differences in the gut microbiota between infants who later do or do not develop atopy (269). Although FISH has been widely used for intestinal microbiota assessment this technique is laborious, there is some difficulties for the visual counting of the samples and is extremely time consuming, thus limiting its further applicability. Multi-color FISH would allow the detection of a few microorganisms by a single hybridization reaction. This approach has been applied to the analysis of seven bifidobacterial species in human feces (320), but still the visual counting is very laborious. Because of that, alternative methods have been developed in order to solve difficulties in manual-visual counting, such as automated image analysis (267) or flow cytometry (349). In FISH results can be influenced by differences in the availability of the target region, cell permeability or by the ribosome content of the cells. Low fluorescence levels in positively hybridized cells can also significantly overlap signals of the negative controls (280). Coaggregation of bacteria rests of broken cells or contaminating compounds make the counting difficult. Therefore, more rapid and accurate procedures have been developed and are commented on next. 11. Quantitative Real-Time PCR. Quantitative real-time PCR is a promising tool to study the composition of complex communities such as the GIT. This procedure has attracted the attention of researchers in recent years as a consequence of the need for new rapid and accurate quantitative cultureindependent techniques for intestinal microbiota analyses. Different real-time quantitative PCR assays have been developed. By using the SYBR Green dye both total fecal bifidobacteria and specific

36


bifidobacterial species or groups have been quantified (290, 305). In addition, 50 nuclease assays have also been developed for Bifidobacterium and Lactobacillus quantification by using TAQMAN probes (253, 254, 305) or probes labeled with fluorescent lanthanide quelates (248, 251). Real-time quantitative PCR has also been applied to quantification of other intestinal microorganisms, such as Clostridium difficile in feces by using molecular beacons (217), Escherichia coli and Bac. vulgatus in gastrointestinal mucosa by means of the 50 nuclease assay with TAQMAN probes (265) or Desulfovibrio in feces and mucosa by using the SYBR Green assay (239). Real-time PCR has been employed to characterize and compare the fecal microbiota between healthy and hospitalized elderly subjects (216), proving to be a useful tool for quantitative microbiota monitoring. This procedure has also been used for the quantification of total bacteria and some characteristic species of dental plaque and caries dentine (284, 299). Similarly to other techniques based on the PCR, the use of 16S rRNA instead of DNA (reverse-transcriptase quantitative PCR) would provide data on the activity/viability of the microorganisms rather than on cellular levels. This methodology may also be applied to monitor in situ the expression of specific genes by targeting the corresponding mRNA, as has been demonstrated by Fitzsimons and coworkers (240) using the gene slpA of Lactobacillus acidophilus. In this regard reverse-transcriptase quantitative PCR provides a very useful tool for monitoring bacterial activity and gene expression in gastrointestinal conditions. Nowadays, the 16S rRNA genes are being used as target molecules, but as more bacterial sequences are becoming available, new specific primers and probes targeting other genes will also be available in the near future to be used in cases in which the 16S rDNA is not an adequate target. In this regard, it must be taken into account that the bacterial quantification by real-time PCR can be influenced by differences in the number of rRNA operons among the quantified species or groups, sequence heterogeneity among different operons within the same species or by differential amplification of different DNA molecules (312, 340). 12. “Omics.” During recent years the so-called “omics” revolution (genomics, proteomics, metabolomics) has provided an impressive amount of new information allowing the development of new very powerful molecular techniques. The genome information about some gut microbiota members has increased our understanding on the adaptation of these microorganisms to the intestinal environment (310). Metagenomic and metaproteomic approaches have been applied to the study of the intestinal microbiota. These approaches consist of the procurement and study of a genetic library containing all the genetic material present in a sample (metagenomics) or the study of all the proteins present (metaproteomics). Metagenomic analyses have been used to study the microbiota of the large intestine (245) or to assess the diversity of fecal microbiota in Crohn’s disease (286). Klaassens and


37

coworkers (274) applied metaproteomics for the first time to the study of the intestinal microbiota in infants. When using omics, as with any other techniques, the possible bias due to the methodologies used must be considered. In this regard, in metagenomic studies, possible biases due to differences in bacterial lysis or cloning efficiencies among different bacteria or DNA sequences should be taken into account (244). 13. Other Methods. There are also other methods that have been applied to the assessment of intestinal microbiota without the need for cell culture. The analysis of cellular fatty acids profiles in fecal samples (264) has been frequently used. Metabolic activities (bile acids deconjugation or dehydroxilation, vitamin K production, some enzymatic activities, etc.) can be also used as a crude signature of the microbiota and compositional changes may be tracked by noting changes in these metabolic activities (295). Flow cytometry coupled with fluorescent labeling of live–dead bacteria has been applied to the identification of the viable and active populations in the gut (219). Another interesting approach is the rRNA-stable isotope probing to identify the specific microorganisms responsible for the utilization of a substrate among those present in the complex intestinal ecosystem (235). Two-dimensional polyacrylamide gel electrophoresis of the amplified rRNA genes from a population has also been found to be a high performing technique for the study of complex microbial populations (268) although it has not yet been used to assess gut microbiota composition. 1.3.2

Detection and Enumeration in Dairy Products

Fermented dairy products are considered as one of the most suitable vehicles for the administration of probiotic bacteria. Lactobacillus and Bifidobacterium species are the most commonly used probiotics, which are often implemented in dairy products in combination with other LAB. In spite of the availability of culture-independent molecular tools for quantification of probiotics in commercial products, most manufacturers still use conventional culture techniques for enumeration purposes. In addition, culture-dependent methods are crucial to determine possible physiological or biochemical changes in the population of probiotic bacteria during the refrigerated storage of the product (329). From a practical point of view, differential enumeration of probiotic and starter bacteria in food products is rather difficult due to the presence of several closely related species of LAB. The majority of media currently available for the selective enumeration of probiotics and LAB included in dairy products are based on differentiation by colony appearance (223, 300, 307, 321, 328). However, this is not always a stable phenotypic feature and, in addition, it is largely dependent on the subjectivity of each one. Therefore, for a more conclusive identification and enumeration of probiotic bacteria, some selective media for each targeted species have also been developed (326). The disadvantage of these media is that they can underestimate counts of the microbial group selected.

38


Among the great variety of general, modified, selective, and differential media, only a few of them have proven in comparative studies to be suitable for quantification of a given probiotic species on the basis of their high recovery, and clear differentiation from or inhibition to other LAB also present. In spite of that, authors in general agree that no unique, selective or differential medium provides reliable counts of probiotic bacteria in all dairy products available and the most representative for fermented milks are indicated in Table 1.4. It is worthy to mention an enzyme-based most probable number (MPN) method for the enumeration of Bifidobacterium in dairy products developed by Bibiloni et al. (220). It is based on the selectivity for bifidobacteria of MRS broth containing 0.3% bile and subsequent analysis of the F6PPK activity in grown tubes. Several studies have been performed using selective and differential media for the correct identification of bacterial species claimed in the product label and for following the viability of probiotics and starter cultures during the refrigerated storage of fermented milks. Probiotics often show poor viability in market preparations (217, 249, 304, 316). Several factors could be involved in affecting the viability of probiotic cultures in fermented milks such as fat content (329), temperature, oxygen content, acidity, pH, and the presence of other LAB, among others (315). 1.3.3

Detection and Enumeration of Specific Probiotics in the Gut

To detect or enumerate a specific probiotic strain among the vast array of microorganisms present in the intestinal environment is often a challenging issue. However, it is essential in order to study the survival in the gut or the colonization ability of probiotic strains. Several different methods, both culture-dependent and cultureindependent, have been used to this end (Table 1.5). Traditionally, culture followed by morphological colony characteristics or strain isolation for genotypic or phenotypic characterization has been used. Nevertheless, this approach shows all the limitations of culture-dependent techniques and if the probiotic strain is outnumbered by similar microorganisms present in the gut, the proper isolation and further identification of the specific strain is difficult to achieve. In some cases antibiotics are used as selective agents in the media. After culture in appropriate media the identity of the isolated strains is confirmed by a highly discriminatory technique such as RAPD (242, 247, 288), ARDRA (224, 297), or REA-PFGE (275, 283). Fluorescent hybridization has also been used for this purpose (283). Antibiotic-resistant variants of the probiotic strains may also be used to allow specific enumeration by using media supplemented with the appropriate antibiotic (242, 302). The combination of selective culture media with monoclonal antibodies has also been applied (346). PCR primers have been developed for some probiotic strains (222, 243, 318) and then used to confirm colony identity (243, 250, 318, 344) or for direct detection in the samples (250). Molecular biology offers also the possibility to label the strain by transforming it with a plasmid containing a gene marker (238). However, it must be taken into consideration that the use of GMOs may imply certain limitations, especially in the setting of clinical studies.

39

L. acidophilus

L. casei

MRS

MRS

MRS

Basic medium

MRS

Nutrient agar

MRS

T-MRS

Bile-MRS

MRSclindamycin LC medium

MRS-AC

NA-salicin

LP-MRS

B. bifidum

L. paracasei L. acidophilus

L. rhamnosus L. rhamnosus

L. paracasei

L. acidophilus

L. bulgaricus L. acidophilus B. bifidum L. acidophilus

S. thermophilus

MRS

G-MRS

Microorganisms Counted

Basic Medium

Agar Medium

Lithium chloride Sodium propionate

Salicin

HCl until pH 5.1 Bromocresol green Ribose Acetic acid until pH 5.2

Clindamycin

Trehalose (carbon source) Bile

Galactose (carbon source)

Supplements Added

Selective/ differential Selective

Selective

Selective and modified

Selective

Selective

Modified

Modified

Type of Medium

Inhibition/ colony appearance Inhibition of other LAB

Inhibition of other LAB

No growth of other LAB Inhibition of other LAB Inhibition of other LAB Inhibition/no growth of other LAB

Colony appearance

Differential Count Based on

Anaerobiosis

Anaerobiosis

Anaerobiosis

Anaerobiosis

(continued)

(282)

(281)

(304)

(266)

Aerobiosis Anaerobiosis

(266)

(317)

References

Anaerobiosis

Anaerobiosis

Oxygen Conditions for Incubation

TABLE 1.4 Media for Viable Cell Counts of Probiotic Lactobacillus and Bifidobacterium in Fermented Milks Containing the Yogurt Starters S. thermophilus and L. delbrueckii subsp. bulgaricus

40

–

BFM

DP

Anaerobiosis

Anaerobiosis

Oxygen Conditions for Incubation

Inhibition of other LAB Anaerobiosis

Inhibition of other LAB Anaerobiosis


Selective

Selective


Differential Count Based on

Selective

Type of Medium

Bifidobacterium sp. Lactulose (carbon source) Selective Propionic acid Methylene blue Lithium chloride

Bifidobacterium sp. Neomycin sulfate Paromomycin sulfate Nalidixic acid Lithium chloride Bifidobacterium sp. Nalidixic Reinforced acid clostridial medium Polymyxin B Iodoacetate 2,3,5-triphenyltetrazolim chloride Lithium propionate Columbia agar Bifidobacterium sp. Dicloxacillin base Propionic acid

AMC

MRS

Supplements Added

MRS-NPLN

Microorganisms Counted

Basic Medium

Agar Medium


(300)

(220)

(214)

(227)

References


41

TABLE 1.5 Methods Used for Detection of Some Probiotic Strains in Human Fecal/Intestinal Samples Strains

Culture Step

B. animalis DN173010 B. animalis BB-12

Yes Yes

L. L. L. L.

Yes Yes Yes Yes

johnsonii La1 rhamnosus GG plantarum 299v gasseri SBT2055SR

L. casei DN114001

Yes

L. L. L. L.

Yes Yes Yes No

casei Shirota paracasei B21060 paracasei CRL-341 rhamnosus GG

Identification Techniques ARDRA PFGE or fluorescent hybridization PCR PCR RAPD Use of streptomycin-rifampicin resistant mutant and RAPD Use of rifampicin-resistant spontaneous mutant Monoclonal antibodies ARDRA PFGE PCR

References (224) (283) (243) (250) (247) (242) (302) (346) (297) (283) (250)

1.3.4 The Problem of the Viability and Physiological State of Intestinal Bacteria Microorganisms in different ecological niches, including the GIT and acidic food products, may exist in several physiological states of viability. Traditionally, microorganisms were considered viable if they were capable of multiplying in an appropriate medium, being culture-based methods such as plate counts and MPN counts largely used to enumerate viable cells. However, certain microorganisms, which are readily cultivable can also exist in other states where the cell fails to replicate, but retains some metabolic activities typical of viable cells and may return to be cultivable under certain conditions. This is the case of the so-called viable but uncultivable cells (306), starved cells (301), dormant cells (270), or sublethally injured cells (345). While in pathogenic and environmental bacteria the phenomenon of the different states of viability has received quite a lot of attention, these studies are considerably less developed in probiotics and intestinal bacteria. Bacteria under stressful conditions may modify their viability maintaining equilibrium between multiplication and survival activities (301). Recently, strains of Bifidobacterium used as health-promoting probiotic bacteria, have been shown to become dormant during storage of fermented products (277) or sublethally injured following stress treatment (218). Moreover, Ben-Amor et al. (219) demonstrated a great physiological heterogeneity within separated populations of viable, injured, and dead fecal bacteria. Methods measuring multiplication as the sole criterion of viability have been extensively used although temporally uncultivable cells fail to be detected. Therefore, other viability assays apart from those based on multiplication in culture media have been developed. For example, using the antibiotic ciprofloxacin as an inhibitor of

42


cellular division, Barcina et al. (215) used changes occurring in cell morphology and elongation of cells to determine microscopically “direct viable counts.” Nevertheless, most currently available methods for measuring the viability are based on the employment of fluorescence techniques that generally use two fluorochromes with different emission wavelengths in combination to discriminate between intact or viable cells, injured or damaged cells, and dead cells. Membrane integrity has been employed as a criterion of viability for intestinal bacteria and probiotics (278–280, 299). The commercial LIVE/DEAD BacLight kit contains two nucleic acid stains: the green fluorochrome SYTO 9 is a small molecule that can penetrate all membranes whereas the larger red fluorochrome propidium iodide can penetrate only compromised membranes, thus rendering cells green when they are viable or red when they are dead. Other criteria that have been used as markers for viability and different cell states of probiotic and intestinal microbiota include the assessment of intracellular esterase activity (279), the maintenance of intracellular pH (279), and quantification of the 16S rRNA (276). 1.3.5

Conclusions

The intestinal microbiota is a complex ecosystem showing great variations among individuals and which is influenced by environmental and physiological factors of the host, making its study difficult. Culture-dependent methodologies have been traditionally used for intestinal microbiota assessment, allowing the isolation of some cultivable intestinal microorganisms for their further characterization. The development of culture-independent methods provides more rapid and accurate tools for the study of complex microbial intestinal populations, which has lead in recent years to a significant increase in our understanding of intestinal microbiota composition and its interaction with the host. Most culture-independent techniques target the rDNA, although the rRNA has also been used instead of rDNA, allowing the identification of the metabolically active microorganisms. Techniques such as the PCR-DGGE/PCR-TGGE and especially DNA microarrays that use the information of genome sequences available, greatly contributed to the study of the qualitative content and the predominant species of the intestinal microbiota. However, they failed to provide reliable data on its quantitative content or on the less abundant groups. Among the quantitative culture-independent methods, FISH has been widely used for the assessment of changes in the levels of predominant and minor components of the intestinal microbiota. However, it is laborious and time consuming, which is limiting its further applicability. Real-time quantitative PCR is becoming very promising for studies of intestinal microbiota composition and when it is targeted to the rRNA also provides a very useful tool for monitoring bacterial activity and gene expression in gastrointestinal conditions. The recent development of metagenomics and metaproteomics allows the study, at the same time, of all the genetic material or the proteins present in a sample. In spite of all that is indicated here, since the GIT is a very stressful environment the possibility that microorganisms may exist in several physiological states that could condition their metabolic activity should be taken into consideration and

ENTERIC MICROBIAL COMMUNITY PROFILING

43

investigated further. All the classical and molecular techniques currently available enhance our understanding of microbial ecology in the gut but at the same time have evidenced that our current knowledge of intestinal microbiota composition and interactions with the host is still limited. 1.4 ENTERIC MICROBIAL COMMUNITY PROFILING IN GASTROINTESTINAL TRACT BY TERMINAL-RESTRICTION FRAGMENT LENGTH POLYMORPHISM (T-RFLP)

Toni A Chapman and James JC Chin Immunology and Molecular Diagnostic Research Unit (IMDRU), Elizabeth Macarthur Agricultural Institute, NSW Department of Primary Industries, Menangle, New South Wales, Australia

Traditional culture-dependent methods of analyzing complex microbial communities such as those found in the GIT of all life forms have been limited because of cultural bias when selective culture medium is used for bacteria isolations. This is almost always associated with the tedium of having to conduct colony enumerations followed by characterization and identification based on metabolic chemistries. Since the primary objective in many community studies is aimed at understanding the diversity and richness of bacteria species that have colonized various niche compartments in the GIT, culture-independent methods of enumeration with minimal cultural bias would be desirable, especially if these methods also enabled identification of OTU or phylotypes. With a rapidly burgeoning database of 16S rDNA sequences as well as a suite of software tools to query alignment homologies and primer design, molecular PCR-based techniques such as denaturing/thermal gradient gel electrophoresis (DGGE/TGGE) (369)), single-stranded site conformational polymorphism (SSCP) (357), and terminal-restriction fragment length polymorphism (T-RFLP) (366) are becoming viable alternative tools for dissecting and analyzing complex microbial communities. 1.4.1

T-RFLP

T-RFLP is a quantitative molecular technique for the analysis of microbial communities and is based on the use of common or universal primers where one of them (usually the forward or f-primer) has been fluorescent labeled at the 50 end (364) with a DNA dye. PCR products amplified in this way from source DNA are then subjected to carefully selected restriction enzyme (usually 4-base cutters) digestion. DNA fragments or digestion products from generated amplicons representing various OTUs are identified by variations in the length of the fluorescent and terminally labeled restriction fragments (TRFs). The entire mix of TRFs is analyzed by sequencing capillary electrophoresis. Only fluorescent peaks are visualized and profiled based on the length of the nucleotide sequence. Restriction fragments (RF) that are not terminally labeled by the fluorescent primer remain as invisible debris.

44

1.4.2


Universal and Group-Specific Primers

A review of recent publications on T-RFLP describes more than 95% of citations base microbial diversity analysis on polymorphisms around the small subunit-rRNA gene (SSU 16S rDNA) sequence. The ribosomal database project (RDP) (365) has available an unaligned SSU rDNA sequences of 14,870 nucleotides from which primer sequences can be designed depending upon degeneracy or conservation. The first key requirement of T-RFLP is the selection of “universal” primers to amplify the targeted region of 16S rRNA that is representative of the domain Bacteria. The most commonly used universal primer is the 8f-926r domain primer pair proposed by the original developers of T-RFLP (364). Depending upon the needs of the investigator, primer pairs can be universal but relatively specific such as the detection of Bacteroides/ Prevotella group in feces (352) or pathogens in prosthetic joints (372). Table 1.6 provides a list of some of the more commonly used primer/probes in T-RFLP. It is important that various applications require more rigorous scrutiny of the universality of universal primers as different combinations of primer pairs can provide quite different levels of diversity coverage for Gram-positive and -negative lineages to division level (358). With time, as the microbial genome database is built from the gold standard approach of assessing sequence polymorphisms and phylogenetic diversity via clone libraries and high-throughput sequencing, it can be anticipated that intergenic spacer (IGS) (371) or internal transcribed spacer (ITS) (356) regions between or within ribosomal operons will be deployed in community profiling analyses. Intending users of T-RFLP are advised to consult the T-RFLP analysis program (TAP) located at the RDP website (367) for guidance in primer designing. 1.4.3

Fluorescent Dyes

The most common fluorophore used in terminal labeling of the forward primer is the blue dye FAM (http://docs.appliedbiosystems.com/pebiodocs/00115046.pdf). It is theoretically possible to use a number of other colored dyes such as HEX, VIC, JOE, and TET (green); TAMRA, NED (yellow); ROX, PET (red), and LIZ (orange). It is possible to increase the interrogative potential of T-RFLP by combining various universal primer pairs in a multiplex PCR (MPX). In this case, different dyes have been tagged to the forward primer of each universal primer pair or different color combinations for different forward primer pairs. We have observed an effect of dyes in shifting the TRF size of OTUs when the same universal primer is being evaluated in different dye configurations. The reason for testing different dyes is the potential to combine one-colored universal primer pair with a differently colored group specific primer pair or various other combinations thereof in a MPX reaction. The resolution is dependent on certain dye combinations for each MPX and great care must be taken to optimize the PCR reaction for each specific application to ensure that artifacts are not generated in the TRF profiles. Despite this limitation, the added versatility of different colored TRFs generated from the use of dual-labeled forward and reverse primers increases the complexity of analysis as there will now be two sets of terminally labeled restriction fragments. In this case, one color can provide matching confirmation or not

45

a

Modified from Horz (358).

This article LAB group specific r-primer

This article universal primer

Eubacteria (378)

Dental bacteria (376)

Human feces (377)

Intestinal microflora (375)

Environmental bacteria (379)

Domain primers archaea (355)

Domain primers bacteria (364)

Application (Reference)

349–365 787–806 516–540 46–65 518–536 516–532 1510–1492 331–349 772–797 506–528

16S rDNA Position

27F 1492R 7f 1510r 7f LbLMA1r

8f 926r Ar109F Ar912R Bac349F Bac806R Bac516F ANA1F K2R 516f 1510r

Primer or Probe

TABLE 1.6 List of Universal and Specific Primer/Probes Used in T-RFLP a

f-AGAGTTTGATCCTGGCTCAG r-CCGTCAATTCCTTTRAGTTT f- ACKGCTCAGTAACACGT r- CTCCCCCGCCAATTCCTTTA f-AGGCAGCAGTDRGGAAT r-GGACTACYVGGGTATCTAAT p-TGCCAGCAGCCGCGGTAATACRDAG f-GCCTAACACATGCAAGTCGA r-GTATTACCGCGGCTGCTGG f-TGCCAGCAGCCGCGGTA r-GGTTACCTTGTTACGACTT f-TCCTACGGGAGGCAGCAGT r-GGACTACCAGGGTATCTAATCCTGTT p-CGTATTACCGCGGCTGCTGGCAC f–AGAGTTTGATCCTGGCTCAG r-GGTTACCTTGTTACGACTT f- AGAGTTTGAT(C/T)(A/C)TGGCTCAG r- ACGG(C/T)TACCTTGTTACGACTT f- AGAGTTTGAT(C/T)(A/C)TGGCTCAG r- CTCAAAACTAAACAAAGTTTC

50 –30 Sequence

46


of community diversity and richness by the other. By using different restriction enzymes, an entire series of profiles can be generated from a simple reaction. Even more complex diversity analysis will become feasible if current T-RFLP protocols can be overlaid with MPX-enabled fluorescent primer pairs for IGS or ITS. These strategies will offset the limitation that more than one OTU may be associated with each TRF (368). 1.4.4

DNA Extraction

Various protocols have been used to extract total community DNA. Intestinal washings and fecal suspensions are frequently particulate in texture and can be further disrupted by homogenization in stomacher bags in tryptone–salt solution. Aliquots can be removed at this stage for culture-dependent enumeration. Otherwise, the uniformly dispersed suspension is pelleted by centrifugation, resuspended, and washed in buffer or water, and the bacteria lysed mechanically in the presence of glass or ceramic beads with a bead beater (374). Mechanical disruption of DNA should be limited to 30–60 s to avoid excessive DNA shearing (363). Final selection for DNA extraction methods should be decided upon by trialing different protocols dependent upon the samples undergoing evaluation (363). Washed bacteria cell pellets can also be ground in a mortar/pestle in the presence of 4 M guanidine thiocyanate–150 mM Tris-HCl (pH 7.5)–1% N-lauroyl-sarcosine; de-proteinized in phenol–chloroform and precipitated with isopropanol. Occasionally, substances present in feces can be inhibitory to PCR polymerase. Further purification of DNA is then required and an excellent protocol involves the use of benzyl chloride – sodium dodecyl sulfate (373). Genomic DNA is then captured on a membrane in spin column format, and eluted and rehydrated for PCR analysis. Alternatively a number of commercial kits such as UltraClean soil DNA isolation kit by MO BIO Laboratories (354, 359, 360) and Fast DNA kit by QBiogene (363) can be used. The concentration (mg/mL) of purified genomic DNA can be determined by spectrometry as follows: [36(A280–A320)] þ [62.9(A260–A320)] and its integrity evaluated by agarose gel electrophoresis. 1.4.5

PCR Amplification

Conditions of PCR amplification vary with different applications. In particular, the number of amplification cycles must be optimized to reduce artifacts such as the formation of chimeric amplicons. This bias can be minimized by limiting the number of PCR cycles to 20–35 (370). The pooling of multiple PCR reactions from a single sample can also ensure the minimization of random artifacts (361). With some samples, the presence of “interfering” agents that inhibit PCR reactions can be eliminated by the addition of aluminum ammonium bisulfate (353). 1.4.6 Generation of Terminal Restriction Fragments (TRF) by Digestion of Amplicons with Restriction Enzymes The selection of restriction enzyme is very important to generate fluorescent-labeled TRFs following community DNA amplification with universal primers. Most T-RFLP


47

applications utilize 4-base cutters and depending upon the GC content of the community, restriction enzymes like CfoI (GCG/C); HaeIII (GG/CC); HpaII and MspI (C/CGG) are commonly used for GC-rich communities while others such as AfaI or RsaI (GT/AC) AluI (AG/CT) and MseI (T/TAA) can provide phylotype discrimination for less GC-rich communities. A number of websites are available without subscription fees to assess what restriction enzyme to use against different universal primers under evaluation. One of these, microbial community analysis III or MiCA3 can be accessed at http://mica.ibest.uidaho.edu/trflp.php.In silico modeling of TRFs can be quite useful in trying to establish actual and theoretical phylotype diversity. On a precautionary note, secondary T RF can be a complicating artifact, generating “pseudo” T-RFLP peaks. These can be eliminated by digestion of amplicons with single-strand-specific mung bean nuclease prior to analysis of T RF (355). 1.4.7

Software and Data Processing

T RFs can be resolved by capillary electrophoresis using systems such as the Applied Biosystems 3730 DNA Analyzer. The 48-capillary analyzer is fitted with argon–ion multi-line, single-mode laser with primary excitation lines of 488 and 514.5 nm. The machine utilizes in-capillary detection by dual-side illumination. Multiple filter sets allow for the reading of five dyes in a single run. Community profiles can be further processed using the STRand software developed by the Davis’ Veterinary Genetics Lab at University of California. This software is freeware available at http://www.vgl. ucdavis.edu/informatics/STRand/. Sequencer data files generated by ABI 3730; ABI 377, ABI 373, and MJ GeneSys Base Station are supported by this software. Readers interested in statistical methods for processing and comparing TRF data sets including binning, clustering, and statistical analysis should refer to Abdo (351). 1.4.8

Microbial Diversity in Different Intestinal Compartments of Pigs

To illustrate the enteric microbial community profiling capabilities of T-RFLP, we show in Fig. 1.4 the distribution of phylotypes based on TRFs in different gastrointestinal compartments of subclinical pigs (see Section 5.4.3). Amplicons were generated using the universal primers 7f and 1510r (Table 1.6). Two restriction enzymes—Hha1 and MspI—were used on different aliquots of the same PCR reaction. In profiles (Fig. 1.4, Table 1.7) representing the duodenal contents, HhaI resolved a very strong E. coli peak (TRF 370, >2000 FI) while this is not visible in Msp1 digests. Clostridium and Corynebacterium complex are seen as smaller peaks at T RF 231 and 358 respectively in HhaI digests while the second most prominent peak in MspI digests is represented by Campylobacter species. Both restriction enzymes generate increased richness of phylotypes in the small intestine (ileum) but the relative abundance in terms of fluorescence intensity (FI) is decreased by about fourfold compared to the duodenum or colon (500 FI vs. 2000 FI). In general, MspI produced a richer OTU profile in the cecum and colon compared to HhaI. These results highlight the importance of using different restriction enzymes to generate more information about community diversity. If this were combined with the use of universal primers and group-specific primers, then it would be possible to mine a plethora of information on

48


FIGURE 1.4 Enteric microbial community profiles of genomic DNA extracted from different intestinal compartments of pig. HhaI and MspI digests are profiled on the left and right columns respectively, showing profiles from duodenum (Du), ileum (Il), caecum (Ce), and colon (Co) from top to bottom.

the microbial community. We have found the EMCoP profiles very reproducible within assays and between animals in any one treatment group. This enables temporal comparisons to be conducted with treatment protocols such as growth promotants, dietary changes, and therapeutic antibiotics. 1.4.9

Tracking the Fate of Orally Delivered Probiotics in Feces

In Chapter 5, Section 5.4.3, we described a LAB formulation consisting of L. salivarius, L. casei, L. plantarum, and L. acidophilus that had been developed specifically to target enterotoxigenic Escherichia coli (ETECs) strains responsible for neonatal and postweaning diarrhea in pigs. In one on-farm trial, this LAB formulation (ColiGuard) was administered (109 cfu/g weaner mash) to newly weaned pigs for 10 days. At this time, rectal swabs or feces can be taken from control and probioticsupplemented pigs, DNA extracted, and T-RFLP analysis carried out with VIC-LABspecific group primer pairs 7f and LbLMA1r (see Table 1.6). Under normalized PCR conditions, the profiles (Fig. 1.5) of pigs in the control group show the presence of only L. acidophilus at a comparatively low intensity (738 FI). After 10 days of ColiGuard,


49

TABLE 1.7 List of Operational Taxonomic Unit Identities Based on Terminally Labeled Restriction Fragments (TRF) Generated Following HhaI (A) or MspI (B) Restriction Digestion of Amplicons Fragment Size (bp) 2A HhaI Digest 147 172 180 188 190 202 210 231

234 236 266 301–305 321–322 356 358 360 368 370 381 402 468

471 2B MspI Digest 132 134 141 148 150 151 152

Organism Name Fibrobacter intestinalis Enterococcus saccharolyticus Bifidobacterium thermophilum Eubacterium hallii Clostridium symbiosum, Clostridium clostridiiforme Eubacterium ruminantium Fusobacterium simiae Clostridium botulinum, Clostridium scatologenes, Clostridium tetani, Clostridium sporogenes, Clostridium collagenovoransm, Clostridium ljungdahlii, Clostridium algidicarnis Lactobacillus sp. Clostridium subterminal, Clostridium sp. Lactobacillus mucosae Flexibacter filiformis Unidentified Corynebacterium variabilis Corynebacterium genitalium, Corynebacterium pseudogenitalium Clostridium tetanomorphum Desulfovibrio desulfuricans E. coli Desulfotomaculum thermosapovorans Lactobacillus fermentum Lactobacillus reuteri Streptomyces tendae, Streptomyces diastatochromogenes, Streptomyces bottropensis, Streptomyces scabiei, Streptomyces coelicolor, Streptomyces ambofaciens, Streptomyces ornatus, Streptomyces nodosus, Streptomyces caelestis Streptomyces bluensis, Streptomyces mashuensis, Streptomyces vellosus Fibrobacter intestinalis Desulfovibrio gigas Eubacterium dolichum Bacillus badius, Bacillus firmus Fusobacterium russii Fusobacterium varium Fusobacterium moriferum, Fusobacterium gonidiaformans (continued)

50


TABLE 1.7 (Continued) Fragment Size (bp)

Organism Name

153

Bacillus macroides, Bacillus benzoevorans, Bacillus sphaericus, Bacillus fusiformis Desulfotoaculum halophilum Lactobacillus gallinarum Leptotrichia sp. Lactobacillus gasseri, Lactobacillus crispatus Clostridium irregularis, Clostridium bifermentans Desulfotomaculum thermobenzoicum Eubacterium hallii, Eubacterium barkeri, Eubacterium limosum Clostridium filamentosum Fusobacterium simiae Ruminococcus flavefaciens R. flavefaciens Bifidobacterium inopinatum Clostridium ramosum Eubacterium desmolans, Eubacterium yurii subsp. Eubacterium sp. Eubacterium sp. Butryvibrio fibrisolvens B. fibrisolvens Unidentified Camplyobacter sp., Camplyobacter showae, Camplyobacter concisus, Camplyobacter rectus Camplyobacter sp. Peptostreptococcus anaerobius Flexibacter flexilis E. coli

160 181 187 191 193 210 221 266 281 282 283 285 292 296 304 308 312 321 356, 391, and 393 468 471 474 480 490

the probiotic-treated group shows significant increases in the L. acidophilus, L. casei, and L. plantarum peaks (note log increase in FI scale). L. acidophilus is located at position TRF247 and has an increased FI of 29.3-fold relative to nonprobiotic supplemented pigs. Due to redundancy in the 16S rDNA sequence for the LAB primer pair, L. plantarum and L. casei are phylotyped at positions TRF 327 and 328 respectively and therefore appear as two very close proximity peaks with fluorescent intensities of 8061 and 32,088 respectively. Since each animal would consume on the average about 300 g of feed per day, one would expect delivery of about 7.5 1011 cfu of each of the four LAB strains per day. This would contribute to the significant increases observed in FI of all LAB phylotypes with the possible exception of L. salivarius (projected location at TRF 279 and 281). Pending further analysis, the fate of L. salivarius in the GIT of probiotic-treated pigs can only be speculated at this point. It may be that L. salivarius is a very efficient colonizer with most community members domiciled in as yet undefined intestinal compartments. Alternatively,


51

FIGURE 1.5 EMCoP profile of LAB in DNA extracted from the feces of pigs treated with ColiGuard probiotic and nonprobiotic-supplemented animals (control).

L. salivarius may have limited viability and may not be as competitive as other strains, dying off rapidly after it has delivered its impact in altering the gene signatures of ETECs in the GITof subclinical pigs (Section 5.5.2). In any event, this example clearly documents the usefulness of T-RFLP in tracking the LAB community and if combined with time course sampling, will provide a temporal estimate of persistence of orally delivered probiotics. 1.4.10

Conclusion

Even though TRFLP was first developed for the analysis of community diversity in soil and environmental samples, its adaptation to gut microflora has provided a strong impetus in its use as a tool to unmask the impact of pre- and probiotics in the GIT. It is a far simpler procedure to use than DGGE, highly reproducible, amenable to fine-tuning at the level of primer design, and restriction fragment generation. T-RFLP also does not suffer from the disadvantage of longer primer sequences needed to design GC clamps for the DGGE procedure that can in turn cause artifacts during the annealing step; as well as the production of heteroduplexes that are innately unstable under the denaturing conditions of a DGGE run (362). We anticipate that T-RFLP will become a very important analytical protocol in enteric microbial community profiling.

52


Acknowledgments The authors acknowledge Jannine Patterson who established the T-RFLP protocol in the IMDRU laboratory and Kent Wu for contributions of group-specific LAB T-RFLP. The expertise and input of Bernadette Turner merits special mention for technical work well done. This program was funded substantively by a Commonwealth Research and Development Start Grant awarded to International Animal Health (C. Lawlor and K. Healey) in conjunction with CSIRO and NSW DPI. ColiGuard probiotic strains were provided by International Animal Health, Sydney, Australia.

1.5 EFFECTIVE DOSAGE FOR PROBIOTIC EFFECTS

Yuan Kun Lee Department of Microbiology, National University of Singapore, Singapore

Among the human clinical trials cited in Section 4.3 (Effects on human health and diseases), the probiotics were administered in great variation in accordance to the following: . . . . . . .

Type of probiotics (lactobacilli, bifidobacteria, yeasts, enterococci); Daily dose (107–1010 cfu); Daily frequency of administration (1–4 times); Timing of administration (before, during, and after meal); Duration of administration (1 day to several months); Method of delivery (fermented food, beverage, capsule, tablet, or powder); Viability.

To achieve probiotic effects, the probiotics and their products need to be delivered to the desired gastrointestinal site in sufficient quantity. The importance of viability depends on the mechanism of the probiotic effect and each probiotic bacteria needs to be evaluated respectively. The method of delivery appears to have minimal effect on probiotic efficacy, as different preparations of the same dose were reported to achieve the same preventive or therapeutic efficacy. An example is the treatment of diarrhea (Section 4.3.3). The duration of administration would depend largely on the needs and nature of the diseases; for example treatment for diarrhea is short term whereas cancer prevention is of longer term. There is no information as to when is the best time to administer probiotic preparation. It is logical to assume that probiotics administered orally before meal should have the capability to tolerate the extreme pH condition and digestive enzymes and bile present in the intestinal tract. Probiotics taken together with meal would be diluted by food materials, which could reduce the chances and frequency of physical encounter between the probiotic organisms and the mucosal receptors. Moreover, food

EFFECTIVE DOSAGE FOR PROBIOTIC EFFECTS

53

matrix may compete with mucosal receptors for probiotic and product binding. Hence it is reasonable to assume that the best period for the administration of probiotics is between meals, and be carried in liquid media. It is not so clear if the frequency of administration has any effect on probiotic efficacy. Microbiologically, 1 1010 cfu administered four times daily has little different from 4 1010 cfu administered once a day. It could nevertheless be assumed that a probiotic strain, which does not adhere well on the mucosal receptors and is unable to colonize temporarily would need to be administered more frequently. And probiotic strains that are denatured readily by the gastrointestinal conditions should be administered in larger dosage to counter the wastage. This leaves us with the remaining factors of dosage and strain of probiotics. How much a probiotic needs to be consumed to achieve the probiotic effects is crucial information in the formulation of probiotic functional foods as well as the therapeutic products. So far, there is no systematic study on the effective dosage of the respective probiotics for specific applications. We could nevertheless obtain a glimpse from the human clinical studies available. The dose effect of probiotics on specific disease also shed light on the mechanisms of probiotic effects and the interaction between probiotic organisms and the host. 1.5.1

Acute (Rotavirus) Diarrhea in Children

Mean reduction in days of diarrhea

Probiotics used as adjunctive therapy appeared to improve the treatment of acute diarrhea in 18 out of the 23 clinical trials conducted among children (Section 4.3.3.1). The trials involved more than 1800 children. When the mean days of reduction in diarrhea in the probiotic group in comparison to that of the placebo group were plotted against the dosage of the respective probiotic administered per day, no direct correlation between the treatment efficacy and the dosage could be recognized, as shown in Fig. 1.6. No direct correlation was observed even among the same probiotic of different dosage. 3

2

1

0 7

8

9 Log dose per day

10

11

FIGURE 1.6 The efficacy of daily probiotic dose on the recovery from acute diarrhea among children. The data were extracted from Section 4.3.3.1.


Days of diarrhea probiotic group

54

5 4.5 4 3.5 3 2.5 2 1.5 1 0.5 0 0

1

2 3 4 5 Days of diarrhea placebo group

6

7

FIGURE 1.7 Correlation between days of diarrhea in probiotic group and corresponding placebo group among children suffering from acute diarrhea. The data were extracted from Section 4.3.3.1.

When the days of diarrhea in the probiotic group was plotted against the corresponding placebo group, a linear correlation was obtained (Fig. 1.7) with a slope of 0.78, which intercepts the origin. This implies that a constant reduction of 22% in the number of days of diarrhea was achieved through the consumption of all the probiotics tested, namely L. acidophilus, L. bulgaricus, L. reuteri, L. rhamnosus, Streptococcus thermophilus, B. infantis, and Saccharomyces boulardii, applied singly or in various combination. The efficacy was the same with daily dose of 4 107 to 6 1010 cfu, suggesting that the probiotics have a common mechanism in relieving acute diarrhea, which contributes to 22% of the cure of diarrhea. It can be concluded that probiotics could assist in the speedy recovery of acute diarrhea among children but are not able to prevent and cure diarrhea. 1.5.2

Antibiotic-Associated Diarrhea

Probiotics were widely reported to reduce the incidence of antibiotic-associated diarrhea (Section 4.3.3.2). The probiotics were used singly (L. rhamnosus GG, Saccharomyces boulardii) or in combination (L. acidophilus þ bifidobacteria or Streptococcus thermophilus). 1.5.2.1 Combination of L. acidophilus þ bifidobacteria or Streptococcus thermophilus When the probiotics were used in combination involving 194 subjects, a 0.5 risk ratio was achieved at a daily dose of 6 108 cfu (Fig. 1.8A). The risk factor of the combined probiotics decreased with the daily dose in a hyperbolic manner to reach a value of 0.3 in antibiotic-associated diarrhea at a daily dose of 1 1011 cfu. The interaction could be described as the competition for specific receptor binding between the probiotics, pathogens and the host surface (380). Let us assume that (a) diarrhea is caused by the adhesion of diarrheic microbes on the intestinal surface and the biochemical reactions initiated, (b) the protective effect


55

(a) 0.6

Risk Ratio

0.5 0.4 0.3 0.2 0.1 0 8

9

10 Log dose per day

11

12

(b) 0.6

Risk Ratio

0.5 0.4 0.3 0.2 0.1 0 0.08

0.09

0.1 0.11 1/log dose per day

0.12

0.13

FIGURE 1.8 Dose-dependent efficacy of combination of L. acidophilus þ bifidobacteria or Streptococcus thermophilus in the prevention of antibiotic-associated diarrhea. The data were extracted from Section 4.3.3.2.

of probiotic bacteria is due to the competition for binding onto intestinal surface and it is a simple dissociation process: Kþ1

Microbial cell þ Intestinal cell ! MicrobeIntestinal Cell Complex K1

Where K þ 1 and K 1 represents the association and dissociation constant of the reaction, respectively. The process is similar to the interaction between a substrate and the receptor on an enzyme that forms a substrate–enzyme complex, but without the subsequent formation of products. There are three assumptions in the relationship: 1. The interaction between the microbial cells and the intestinal cell surface receptor remains in equilibrium. This condition should be achieved if the microbial cells do not penetrate the intestinal cells. 2. Microbial concentration remained essentially unchanged throughout the clinical studies, so that the concentrations of the microbial cells can be considered equal to the initial microbial concentrations. This condition could be achieved when the total number of microbial cells present is much greater than the number of microbial cells adhering to the intestinal surface. This is probably the case, where the concentration of the probiotic bacterial cells consumed is

56


usually in the range of 105–108 per mL, whereas the number of bacterial cells adhering to the intestinal cells is fewer than 10 per cell. 3. In the simple dissociation equation described above, if X is the concentration of the microbial cell suspension, e is the epithelial cell or mucus concentration, and ex is the concentration of the microbe–intestinal cell–mucus complex, then the concentration of free epithelial cells or mucus will be (e ex). Since the process is in equilibrium, the dissociation constant for the process (Kx) can be defined as K1 X ¼ ðeex Þ : Kx ¼ Kþ1 ex This equation can be rearranged to give an expression for the concentration of the microbe–intestinal cell–mucus complex, ex ¼

eX : Kx þX

When X is very much larger than Kx, the intestinal cells or mucus is saturated with microbial cells (i.e., ex approaches e), and the maximum value of ex, em is obtained. As it is technically easier to estimate the maximum concentration of adhered microbial cells (em) than the epithelial cells/mucus concentration (e), the equation could thus be re-written as ex ¼

em X : K x þX

ð1:1Þ

The equation could be further re-arranged to give a linear relationship, 1 1 Kx : ¼ þ ex em em X

ð1:2Þ

The values of ex and Kx are independent of each other. That is, a microbe that adheres on intestinal surface in large number could have a low affinity for the intestinal surface receptors and vice versa. In the case where the probiotic bacteria and the diarrheic microbes are present at the same time and compete for the same receptors on the intestinal surface, the competition for adhesion of each of the microorganisms is determined by the affinity of the competing organisms to the intestinal surface (Kx) and the concentration of the microbial cells (X). Thus, the ratio of ex for probiotic bacteria (p) and diarrheic microbes (d) in the mixed microbial system can be described as exp emp Xp Kxd þXd ¼ : exd emd Xd Kxp þXp

ð1:3Þ

The relationship in Equation 1.3 above suggests that the outcome of competition between two microorganisms for adhesion on the same receptors on intestinal surface is determined by the ratio of the respective microbial concentrations around the receptors and the affinity of the respective microbes for the receptors.


57

If the concentrations of the diarrheic microbes were of comparable magnitude in the clinical trials reported, the values of exd, (emp/emd), Xd, Kxd, Kxp were constant values. 0

Kxp þXp exd K Kxp exd 1 1 ¼ ðKxd þXd Þ ¼ : exp emp =emd Xd Xp exp Xp þK 0

ð1:4Þ

Since exd/exp determines the risk ratio in the clinical studies, the plot of the risk ratio versus the 1/(daily dose of probiotic, Xp) should yield a linear relationship as shown in Fig. 1.8B. The data points in Fig. 1.8B are too few to obtain a statistically meaningful linear plot. Nevertheless the dosage where risk ratio is 1 (total prevention of diarrhea) is estimated at 1013 probiotic bacteria per day. 1.5.2.2 L. rhamnosus GG or Saccharomyces boulardii Applied Singly In the cases of L. rhamnosus GG involving 281 subjects or S. boulardii involving 888 subjects, applied singly, near 90% of preventive efficacy was achieved at a daily dose of about 1 1010 cfu (Fig. 1.9). At above a daily dose of 1 1010 cfu, the diarrheapreventing efficacy dropped precipitously. Negative corporative effect, where the binding of a probiotic on the mucosal surface receptor resulted in a reduction in affinity for the subsequent bacterial binding could have occurred (380). It is a demonstration that maximal probiotic efficacy is achieved at the optimal probiotic dose, which needs to be determined for respective probiotic strains.

0.6

0.5

Risk ratio

0.4

0.3

0.2 L. rhamnosus GG 0.1

S. boulardii

0 9.5

10

10.5

11

Log dose per day

FIGURE 1.9 Dose-dependent efficacy of L. rhamnosus GG and S. boulardii in the prevention of antibiotic-associated diarrhea. The data were extracted from Section 4.3.3.2.

58


Eradication odds ratio

5

4

3

2

1 6

7

8 9 Log dose per day

10

11

FIGURE 1.10 Dose-dependent efficacy of probiotics (L. acidophilus, L. casei, L. rhamnosus, Propionibacteriumfreudenreichii,B.breve,B.animalissinglyorincombination) inenhancingthe eradication of H. pyroli during antibiotic treatment. The data were extracted from Section 4.3.3.2.

1.5.3

Helicobacter pyroli

Some probiotics have been demonstrated to enhance the eradication of H. pyroli during antibiotic treatment and reduce the occurrence of side effects. The eradication efficacy involving 478 subjects was dose dependent (Fig. 1.10), and the minimal effective dose is estimated to be about 5 106 cfu per day, when the graph in Fig. 1.10 intercepts the eradication odds ratio of 1. 1.6 INCORPORATING PROBIOTICS INTO FOODS

Ross Crittenden Food Science Australia, Australia

Probiotics have for decades been used in fermented dairy products such as yogurts and fermented milks. The techniques and technologies to incorporate these organisms into fresh, refrigerated dairy products are now relatively mature. The continuing emergence of clinical evidence for benefits to consumers and the subsequent marketing power these ingredients bring have now seen probiotics become the fastest growing category of functional food ingredients (458). Food companies worldwide are seeking ways to incorporate these ingredients into a much broader range of foods and beverages. However, incorporating live probiotic microorganisms into foods and then keeping them alive throughout shelf life is a significant challenge for food technologists. Indeed, it is an anathema to usual food-processing methods and matrices that have always been designed to minimize the survival of microorganisms with food safety considerations foremost in mind.

INCORPORATING PROBIOTICS INTO FOODS

59

Although the need for probiotic viability for some health impacts, such as immunomodulation (390, 402), may not require the bacteria to be alive, viability may still be an essential property of probiotics for some health effects (421). Indeed, probiotics remain defined as live microorganisms that when administered in adequate amounts confer a health benefit on the host (407). Viability (in fact, more accurately defined as cultivability) is in reality only a convenient surrogate marker of probiotic activity. However, since the ability of probiotic organisms to impart benefits to the health of the host are usually only quantifiable through animal or clinical studies, viability remains the only really practical quality assurance measure for probiotics. Health benefits have usually been attributed in clinical studies to doses of probiotics in excess of 108–09 viable cells per day (427). Therefore, food regulatory/advisory bodies generally stipulate that foods containing probiotic organisms need to have >106–107 cfu/g at the time of consumption (e.g., International Standard of Federation Internationale de Laiterie/International Dairy Federation (403)). The viable count of probiotic organisms generally declines during product storage (10–100-fold or more) (433). An acceptable viable count can sometimes be achieved by introducing higher numbers of probiotics during manufacture (called overage). The consumption of probiotic organisms at high doses is safe (440, 452, 463), and so oversupplying consumers does not appear to pose a health risk. However, in practice the addition of considerable overage can be an expensive proposition given the relatively high cost per weight of probiotic cultures as ingredients. There may also be organoleptic limitations to the amount of a probiotic that can be acceptably added to foods. Therefore, there is a strong imperative to maintain the viability of probiotics in foods during production and shelf storage. Overall, there are five main points to address when incorporating probiotics into foods: 1. Select a compatible probiotic strain/food type combination. 2. Use food-processing conditions that are compatible with probiotic survival. 3. If fermentation is required, ensure that the food matrix will support probiotic growth. 4. Select a product matrix, packaging, and environmental conditions to ensure adequate probiotic survival over the product’s supply chain and during shelf storage. 5. Ensure that addition of the probiotic does not adversely impact on the taste and texture of the product. This chapter summarizes the main parameters that affect probiotic survival during manufacture and storage of foods and provides examples of successful incorporation of probiotics into a range of shelf-stable foods. It aims to provide food technologists with the knowledge to select and incorporate suitable probiotics into foods beyond the traditional fermented dairy food sector, and to maximize their survival over extended shelf lives.

60


1.6.1

Probiotic Ingredients

Probiotic organisms are predominantly bacteria selected from the genera Lactobacillus and Bifidobacterium, which are normal constituents of the human intestinal microbiota. A range of different species within each genus is commonly used and within each species there are particular strains that have been shown to have probiotic attributes (Chapter 6). Considerable strain-to-strain differences have been observed within species and probiotics are generally defined down to the strain level (for example, Lactobacillus rhamnosus GG and Lactobacillus rhamnosus LC-705) (406). Probiotic organisms have typically been selected via screening regimes to perform well technologically, to survive intestinal transit, and to impart health benefits on consumers. Good probiotic strains have demonstrated health and safety data from randomized, controlled clinical trials. Probiotics organisms are usually supplied by manufacturers of these ingredients as either dry powders (freeze-dried or spray-dried) at 1010–1012 cfu/g or as frozen “direct vat set” concentrates at 109–1010 cfu/g (430). When received as ingredients, it is important that the probiotic be correctly stored as per the manufacturer’s instructions in order to avoid rapid losses in probiotic viable counts. For dried powders, this means storing the probiotics cold and avoiding moisture or humidity, while for frozen cultures is it important to maintain constant temperatures and to avoid repeated freeze–thawing. Probiotics can be incorporated into foods and beverages in a variety of ways. . . .

Dry blended into foods and powders such as infant formulas. Dispersed into liquid or semiliquid products such as juice or ice-cream. Inoculated into fermented products such as yogurts and fermented milks.

In the first two cases, the probiotics do not multiply in the product and are generally added at doses in the order of 107–108 cfu/g. For a standard probiotic freeze-dried powder at 1011 cfu/g, this represents addition of the probiotic at 0.01–0.1% (w/w) of the final product. In fermented products there may be some growth and increase in probiotic numbers during fermentation, allowing a lower number of organisms to be initially added (for example 106 cfu/g). The number of viable probiotic organisms then usually declines during product storage, with the rate of decline dependent on a range of factors as discussed in the following sections. Ensuring losses in probiotic viability are minimized is the one of the main goals for food technologists developing foods containing probiotics. 1.6.2

Factors Affecting the Viability of Probiotics in Foods

A number ofintrinsic and extrinsic factors influence the survival of probiotics in foods. It is important to consider these factors at all stages between addition of the probiotic to the food and delivery of the probiotic to the gut of the consumer. These include manufacturing processes, food formulations and matrices, packaging materials, and environmental conditions in the supply chain and during self-storage. The main factors to be considered that may influence the ability of the probiotics to survive in food products include:


1. 2. 3. 4. 5.

61

the physiological state of the added probiotic; the physical and chemical conditions of food processing; the physical conditions of product storage (e.g. temperature); the chemical composition of the product (acidity, nutrients, moisture, oxygen); interactions with other product components (inhibitory or protective).

The first stage of product development is to align a compatible combination of probiotic strain(s) and food product(s). 1.6.2.1 Choice of Probiotic Organism/Food Combinations Probiotic organisms are generally selected from constituent intestinal lactobacilli and bifidobacteria, which have evolved to grow and survive in environmental conditions within the human intestinal tract. In the small intestine and colon, the pH is generally close to neutral, the temperature is constant (37–39 C), a complex nutrient supply is constantly available and there is little oxygen. These conditions are of course very different to those found in food processes and food matrices. Nonetheless, bacteria show a remarkable ability to survive in adverse environments and probiotics can survive in food environments, to a point. Probiotic ingredients are not all the same. Differences extend from the genus to the species and even strain level, and apply both to their physiological impacts on the consumer and to their technological attributes in foods (406, 410). The closer probiotic organisms are related, usually the more similarly they will perform. However, considerable strain-to-strain differences are still apparent that can significantly impact on the performance of probiotics in foods (Fig. 1.11). The differences in the technological characteristics of different probiotic species and strains means that care must be taken in selecting the most appropriate strain for a particular food application. Indeed, the first step in incorporating a probiotic into a food is identifying compatibilities between the attributes of the selected strains and the food production steps, food matrix and storage conditions. This may involve a compromise between the desired health attributes and technological capabilities of particular strains for particular food applications. When developing new products some research may be required to ensure that the selected strain is able to survive well in the food, provide the appropriate technological properties (e.g. acidification during fermentation, if required) and importantly, that the added probiotic does not adversely affect the taste, smell, and texture of the food or beverage. While emphasizing the importance of strain specificity of technological attributes of probiotics, some generalizations can still be made on the robustness of probiotic organisms. Generally, lactobacilli are more robust than bifidobacteria (406, 431, 449). There is a wider range of probiotic Lactobacillus species that are technologically suitable for food applications than bifidobacteria. Common examples include L. acidophilus, L. johnsonii, L. rhamnosus, L. casei, L. paracasei, L. fermentum, L. reuterii and L. plantarum. Often, the L. acidophilus group of organisms, while resistant to low pH, prove less robust than other lactobacillus

62


1.8 1.6

Growth – optical density (A540)

1.4 1.2 1.0 0.8 0.6 0.4 0.2 0.0 0

2

4 6 8 NaCl concentration in growth medium (%w/v)

10

FIGURE 1.11 Inter- and intraspecies variation in the ability of probiotic lactobacilli to grow in the presence of salt. This characteristic is important, for example, in meat fermentation. The figure demonstrates the importance of selecting probiotic species and strains that are compatible with a particular food. The lactobacilli were grown in MRS broth containing various concentrations of NaCl, at 37 C, for 24 h. Error bars represent 1 standard deviation from the mean of three biological replicates. Lactobacillus rhamnosus GG (&); Lactobacillus rhamnosus CSCC 5277 (&); Lactobacillus acidophilus MJLA1 (. ) Lactobacillus acidophilus CSCC 2401 (*). From Crittenden R, Morris L, and Playne MJ. Unpublished data, Food Science Australia.

species in non-traditional probiotic food applications (391, 413, 415, 445, 453, 461). The Bifidobacterium species most commonly used in foods is B. animalis subsp. lactis (398). This species is significantly more robust than human intestinal species such as B. longum (infantis), B. breve, and B. bifidum, although certain strains of these species are able to survive well in some foods (395, 398, 409). B. adolescentis is a common species in the intestinal tract of adult humans, but tends to be sensitive to environmental conditions in foods (395, 457, 462) and is rarely used commercially as a probiotic. The metabolism of the probiotic organism is an important consideration in fermented probiotic foods, not only for probiotic growth and survival, but also for food quality. For example, heterofermentative lactobacilli that produce CO2 as a metabolic end product are not suitable where gas formation adversely impacts on food quality (384). Bifidobacteria produce acetate and lactate as end products of carbohydrate fermentation, and a more vinegar-like taste profile if they are actively fermenting in food products (395, 404).


63

The ability to utilize the available carbon and nitrogen substrates in a product may be required for probiotic growth and acidification (455). Lactobacilli and bifidobacteria can generally utilize a wide range of carbon substrates, with differences in the carbon substrate profiles occurring between species and strains. Probiotic strains may also be selected on the basis that they metabolize desirable bioconversions, such as deconjugation of isoflavones in soy (375), or indeed, because they do not metabolize other ingredients in the food. For some fermented foods where LAB form part of the native microbiota (e.g. fermented meats), an approach has been taken where the probiotic attributes of cultures isolated from these foods (and therefore known to survive well) have been examined to select new probiotic strains (422, 426, 443). 1.6.2.2 Physiologic State of the Probiotic Animportantfactorin probiotic survival is the physiological state of the bacteria when prepared, and the physiological state of the bacteria in the product itself. If the food product is dry (e.g., a powdered infant formula) the probiotic will also be dried and in a quiescent state during storage. However, when included in a wet product such as a yogurt, the bacteria will be in a vegetative state and potentially metabolically active (albeit slowly at refrigeration temperatures). The state of the bacteria will have a large bearing on the possible shelf life of the bacteria, with longterm survival of vegetative cells only possible at low temperatures (403). In comparison, dried,quiescentcellsmayhavelongershelflivesatambienttemperatures,thoughtheytoo will be more stable at lower temperatures. Bacteria are able to respond to stressful environments through the induction of various stress tolerance mechanisms. The induction of stress proteins by exposure of the cells to sublethal stresses such as heat, cold, starvation, low pH, and osmotic tension can condition probiotics to better tolerate environmental stresses in food production, storage, and gastrointestinal transit (449, 456). Cross-protection has often been observed, where exposure to one stress provides protection against other stresses (403, 449, 456). The main point to emphasize is that while different probiotic strains have their own intrinsic tolerances to environmental conditions, tolerance can also be influenced by how the culture is prepared. Stress responses can be exploited to make probiotic strains more resilient and likely to survive in food matrices. 1.6.2.3 Temperature The temperature at which probiotic organisms grow is important in food applications where fermentation is required. The optimum temperature for growth of most probiotics is between 37 C and 43 C (395, 403). Species of bifidobacteria isolated from the human intestinal tract such as B. longum (infantis), B. breve, B. bifidum, and B. adolescentis have optimum growth temperatures in the range of 36–38 C, whereas B. animalis subsp. lactis can grow at higher temperatures of 41–43 C (398, 403). Usually no growth is observed for bifidobacteria at temperatures below 20 C or above 46 C (403). Probiotic lactobacilli can grow well over a similar temperature range though some can grow at up to 44 C and at mesophilic temperatures down to 15 C (454).

64


Temperature is also a critical factor influencing probiotic survival during manufacture and storage. In practical terms, the lower the temperature the more stable probiotic viability in the food product will be. During processing, temperatures above 45–50 C will be detrimental to probiotic survival. The higher the temperature, the shorter the time period of exposure required to severely decrease the numbers of viable bacteria, ranging from hours or minutes at 45–55 C to seconds at higher temperatures. It is obvious that probiotics should be added downstream of heating/ cooking/pasteurization processes in food manufacture. Elevated temperature also has a detrimental effect on stability during product shipping and storage. Again, the cooler a product can be maintained, the better probiotic survival will be. For vegetative probiotic cells in liquid products, refrigerated storage is usually essential (403). In dried products containing quiescent bacterial cells, acceptable probiotic viability can be maintained in products stored at ambient temperatures for 12 months or more. As discussed later, there is a substantial interaction between temperature and water activity. Therefore, producing and maintaining low water activities in the foods is the key to maintaining probiotic viability during nonrefrigerated storage. 1.6.2.4 pH Lactobacilli and bifidobacteria produce organic acid end products from carbohydrate metabolism. Hence, these genera can tolerate lower pH levels than many bacteria. Indeed, numerous in vitro and in vivo studies have demonstrated that probiotic organisms can survive gastric transit where the cells are exposed to pH values as low as 2.0, though the time of exposure (1–2 h) is relatively short (398, 452). Adapted vegetative cells are usually able to survive better in acidic environments compared to quiescent cells (448). In food products, lactobacilli are able to grow and survive in fermented milks and yogurts with pH values between 3.7 and 4.3 (395). Bifidobacteria tend to be less acid tolerant, with most species surviving poorly in fermented products at pH levels below 4.6 (395, 449). Again, B. animalis subsp. lactis is more acid tolerant than human intestinal species and, hence, is the species of Bifidobacterium most commonly used in acidic foods (398). A recently described phenotypic group, B. thermoacidophilum is even more tolerant to low pH (and heat) (398, 403), but has not been characterized thoroughly for probiotic traits and is not used commercially, at least so far. Survival in low pH beverages such as fruit juices (pH 3.5–4.5) posses a significant challenge to probiotic survival, but commercially successful products have been produced, such as Gefilus (Valio Ltd, Finland), which contains Lactobacillus rhamnosus GG. Carriers such as dietary fibers have been shown to improve viability at low pH (451). Survival of lactobacilli in acidic environments has also been enhanced in the presence of metabolizable sugars that allow cell membrane proton pumps to operate and prevent lowering of intracellular pH (397). This can improve survival during gastric transit, but may not be applicable to improving probiotic survival over the time frames of shelf-storage. 1.6.2.5 Water Activity For quiescent, dried, probiotic bacteria water activity is a crucial determinant of survival in food products during storage (430, 434, 436, 444). As


65

102 101 100

Percent survival

10-1 10-2 10-3 10-4 10-5 10-6 10-7 10-8 0

1

2

3

4

5

6

Time (weeks)

FIGURE 1.12 The impact of water activity on the survival of a freeze-dried probotic Lactobacillus rhamnosus strain stored at 38–40 C. The probiotic was stored in the same type of food matrix, but the water activity controlled at various levels: aw ¼ 0.1 (. ); aw ¼ 0.15 (*); aw ¼ 0.22 (&); aw ¼ 0.25 (&). Error bars represent the standard deviation from two to three biological replicates. From Crittenden R, Weerakkody R, and Sanguansri L. Unpublished data, Food Science Australia.

moisture levels and water activity are increased the survival of probiotics is substantially decreased (Fig. 1.12). Probiotics can survive well over long shelf lives (12 months or more) at ambient temperatures in dried products as long as the low moisture levels in the products can be maintained (at least below aw 0.2–0.3). In general, the lower the water activity, the better the bacterial survival will be (434). There is a substantial interaction between water activity and temperature with respect to their impact on the survival of quiescent probiotics. As the storage temperature is increased the detrimental impact of moisture is magnified (Fig. 1.13). Although the precise mechanisms of cell death remain unclear, osmotic stresses appear to play a role, with the presence of smaller molecules resulting in poorer bacterial survival (434). Despite the clear evidence that very low water activities improve probiotic survival there may be technological limitations to reducing water activity to very low levels. These include the energy costs of drying, adverse impacts on the palatability of foods and difficulties in wetting and dispersing powders. Moisture barrier packaging may be applied to prevent the egress of moisture from the environment during storage. Maintaining probiotic viability in moderate water activity foods (0.4–0.7) is a major challenge and solutions such as microencapsulation or incorporation of probiotics into fat phases of products can provide improved survival. 1.6.2.6 Oxygen Both bifidobacteria and lactobacilli are considered strict anaerobes and oxygen can be detrimental to probiotic growth and survival (419). However,

66

PROBIOTIC MICROORGANISMS 1012 1011

Viable count (cfu/g)

1010 109 108 107 106 105 104 103

0.4

0.5 0.6 Water activity

0.7

FIGURE 1.13 The viable count of a freeze-dried probiotic Lactobacillus acidophilus strain after 3 weeks of storage at moderate water activities at either 20 C (. ) or 30 C (*). Increased temperature magnified the detrimental impact of water activity on the survival of the dried probiotic. Error bars represent the standard deviation from triplicate biological replicates. From Crittenden R, Weerakkody R, and Sanguansri L. Unpublished data, Food Science Australia.

the degree of oxygen sensitivity varies considerably between different species and strains (419). In general, lactobacilli, which are mostly microaerophilic, are more tolerant of oxygen than bifidobacteria, to the point where oxygen levels are rarely an important consideration in maintaining the survival of lactobacilli. Most probiotic bifidobacteria do not grow well in the presence of oxygen (398). However, many bifidobacteria have enzymatic mechanisms (via NADH-oxidase and NADHperoxidase) to limit, oxygen toxicity (457). B. animalis subsp. lactis is relatively resistant to oxygen stress, and B. longum (infantis) and B. breve are more resistant to oxygen than B. adolescentis (395, 432, 457). For oxygen sensitive strains, some strategies are available to prevent oxygen toxicity in food products. Antioxidant ingredients such as ascorbic acid or cysteine have been shown to improve probiotic survival (394, 401), as well as the use of oxygen barrier or modified atmosphere packaging (459). Since oxygen toxicity can sometimes influence probiotic survival in foods, it is advisable to minimize processes that are highly aerating, particularly when using bifidobacteria. 1.6.2.7 Toxicity of Ingredients The compatibility of probiotics with other ingredients within food formulations can have a significant impact on bacterial survival. Interactions between probiotics and other ingredients can be protective, neutral, or detrimental to probiotic stability (430). Obviously, the inclusion of antimicrobial preservatives can inhibit probiotic survival. Elevated levels of ingredients such as salt, organic acids, and nitrates can inhibit probiotics during storage (387, 395, 423), while


67

starter cultures can sometimes inhibit the growth of probiotics during fermentation through the production of specific bacteriocins (384, 395). 1.6.2.8 Growth Factors, Protective, and Synergistic Ingredients Probiotic lactobacilli and, in particular, bifidobacteria are only weakly proteolytic and grow relatively slowly or poorly in milk (395, 423, 455). The growth of bifidobacteria can be enhanced by the presence of suitable companion cultures, including starter cultures, which can aid in protein hydrolysis and through the production of growth factors (430, 455). Alternatively, growth substrates such as carbon sources (e.g. glucose), nitrogen sources, and growth factors (e.g. yeast extract or protein hydrolysates) or antioxidants, minerals, and vitamins can be added to improve growth (430, 455). Other ingredients can protect the viability of probiotics in foods by acting as carriers (449– 451). Finally, the food matrix itself can be protective. An example is cheese, where the anaerobic environment, high fat content and buffering capacity of the matrix helps to protect the probiotic cells both in the product and during intestinal transit (395). 1.6.2.9 Freeze–Thawing Freezing probiotic cells damages cell membranes and is detrimental to survival (388, 410). Protectants are usually added to cultures to be frozen or dried in order to prevent, or at least mitigate, cell injury. The most common protectants used at industrial scale are lactose or sucrose, monosodium glutamate, milk powders, and ascorbate (430). Once frozen, probiotics can survive well over long shelf lives in products such as frozen yogurts and ice-cream. Use of slow cooling rates, or conditioning cells with prefreezing stress, can significantly improve cell survival (388). Repeated freeze–thawing cycles are highly detrimental to cell survival and should be avoided. The cell membrane damage caused by freezing can also render probiotic cells more vulnerable to environmental stresses (410). In the example shown in Fig. 1.14, the survival of a probiotic Lactobacillus paracasei in a low pH fermented whey drink was studied during shelf storage. In one sample the culture was frozen during supply chain transport and then thawed. A parallel sample was only refrigerated during transport. It was evident that freeze–thawing increased the sensitivity of the cells to the acidic environment. 1.6.2.10 Sheer Forces Probiotic lactobacilli and bifidobacteria are Grampositive bacteria with thick cell walls that are able to tolerate the sheer forces generated in most standard food production processes. Some high-sheer processes such as highspeed blending or homogenization may result in cell disruption and losses in viability. 1.6.3

Synbiotics

Probiotics are not the only functional food ingredients developed to improve human health by modulating the intestinal microbiota. Prebiotic ingredients represent an alternative and potentially synergistic approach. These nondigestible carbohydrates pass through to the colon where they selectively stimulate the proliferation and/or activity of beneficial microorganisms within the intestinal microbiota (412). Ingredients and foods that contain both prebiotics and probiotic are called synbiotics. A

68


109 108

Viable count (cfu/m)

107 106 105 104 103 102 0

1

2 3 4 Storage time (weeks)

5

FIGURE 1.14 The impact of freeze–thawing on the subsequent refrigerated storage stability of a probiotic strain in a low-pH (3.8) whey drink. A culture of Lactobacillus paracasei was divided into two aliquots. One was frozen at 20 C for 72 h (*) while the other was stored refrigerated at 4 C for 72 h (. ). The frozen culture was then thawed and the viability of the probiotic in both aliquots was monitored during subsequent storage at 4 C for 5 weeks. A single freeze–thaw cycle proved highly detrimental to the storage stability of the probiotic. From Crittenden R. Unpublished data, Food Science Australia.

range of nondigestible sugars, oligosaccharides, and polysaccharides can act as prebiotics, and possess a range of physiological and physicochemical properties that make them attractive food ingredients. Prebiotics are discussed in more detail in Chapter 7. 1.6.4

Delivery Systems

1.6.4.1 Microencapsulation Providing probiotics with a physical barrier to environmental conditions by microencapsulating the bacteria is an approach that has been trialed using a range of materials and techniques. Microencapsulation of probiotics, though, is not a simple undertaking. There are many demands for a successful probiotic microencapsulant: . . .

The materials have to be food grade, inexpensive, and compatible with the food into which the probiotic will be encapsulated. The microencapsulation process must be simple, inexpensive and must not reduce probiotic viability. The encapsulation efficiency must be high (i.e. close to 100% of the bacteria in a suspension should be encapsulated).

INCORPORATING PROBIOTICS INTO FOODS . . .

. .

69

The microcapsules must contain a high loading (%v/v) of probiotics. The microcapsules must not adversely impact on the taste and texture of food and beverages (small capsules 3% CO2 in air

Chloramphenical (100 mg/L)

Air

a After Butler JP, editor. Bergey’s Manual of Systematic Bacteriology, Vol. 2. Williams & Wilkins, Baltimore, 1986. b After Balows A, Tr€ uper H, Devorkin M, Harder W, and Schleifer K-H, editors. The Prokaryotes. A Handbook on the Biology of Bacteria: Ecophysiology, Isolation, Identification, Applications, Vol. II, Springer Verlag, New York, 1992. c To eliminate yeasts. d To isolate anaerobic lactobacilli from intestinal sources. e Examples are meat extract, tomato juice, fresh yeast extract, malt extract, ethanol, mevalonic acid (sake), beer, and juices, to improve the isolation of lactobacilli, which are adapted to a particular ecological niche. f Replacement of glucose by maltose, fructose, sucrose, or arabinose is recommended for the isolation of heterofermentative lactobacilli. g TPY medium: trypticase (BBL), 10 g; phytone (BBL), 5 g; glucose, 5 g; yeast extract (Difco), 2.5 g; Tween 80, 1 mL; cysteine hydrochloride, 0.5 g; K2HPO4, 2 g; MgCl26H2O, 0.5 g; ZnSO47H2O, 0.25 g; CaCl2, 0.15 g; FeCl3, a trace; agar, 15 g; distilled water, 1000 mL. Final pH value is about 6.5 after autoclaving at 121 C for 25 min; dilutions can be made with the same liquid medium. h Use of kanamycin, neomycin, paramomycin, sodium propionate, lithium chloride, sorbic acid, or sodium azide could improve selectivity in some cases. i Strep Base: proteose peptone, 20 g/L; yeast extract, 5 g/L; NaCl, 5 g/L; Na2HPO4, 1 g/L; glucose, 5 g/L. Dissolve ingredients in distilled water, adjust pH to 7.6. Autoclave at 121 C for 15 min. j TYC medium: trypticase, 15.0 g/L; yeast extract, 5.0 g/L; L-cysteine, 0.2 g/L; Na2SO3, 0.1 g/L; NaCl, 1.0 g/L; NaHCO3, 2.0 g/L; Na2HPO412H2O, 2.0 g/L; sodium acetate (3H2O), 20.0 g/L; sucrose, 50.0 g/L. Adjust pH to 7.3. Autoclave at 121 C for 15 min. k Brainheart infusion medium: calf brain infusion solids, 12.5 g/L; beef heart infusion solids, 5.0 g/L; proteose peptone, 10.0 g/L; dextrose, 2.0 g/L; NaCl, 5.0 g/L; Na2HPO4, 2.5 g/L; pH 7.4. Sterilize by autoclaving at 121 C for 15 min. l Kanamycin aesculin medium: tryptone, 20 g/L; yeast extract, 5 g/L; NaCl, 5 g/L; sodium citrate, 1 g/L; aesculin, 1 g/L; ferric ammonium citrate, 0.5 g/L; sodium azide, 0.15 g/L; kanamycin sulfate, 0.02 g/L. Bring to boil to dissolve completely. Sterilize by autoclaving at 121 C for 15 min. m YPD medium: yeast extract, 3 g/L; peptone, 5 g/L; dextrose, 10 g/L; malt extract, 3 g/L; final pH 6.2. Bring to boil to dissolve. Sterilize by autoclaving at 121 C for 15 min. n Rose Bengal medium: mycological peptone, 5 g/L; glucose, 10 g/L; dipotassium phosphate, 1 g/L; magnesium sulfate, 0.5 g/L; Rose Bengal, 0.05 g/L; pH 7.2. Bring to boil to dissolve completely. Add chloramphenical and mix gently. Sterilize by autoclaving at 121 C for 15 min.

2.2 SELECTION OF PROBIOTIC MICROORGANISMS Common criteria for the selection and development of a new probiotic strain are mentioned below.

179

SELECTION OF PROBIOTIC MICROORGANISMS

2.2.1

Manufacturing Criteria (General Criteria)

A pleasant aroma and flavor profiles are of importance in the formulation of probiotic functional foods. More importantly, probiotic strains should be hardy and stable enough to withstand conventional industrial production processes. These criteria may include the following: (a) ease in maintaining in storage without loss of viability; (b) ability to revitalize and grow quickly to the maximum concentration in a simple and cheap fermentation medium; (c) ability to grow and survive in microaerophilic or aerobic conditions; (d) ability to withstand physical handling without significant loss of viability; (e) ability to survive in the food matrices and during processing. In general, lactobacilli are insensitive to cold storage at 12 C or lower (5), but sensitive to freezedrying process. A 5% glycerol in suspension medium (1) and chopped meat broth with 12% sucrose (10) increase survival during lyophilization. Most lactic acid bacteria can be cultured in conventional stirred tank fermentor and are rather resistant to centrifugation. During animal feed pellet production, heat treatment at 90 C, over a very short period of 14 s, kills most of the lactic acid bacteria and yeasts, except for bacterial spores. 2.2.2

Shelf Life and Gut Transit (General Criteria)

If the desirable probiotic properties are dependent on the metabolic activities and the close vicinity of probiotics to host cells for a prolonged period of time, sufficient numbers of viable cells must be present at the time of consumption and the probiotics must be able to colonize on the intestinal mucosal surface. 2.2.2.1 Shelf Life of Viable Probiotics Under Different Storage Conditions The shelf life of viable probiotic microorganisms is determined largely by their storage temperature. Cell Survival During Cold Storage of Cultured Milk at 4 C

Organisms L. casei strain Shirota L. casei NCIMB 8822 L. casei NCIMB 11970

Initial Cell Concentration (cfu/mL) 1.6 10 1.3 108 1.5 108 8

Viable Cell Concentration (% Initial) Day 0 Day 14 100 100 100

93.8 43.1 43.3

Day 28

Day 49

93.8 6.8 8.0

87.5 2.5 4.6

(continued)

180

SELECTION AND MAINTENANCE OF PROBIOTIC MICROORGANISMS

(Continued)

Organisms

Initial Cell Concentration (cfu/mL)

L. paracasei NCIMB 8001 L. paracasei NCIMB 9709 L. paracasei NCIMB 9713 L. rhamnosus NCIMB 6375 L. rhamnosus GG L. acidophilus NCIMB 8690 L. acidophilus CH 5 L. bulgaricus NCIMB 11778 S. thermophilus NCIMB 10387

3.6 108 1.4 108 3.3 108 4.8 108 2.0 108 1.7 108 7.0 107 5.2 107 3.2 106

Viable Cell Concentration (% Initial) Day 0 Day 14 100 100 100 100 100 100 100 100 100

100 100 100 64.5 90 25.9 0.03 67.3 10.3

Day 28

Day 49

94.4 100 75.8 10.4 50 1.9 0.0014 1.2 0.25

83.3 100 42.4 4.0 49 0.008 0.001 0.06 0.072

Data provided by Lee YK, National University of Singapore.

Cell Survival During Storage of Cultured Milk at 25 C (Room Temperature)

Organisms

Initial Cell Concentration (cfu/mL)

L. casei strain Shirota L. casei NCIMB 8822 L. casei NCIMB 11970 L. paracasei NCIMB 8001 L. paracasei NCIMB 9709 L. paracasei NCIMB 9713 L. rhamnosus NCIMB 6375 L. rhamnosus GG L. acidophilus NCIMB 8690 L. acidophilus CH 5 L. bulgaricus NCIMB 11778 S. thermophilus NCIMB 10387

1.6 10 1.3 108 1.5 108 3.6 108 1.4 108 3.3 108 4.8 108 2.0 108 1.7 108 7.0 107 5.2 107 3.2 106 8

Viable Cell Concentration (% Initial) Day 0 Day 14 100 100 100 100 100 100 100 100 100 100 100 100

87.5 60.8 66.7 72.2 71.4 93.9 25 65 2.3 0.005 21 0.013

Day 28

Day 49

62.5 57.7 42 20.8 12.9 17.9 7.1 46.5 0.03 0.05 >0.05

(123)

(124)

5 1010 cfu daily) of specific probiotic strains or specific probiotic combinations can prevent recurrent intestinal inflammation and may possibly treat active IBD, with best results in pouchitis and to a lesser extent, ulcerative colitis. 4.3.6

Treatment of H. pylori Infection

Helicobacter pylori infection of gastrointestinal tract was observed in 70–90% of the population in developing countries and 25–50% in developed countries (227), and it was linked to the development of gastric and duodenal ulcers, gastric cancer, atrophic gastritis, mucosa-associated lymphoma tissue lymphoma, and other gastric complications (222, 223, 233) and a Class 1 carcinogen in the list of the International Cancer Research Institute. The recommended treatment for the eradication of H. pylori is a combination of proton-pump inhibitor and antibiotics. The regimens achieve high eradication rate; however, there is approximately 10–35% of patients failed in the treatment. Antibiotic-associated gastrointestinal side effects such as diarrhea, nausea, vomiting, bloating, and abdominal pain are the drawbacks of anti-H. pylori therapies, often resulting in discontinuation of therapy (221). These manifestations are related to the changes in the intestinal microbiota profile. Several studies reported that certain probiotic bacteria exhibit inhibitory effect against H. pylori in vitro and in vivo (219, 232). The following table summarizes clinical reports on the supplementation of probiotics in H. pylori eradication treatment (proton pump inhibitor plus two or three antibiotics). Only randomized controlled trials are included.

293

L. rhamnosus GG, L. rhamnosus LC705, Propionibacterium freudenreichii ssp. Shermanii JS, Bifidobacterium breve Bb99 L. rhamnosus GG, L. acidophilus, Saccharomyces boulardii

L. rhamnosus GG

Lactobacillus acidophilus LB L. casei DN-114 001

6 109, 5 109, 6 109 cfu P: 64, C: 21

2 109 spores TDS P: 54, C: 52 40 mg TDS P: 47, C: 50 5 109 heat-killed P: 60, TDS C: 60 P: 39, 1 1010 cfu in C: 47 100 mL fermented milk 6 109 cfu P: 60, C: 60 1 109 cfu/mL P: 23, milk-base, fruit C: 24 drink twice daily

Bacillus clausii

Clostridium butyrium

Dose/Day

Probiotics

Subject No.

14 days

UBT

UBT

4 weeks

UBT, SAT

14 days

UBT

UBT, H

10 days

14 days

UBT

UBT

7 days

14 days

Treatment

Test Method

5–6

16

6

4

6

4

6

Follow-Up Period (Weeks)

0.92 (0.31–2.76)

0.61 (0.09–4.01)

1.23 (0.38–3.97) 0.16 (0.05–0.46)

2.76 (0.48– 15.95)

1.22 (0.51–2.91) 0.48 (0.23–0.99)

4.07 (1.43– 11.58)

2.79 (1.10–7.04) 1.00 (0.30–3.30)

(continued)

(226)

(230)

(220)

(235)

(224)

(229)

(231)

Overall Side Effects (95% CI) References

2.00 (0.47–8.51) 0.34 (0.12–0.97)

1.05 (0.45–2.45)

Eradication Odd Ratios (95% CI)

294 P: 524, C: 490

P: 33, C: 32 P: 64, C: 64

P: 80, C: 80

Subject No.

7 days

3 months

5 weeks

Treatment

4–12

4–8

Follow-Up Period (Weeks)

UBT, 4 ELISA

UBT

UBT

Test Method

1.84 (1.34–2.54)

2.63 (0.49–14.07)

1.39 (0.52–3.74)

2.81 (1.10–7.22)

Eradication Odd Ratios (95% CI)

0.44 (0.30–0.66)

(225)

(228)

(234)

Overall Side Effects (95% CI) References

P: probiotic; C: control; UBT: 13C-urea breath test; ELISA: enzyme-linked immunosorbent assay for specific antibody; H: histology; SAT: stool antigen test; BD: twice daily; TDS: three time a day. Overall side effects: diarrhea þ epigastric pain þ nausea þ taste disturbance.

Bifidobacterium longum, Faecal streptococci, L. acidophilus Total

One capsule

5 109 cfu in 200 mL yogurt, BD 1 107 cfu

Lactobacillus þ Bifidobacterium

B. animalis þ L. casei

Dose/Day

Probiotics

(Continued)

EFFECTS ON HUMAN HEALTH AND DISEASES

295

General Conclusion: The odds ratio of the pooled H. pylori eradication (1.84, 95% CI 1.34–2.54) and the occurrence of side effects (0.44, 95% CI 0.30–0.66) are in favor of patients receiving probiotic supplement. Both the eradication rate and prevention of side effects of treatment appeared to be strain dependent rather than dose dependent. The Bacillus clausii supplement seems to have no positive effect on the anti-H. pylori treatment (OR 1.05) despite of a comparable daily dosage (6 109 cfu) being given for 14 days, while L. rhamnosus GG (OR 1.22), L. rhamnosus GG þ L. acidophilus S. boulardii (OR 1.23), and B. animalis þ L. cacei (OR 1.39) have little effect in preventing the side effects. L. casei DN-114 001 showed a high (OR 4.07) success rate of eradication at a high daily dosage of 1 1010 cfu. 4.3.7

Prevention of Postoperative Infections

Septic complications remain a major cause of morbidity and mortality in patients undergoing elective abdominal surgery despite the routine use of antibiotic prophylaxis (239, 241). In many cases the patients were immune compromised and surgical stress exacerbated immune dysfunction, causing the patients susceptible to infections. There are reports suggesting that infections in immunocompromised surgical patients often arise from their intestinal microbiota (242). If this is the case, it may be possible to reduce infection by correcting intestinal microbial imbalance induced by surgical stress. The few blinded randomized controlled studies that investigated the clinical efficacy of symbiotics (combination of probiotics and prebiotics) are summarized in the following tables.

296 19% infectious in Enteral or 54 patients symbiotic group versus oral feeding of (average age 63) 52% in controls 1 g probiotic with biliary (p < 0.05); or placebo with 12 g cancer undergone galactooligosaccharides postoperative changes in combined liver lactulose–mannitol for 14 days and extrahepatic ratios (assay for bile duct resection intestinal permeability) with hepaticojejunostomy: and serum diamine probiotic: 21, oxidase (marker of placebo: 23 intestinal integrity) activities were identical between the two groups. Thus infections were not due to alteration of intestinal permeability and mucosal integrity.

1 108 cfu þ 1 108 cfu/g

Clinical Trials

B. breve strain Yakult, L. casei strain Shirota

Treatment

Subjects

Dose/Day

Probiotics

Positive Effects

(237)

References

297

L. plantarum 299

172 patients following major abdominal surgery or liver transplantation

After liver, gastric and Given either: (A) pancreas resection, conventional parenteral bacterial infection 31% or enteral nutrition, in conventional group A (B) enteral nutrition versus 4% in probotic with fiber and live group B, 13% in placebo probiotics, or group C; (C) nutrition with fiber In the 95 liver transplant and heat inactivated recipients, 13% group B Lactobacilli (placebo) patients developed infection versus 48% group a, 34% group C patients; Difference between groups A and B was statistically significant in both cases; Cholangitis and pneumonia: most frequent infection; Enterococci: most frequently isolated bacteria

(240)

298 129 patients (age 58–77) undergoing elective major abdominal surgery: probiotic: 64, placebo: 65

5 10 cfu/mL oatmeal based drink, 500 mL daily

L. plantarum 299v

4 109 cfu/capsule L. acidophilus La5 þ L. bulgaricus þ B. Lactis Bb-12 þ S. thermophilus 137 patients (age 47–80) undergoing elective abdominal surgery: probiotic: 72, placebo: 65

Subjects

7

Dose/Day

Probiotics

No Effects

Given either placebo or probiotics with oligofructose for 2 weeks preoperative and continue in postoperative until discharge

Given treatment at least 1 week preoperative and in postoperative period

Treatment No significant difference between the two groups in bacterial translocation (12% versus 12%, p ¼ 0.82), gastric colonization with enteric organisms (11% versus 17%, p ¼ 0.42), or septic morbidity (135% versus 15%, p ¼ 0.74) No significant difference between the two groups in bacterial translocation (12.1% versus 10.7%, p ¼ 0.808), gastric colonization (41% versus 44%, p ¼ 0.719), systemic inflammation, or septic complications (32% versus 31%, p ¼ 0.882)

Clinical Trials

(236)

(238)

References


299

General Conclusion: The few clinical reports on the effects of probiotics in the prevention of postoperative infection are conflicting and a further evaluation is required. 4.3.8

Prevention and Treatment of Respiratory Tract Infections

Common virus respiratory infections such as common cold and influenza continue to cause considerable health and economic burden in children and adults alike. Several strains of probiotic microorganisms have been reported to enhance mucosal immunity against pathogens. It is reasonable to assume that probiotics may have positive effects in the prevention and treatment of respiratory tract infections.

300

157 chronic patients: probiotic: 78, placebo: 79

Recurrence hypertrophic sinusitis

Enterococcus faecalis and autolysate (Symbioflor 1)

Relapse of 136 chronic chronic recurrent patients: bronchitis probiotic: 70, placebo: 66

Subjects

Disease

Probiotics

30 drops Symbioflor three times a day

During treatment, occurrence of 6 months relapses: 17 incidents in probiotic treatment, group versus 33 in placebo 8 months (p ¼ 0.019); follow-up during follow-up: probiotic 33 incidents versus placebo 57 (p ¼ 0.013); time interval to first relapse in probiotic group 513 days versus 311 days in placebo; severity and clinical parameters of the acute relapses was comparable in both group During treatment, occurrence 6 months of relapses: 12 incidents treatment, in probiotic group versus 27 in 8 months placebo (p ¼ 0.013); follow-up during follow-up: 27 in probiotic versus 39 in placebo (p ¼ 0.127); time interval to first relapse: 699 days in probiotic versus 334 days in placebo; at end of observation, 91% probiotic experienced 1 relapse versus 62% in placebo (p ¼ 0.01); four patients in probiotic group required antibiotic versus 13 in placebo 30 drops Symbioflor three times a day

Clinical Trials

Treatment

Dose

(245)

(246)

References

301

Respiratory infection

3 weeks

454 healthy adults 505 cfu spray dried/ (18–67 years) not tablet/day vaccinated 2 Winter/ Spring (3 and 5 months each)

5–10 105 cfu/mL 7 months 571 healthy children, (1–6 milk, 260 mL daily, years): probiotic: three times feeding a 282, day, 5 days a week. placebo: 289 Mean compliance 60%

Winter respiratory 180 elderly infection

L. gasseri PA16/8, Common cold B. longum SP07/ 03, B. bifidum MF20/5

L. rhamnosus GG

L. casei DN114001, yogurt

(248) No difference in incidence of infections; duration infections: 7.0 3.2 days probiotic group versus 8.7 3.7 days in placebo group (p ¼ 0.024); maximum temperature of probiotic group 38.3 0.5 C versus control group 38.5 0.6 C (p ¼ 0.01) (247) A relative 17% (17.2–0.1%) reduction in number respiratory infection (p ¼ 0.05); age adjusted odds ratio 0.75 (p ¼ 0.13); a relative 19% reduction in antibiotic treatments for respiratory infection (p ¼ 0.03); adjusted odds ratio 0.72 (p ¼ 0.08) No effect on incidence of common (243, 244) cold (placebo 153 episodes versus probiotic 158); shorten duration of episode by almost 2 days (placebo 8.9 1.0 versus probiotic 7.0 0.5 days, p ¼ 0.045); days with fever placebo1.0 0.3 versus probiotic 0.24 0.1 (p ¼ 0.017); increased in cytotoxic T cells plus T suppressor cells in 14 days (placebo 19 19 106 L1 blood versus probiotic 64 15 106 L1 blood, p ¼ 0.035)

302

ROLE OF PROBIOTICS IN HEALTH AND DISEASES

General Conclusion: The intake of probiotics in general, reduced the incidents and duration of respiratory infections among children and adults. 4.3.9

Prevention and Treatment of Allergic Diseases

Allergy, in the form of atopic diseases, such as atopic eczema, allergic rhinitis, and asthma, is a chronic disorder of increasing prevalence in the more developed countries (251). A survey conducted in 1998 in Bangkok area, Thailand as compared to a similar survey in 1990 showed that the period prevalence of asthma increased fourfold, allergic rhinitis increased nearly threefolds, whereas eczema remained stable (271). The 1998 survey of 3628, 6–7 years old and 3713, 13–14 years children reported that the cumulative 12-month period prevalence of wheezing was between 18.3% and 12.7%; rhinitis 44.2% and 39.7%; and eczema 15.4% and 14.0%, respectively. Surveys conducted in 1994–1995 in various regions of Finland reported that among the children of ages 13–14, 10–20% of the children had symptoms of asthma, 15–23% allergic rhinitis and 15–19% atopic eczema (262, 265). There appears to be an inverse association between atopy and infection in early life, exposure to farm life, animals, and elder siblings, which implies that the recent rapid rise in atopy might be a result of improved hygiene (260, 267–269). Other reports, however, did not support the “Hygiene Hypothesis” (261) or indicated variation in different time points of near history (253). There was a proposal that specific microbes in the commensal gut microbiota are more important than sporadic infections in atopic disease prevention and that atopic diseases can be predicted by specific intestinal microbiota aberrancies in infants prior to the occurrence of atopic symptoms or atopic disease (254). Based on the microbiota aberrancies and the hygiene hypothesis several treatment and prevention studies have been conducted. The following tables summarize human clinical trials in the investigation of probiotic consumption and prevention of atopic diseases. Only double-blind randomized placebo-controlled trials are included.

303

Subjects 27 infants (mean age 4.6 months) with atopic eczema during exclusive breast feeding

B. lactis 1 10 cfu/g whey formula, LGG 3 108 cfu/g whey formula

B. lactis Bb-12 or L. rhamnosus GG (ATCC53103)

9

Dose/Day

Probiotics

Positive Effects Clinical Trials

Median (interquartile range) Weaned to probiotic SCORAD score 16 (7–25) supplemented during breast feeding; hydrolyzed whey formulas or without after 2 months, median SCORAD in Bifidobacterium group 0 (0– probiotics 3.8), in Lactobacillus group 1 (0.1–8.7), in unsupplemented group 13.4 (4.5–18.2) (p ¼ 0.01); In parallel a reduction in soluble CD4 in serum (p ¼ 0.005) and eosinophilic protein X in urine (Bifidobacterium p ¼ 0.01, Lactobacillus p ¼ 0.04), suggesting alleviation of allergic inflammation; at 2 months, serum TGF-b1 decreased in Bifidobacterium group (p ¼ 0.04) but tended to increase with Lactobacillus (p ¼ 0.07); serum IL-1ra, TNFa, GM-CSF, sICAM-1, RANTES, MCP-1a not modified by probiotics; after 6 months the median SCORAD score 0 (0–6.6) in all groups alike

Treatment

(continued)

(252)

References

304 159 mothers with family history of atopic disease

1 1010 cfu/capsule

L. rhamnosus GG

Probiotic: 53, placebo: 54

Subjects

Dose/Day

Probiotics

(Continued) Clinical Trials

Received two capsules At 2 years, frequency of atopic eczema probiotics group 23% daily for 2–4 weeks versus placebo 46% before expected (p ¼ 0.008), relative risk (95% delivery; CI) 0.51 (0.32–0.84); after delivery Preventive effects not depend on breastfeeding mode of administration, in mothers or bottle probiotic group atopic eczema feeding children diagnosed in 25% infants who took probiotic for consumed probiotic themselves 6 months and 21% whose breastfeeding mothers took capsules (p ¼ 0.74); Concentration of total IgE, frequencies of increased antigen-specific IgE concentration and positive reaction in skin-prick tests were similar between two groups Follow-up of At 4 years, 26.4% Lactobacillus Kalliomaki et al., group versus 46.3% placebo 2001 developed atopic eczema; relative risk 0.57, 95% CI (0.33–0.97); Skin prick test reactivity same in both group

Treatment

(255, 256)

(255)

References

305

L. rhamnosus 19070-2 or Lyophilized 1010 cfu L. reuteri DSM12246 each/g

3 108 cfu/g whey formula

Follow-up of Kalliomaki et al., 2001

(continued)

At 7 years, 42.6% Lactobacillus (255, 257) group versus 66.1% placebo developed atopic eczema; relative risk 0.64, 95% CI (0.45–0.92) (258) 35 infants (mean age Received hydrolyzed SCORAD scores (interquartile range) decreased from 13 whey formula 5.5 months) with (range 4–29) to 8 (0–29) units supplemented with atopic eczema and in placebo group; viable or heatcow’s milk allergy from 19 (4–47) to 5 (0–18) inactivated probiotic (CMA) units in viable probiotic group; from 15 (0–29) to 7 (0–26) units in heat-inactivated probiotic group; Heat-inactivated probiotic group showed adverse gastrointestinal symptoms and diarrhea (266) Frequency of gastrointestinal Orally fed 1 g each 41 children (median symptoms (diarrhea, vomiting, strain or placebo in age 4 years) with abdominal pain) placebo 39% 2.5–5 mL water moderate (SCORAD versus 10% probiotic treatment twice daily for 6 score 16–40) and (p ¼ 0.02); weeks, 6-week severe (SCORAD positive association between washout between score >40) atopic lactulose:mannitol ratio (small each intervention dermatitis(AD) intestinal permeability) and period eczema severity (r ¼ 0.61, p ¼ 0.02 after placebo; r ¼ 0.53, p ¼ 0.05 after probiotic treatment) Probiotic: 53, placebo: 62

306 44 adults with clinical 2 g twice daily with 100 mL milk for history (>2 years, 13 weeks during and serum JCPpollen season specific IgE) of Japanese cedar pollinosis (JCPsis)

5 1010 cfu/2 g dextrin powder

B. longum BB536

53 children (aged 6–18 months) with moderate or severe AD

1 109 cfu Twice daily for 8 weeks; a final assessment at 16 weeks

One capsule content mixed with food twice daily for 4 weeks

230 infant (mean age 6.4 months) with suspected CMA: LGG: 80, mixture: 76, placebo: 74

LGG 5 10 cfu/ capsule

L. rhamnosus GG (ATCC53103) or LGG 5 109 cfu þ L. rhamnosus LC705 5 109 cfu þ Bifidobacterium breve Bb99 2 108 cfu þ Propionibacterium freudenreichii ssp. Shermanii JS 2 109 cfu/capsule L. fermentum VRI-033 PCC

Treatment

Subjects

9

Dose/Day

Probiotics

(Continued)

(274)

(273)

(272)

References

Reduction in SCORAD index was significant in probiotic group (p ¼ 0.03) but not placebo group; significantly more children receiving probiotics (92%) had a SCORAD index better than baseline versus placebo group (63%); at completion, more children in probiotic group had mild AD (54%) versus placebo group (30%) Subjective symptom scores indicated significant decreased in rhinorrhea (p ¼ 0.0167), nasal blockage (p ¼ 0.0118), and composite scores

Four weeks after treatment, CMA was diagnosed in 120 infants. No differences in SCORAD index and CMA between groups; in IgE-sensitized infants, LGG group SCORAD group 26.1 versus placebo 19.8 from baseline (p ¼ 0.036)

Clinical Trials

307

L. rhamnosus GG (ATCC 53103) 5 109 cfu þ L. rhamnosus LC705 (DSM 7061) 5 109 cfu þ B. breve Bb99 (DSM 13692) 2 108 cfu þ Propionibacterium freudenreichii spp. Shermanii JS (DSM 7076) 2 109 cfu/ capsule

One capsule

(p ¼ 0.0339) in probiotic group versus placebo; no significant difference in scores for sneezing, nasal itching, eye, and throat symptoms; probiotic significantly suppressed increases in plasma thymusand activation-regulated chemokine (a Th2 marker) and tended to suppress elevation of JCP-specific IgE (p ¼ 0.067) At 2 years, no effect on the 1223 pregnant mothers Mothers took one cumulative incidence of capsule twice daily carrying children in allergic diseases (food allergy, during 2–4 weeks risk for allergy; eczema þ asthma þ allergic before delivery. Infants: probiotic 461, rhinitis) between the groups, Their newborn placebo 464 but probiotic group tended to infants received one reduce IgE-associated (atopic) opened probiotic diseases (odds ratio, 0.71; 95% capsule mixed with CI 0.50–1.00; p ¼ 0.052); 20 drops sugar probiotic treatment reduced syrup þ 0.8 g galactooligosaccharides eczema (OR 0.74; 95% CI 0.55–0.98; p ¼ 0.035) and once daily for atopic eczema (OR 0.66; 95% 6 months after birth; CI 0.46–0.95; p ¼ 0.025); The placebo group Lactobacilli and Bifidobacteria received more frequently (p ¼ 0.001) microcrystalline colonized guts of cellulose without galactooligosaccharides supplemented infants (259)

308 Subjects 36 young adults and teenagers allergic to birch pollen: probiotic 18, placebo 18

50 infants below 5 months fulfilling Hanifin criteria for AD and diagnosed with CMA: L. rhamnosus 17, LGG 16, placebo 17

Dose/Day

55 109 cfu/ capsule

3 108 cfu/g hydrolyzed whey formula (ca. 5 109 cfu/ 100 mL formula)

Probiotics

L. rhamnosus GG (ATCC 53103)

L. rhamnosus or L. rhamnosus GG

No Effects

4–6 weeks whey formula, followed by treatment for 3 months

Two capsules twice daily for 5.5 months (2.5 months before pollen season, 1 month during season, 2 months after)

Treatment Probiotic treatment did not alleviate symptoms (nasal, eye, lung) and skin prick tests or reduce their use of medication during the birch-pollen season or subsequent 2 months; Treatment did not significantly affect symptoms caused by apple in oral challenge tests (60 g slice chewed 1 min and swallowed) No statistically significant effect of probiotic on SCORAD, sensitization (total IgE and food-specific IgEs, skin prick testing for cow’s milk), inflammatory parameters (blood eosinophils, eosinophil protein X in urine, fecal a-1antitrypsin) and cytokine production (IL-4, IL-5, IFN-d production by peripheral blood mononuclear cells after polyclonal stimulation)

Clinical Trials

(249)

(250)

References

309

L. acidophilus LAVRI-A1 (also identified as LAFTI-L10)

3 109 cfu 177 newborns of women with allergy: probiotic 89, placebo 88

6 months

Probiotic group showed significantly higher rates of Lactobacilli colonization ( p ¼ 0.039); at 6 months, AD rates similar in probiotic (25.8%) versus placebo (22.7%), p ¼ 0.629; no difference in AD rates at 12 months, but proportion of children with allergen skin prick test þ AD significantly higher in probiotic group ( p ¼ 0.045); at 12 months, rate of sensitization significantly higher in probiotic group ( p ¼ 0.03); The presence of culturable Lactobacilli in stools at 6 months associated with increased risk of subsequent cow’s milk sensitization ( p ¼ 0.012)

(270)

310


General Conclusion: The prevention studies suggest that there is a clear effect on specific strains to prevent atopic eczema in children with intestinal and food involvement. Also positive demonstrations have been reported for specific probiotics in treatment of atopic eczema in infants. The studies, which showed positive effect of probiotics suggest that impairment of intestinal mucosal barrier is involved in pathogenesis of atopic diseases, and probiotics stabilize intestinal barrier function and decrease gastrointestinal symptom in children with atopic diseases. In addition, immunomodulation may be involved in the probiotic effects as noted, for example, in the TGF-b levels in breast milk of probiotic-treated mothers (264). Supplementation of infant formula with viable but not heat-inactivated probiotics is beneficial to young children with suffering from atopic diseases with intestinal involvement. Probiotics were equally effective among children receiving probiotics in whey/milk formula, in water suspension, and through mothers’ milk where mothers took probiotic-containing capsules. Probiotics have shown some efficacy in relieving or delaying IgE-mediated type 1 allergy to pollen. Other studies using the same strains of probiotics; however, could not confirm the impact of these probiotics on the symptoms of infant allergic diseases and pollen allergy in adults. The differences could not be explained by dosage of probiotics, temporary intestinal colonization of probiotics, age of children, disease history, and length of study. Why are there differences in the study results with different probiotics? A study suggested that early probiotic supplementation was associated with increased allergen sensitization. However, this study was conducted using a previously uncharacterized probiotics L. acidophilus LAVRI. This has later been characterized as L. acidophilus LAFTI-L10. Additionally, the preparation was given postnatally and the previous prevention studies have all used prenatal and postnatal administration of the probiotics. Another recent studies (264a, 264b) clearly demonstrated protection against sensitization when a combination of well-characterized probiotics (Lactobacillus rhamnosus GG and Bifidobacterium lactis Bb12) were used. Other sources of differences in clinical efficacy may include probiotic factors (strains, dose, viability, properties, prenatal/postnatal administration), host/mother factors (genetics, type of microbiota, colonization, health status, compliance), and environment factors (mode of delivery, microbiotic composition, transfer of microbiota, breast feeding, feeding regimens, antibiotics, immunomodulatory drugs). The allergy studies are ongoing but not yet completed. The reasons for differences in clinical efficacy have been reviewed by Prescott and Bj€ orksten (263). 4.3.10

Antitumor Effects

There are numerous claims on the association of intestinal microecology and cancers (278, 280, 282). There are also several mechanistic studies on the effects of probiotics binding to carcinogens and reducing the mutagenicity of urine and intestinal contents, and their inhibitory properties on tumor in in vitro and in animal models (277, 279, 281). There is, however, few randomized controlled clinical trials and epidemiological studies demonstrating the antitumor effects of probiotics in human, these are summarized in the following table.

311

Probiotics

L. casei Shirota

Cancer

Superficial bladder cancer

10

Subjects

58 patients with superficial bladder 1 10 cfu/g, three times daily cancer (age 50–69); 16 primary cases with multiple lesions (6 in probiotic group/10 in placebo), 9 recurrent cases with single lesion (5/4), 23 recurrent cases with multiple lesions (12/11); after transurethral resection of bladder tumor (TUR-Bt), subjects given oral doses for a year 1 1010 cfu/g, 138 patients (under 80 years) had three times daily transitional cell carcinoma of bladder; after transurethral resection of tumor, patients were divided into: group A multiple lesions without history of recurrent; group B single lesion with a history of recurrence; group C multiple lesions with a history of recurrence; patients received treatment for a year

Dose/Day

(276)

50% recurrence-free interval 688 days in probiotic group versus 543 days placebo group; risk of tumor recurrence 2.58-fold higher in placebo than probiotic group in Cox’s multiple life table analysis; Comparison of recurrence-free curve showed a shorter recurrence-free period in group C compare to groups A and B; mild transient adverse reactions, including diarrhea, constipation, hepatic transaminases, occurred in three patients in placebo group and three in probiotic group

(continued)

(275)

References

50% recurrence-free interval after TUR-Bt determined by Kaplan– Meier method, was longer in probiotic treatment (350 days) versus placebo (195 days) (long rank test p ¼ 0.03); no adverse side effect

Clinical Trials

312

Yogurt (probiotic strains not indicated)

Breast cancer

Yogurt and buttermilk (probiotic strains not indicated)

Probiotics

Cancer

(Continued)

180 cases (mean age 67 10) and 445 population-based controls matched by gender and age

1 10 cfu/bottle

Clinical Trials

Compare to population-based controls, odds ratio (smoking adjusted) of probiotic group drank for previous 10–15 years were 0.46 (0.25–0.84, p ¼ 0.01) for 1–2 times/week and 0.65 (0.38–1.13, p ¼ 0.13) for 3–4 or more times/week Yogurt reduced odds ratio in both Population-based case-control premenopausal (OR ¼ 0.4, CI ¼ (for age, education, age at menarche, 0.1–1.1 for highest versus lowest age at first pregnancy), white female quartile) and postmenopausal patients 172 and controls 190, women (OR ¼ 0.2, CI ¼ 0.0–0.8) age 20–54 years Significantly lower consumption of Case-control Caucasian women (age fermented milk products (yogurt 25–44 or 55–64 years); 133 incident and buttermilk) among breast breast cancer cases versus 289 cancer cases versus population population control control (116 100 versus 157 144 g/day, p < 0.01); age adjusted odds ratio of daily consumption of 1.5 glasses (>225 g) fermented milk versus none was 0.5 (95% confidence interval 0.23–1.08); odds ratio expressed per 225 g fermented milk was 0.63 (multivariate-adjusted 95% confidence interval 0.41–0.96); daily intake of milk showed no significant differences between cases and controls

Subjects

10

Dose/Day

(285)

(284)

(277)

References


313

General Conclusion: The few clinical studies do provide evidences that dietary probiotics interact with the host and possibly with the intestinal microbiota and dietary content to exert protective effects in the etiology of some cancers such as superficial bladder cancer and breast cancer. 4.3.11

Reduction of Serum Cholesterol

Hypercholesterol is a risk factor for cardiovascular diseases, which is a leading cause of death in many countries (294). A 1% reduction in serum cholesterol is estimated to result in 2–3% reduction in the risk of coronary artery disease (297). It is suggested that intestinal Lactobacilli may reduce serum cholesterol level through bacterial assimilation in the intestine (289) and deconjugation of bile salts (288, 293). Short-chain fatty acids produced by Lactobacilli may also inhibit hepatic cholesterol synthesis and distribution of cholesterol in the plasma and liver (298). Human clinical studies using various probiotics have given mixed results and do not allow any general conclusion.

314 Clinical Trials

Enterococcus faecium M-74

L. acidophilus 145 þ B. longum 913

30 healthy men (age 33–64 years), mean serum total cholesterol 5.23 1.03 mmol/L

Three times daily 125 mL Probiotic milk significantly lower milk products þ 2.5% serum total cholesterol fructooligosaccharides; 4.4% (p < 0.001), LDL 2-way crossover with 3 cholesterol 5.4% weeks treatment period ( p < 0.005), LDL/HDL and 1 week wash-out in ratio 5.3% ( p < 0.05); between Serum HDL cholesterol, triglycerides, blood glucose unchanged L. acidophilus No difference in total and 300 g yogurt þ 1% 29 healthy women (age 1 106–108 cfu; LDL cholesterol; oligofructose daily, 19–56 years), 15 crossover study 7 weeks HDL increased normocholesB. longum 1 105 cfu/ significantly by each terolaemic, 14 g yogurt 0.3 mmol/L hypercholesterolaemic ( p ¼ 0.002); LDL/HDL decreased from 3.24 to 2.48 (p ¼ 0.001) 2 109 cfu/capsule Probiotic reduced total 1 capsule þ 50 mg 43 volunteers: probiotic cholesterol by 12%, selenium for 60 weeks 20, mean age 75.4 1.5 achieved by fall in LDL daily years; cholesterol (3.85 0.27 placebo 18, mean age week 0 versus 78.1 1.7 years 3.09 0.21 mmol/L week 56); no significant change in HDL and triglycerides

Treatment

L. acidophilus

Subjects

Dose

Probiotics

Positive Effects

(291)

(293)

(300)

References

315

E. faecium þ S. termophilus

1 108–1011 cfu/L 58 healthy, nonobese, 200 mL daily fermented normocholesterolaemic milk for 6 weeks males (age 44 years)

Total cholesterol reduced significantly in probiotic group (0.37 mmol/L, CI 0.51 to 0.23), no change in placebo group (0.02 mmol/L) ( p ¼ 0.01); LDL cholesterol reduced by 0.42 mmol/L (10%); HDL and triglyceride unchanged in both group

(286)

316 Subjects 78 volunteer with normal to borderline high cholesterol levels (5.4 0.7 mmol/L) 80 volunteers (mean age 46.5 years) with elevated cholesterol

354 nonfasting volunteers

37 postmenopausal women with total cholesterol 5 mmol/L

Dose

5 109 cfu/L

3 1010 cfu/ capsule

2 106 cfu/tablet

3 108 cfu/capsule

Probiotics

L. acidophilus L-1

L. acidophilus LA-1 freeze-dried, reduce cholesterol in vitro

L. acidophilus þ L. bulgaricus

L. acidophilus DDS Plus þ B. longum

No Effects

500 mL daily control yogurt for 2 weeks, followed by 500 mL daily treatment for 6 weeks Two capsules three times daily for 6-week, followed by 6 weeks washout, crossover for 6 weeks on capsules One tablet four times daily for 6 weeks, 3 weeks washout, crossover for 6 weeks 3 capsules daily þ 15– 30 mg fructooligosaccharide in milk or soy protein isolate for 6 weeks

Treatment

No significant difference in total lipoprotein, LDL and HDL concentration in both groups No significant difference in the reduction of total cholesterol, HDL, LDL, and triglycerides between the groups

No change in serum total cholesterol, HDL, LDL and triglycerides from baseline

No significant difference in serum total cholesterol, LDL, HDL and triglycerol level

Clinical Trials

(290)

(296)

(295)

(287)

References

317

2 109 cfu/capsule

1 108–1011 cfu/L

L. fermentum PCC

E. faecium þ S. thermophilus 87 nonobese, normocholesterolemic volunteers (age 50–70 years)

No significant difference in the reduction of LDL cholesterol (probiotic 7.0% versus placebo 5.2%, p > 0.05), total cholesterol, HDL % triglycerides, liver enzymes 200 mL daily for 6 months Reduction of LDL by 0.21 mmol/L in probiotic group (p < 0.02) after 1 month and 0.32 mmol/L after 3 months (p < 0.001); at 6 months, no difference in LDL, HDL, triglyceride in both group

Two capsules twice daily 46 volunteers with total for 10 weeks cholesterol 4 mmol/L: probiotic 23, age 50 12 years; placebo 21, age 53 11 years

(299)

(301)

318

4.3.12


Enhancement of Vaccine Responses

The evidence on the immunomodulatory impact of probiotics on the host is accumulating rapidly. Probiotics are increasingly administered in infancy, raising the question of their effect on the immunological responses to vaccines.

319

Dose/Day

L. rhamnosus GG or L. acidophilus CRL431

Rhesus-human reassortant rotavirus vaccine strain DXRRV, corresponding to human rotavirus VP7 serotype 1

Vaccine

1010 cfu in Live attenuated poliomyelitis 100 mL viruses type 1 fermented milk strain LSc1, type 2 strain P2712 and type 3 strain Leon 12a1b

10

L. rhamnosus 5 10 cfu/0.1 g dry powder in GG (ATCC 53103) 5 mL water

Probiotics

Treatment

5 weeks, in 64 healthy male volunteers (aged second week, subjects were 20–30 years): vaccinated LGG 21, L. acidophilus 21, placebo 22

5 mL given orally 2–5 months old before vaccination; healthy infants: administration probiotic 28, continued at home placebo 27 for 5 days, two doses daily

Subjects

(303)

(304)

References

(continued)

Rotavirus IgM seroconversion detected in 96% probiotic group versus 85% placebo (p ¼ 0.15); rotavirus IgA seroconversion detected in 93% probiotic group versus 74% placebo (p ¼ 0.05) Probiotics increased poliovirus neutralizing antibody titers by 3.9 (p ¼ 0.047), 2.2 (p ¼ 0.083) and 3.9 (p ¼ 0.036) folds, respectively, for IgM, IgG and IgA; no consistent difference noted between probiotic strains

Clinical Trials

320

Dose/Day

One capsule L. rhamnosus GG (ATCC 53103) 5 109 cfu þ L. rhamnosus LC705 5 109 cfu þ B. breve Bbi99 2 108 cfu þ Propionibacterium freudenreichii spp. Shermanii JS 2 109 cfu/ capsule

Probiotics

(Continued) Subjects

Treatment

DTwP vaccine: 1223 allergy high 4 weeks before expected diphtheria toxoid, delivery, mothers took risk infants: tetanus toxoid, one capsule twice daily; probiotic 32, inactivated Their infants received placebo 29 Bordetella pertussis; one opened capsule in Hib conjugate 20 drops sugar syrup vaccine: containing 0.8 g Haemophilus galactooligosaccharides influenzae type b, once daily for 6 months; tetanus toxoid, The infants received a Corynebacterium DTwP vaccine at 3, 4, diphtheria toxin and 5 months, and a Hib CRM197 conjugate at 4 months

Vaccine Protective Hib antibody concentrations (>1 mg/mL) occurred more frequently in probiotic group (50%) than placebo (21%), p ¼ 0.02; Geometric mean (interquartile range) Hib IgG tended to be higher in probiotic group, 0.75 (0.15–2.71) mg/mL than placebo, 0.40 (0.15–0.92) mg/mL (p ¼ 0.064); diphtheria IgG in probiotic 0.38 (0.14–0.78) versus placebo 0.47 (0.19–1.40) IU/mL (p ¼ 0.449); tetanus IgG in probiotic 1.01 (0.47–1.49) versus placebo 0.81 (0.56–1.39) IU/mL (p ¼ 0.310)

Clinical Trials

(305)

References

EFFECTS ON FARM ANIMALS

321

General Conclusion: There is no evidence that suggests impairment of vaccine responses. The probiotics may improve response to some of the vaccines, such as Haemophilus influenzae, rotavirus, and polio vaccines. 4.4 EFFECTS ON FARM ANIMALS

Allan Lim and Hai-Meng Tan Kemin Industries (Asia) Pte Ltd Singapore, Singapore

Probiotics are useful in the treatment of disturbed intestinal microbiota and increased gut permeability, which are characteristics of many intestinal disorders. Such bacteria are able to survive gastric conditions to colonize the intestine, at least temporarily, by adhering to the epithelium. They have been reported to improve the growth rate and feed utilization in pigs, chicken, and calves, and to improve their feed conversion ratio. There is a significant decrease in the occurrence of diarrhea as observed in pigs and calves fed with probiotics (352). Probiotics are also believed to neutralize the effect of enterotoxin from E. coli, which is pathogenic for pigs (326). The beneficial effects of probiotics ranged from displacement of harmful bacteria, such as Clostridium perfringens to reduction of bacterial urease activity, to synthesis of vitamins, stimulatory effects on the immune system, maintenance of a healthy normal balanced microbiota (eubiosis), and contribution to digestion (339, 358, 391–393). The positive effects of probiotics have been harnessed by humans since biblical times when fermented milk and dairy products were widely consumed by different cultures. In contrast, probiotics were only introduced to farm animals in the last two decades. As might be expected, most of the effects of probiotics in animals are associated with improved performance and to a lesser extent improved immunity against infections. The interest in using probiotics was also accelerated by the movement in developed countries especially the European Union to ban antibiotic growth promoters (AGP) from animal diets. The use of probiotics in place of growth promoting antibiotics has also been viewed by many leading animal meat producers as a major differentiation factor in highly sophisticated markets such as Japan. The effects of probiotics on animal performance can be influenced by the variability in farm practices, species, age, method of application, strains of microorganisms, and diet. It is now widely accepted that probiotics can improve animal performance through competitive exclusion with pathogens in the digestive systems, and that animals generally benefit from probiotic microorganisms isolated from their own digestive tracts (352, 401). There is also an evidence to suggest that probiotics compete with pathogens for specific receptors at the intestinal surfaces. In many cases, the propensity for pathogens to adhere to the intestinal surface is subjected to the dynamic microbial– host interactions in the gut, which can be further modulated by species, genotype, and age. The effects of probiotics on the gut immune system has been the subject of intense research in recent years. It is believed that probiotic supplementation to young animals will accelerate the maturation of the gut immune system resulting in lower morbidity

322


and mortality. As the use of synbiotics, which is a combination of pre- and probiotics, is gaining scientific credibility as functional food ingredients at nutritional and therapeutic levels (355, 377), there is also an increasing evidence to show its effectiveness in helping young animals to achieve a better growth performance (371, 332). 4.4.1

Poultry

Due to the higher sensitivity of poultry production to profitability, the impact of the ban on growth promoting antibiotics in Europe with effect from 1 January 2006 has a profound impact on poultry farming. Many alternatives to AGP have been evaluated in poultry production with mixed results. One of the more successful probiotic bacteria used in poultry production is Bacillus subtilis, from which proprietary strains have been offered (e.g., under the CloSTAT trade name (Kemin Industries, Inc., USA)). Apart from improving the growth benefits, B. subtilis is also known to inhibit the growth of pathogens in the digestive tract of chickens, which can lead to a considerable economic loss. The unique ability of a patented B. subtilis strain PB6 to kill Clostridium perfringens, Campylobacter jejuni, and Streptococcus pneumoniae has been demonstrated (354, 391) (Figs. (4.3–4.5). The spore-forming property of B. subtilis is also a huge advantage in their survival during pellet formation, which is now widely used for broiler feed production. Other commercial probiotics contain either a single strain of Enterococcus faecium (Protexin (Protexin, UK)) or a combination of strains from Lactobacillus, Streptococcus, and Enterococcus (Lactina, Lactina Ltd., Bulgaria). As the protective effect of probiotics on poultry is believed to be by competitive exclusion of pathogens, the adhesion of probiotics to the gastrointestinal tracts of poultry is a key performance parameter. Extensive studies have indicated that lactic acid bacteria (344, 322, 352), B. subtilis (391), and Enterocuccus faecium (363) have strong ability to colonize the intestines of animals. Many beneficial effects of probiotics are suggested such as improved immune system, modification of gut microbiota, reduced inflammatory reactions, decreased ammonia and urea

FIGURE 4.3 The effect of B. subtilis PB6 (CloSTAT) on Clostridium perfringens: (a) intact cell of C. perfringens and (b) rupture and death of the C. perfringens cell after 4 h of exposure to B. subtilis PB6 (CloSTAT) (transmission electron micrograph magnification: 29,000).


323

FIGURE 4.4 The effect of B. subtilis PB6 (CloSTAT) on Campylobacter jejuni at 37 C: (a) normal cells (magnification 29,500), (b) pertubation of cell wall after 1 h (magnification 47,000), and (c) rupture and cell death after 4 h (magnification 47,000).

excretion, lower serum cholesterol, improved mineral adsorption (393, 331, 372) that may have an indirect positive impact on the profitability of poultry production. There are other studies that document the tendency of probiotics to improve the growth performance of layers and egg quality. Table 4.1 summarizes the effects of probiotics on growth and other aspects of poultry production. 4.4.2

Swine

Pigs in the postweaning period are most vulnerable to enteric bacterial diseases, and are therefore subject to extensive antibiotic treatments to reduce mortality and morbidity. With the ban on growth promoting antibiotics in EU and more stringent use of therapeutic antibiotics, the use of probiotics to improve growth performance and resistance against bacterial diseases in pigs has been widely studied. The most notable project was the HEALTHYPIGUT sponsored by the EU between 2001 and 2004, which allowed scientists from nine research institutes to evaluate alternatives to

FIGURE 4.5 The effect of B. subtilis PB6 (CloSTAT) on Streptococcus pneumoniae at 37 C: (a) normal cells, (b) and (c) rupture and cell death after 4 h (magnification 29,500).

324 Turkeys

Layers

0.25 10 , 0.5 10 , and 1 106 cfu/g feed

8.8 108 cfu/g feed

20 mg/g diet

B. subtilis

Lactobacillus (Lacto)

B. subtilis (FPBS)

Female broilers

Animals 6

Dosage

Probiotics

6

Effects of Probiotics on Poultry

TABLE 4.1 Other Effects

Increased crop and cecal Significantly increased (p < 0.01) BW gain after B. sultilis counts but no 12 weeks and improved effects on intestinal E. coli and (p < 0.05) feed Lactobacillus counts efficiency after 20 weeks Significantly improved Significantly improved (p < 0.05) egg weight, (p < 0.05) BW gain for egg mass and egg size. corn–soybean meal and Significantly increased barley–corn–soybean (p < 0.05) passage rates meal diets by 24% and of digesta. Significantly 21%, respectively; no increased (p < 0.05) effects on feed retentions of fat, consumption and calcium, phosphorus, conversion copper, and manganese; no significant (p > 0.05) effects on internal egg quality and egg specific gravity Significant reductions Significant reductions (p < 0.05) in feed (p < 0.05) in the ratio of efficiency and nitrogen abdominal fat or liver to utilization BW, acetyl coenzyme A carboxylase activity, liver, and serum cholesterol contents

Growth Effects

(383)

(361)

(344)

References

325

Layers

Broiler chicks

Broilers

Broilers

4.84 107 cfu/g feed

2.4 105 cfu/g feed

1.6 107 (days 1–7), 4.0 106 (days 8– 40) cfu/g diet

0.5 106, 1.0 106, 1.5 106 cfu/g; 0.1% and 0.15% culture

Lactobacillus

L. casei

B. coagulans

Culture of L. acidophilus, L. fermentum, L. crispatus, and L. brevis

Significantly increased (p < 0.05) egg size by 2.1%; significantly improved (p < 0.05) nitrogen and calcium retention Significantly decreased (p < 0.05) urease activity in the small intestine during the first 3 weeks —

Numerical improvement in feed conversion (33–39 days), significantly higher (p < 0.054) mean BW and daily weight gain after 33 and 49 days Significantly Supplementation at reduced (p < 0.05) 0.5 106 and cecal coliform and 1.0 106 cfu/g Lactobacilli significantly improved counts after10 days (p < 0.05) feed Significantly conversion by 6% and reduced (p < 0.05) 13%, respectively, and serum cholesterol increased (p < 0.05) after 30 days BW from 1 to 42 days

Significantly increased (p < 0.05) average daily weight gain by 7.0% after 3 weeks

Significantly increased (p < 0.05) daily feed consumption by 2.5% during the laying phase

(continued)

(343)

(322)

(404)

(362)

326 Animals Male broilers

Dosage

—

Probiotics

Bacillus, Lactobacillus, Streptococcus, Clostridium. Saccharomyces, and Candida


Improved productivity

Growth Effects Significantly reduced (p < 0.05) water and increased (p < 0.05) lipid content in liver. Significantly decreased (p < 0.05) cholesterol content in thigh meat and liver, and significantly increased (p < 0.05) the linolenic acid and the unsaturated fatty acid/saturated fatty acid ratio in pectoral and thigh meat. Significantly reduced (p < 0.05) the number of E. coli and Salmonella in ceca, and significantly reduced (p < 0.05) the pH value of cecal contents. Significantly reduced (p < 0.05) the concentration of ammonia and increased (p < 0.05) the concentration of acetic acid in ceca

Other Effects (330)

References

327

Female broilers

Layers

1 106 cfu/g feed

0.5 106, 1.0 106, 1.5 106 cfu/g feed

0.5%, 1.0%, 2.0%

Lactobacillus culture

E. faecium

B. subtilis (FPBS)

Female broilers

Broilers

3 105 viable spores (cfu)/g feed

B. subtilis C-3102

Significant increase (p < 0.05) in BW after 21 days. Significant improvement (p < 0.05) in FCR by 1.9–3.0% between 21 and 42 days Significantly increased (p < 0.05) BW at day 21 by 22%; significantly increased (p < 0.05) weight gain and feed intake from day 1 to 42. Feed efficiency significantly improved by 42% from day 1 to 21 Significantly lower (p < 0.05) feed consumption and feed conversion for 500 ppm supplementation only FPBS at 0.5% and 1.0% significantly reduced (p < 0.05) feed intake and improved feed efficiency by 9.8% and 8.6%, respectively (384) FPBS at 1% and 2% significantly reduced (p < 0.05) ammonia gas excretion. Significantly reduced (p < 0.05) hepatic triglyceride and cholesterol contents

(continued)

(312)

(409)

(333)

Significantly lower damaged eggs for dosage at 1.0 106 cfu/g only

Significant reductions in aerobic plate count (p < 0.001) coliforms (p < 0.001), and Campylobacter (p < 0.05) in carcass Significantly increased antibody titer against Newcastle disease vaccine by 36% after 42 days

328 Chickens

Layers

0.5 10 , 1 10 , 3 106/g feed

2.7 105, 5.4 105 cfu/g feed

B. subtilis var. Natto

L. acidophilus þ L. casei, B. bifidum þ A. oryzae þ S. faecium þ Torulopsis spp. (Probiolac)

6

Animals

6

Dosage

Probiotics

TABLE 4.1 (Continued) Other Effects

Significantly higher Numerical increase in (p < 0.05) villus in feed intake and BW duodenum and ileum. gain after 28 days. Significantly broader Numerical (p < 0.05) cells in the improvement in feed duodenum and jejunum. efficiency after 28 days Significant increase (p < 0.05) in cell mitosis in jejunum. Significantly reduced (p < 0.05) serum ammonia after 28 days Significantly increased No effects on feed (p < 0.05) hen-housed conversion and BW egg production, shell gain weight and thickness. Significantly higher antibody titer against sheep red blood cells, and significantly higher cutaneous basophilic hypersensitivity CBH response phytohaemagglutinin

Growth Effects

(370)

(382)

References

329

Protexin Boost (L. plantarum, L. bulgaricus, L. acidophilus, L. rhamnosus, B. bifidum, S. thermophilus, E. faecium, A. oryzae, C. pintolopessi) Lactina (S. thermophilus, E. faecium, Lactobacillus)

E. faeium (Cernelle) 68 SF68

Broilers

Mule ducklings

0.3 mg/g feed

Broilers

—

0.035 mg/g diet

(continued)

(369) Numerical improvements Significantly reduced in feed consumption and (p < 0.05) serum aspartate feed efficiency aminotransferase (AST) and alanine aminotransfera (ALT) levels, and serum cholesterol. No effects on small intestine weight and ileum pH. No effect on blood parameters (346) Significantly increased Significantly increased (p < 0.01) carcass yield, (p < 0.01) live weight breast and leg weights. gains at 2nd, 4th, 5th Significantly higher and 6th weeks (p < 0.01) antibody titer to sheep red blood cells antigen, and significantly increased (p < 0.05) weights of bursa and spleen (328) Significantly increased Significantly increased (p < 0.05) weight of (p < 0.05) average BW by 3.4%, improved feed internal organs after 54 and 93 days. conversion by 3.74%, Significantly reduced and reduced mortality (p < 0.05) number of after 93 days E. coli, Lactobacilli, and Salmonella in cecum. No effects on blood parameters and serum cholesterol

330 Male broilers

Male broilers

102–103 cfu/g feed

B. subtilis PB6

Animals

10 cfu/g feed

3

Dosage

B. subtilis PB6

Probiotics


Numerically increase in Significantly improved Lactobacillus cell (p < 0.05) BW of counts in chime in unchallenged and jejunum of broilers, challenged broilers by unchallenged and 4.6% and 7.4%, challenged with a respectively, after 42 pathogenic strain of days. Significantly E. coli reduced (p < 0.05) feed conversion of the challenged broilers by 7.6% or 15% points after 42 days — Significantly decreased (p < 0.05) feed intake by 5.9% and improved (p < 0.05) feed conversion 2.6% from 21 to 42 days. Significantly increased (p < 0.05) in weight gain and feed intake from 1 to 42 days

Growth Effects

(393)

(392)

References


331

antibiotics in improving gut health in pigs, especially during the postweaning period. In one particular study, a combination of live yeast and Pediococccus acidilactici in piglet diets was found to improve the piglet’s intestinal mucosa, which is critical to nutrient absorption and immunity against pathogens. As can be seen in Table 4.2, the effects of probiotics is highly variable but it is with piglets that most of the significant success was observed. 4.4.3

Ruminants

The rumen is the site of active metabolism of carbohydrates and protein, accounting for almost all the energy and two-thirds of amino acids available to the ruminants. The condition in the rumen, which is characterized by constant temperature and pH (5.6 and 6.8), and lack of oxygen, is well suited for many strains of anaerobic bacteria, protozoa, and fungus. One of the earliest applications of probiotics was to treat ruminal acidosis by yeast. Ruminal acidosis is a condition characterized by the overproduction of volatile organic acids such as propionic acid and acetates when nonfiber carbohydrates are fed to cows and cattle. If left untreated, ruminal acidosis can lead to decreased appetite, lameness, diarrhea, and decreased milk fat content. Feeding yeasts to these animals often alleviated the effects of ruminal acidosis, probably due to lowering of redox potential in the rumen, increase in cellulolytic bacteria (325), and general improvement in ruminal digestion (399). Apart from treating ruminal acidosis, fungus, yeasts, and bacteria have been used in ruminants with varying success since the 1970s to increase milk production and weight gain, improve health status, and resistance to diseases. The high variability in trial results is in part attributed to the rumen microbiota, age, and diet of the animals. As the bacteria, yeast, fungus, and protozoa in the rumen of adult ruminants are formidable barriers to exogenous microorganisms, most of the success in probiotic application has been with calves. Since the microbiota of the small and large intestines of these immature ruminants are similar to the rumen except the absence of protozoa, many digestive disorders in calves can be treated by probiotics (380). The rumen of calves is populated first by cellulotytic and methanogenic bacteria, followed by cellulotytic and lactate fermenting bacteria by the 3rd week (308). The population of lactate fermenting bacteria will decrease gradually and by the 13th week, the ruminal flora of the calf will be similar to that of the adult ruminant (319). Protozoa are usually found after week 13 (319), although their establishment could be accelerated by switching milk to dry feeds (365). One of the main objectives of feeding calves with probiotics is to reduce morbidity and mortality caused by intestinal and respiratory diseases, and this was confirmed by a recent report on veal calves treated with multi-species probiotic (MSPB) (395). In beef cattle, the effects of probiotics is heavily dependent on the type of diet, age, and type of probiotics. Wallace and Newbold (400) pointed out that improvement in average daily gain is higher for beef cattle fed high forage diets than those on 50% concentrate. Among the different probiotics tested so far, several strains of lactic acid

332 Pigs

Pigs (4 weeks old)

Pigs (growingfinishing)

Gnotobiotic piglets

—

0.750 mg/g feed

0.500 mg/g feed, 0.500 mg/g feed

2 1012 cfu/milk feed

L. fermentum, S. salivarius

L. acidophilus (Probios), S. faecium type Cernelle 68 (Feed-Mate)

L. acidophilus (Probios), S. faecium type Cernelle 68 (Feed-Mate) L. acidophilus

Animals

Dosage

—

L. acidophilus tended to improve average daily gain and feed conversion with and without antibiotic supplementation. S. faecium type Cernelle 68 tended to decrease average daily gain Numerical reduction in average daily gain and feed conversion

—

Growth Effects

(373)

(372)

—

Significantly increased (p < 0.001) population of L. acidophilus in tissues and feces. Increased (p ¼ 0.06) white blood cell counts but had no effect on hemotocrit

(372)

(309)

References

Decreased E. coli in stomach —

Other Effects

Effects of Probiotics on the Performance of Pigs from Selected Studies Carried Out Since 1980

Probiotics

TABLE 4.2

333

4 103 cfu/g feed

4 103 cfu/g feed Growingfinishing (pigs 20kg), 2 103 cfu/g feed

L. acidophilus

L. acidophilus

Piglets

2 1012 cfu/day, Piglets 4 103 cfu/g feed

L. acidophilus (DDS 1), L. acidophilus (Probios)

Conventional piglets

2 1012 cfu/milk feed

L. acidophilus

Numerical improvement in average daily gain and feed conversion by 11% and 1.5%, respectively, by L. acidophilus (DDS 1). Numerical improvement in average daily gain and feed conversion by L acidophilus (Prebios) þ lactose. Numerical increase in average daily gain by L. acidophilus (Probios) No effects on daily gain, feed intake, and feed efficiency in three trials Significantly reduced (p < 0.05) daily gain by 5.8% in two trials. No effects on feed intake and feed efficiency

Slight reduction (p < 0.1) in average daily gains

—

—

Significant increased (p < 0.001) population of Lactobacilli in the intestines. Significantly reduced (p < 0.01) coliform counts L. acidophilus significantly increased (p < 0.05) fecal Lactobacilli counts. No effect on fecal coliform counts

(continued)

(336)

(336)

(374)

(373)

334 Small piglets

Sows

Pigs

—

106 cfu/g feed

0.5 mL/day

5 1010 cfu/day, 5 1010 cfu/day

S. faecium

S. faecalis

Lactobacillus fermentation product

L. acidophilus P47, L. acidophilus RP32

—

Numerical increase in average daily gain

—

Pigs (average Numerically improved weight of 31.2 kg) (p > 0.05) daily gain and feed intake by 1.4% and 2.3%, respectively, in three trials No significant Gnotobiotic effect on growth pigs (E. coli challenged)

2 10 cfu/g feed

L. acidophilus

Growth Effects

Animals

3

Dosage

Probiotics


(396)

Reduced diarrhea and recovered faster from E. coli challenge. Reduced mortality from 18% to 8.5% Significantly increased (p < 0.05) fecal coliforms and aerobic spore-forming bacilli counts. Inhibition of Salmonella sp. in the intestines of piglets Numerical reduction in E. coli in stomach. Jejunal coliform cell counts increased when challenged with E. coli. No effect on histopathology L. acidophilus RP32 significantly reduced (p < 0.05) serum cholesterol

(334)

(375)

(368)

(336)

References

—

Other Effects

335

Piglets

Pigs

0.1%

1 107 cfu/pig on days 1 and 7, 2 107 cfu/pig at weaning

L. bulgaricus, S. thermophilus

Lactobacillus sp.

L. plantarum, L. acidophilus, L. casei, S. faecium (Probios)

Piglets (weaned at day 2) Piglets (weaned at day 2)

Supplied in fermented milk Supplied in fermented milk

L. ruteri Significantly increased (p < 0.05) feed gain Increased feed intake and weight gain —

No effect on growth

Significantly increased (p < 0.05) lactase and dipeptidase activities during preweaning stage. Significantly increased surcease (p < 0.001), lactase (p < 0.01), tripeptidase (p < 0.05) at 17 days. Significant difference in the activities of sucrase (p < 0.01), dipeptidase (p < 0.05) and tripeptidase (p < 0.05) between the proximal and distal sites of the small intestines

—

Decreased pH and E. coli in the gut Decreased pH and E. coli in the gut

(continued)

(323)

(353)

(378)

(378)

336 Pigs

Sows, piglets

0.5 106 to 1 106 spores/g feed

B. cereus (CenBiot)

B. subtilis, B. licheniformis, B. pumilus

Piglets

Piglets

3 108–3 109 cfu/ piglet (suckling– weaning), 3 108– 3 109 cfu/piglet (suckling– weaning) 1 1010 cfu þ 1 1010 cfu/ piglet in milk replacer without antibiotics 3 106 cfu/g feed

B. pseudolongum, L. acidophilus

B. thermophilum þ B. animalis

Animals

Dosage

Probiotics


Significantly increased (p < 0.05) average daily weight gain by 24%. Significantly improved (p < 0.05) feed conversion during nursery phase

—

Significantly increased (p < 0.05) mean BW gain

Reduced fecal coliform counts, increased fecal lactic acid bacteria count. No effects on dry matter, NDF, ADF, ash and N digestibility Significantly reduced (p < 0.05) diarrhea from 35% to 18% in piglets. E. coli K88 was not detected in piglets fed B. cereus during suckling phase as compared to 18% in control

Significantly increased (p < 0.05) survival rate from 75% to 95%

Significantly increased (p < 0.005) — BW gain. B. pseudolongum significantly increased feed conversion by 8.3%

Growth Effects

(406)

(348)

(305)

(305)

References

337

1.6 106– 1.2 106 cfu/g feed (sows), 1.7 105– 1.2 105 cfu/g feed (piglets)

1.3 g/day

E. faecium SF68

A. oryzae (Amaferm)

E. faecium

107 viable spores/g feed, 106 viable spores/g feed —

B. licheniformis, B. toyoi

Sows

Sows, piglets

Piglets

Piglets

No significant effects on feed intake, body condition, piglet weaning weight or return to estrus

—

—

—

Reduced incidence of diarrhea, no infection of enterogenic E. coli Reduced infection of Chlamydiaceae from 85% to 60% (p < 0.05) Significantly reduced total IgG in piglets at 8 weeks (p < 0.01) and T cell (CD8þ) in the jejunal epithelium of piglets (p < 0.001). Reduction of up to 50% in frequency of b-hemolytic and O141 serovars of E. coli in piglets. No effects on fecal anaerobic and coliform bacteria counts of piglets and sows, and no effect on immune system of sows No significant effects on piglet and nursery pig growth

(continued)

(341)

(386)

(376)

(350)

338

E. faecium NCIMB 10415 (SF68), B. cereus var. toyoi NCIMB 40112

Probiotics


Piglets

1.5 mg/g feed

1.6 106, Gestating sows, lactating 1.2 106, sows, nursed 1.7 105, piglets, weaned 2 105 cfu/g dry piglets weight feed; 2.6 105, 4 105, 1.3 106, 1.4 106 cfu/g dry weight feed

Animals

Dosage No significant effects on average daily gain, feed intake, and feed-to-grain ratio —

Growth Effects

Supplementation with B. cereus significantly increased fecal IgA of sows (p ¼ 0.045) and piglets before weaning (p ¼ 0.004). Serum IgG was significantly increased (p < 0.001) by E. faecium and B. cereus in weaned piglets

—

Other Effects

(387)

(341)

References


339

bacteria and propionibacteria appear to have reproducible positive effects on daily gain and feed efficiency (349). These effects are probably the cumulative result of alterations to the chemical and biological environment of the rumen and the intestines (349). Since feedlot cattle have been recognized as a host for E. coli O157:H7, much attention has been focused on the reduction of this pathogen by competitive exclusion of probiotics. There are already some trials showing growth inhibition of E. coli O157:H7 by certain strains of E. coli (407) and reduced shedding of E. coli O157:H7 during slaughter (349). The effects of probiotics on the performance of dairy cattle has also attracted considerable attention due to the potential economic returns. Cultures of S. cerevisiae and A. oryzae have been used with mixed results on lactating cows. Some studies have reported significant improvements in dry matter intake, milk yield, and milk composition in cows fed probiotics. Most of the variability in the results can be attributed to farm environments, physiological status of animals, diets, and types of probiotics. In general, probiotics of fungal origin tended to be more effective in cows fed with medium to high amounts of concentrates or during early lactation (340). Interestingly, some studies have shown tendencies for improved growth and lactating performance in ruminants fed a combination of probiotics and prebiotics, such as lactic acid bacteria and mannanoligosaccharide on cows (335), and E. faecium and lactulose on calves (332). It is, however, not conclusive whether the positive effects of synbiotics (pro and prebiotic) are additive or synergistic. The effects of probiotics on health, growth, and performance of ruminants are summarized in Table 4.3. 4.4.4

Rabbits

Rabbits have been regularly used as test models for human probiotics (360), mainly due to the similarity of the digestive systems. As such, most of the studies concentrated on the ability of potential human probiotics to adhere and colonize the gastrointestinal tract of rabbits. There are a limited number of studies focused on improving the growth and well being of these animals. Yu and Tsen (405) reported that due to the limited resistance to the gastric juice and lack of adhesive capacity in the intestinal tract, the use of lactobacillus as probiotics in rabbits maybe limited. Table. 4.4 summarize the effects of probiotics on rabbits. 4.4.5

Pets

In 2006, the world’s dog and cat food imports by major importing countries were estimated at US$700, an increase of 11% over the previous year (410). One of the fastest growing markets for pet food is China, largely due to the growing affluence of the urban population and the perceived prestige associated with pet ownership (410). As pets are now regarded as human companions, their diets have also evolved from table scraps that fulfill the basic metabolic needs to highly formulated foods. In addition, providing nutritionally balanced diets to dogs and cats is now regarded as part of the pet owners’ responsibility to maintain the health and

340 Steers, lambs

Cows Female calves Female calves

1.85% in feed

0.3 108.7 cfu/day

—

1 107 cfu/g in milk replacer 109–1010 cfu/d/ calve

Yeast culture (Diamond V Mills, Inc., USA)

S. faecalis

S. faecium SF-68

S. faecium M 74 Calves

Calves (0–9 weeks)

1.5 10 – 24 108 cfu/feed

L. bulgaricus

L. acidophilus

Animals

8

Dosage

Probiotics

Improved fattening performance Numerically improved average daily gain No significant difference in growth performance and health

—

Significantly increased (p < 0.05) average daily gain by 43% in one of three trials for calves fed with Lactobacillus at 6 108 cfu/feed No significant effect on dry matter intake

Growth Effects

TABLE 4.3 Effects of Probiotics on Calves from Studies Since 1980

No significant effects on fecal lactobacillus and coliform counts, and no significant effects on nutrient digestibilities and nitrogen intake Significantly increased (p < 0.05) liquid flow rate in steers. No significant effects on liquid turnover time and ruminal fermentation of steers. No significant effects on dry matter intake, digestibility, water intake and urine excretion in lambs Significantly increased (p < 0.05) Bifidobacteria in the feces No significant effect on carcass quality No significant effect on carcass quality Significantly increased (p < 0.05) fecal Lactobacilli count

Other Effects

(345)

(318)

(317)

(368)

(306)

(388)

References

341

Calves

Calves

2.2 109, 2.2 106, 1.1 109 cfu/day; 1.24 1010 cfu/day

L. acidophilus, L. lactis, B. subtilis (Biomate FG), B. subtilis (Biomate 2B)

Calves

—

0.92–5.5 g/kg starter before weaning, 0.28– 1.65 g/kg starter after weaning

Cows

90 g/day, 90 g/day, 2.63 g/day

A. oryzae (Amaferm)

Yeast culture (Diamond V Mills, Inc., USA), Yeast þ A. oryzae fermentation extract (Vitaferm), A. oryzae fermentation extract (Amaferm) A. oryzae Increased feed intake and weight gains Significantly reduced the number of weeks to weaning in heifer calves (p < 0.05) and heifer subset (p < 0.01). Amaferm at higher dosage significantly increased (p < 0.05) feed intake from week 5 to 10 No significant effect on growth by both probiotics. Calves fed B. subtilis concentrate tended to have highest feed efficiency

—

Numerically higher fecal Lactobacilli counts in calves fed mixed concentrate

Significantly increased (p < 0.05) ruminal ammonia content. No significant effects on the content of lactate, volatile fatty acid, and ratio of acetate: propionate in the rumen

Crude protein and hemicellulose digestibility, and ruminal cellulolytic bacteria count were significantly increased (p < 0.01) by all fungal supplements. Dry matter digestibility was significantly increased (p < 0.05) by supplements containing A. oryzae. Numerical increase in acetate:propionate ratio by all fungal supplements —

(continued)

(342)

(314)

(307)

(402)

342 Calves

Calves

109 cfu/day, 109 B. pseudolongum, L. acidophilus, cfu/day, B. thermophilum þ 1 1010 cfu þ E. faecium þ 1 1010 cfu þ L acidophilus 1 109 cfu/day in milk replacer

1 1010 cfu þ 1 1010 cfu þ 1 109 cfu/day in milk replacer 5.5 105, 5.5 102, 2.75 105, cfu/g milk replacer 5 107 cfu/feed/ calve

L. acidophilus, L. lactis, B. subtilis (Biomate FG) L. acidophilus Calves

Bull calves

Cows

1.68 10 cfu of S. cerevisiae/day in TMR

S. cerevisiae, A. oryzae extract (Diamond V Mills, Inc., USA)

B. thermophilum þ E. faecium þ L acidophilus

Animals

9

Dosage

Probiotics


Significantly improved (p < 0.01) BW gain during first 2 weeks. No significant difference in total BW gain and feed efficiency

BW gain was significantly increased by B. pseudolongum and L. acidophilus by 25% and 22%, respectively. Feed conversion was significantly improved by B. pseudolongum and L. acidophilus by 11% and 13%, respectively Numerical increased (p > 0.05) BW gain and improved (p > 0.05) feed conversion No significant effect, on BW gain and starter consumption

—

Growth Effects

(359)

(324)

No significant effect on occurrence of diarrhea

(305)

(305)

(337)

References

Significantly increased mean capsular volume of blood after 10 days

Reduced diarrhea from 78% to 10%

Significantly reduced (p < 0.05) lactose and SNF (solidsnonfat) contents. No effects on milk yield, milk fat, and protein contents No significant effect on fecal score

Other Effects

343

Calves

Beef steers

Beef steers

Beef steers

Cows

1010 cfu/calve in 2% skimmed milk

109 þ 106 cfu/g feed, 109 þ 106 cfu/g feed, 109 þ 108 cfu/g feed

1 107– 1 109 cfu/day

1 106, 1 109, 1 109 cfu/ animal/day

5 g/day in TMR

E. coli (17 strains), Proteus mirabilis

P. freudenreichii (PF24) þ L. acidophilus (LA45), P. freudenreichii (PF24) þ L. acidophilus (LA45þLA51) P. acidipropionici

L. acidophilus (NP45), L. acidophilus (NP51), P. freudenreichii A. oryzae fermentation extract (Amaferm)

Cows

5 1011 cfu/day

S. cerevisiae (Biomate Yeast Plus)

No significant difference to growth performance when in treatments with single or combination of probiotics —

—

Significantly increased (p < 0.05) average daily gain and feed efficiency by 6.9% and 4.8%, respectively

—

No significant effect on dry matter intake (p > 0.10)

Acetate:propionate ratio was significantly reduced (p < 0.05) except at 108 cfu/ day dosage. Significantly decreased (p < 0.01) butyrate with increasing dosage Significant reduction in lamina propria thickness (p ¼ 0.02) and decreased fecal E. coli shedding (p ¼ 0.06) by L acidophilus No effects on lactation performance and rumen parameters

Numerically increased milk urea nitrogen (p > 0.10). No effect, on milk yield and milk composition (p < 0.10) E. coli O157:H7 was not recovered from the rumen of the calves challenged with the pathogen Tended to increase carcass quality (p > 0.05)

(continued)

(338)

(329)

(347)

(381)

(407)

(389)

344 Animals Cows

Beef steers

5 10 , 5 109 cfu/ cow/day

1 109 cfu/steer/ day, 1 107, 1 108, 1 109 cfu/steer/ day

E. faecium, S. cerevisiae (Probios TC)

P. freudenreichii (NP24), L. acidophilus (NP51)

9

Dosage

Probiotics


No significant effects (p > 0.10) on final BW and dry matter intake. Mixture of P. freudenreichii and L. acidophilus significantly improved (p < 0.05) gain efficiency by approximately 2%

No significant effects on BW change

Growth Effects Significantly reduced in situ undegraded forage dry matter at 12 h (p < 0.05), 24, 28, and 72 h (p < 0.01). Increased dry matter intake at prepartum (p < 0.1) and postpartum periods. Significantly increased milk lactose content (p < 0.05). Numerically increased milk protein yield (p > 0.1). Significantly increased (p < 0.05) blood glucose 7 days postpartum and reduced b-hydroxybutyrate at 1 day (p < 0.01), þ1 (p < 0.09) and þ7 (p > 0.05) days postpartum Numerical increase (p ¼ 0.10) in marbling score and percentage of USDA choice cattle

Other Effects

(398)

(366)

References

345

Animals Rabbits

Infant rabbits

Rabbits

Dosage

108 cfu/kg BW

—

5.8 1010 cfu/day, 3.6 1010 cfu/ day

L. delbrueckii subsp. Bulgaricus, S. thermophilus, L. acidophilus

L. casei Shirota

S. thermophilus (Sc. t.), L. delbrueckii ssp. bulgaricus (Lb. b.)

The Effects of Probiotics on Rabbits

Probiotics

TABLE 4.4

—

—

No effect on growth in rabbits on casein diets

Growth Effects Rabbits fed with L. delbrueckii subsp. Bulgaricus and S. thermophilus showed increased in intestinal Enterococcus population. Reduced cecal C. septicum and C. clostridiforme from 80.7% and 12.7%, respectively, to 0. Significantly reduced (p < 0.05) plasma cholesterol Decreased severity of diarrhea and lowered the level of STEC colonization in the gastrointestinal tract Probiotic strains were recovered in wet feces for the stomach, the duodenum and large intestine at 105, 107 cells/mL, and 107 cells/g, respectively, after supplementation

Other Effects

(continued)

(327)

(367)

(320)

References

346 Animals Doe rabbits

Rabbits

0.2 10 spores/g feed

2 105–1 106 spores/g feed

B. cereus var. toyoi

B. cereus var. toyoi

6

Dosage

Probiotics


Significant increase (p ¼ 0.002) in final live weight by 2.5%, significant increase (p ¼ 0.01) in daily weight gain by 4.2%, and significantly improved (p ¼ 0.01) feed conversion by 3.7%

No effect on daily feed intake during lactation, feed efficiency increased significantly (p ¼ 0.01) by 15% to 0.314. No effect on doe BW at parturition or at weaning

Growth Effects Significantly shortened (p ¼ 0.05) interval from parturition to effective mating and between parturitions, and tended to improve litter size at weaning (p ¼ 0.09). Litter weight at weaning tended to be higher (p ¼ 0.10) Significantly reduced (p ¼ 0.03) morbidity by 43.4%

Other Effects

(394)

(364)

References

347

Animals Dogs

Gnotobiotic mice

8 weeks old puppy

Dogs

Dosage

7.5 106 cfu/day

109 cells/mL

5 108 cfu/day

9.2 109 cfu/day

Bacillus CIP 5832

L. acidophilus, E. faecium, S. cerevisiae

E. faecium SF68

E. faecium NCIB 10415 —

No significant effects on feed intake and weight gain

Numerical improvement in dry matter, protein, and energy digestibility —

Growth Effects

The Effects of Probiotics on Cats and Dogs from Recent Studies

Probiotics

TABLE 4.5

Mice fed with E. faecium survived challenge with S. typhimurium (p < 0.05). By comparison, survival time was longer (p < 0.05) for mice fed with the three probiotic than those fed with L. acidophilus or S. cerevisiae Significantly increased mature B cells (CD21þ/MHCIIþ) by 7.4% and 4.5% after 31 and 44 weeks, respectively Significant reduction (p < 0.05) in fecal counts of Clostridium spp. in 10 out of 12 dogs; numerical increase in Salmonella spp. and Campylobacter spp. in all dogs

—

Other Effects

(continued)

(397)

(311)

(356)

(315)

References

348 Dogs

>109 cfu/day

L. acidophilus

Animals Canine jejunal mucosa

8

10 –10 cfu/mL

7

Dosage

L. rhamnosus GG, B. lactis Bb12, L. pentosus UK1A, Sk2A, E. faecium M74, SF273

Probiotics


—

—

Growth Effects Significantly reduced (p < 0.05) the adhesion of C. perfringens. Both strains of Enterococci significantly enhanced (p < 0.05) the adhesion of canine pathogen Campylobacter jejuni Significant increases (p < 0.05) in red blood cells, hematocrit, hemoglobin concentration, neutrophils, monocytes, and serum immunoglobin G concentration, and significant reductions (p < 0.05) in RBC fragility and serum nitric oxide concentration

Other Effects

(310)

(379)

References

349

Dogs

Dogs

Adult dogs

—

109 cfu/(g day)

109 cfu/day

L. fermentum AD1

L. acidophilus NCC2628, NCC2766, L. johnsonii NCC2767

L. animalis LA4

Cats

2 108 cfu/day

L. acidophilus (DSM 13241)

—

No significant effect on BW

—

–

Significant reduction in fecal population of Clostridium spp (p ¼ 0.011) and E. faecalis (p < 0.001). Significant increased (p < 0.001) fecal population of Lactobacilli and L. acidophilus. Reduced plasma endotoxin concentration, improved white blood cell counts and phagocytic capacity Significant increase in fecal Lactobacilli and Enterococci counts. Significant increase in serum total protein and total lipid, and significant reduction of serum glucose Significant reduction (p < 0.0001) in Canine Inflammatory Bowel Disease Activity Index in all dogs suffering from food responsive diarrhea Increased fecal Lactobacilli and reduced fecal Enterococci (p ¼ 0.08) (313)

(385)

(390)

(357)

350


well being of these animals (316). The correlation between the gastrointestinal tract and overall health of the animals has led to a deluge of probiotics and prebiotics into pet food in recent years (316). Many such products contain mixtures of probiotic bacteria strains from Pediococcus, Lactobacillus, Bifidobacterium, Bacillus, Streptococcus, Enterococcus, or Saccharomyces yeast with claims of improved digestion, increased appetite, reduced diarrhea, increased firmness of stool, reduction in vomiting, reduction of body odor, reduction of flatulence, or improved swallowing. A more recent patent claimed improved health when pets were fed on a mixture of lactic acid bacteria preparation from Lactobacillus reuteri NCC2581 (CNCM I-2448), Lactobacillus reuteri NCC2592 (CNCM I-2450), Lactobacillus rhamnosus NCC2583 (CNCM I-2449), Lactobacillus reuteri NCC2603 (CNCM I-2451), Lactobacillus reuteri NCC2613 (CNCM I-2452), Lactobacillus acidophilus NCC2628 (CNCM I-2453), and Enterococcus faecium SF 68 (NCIMB 10415) (408). The scientific basis for many such claims remains to be verified by independent studies. Weese and Arroyo (403) reviewed 19 commercial pet foods containing probiotics and concluded that the average bacterial count was 1.8 105 cfu/g, and no relevant bacteria growth was present in five of the products. This implies that a significant number of products may not have enough viable bacteria to colonize the digestive tracts of the pets, and could also explain the mixed response seen in a small number of studies cited by Myers (360). A summary of more recent outcomes on supplementation of the diets of cats and dogs with probiotics is presented in Table 4.5.

REFERENCES 1. Bengmark S, Bacteria for optimal health. Nutrition 2000; 16: 611–615. 2. Camilleri M. Probiotics and irritable bowel syndrome: rationale, putative mechanisms, and evidence of clinical efficacy. J. Clin. Gastroenterol. 2006; 40(3): 264–269. 3. Chouraqui JP, Van Egroo LD, and Fichot MC. Acidified milk formula supplemented with bifidobacterium lactis: impact on infant diarrhea in residential care settings. J. Pediat. Gastroenterol. Nutr. 2004; 38(3): 288–292. 4. Collado MC, Meriluoto J, and Salminen S. In vitro Analysis of probiotic strains combinations to inhibit pathogen adhesion to human intestinal mucus. Food Res. Int. 2007; 40(5): 629–636. 5. FAO/WHO. Guidelines for the evaluation of probiotics in food. Food and Agricultural Organization of the United Nations and World Health Organization. Working Group Report, 2002. 6. Forestier C, De Champs C, Vatoux C, and Joly B. Probiotic activities of Lactobacillus casei rhamnosus: in vitro adherence to intestinal cells and antimicrobial properties. Res. Microbiol. 2001; 152: 167–173. 7. Gaudier E, Michel C, Segain JP, Cherbut C, and Hoebler C. The VSL# 3 probiotic mixture modifies microflora but does not heal chronic dextran-sodium sulfate-induced colitis or reinforce the mucus barrier in mice. J. Nutr. 2005; 135(12): 2753–2761.

REFERENCES

351

8. Gotteland M, Brunser O, and Cruchet S. Systematic review: are probiotics useful in controlling gastric colonization by Helicobacter pylori? Aliment. Pharmacol. Ther. 2006; 23(8): 1077–1086. 9. Juntunen M, Kirjavainen PV, Ouwehand AC, Salminen SJ, and Isolauri E. Adherence of probiotic bacteria to human intestinal mucus in healthy infants and during rotavirus infection. Clin. Diagn. Lab. Immunol. 2001; 8(2): 293–296. 10. Kajander K, Hatakka K, Poussa T, Farkkila M, and Korpela R. A probiotic mixture alleviates symptoms in irritable bowel syndrome patients: a controlled 6-month intervention. Aliment. Pharmacol. Ther. 2005; 22(5): 387–394. 11. Kalliom€aki M, Salminen S, Arvilommi H, Kero P, Koskinen P, and Isolauri E. Probiotics in primary prevention of atopic disease: a randomised placebo-controlled trial. Lancet 2001; 357: 1076–1079. 12. Kim HJ, Vazquez Roque MI, Camilleri M, Stephens D, Burton DD, Baxter K, Thomforde G, and Zinsmeister AR. A randomized controlled trial of a probiotic combination VSL#3 and placebo in irritable bowel syndrome with bloating. Neurogastroenterol. Motil. 2005; 17(5): 687–696. 13. McFarland LV. Meta-analysis of probiotics for the prevention of antibiotic associated diarrhea and the treatment of Clostridium difficile disease. Am. J. Gastroenterol. 2006; 101: 812–822. 14. Parvez S, Malik KA, Ah Kang S, and Kim HY. Probiotics and their fermented food products are beneficial for health. J. Appl. Microbiol. 2006; 100(6): 1171–1185. 15. Rautava S, Arvilommi H, and Isolauri E. Specific probiotics in enhancing maturation of IgA responses in formula-fed infants. Pediatr. Res. 2006; 60(2): 221–224. 16. Salminen S, Bouley C, Boutron-Ruault M-C, Cummings JH, Franck A, Gibson GR, Isolauri E, Moreau M-C, Roberfroid M, and Rowland I. Functional food science and gastrointestinal physiology and function. Br. J. Nutr. 1998; 80: S147–S171. 17. Salminen S, Ouwehand AC, Benno Y, and Lee YK. Probiotics: how should they be defined? Trends Food Sci. Technol. 1999; 10: 107–110. 18. Santosa S, Farnworth E, and Jones PJ. Probiotics and their potential health claims. Nutr. Rev. 2006; 64(6): 265–274. 19. Sazawal S, Hiremath G, Dhingra U, Malik P, Deb S, and Black RE. Efficacy of probiotics in prevention of acute diarrhoea: a meta-analysis of masked, randomised, placebocontrolled trials. Lancet Infect. Dis. 2006; 6(6): 374–382. 20. Timmerman HM, Koning CJ, Mulder L, Rombouts FM, and Beynen AC. Monostrain, multistrain, and multispecies probiotics––A comparison of functionality and efficacy. Int. J. Food Microbiol. 2004; 96: 219–233. 21. Turnbaugh PJ, Ley RE, Mahowald MA, Magrini V, Mardis ER, and Gordon JI. An obesity-associated gut microbiome with increased capacity for energy harvest. Nature 2006; 444(7122): 1027–1031. 22. Aduayom I, Campbell PGC, Denizeau F, and Jumarie C. Different transport mechanisms for cadmium and mercury in Caco-2 cells: inhibition of Cd uptake by Hg without evidence for reciprocal effects. Tox. Appl. Pharmacol. 2003; 189: 56. 23. Arredondo M, Orellana A, Garate MA, and Nuu´~nez MT. Intracellular iron regulates iron absorption and IRP activity in intestinal epithelial (Caco-2) cells. Am. J. Physiol.– Gastroenterol. L. 1997; 273: G275–G280.

352


24. Audus KL, Bartel RL, Hidalgo IJ, and Borchardt RT. The use of cultured epithelial and endothelial cells for drug transport and metabolism studies. Pharm. Res. 1990; 7: 435–451. 25. Bernet M-F, Brassart D, Neeser J-R, Servin AL. Adhesion of human Bifidobacterial strains to cultured human intestinal epithelial cells and inhibition of enteropathogen-cell interactions. Appl. Environ. Microbiol. 1993; 59: 4121–4128. 26. Bestwick CS and Milne L. Effects of b-carotene on antioxidant enzyme activity, intracellular reactive oxygen, and membrane integrity within post confluent Caco-2 intestinal cells. Biochim. Biophys. Acta. 2000; 1474: 47–55. 27. Caro I, Boulenc X, Rousset M, Meunier V, Bourrie M, Julian B, Joyeux H, Roques C, Berger Y, Zweibaum A, and Fabre G. Characterization of a newly isolated Caco-2 clone (TC-7), as a model of transport processes and biotransforming of drugs. Int. J. Pharma. 1995; 116: 147–158. 28. Cheng H and Leblond CP. Origin, differentiation, and renewal of the four main epithelial cell types in the mouse small intestine. V. Unitarian Theory of the origin of the four epithelial cell types. Am. J. Anat. 1974; 141: 537–561. 29. Chung YS, Song IS, Erickson RH, Sleisenger MH, and Kim YS. Effect of growth and sodium butyrate on brush border membrane-associated hydrolases in human colorectal cancer cell lines. Cancer Res. 1985; 45: 2976–2982. 30. Cilla A, Laparra JM, Alegria A, Barbera R, and Farre R. Antioxidant effect derived from bioaccessible fractions of fruit beverages against H2O2-induced oxidative stress in Caco-2 cells. Food Chem. 2008; 106: 1180–1187. 31. Collado MC and Sanz Y. Method for direct selection of potentially probiotic Bifidobacterium strains from human feces based on their acid-adaptation ability. J. Microbiol. Meth. 2006; 66(3): 560–563. 32. Crociani J, Grill J-P, Huppert M, and Ballongue J. Adhesion of different Bifidobacteria strains to human enterocyte-like Caco-2 cells and comparison with in vivo study. Lett. Appl. Microbiol. 1995; 21: 146–148. 33. Dantzig AH and Bergin L. Uptake of the cephalosporin, cephalexin, by a dipeptide transport carrier in the human intestinal cell line, Caco-2. Biochim. Biophys. Acta. 1990; 1027: 211–217. 34. Delgado S, O’Sullivan E, Fitzgerald G, and Mayo B. Substractive screening for probiotic properties of Lactobacillus species from the human gastrointestinal tract. J. Food Sci. 2007; 72: 310–313. 35. Ekmekcioglu C. A physiological approach for preparing and conducting intestinal bioavailability studies using experimental systems. Food Chem. 2002; 76: 225–230. 36. Figueiredo PMS, Furumura MT, Aidar-Ugrinovich L, Pestana de Castro AF, Pereira IL, and Yano T. Induction of apoptosis in Caco-2 and HT29 human intestinal epithelial cells by enterohemolysin produced by classic enteropathogenic Escherichia coli. Lett. Appl. Microbiol. 2007; 45: 358–363. 37. Gangloff MB, Glahn RP, Miller DD, Norwell WA, and Van Campen DR. Assessment of iron availability using combined in vitro digestion and Caco-2 cell culture. Nutr. Res. 1996; 16: 479–487. 38. Glahn RP, Gangloff MB, Miller DD, Wien EM, Kapsokefalou M, and Van Campen DR. Use of In vitro digestion and Caco-2 cell culture to study iron uptake/bioavailability. FASEB J. 1994; 8: A712.

REFERENCES

353

39. Gueimonde M, Jalonen L, He F, Hiramatsu M, and Salminen S. Adhesion and competitive inhibition and displacement of human enteropathogens by selected lactobacilli. Food Res. Int. 2006; 39(4): 467–471. 40. Hidalgo IJ, Raub TJ, and Borchardt RT. Characterization of the human-colon carcinoma cell-line (Caco-2) as a model system for intestinal epithelial permeability. Gastroenterol. 1989; 96: 736–749. 41. Hu M and Borchardt RT. Transport of a large neutral amino acid in a human intestinal epithelial cell line (Caco-2): uptake and efflux of phenylalanine. Biochim. Biophys. Acta. 1992; 1135: 233–244. 42. Johnson DM, Yamaji S, Tennant J, Srai SK, and Sharp PA. Regulation of divalent metal transporter expression in human intestinal epithelial cells following exposure to nonhaem iron. FEBS Lett. 2005; 579: 1923–1929. 43. Kaur M, Singh RP, Gu M, Agarwal R, and Agarwal C. Grape seed extract inhibits In vitro and In vivo growth of human colorectal carcinome cells. Clin. Cancer Res. 2006; 12: 6194–6202. 44. Laparra JM, Velez D, Montoro R, Barbera R, and Farre R. Bioavailability of inorganic arsenic in cooked rice: practical aspects for human health risk assessment. J. Agric. Food Chem. 2005; 53: 8829–8833. 45. Laparra JM, Velez D, Montoro R, Barbera R, and Farre R. Evaluation of the human intestinal permeability of As(III) and its effects upon intracellular GSH levels using Caco2 cells. Toxicol. In vitro 2006; 20: 658–663. 46. Lenaerts K, Bouwman FG, Lamers WH, Renes J, and Mariman EC. Comparative proteomic analysis of cell lines and scrapings of the human intestinal epithelium. BMC Genomics 2007; 8: 1–14. 47. Lesuffleur T, Barbat A, Luccioni C, Beaumatin J, Clair M, Kornowski A, Dussaulx E, Dutrillaux B, and Zweibaum A. Dihydrofolate reductase gene amplification-associated shift of differentiation in methotrexate-adapted HT-29 cells. J. Cell Biol. 1991; 115: 1409–1418. 48. Lesuffleur T, Porchet N, Aubert JP, Swallow D, Gum JR, Kim YS, Real FX, and Zweibaum A. Differential expression of the human mucin genes MUC1 to MUC5 in relation to growth and differentiation of different mucus-secreting HT-29 cell subpopulations. J. Cell Sci. 1993; 106: 771–783. 49. Mattila-Sandholm T, Myll€arinen P, Crittenden R, Mogensen G, Fonden R, and Saarela M. Technological challenges for future probiotic foods. Int. Dairy J. 2002; 12: 173–182. 50. Novellaux G, Deville C, El Moualij B, Zorzi W, Deloyer P, Schenider YJ, Peulen O, and Dandrifosse G. Development of a serum-free co-culture of human intestinal epithelium cell-lines (Caco-2/HT29-5M21). BMC Cell Biol. 2006; 7: 1–11. 51. Pinto M, Robine-Leon S, Appay MD, Kedinger M, Triadou N, Dussaulx E, Lacroix B, Simon-Assmann P, Haffen K, Fogh J, and Zweibaum A. Enterocyte-like differentiation and polarization of the human colon carcinoma cell line caco-2 in culture. Biology of the Cell 1983; 47: 323–330. 52. Pontier C, Pachot J, Botham R, Lenfant B, and Arnaud P. HT29-MTX and Caco-2/TC7 monolayers as predictive models for human intestinal absorptioin: role of the mucus layer. J. Pharma. Sci. 2001; 90: 1608–1619. 53. Potten CS. Stem cells in gastrointestinal epithelium: numbers, characteristics and death. Phil. Trans. Royal Soc. Lond. B-Biol. Sci. 1998; 353: 821–830.

354


54. Schaefer S, Baum M, Eisenbrand G, and Janzowski C. Modulation of oxidative cell damage by reconstituted mixtures of phenolic apple juice extracts in human colon cell lines. Mol. Nutr. Food Res. 2006; 50: 413–417. 55. Schlee M, Harder J, Koten B, Stange EF, Wehkamp J, and Fellerman K. Probiotic lactobacilli and VSL#3 induce enterocyte beta-defensin 2. Clin. Exp. Immunol. 2008; 151: 528–535. 56. Van Campen DR and Glahn RP. Micronutrient bioavailability techniques: accuracy, problems and limitations. Field Crops Res. 1999; 60: 93–113. 57. Walter E and Kissel T. Transepithelial transport and metabolism of thyrotropin-releasing hormone (TRH) in monolayers of a human intestinal cell line (Caco-2): evidence for an active transport component? Pharm. Res. 1994; 11: 1575–1580. 58. Walter E, Janich S, Roessler BJ, Hilfinger JM, and Amidon GL. HT29-MTX/Caco-2 cocultures as an in vitro model for the intestinal epithelium: In vitro–In vivo correlation with permeability data from rats and humans. J. Pharm. Sci. 1996; 85: 1070–1076. 59. Wehkamp J, Harder J, Wehkamp K, Meissner W, Schlee M, Enders C, Sonneborn U, Nuding S, Bengmark S, Fellerman K, Schr€oder JM, and Stange EF. NF-kB- and AP-1mediated induction of human beta defensin-2 in intestinal epithelia cells by Eschericia coli Nissle 1917: a novel effect of probiotic bacterium. Infect. Immun. 2004; 72: 5750– 5758. 60. Wikman A, Karlsson J, Carlstedt I, and Artursson P. A drug absorption model based on the mucus layer producing human intestinal globet cell line HT29-H. Pharm. Res. 1993; 10: 843–852. 61. Yokomizo A and Moriwaki M. Effects of flavonoids on oxidative stress induced by hydrogen peroxide in human intestinal Caco-2 cells. Biosci. Biotech. Biochem. 2006; 70: 1317–1324. 62. Zweibaum A, Pinto M, Chevalier G, Dussalux E, Triadou N, Lacroix B, Haffen K, Brun JL, and Rousset M. Enterocytic differentiation of a subpopulation of the human colon tumour cell line HT-29 selected for growth in sugar-free medium and its inhibition by glucose. J. Cell Biol. 1985; 122: 21–29. 63. European, Convention for the Protection of Vertebrate Animals Used for Experimental and Other Scientific Purposes (European Treaty Series 123), Council of Europe, Strasbourg, 1986. 64. European Commission, Provisions of the European Union Member States Regarding the Protection of Animals Used for Experimental and Other Scientific Purposes, Directive 86/609/EEC. Off. J. Eur. Comm. 1986; 1: L358. 65. National Research Council, Institute of Laboratory Animal Resources, Guide for the Care and Use of Laboratory Animals, National Academy Press, Washington D.C., 1996. 66. Russell WMS and Burch RL. The Principles of Humane Experimental Technique, Methuen & Co. Ltd., London, 1959. 67. Gueimonde M, Frias R, and Ouwehand AC. Assuring the continued safety of lactic acid bacteria used as probiotics. Biol. Bratislava. 2006; 61(6): 755–760. 68. Pelletier C, Bouley C, Bourliov P, Carbon C. Evaluation of safety properties of Lactobacillus strains by using an experimental model of endocarditis in rabbit. SOMED Meeting, Paris 1996. 69. Nonaka Y, Izumo T, Izumi F, Maekawa T, Shibata H, Nakano A, Kishi A, Akatani K, and Kiso Y. Antiallergic effects of Lactobacillus pentosus strain S-PT84 mediated by

REFERENCES

70.

71.

72.

73.

74.

75.

76.

77. 78.

79.

80. 81. 82. 83. 84. 85.

355

modulation of Th1/Th2 immunobalance and induction of IL-10 production. Int. Arch. Allergy Immunol. 2008; 145(3): 249–257. Amital H, Gilburd B, and Shoenfeld Y. Probiotic supplementation with Lactobacillus casei (Actimel) induces a Th1 response in an animal model of antiphospholipid syndrome. Ann. N.Y. Acad. Sci. 2007; 1110: 661–669. Bl€umer N, Sel S, Virna S, Patrascan CC, Zimmermann S, Herz U, Renz H, and Garn H. Perinatal maternal application of Lactobacillus rhamnosus GG suppresses allergic airway inflammation in mouse offspring. Clin. Exp. Allergy 2007; 37(3): 348–357. Bauer E, Williams BA, Smidt H, Verstegen MW, and Mosenthin R. Influence of the gastrointestinal microbiota on development of the immune system in young animals. Curr. Issues Intest. Microbiol. 2006; 7(2): 35–51. McVay MR, Boneti C, Habib CM, Keller JE, Kokoska ER, Jackson RJ, and Smith SD. Formula fortified with live probiotic culture reduces pulmonary and gastrointestinal bacterial colonization and translocation in a newborn animal model. J. Pediatr. Surg. 2008; 43(1): 25–29. Mogilner JG, Srugo I, Lurie M, Shaoul R, Coran AG, Shiloni E, and Sukhotnik I. Effect of probiotics on intestinal regrowth and bacterial translocation after massive small bowel resection in a rat. J. Pediatr. Surg. 2007; 42(8): 1365–1371. Ruan X, Shi H, Xia G, Xiao Y, Dong J, Ming F, and Wang S. Encapsulated Bifidobacteria reduced bacterial translocation in rats following hemorrhagic shock and resuscitation. Nutrition 2007; Oct 23(10): 754–761. Daniel C, Poiret S, Goudercourt D, Dennin V, Leyer G, and Pot B. Selecting lactic acid bacteria for their safety and functionality by use of a mouse colitis model. Appl. Environ. Microbiol. 2006; 72(9): 5799–5805. Hau J and van Hoosier GL. In: Animal Models, Vol. II, 2nd ed. Laboratory Animal Science, 2004, pp. 1–9. Nicklas W, Baneux P, Boot R, Decelle T, Deeny AA, Fumanelli M, and Illgen-Wilcke B. FELASA (Federation of European Laboratory Animal Science Associations Working Group on Health Monitoring of Rodent and Rabbit Colonies). Recommendations for the health monitoring of rodent and rabbit colonies in breeding and experimental units. Lab. Anim. 2002; 36(1): 20–42. Nicklas W, Homberger F, Illgen-Wilcke B, Jacobi K Kraft V, Kunstyr I, M€ahler M, Meyer H, and Phlmeyer-Esch G. GV-SOLAS (Working Group on Hygiene). Implications of infectious agents on results of animal experiments. Lab Anim . 1999; Jan 33 (Suppl. 1) S1: 39–S2: 87. Schmidt-Nielsen K, How Animals Work. Cambridge University Press, London, 1972. Schmidt-Nielsen K. Animal Physiology, Adaptation and Environment. Cambridge University Press, London, 1975. Kleiber M. Body size and metabolism. Hilgardia. 1932; 6: 135. Hau J and Poulsen OM. Doses for laboratory animals based on metabolic rate. Scand. J. Lab. Anim. Sci. 1986; 15: 81. Isolauri E, Arvola T, Sutas Y, Moilanen E, and Salminen S. Probiotics in the management of atopic eczema. Clin. Exp. Allergy 2000; 30(11): 1604–1610. Kirjavainen PV, Salminen SJ, and Isolauri E. Probiotic bacteria in the management of atopic disease underscoring the importance of viability. J. Pediatr. Gastroenterol. Nutr. 2003; 36: 223–227.

356


86. Majamaa H, Isolauri E, Saxelin M, and Vesikari T. Lactic acid bacteria in the treatment of acute rotavirus gastroenteritis. J. Pediatr. Gastroenterol. Nutr. 1995; 20: 333–338. 87. Salminen S, Bouley C, Boutron-Ruault MC, et al. Gastrointestinal physiology and function-targets for functional food development. Br. J. Nutr. 1998; 80: S147– S171. 88. WHO, 2002. Available at http://www.who.int/foodsafety/fs_management/en/probiotic_guidelines.pdf 89. De Vres M, Stegelmann A, Richter B, Fenselau S, Laue C, and Schrezenmeir J. Probiotics compensation for lactase insufficiency. Am. J. Clin. Nutr. 2001; 73 (Suppl.): 421S–429S. 90. Deguchi Y, Morishita T, and Mutai M. Comparative studies on synthesis of water-soluble vitamins among human species of Bifidobacteria. Agric. Biol. Chem. 1985; 49: 13–19. 91. Noda H, Akasaka N, and Ohsug M. Biotin production by Bifidobacteria. J. Nutr. Sci. Vitaminol. 1994; 40: 181–188. 92. Oda T, Kado-oka Y, and Hashiba H. Effect of Lactobacillus acidophilus on iron bioavailability in rats. J. Nutr. Sci. Vitaminol. 1994; 40: 613–616. 93. Tannock GW, Dashkevicz MP, and Feighner SD. Lactobacilli and bile salt hydrolase in the murine intestinal tract. Appl. Environ. Microbiol. 1989; 55: 1848–1851. 94. Bayless TM. Lactose malabsorption, milk intolerance, and symptom awareness in adults. In: Paige DM, Bayless TM, editors. Lactose Digestion: Clinical and Nutritional Implications. Johns Hopkins University Press, Baltimore, 1981, pp. 117–123. 95. Kolars JC, Levitt MD, Aouji M, and Savaiano DA. Yogurt-an autodigesting source of lactose. N. Engl. J. Med. 1984; 310: 1–3. 96. Lerebours E, N’Djitoyap Ndam C, Lavoine A, Hellot MF, Antoine JM, and Colin R. Yogurt and fermented-then-pasteurized milk: effects of short-term and long-term ingestion on lactose absorption and mucosal lactase activity in lactase-deficient subjects. Am. J. Clin. Nutr. 1989; 49: 823–827. 97. Marteau P, Flourie B, Pochart P, Chastang C, Desjeux J-F, and Rambaud J-C. Effect of the microbial lactase (EC 3.2.1.23) activity in yogurt on the intestinal absorption of lactose: an in vivo study on lactase-deficient humans. Br. J. Nutr. 1990; 64: 71–79. 98. Martini MC, Kukielka D, and Savaiano DA. Lactose digestion from yogurt: influence of a meal and additional lactose. Am. J Clin Nutr. 1991; 53: 1253–1258. 99. Martini MC, Lerebours EC, Lin WJ, et al. Strains and species of lactic acid bacteria in fermented milks (yogurts): effect on in vivo lactose digestion. Am. J. Clin. Nutr. 1991; 54: 1041–1046. 100. Martini MC, Smith DE, and Savaiano DA. Lactose digestion from flavored and frozen yogurts, ice milk, and ice cream by lactase-deficient persons. Am. J. Clin. Nutr. 1987; 46: 636–640. 101. Rosado JL, Solomons NW, and Allen LH. Lactose digestion from unmodified, low-fat and lactose-hydrolyzed yogurt in adult lactose-maldigesters. Eur. J. Clin. Nutr. 1992; 46: 61–68. 102. Savaiano DA, Abou ElAnouar A, Smith DE, and Levitt MD. Lactose malabsorption from yogurt, pasteurized yogurt, sweet acidophilus milk, and cultured milk in lactase-deficient individuals. Am. J. Clin. Nutr. 1984; 40: 1219–1223. 103. Varela-Moreiras G, Antoine JM, Ruiz-Roso B, Varela G, Effects of yogurt and fermentedthen-pasteurized milk on lactose absorption in an institutionalized elderly group. J. Am. Coll. Nutr. 1992; 11: 168–171.

REFERENCES

357

104. Vesa TH, Marteau PR, Briet FB, Boutron-Ruault MC, and Rambaud JC. Raising milk energy content retards gastric emptying of lactose in lactose-intolerant humans with little effect on lactose digestion. J. Nutr. 1997; 127: 2316–2320. 105. Jiang T, Mustapha A, and Savaiano DA. Improvement of lactose digestion in humans by ingestion of unfermented milk containing Bifidobacterium longum. J. Dairy Sci. 1996; 79: 750–757. 106. Martini MC, Lerebours EC, Lin WJ, et al. Strains and species of lactic acid bacteria in fermented milks (yogurts): effect on in vivo lactose digestion. Am. J. Clin. Nutr. 1991; 54: 1041–1046. 107. Montes RG, Bayless TM, Saavedra JM, and Perman JA. Effect of milks inoculated with Lactobacillus acidophilus or a yogurt starter culture in lactose-maldigesting children. J. Dairy Sci. 1995; 78: 1657–1664. 108. Rosado JL, Solomons NW, and Allen LH. Lactose digestion from unmodified, low-fat and lactose-hydrolyzed yogurt in adult lactose-maldigesters. Eur. J. Clin. Nutr. 1992; 46: 61–68. 109. Sanders M, Walker D, Walker K, Aoyama K, and Klaenhammer T. Performance of commercial cultures in fluid milk applications. J. Dairy Sci. 1996; 79: 943–955. 110. Babaahmady KG, Challacombe SJ, Marsh PD, and Newman HN. Ecological study of Streptococcus mutans. Streptococcus sobrinus and Lactobacillus spp. at subsites from approximal dental plaque from children. Caries Res. 1998; 32: 51–58. 111. Granath L, Cleaton-Jones P, Fatti LP, and Grossman ES. Salivary Lactobacilli explain dental caries better than salivary mutans Streptococci in 4–5-year-old children. Scand. J. Dent. Res. 1994; 102: 319–323. 112. Nase L, Hatakka K, Savilaht E, Saxelin M, Ponka A, Poussa T, Korpela R, and Meurman JH. Effect of long-term consumption of a probiotic bacterium, Lactobacillus rhamnosus GG, in milk on dental caries and caries risk in children. Caries Res. 2001; 35: 412–420. 113. Meurman JH, Antila H, and Salminen S. Recovery of Lactobacillus strain GG (ATCC 53103) from saliva of healthy volunteers after consumption of yogurt prepared with the bacterium. Microbiol. Ecol. Health Dis. 1994; 7: 295–298. 114. Hatakka K, Ahola AJ, Yli-Knuuttila H, Richardson M, Poussa T, Meurman JH, and Korpela R. Probiotics reduce the prevalence of oral candida in the elderlya randomized controlled trial. J. dent. Res. 2007; 86: 125–130. 115. Johnston BC, Supina AL, and Vohra S. Probiotics for pediatric antibiotic-associated diarrhea: a meta-analysis of randomized placebo-controlled trials. CMAJ 2006; 175: 377– 383. 116. McFarland LV, Meta-analysis of probiotics for the prevention of antibiotic associated diarrhea and the treatment of Clostridium difficile disease. Am. J. Gastroenterol. 2006; 101: 812–822. 117. Sazawal S, Hiremath G, Dhingra U, Malik P, Deb S, and Black RE. Efficacy of probiotics in prevention of acute diarrhoea: a meta-analysis of masked, randomised, placebocontrolled trials. Lancet Inf. Dis. 2006; 6: 374–382. 118. Szajewska H, Ruszczynski M, and Radzikowski A. probiotics in the prevention of antibiotic-associated diarrhea in children: a meta-analysis of randomized controlled trials. J. Pediatr. 2006; 149: 367–372. 119. Billoo AG, Memon MA, Khaskheli SA, Murtaza G, Iqbal K, Shekhani MS, and Siddiqi AQ. Role of a probiotic (Saccharomyces boulardii) in management and prevention of diarrhea. World J. Gastroenterol. 2006; 12: 4557–4560.

358


120. Boulloche J, Mouterde O, and Mallet E. Traitment des diarrhe’es aigues chez le nourrisson et le jeune enfant. Ann. Pediatr. (Paris) 1994; 41: 457–463. 121. Costa-Ribeiro H, Ribeiro TC, Mattos AP, et al. Limitations of probiotic therapy in acute, severe dehydrating diarrhea. J. Pediatr. Gastroenterol. Nutr. 2003; 36: 112– 115. 122. Glass RI, Lew JF, Gangarosa RE, et al. Estimates of morbidity and mortality rates for diarrheal diseases in American children. J. Pediatr. 1991; 118: S27–S33. 123. Guandalini S, Pensabene L, Zikri MA, et al. Lactobacillus GG administered in oral rehydration solution to children with acute diarrhea: a multicenter European trial. J. Pediatr. Gastroenterol. Nutr. 2000; 30: 54–60. 124. Guarino A, Canani RB, Spagnuolo MI, Albano F, and Di Benedetto L. Oral bacterial therapy reduces the duration of symptoms and of viral excretion in children with mild diarrhea. J. Pediatr. Gastroenterol. Nutr. 1997; 25(5): 516–519. 125. Guerrant RL, Hughes JM, Lima NL, and Crane J. Diarrhea in developed and developing countries: magnitude, special settings, and etiologies. Rev. Infect. Dis. 1990; 12 (Suppl. 1): S41–S50. 126. Isolauri E, Juntunen M, Rautanen T, Sillanaukee P, and Koivula T. A human Lactobacillus strain (Lactobacillus casei sp strain GG) promotes recovery from acute diarrhea in children. Pediatrics 1991; 88: 90–97. 127. Isolauri E, Kaila M, Mykkanen H, Ling W, and Salminen S. Oral bacteriotherapy for viral gastroenteritis. Dig. Dis. Sci. 1994; 39: 2595–2600. 128. Kaila M, Isolauri E, Soppi E, Virtanen E, Laine S, and Arvilommi H. Enhancement of the circulating antibody secreting cell response in human diarrhea by a human Lactobacillus strain. Pediatr. Res. 1992; 32: 141–144. 129. Kurugol Z and Koturoglu G. Effects of Saccharomyces boulardii in children with acute diarrhea. Acta Paediatr. 2005; 94: 44–47. 130. Lee MC, Lin LH, Hung KL, and Wu HY. Oral bacterial therapy promotes recovery from acute diarrhea in children. Acta. Paediatr. Tw. 2001; 42: 301–305. 131. Majamaa H, Isolauri E, Saxelin M, and Vesikari T. Lactic acid bacteria in the therapy of acute gastroenteritis. J. Pediatr. Gastroenterol. Nutr. 1995; 20: 333–338. 132. Pant AR, Graham M, Allen SJ, Harikul S, Sabchareon A, Cuevas L, and Hart CA. Lactobacillus GG and acute diarrhea in young children in the tropics. J. Trop. Pediatr. 1996; 42: 162–165. 133. Pearce JL and Hamilton JR. Controlled trial of orally administered Lactobacilli in acute infantile diarrhea. J. Pediatr. 1974; 84: 261–26. 134. Rosenfeldt V, Michaelsen KF, Jakobsen M, et al. Effect of probiotic Lactobacillus strains in young children hospitalized with acute diarrhea. Pediatr. Infect. Dis. J. 2002a; 21: 411–416. 135. Rosenfeldt V, Michaelsen KF, Jakobsen M, et al. Effect of probiotic Lactobacillus strains on acute diarrhea in a cohort of nonhospitalized children attending day-care centers. Pediatr. Infect. Dis. J. 2002b; 21: 417–419. 136. Salazar-Lindo E, Miranda-Langschwager P, Campos-Sanchez M, et al. Lactobacillus casei strain GG in the treatment of infants with acute watery diarrhea: a randomized, double-blind, placebo controlled clinical trial. BMC Pediatr. 2004; 4: 18. 137. Shornikova AV, Casas IA, Isolauri E, Mykkanen H, and Vesikari T. Lactobacillus reuteri as a therapeutic agent in acute diarrhea in young children. J. Pediatr. Gastroenterol. Nutr. 1997a; 24: 399–404.

REFERENCES

359

138. Shornikova A, Casas I, Mykkanen H, Salo E, and Vesikari T. Bacteriotherapy with Lactobacillus reuteri in rotavirus gastroenteritis. Pediatr Infect Dis J. 1997b; 16: 1103– 1107. 139. Shornikova AV, Isolauri E, Burkanova L, Lukovnikova S, and Vesikari T. A trial in the Karelian Republic of oral rehydration and Lactobacillus GG for treatment of acute diarrhoea. Acta Paediatr. 1997c; 86: 460–465. 140. Simakachorn N, Pichaipat V, Rithipornpaisarn P, Kongkaew C, Tongpradit P, and Varavithya W. Clinical evaluation of the addition of lyophilized, heat-killed Lactobacillus acidophilus LB to oral rehydration therapy in the treatment of acute diarrhea in children. J. Pediatr. Gastroenterol. Nutr. 2000; 30: 68–72. 141. Villarruel G, Rubio DM, Lopez F, Cintioni J, Gurevech R, Romero G, and Vandenplas Y. Saccharomyces boulardii in acute childhood diarrhea: a randomized placebo-controlled study. Acta Paediatr. 2007; 96: 538–541. 142. Ackermann G, Thomalla S, Achermann F, et al. Prevalence and characteristics of bacteria and host factors in an outbreak situation of antibiotic-associated diarrhea. J. Med. Microbiol. 2005; 54 (Pt. 2): 149–153. 143. Adam J, Barret C, Barret-Bellet A, et al. Controlled double-blind clinical trials of UltraLevure: multicentre study by 25 physicians in 388 cases. Gaz. Med. Fr. 1977; 84: 2072– 2078. 144. Armuzzi A, Cremonini F, Bartolozzi F, et al. The effect of oral administration of Lactobacillus GG on antibiotic-associated gastrointestinal side-effects during Helicobacter pylori eradication therapy. Aliment. Pharmacol. Ther. 2001; 15: 163–169. 145. Arvola T, Laiho K, Torkkeli S, et al. Prophylactic Lactobacillus GG reduces antibioticassociated diarrhea in children with respiratory infections: a randomized study. Pediatrics 1999; 104: e64. 146. Correa NB, Filho P, Luciano A, et al. A randomized formula controlled trial of Bifidobacterium lactis and Streptococcus thermophilus for prevention of antibioticassociated diarrhea in infants. J. Clin. Gastroenterol. 2005; 39: 385–389. 147. Cremonini F, Di Caro S, Covino M, et al. Effect of different probiotic preparations on antiHelicobacter pylori therapy-related side effects: a parallel group, triple blind, placebocontrolled study. Am. J. Gastroenterol. 2002; 97: 2744–2749. 148. Gotz V, Romankiewicz JA, Moss J, et al. Prophylaxis against ampicillin-associated diarrhea with a Lactobacillus preparation. Am. J. Hosp. Pharm. 1979; 36: 754– 757. 149. Jirapinyo P, Thamonsiri N, Densupsoontorn N, et al. Prevention of antibiotic-associated diarrhea in infants by probiotics. J. Med. Assoc. Thai. 2002; 85 (Suppl. 2): S739–S742. 150. Kotowska M, Albrecht P, and Szajewska H. Saccharomyces boulardii in the prevention of antibiotic-associated diarrhoea in children: a randomized double-blind placebo-controlled trial. Aliment. Pharmacol. Ther. 2005; 21: 583–590. 151. LaRosa M, Bottaro G, Gulino N, et al. Prevention of antibiotic-associated diarrhea with Lactobacillus sporogens and fructo-oligosaccarides in children. A multicentric doubleblind vs placebo study. Minerva Pediatr. 2003; 55(5): 447–452. 152. Levy DG, Stergachis A, McFarland LV, et al. Antibiotics and Clostridium difficile diarrhea in the ambulatory care setting. Clin. Ther. 2000; 22: 91–102. 153. Lewis SJ, Potts LF, and Barry RE. The lack of therapeutic effect of Saccharomyces boulardii in the prevention of antibiotic-related diarrhoea in elderly patients. J. Infect. 1998; 36: 171–174.

360


154. McFarland LV, Epidemiology, risk factors and treatments for antibiotic-associated diarrhea. Dig. Dis. 1998; 16: 292–307. 155. McFarland LV, Normal flora: diversity and functions. Microb. Ecol. Health Dis. 2000; 12: 193–207. 156. McFarland LV, Surawicz CM, Greenberg RN, et al. Prevention of beta-lactam-associated diarrhea by Saccharomyces boulardii compared with placebo. Am. J. Gastroenterol. 1995; 90: 439–448. 157. Nista EC, Candelli M, Cremonini F, et al. Bacillus clausii therapy to reduce side-effects of anti-Helicobacter pylori treatment: randomized, double-blind, placebo controlled trial. Aliment. Pharmacol. Ther. 2004; 20: 1181–1188. 158. Orrhage K, Brismar B, and Nord CE. Effects of supplements of Bifidobacterium longum and Lactobacillus acidophilus on the intestinal microbiota during administration of clindamycin. Microb. Ecol. Health Dis. 1994; 7: 17–25. 159. Seki H, Shiohara M, Matsumura T, et al. Prevention of antibiotic-associated diarrhea in children by Clostridium butyricum MIYAIRI. Pediatr. Int. 2003; 45: 86–90. 160. Surawicz CM, Elmer GW, Speelman P, McFarland LV, Chinn J, and van Belle G. Prevention of antibiotic-associated diarrhea by Saccharomyces boulardii: a prospective study. Gastroenterology 1989; 96: 981–988. 161. Szajewska H, Kotowska M, Mrukowicz JZ, et al. Efficacy of Lactobacillus GG in prevention of nosocomial diarrhea in infants. J. Pediatr. 2001; 138: 361–365. 162. Tankanow RM, Ross MB, Ertel IJ, et al. A double-blind, placebo-controlled study of the efficacy of Lactinex in the prophylaxis of amoxicillin-induced diarrhea. DICP 1990; 24: 382–384. 163. Thomas MR, Litin SC, Osmon DR, Corr AP, Weaver AL, and Lohse CM. Lack of effect of Lactobacillus GG on antibiotic-associated diarrhea: a randomized, placebo-controlled trial. Mayo Clin. Proc. 2001; 76: 883–889. 164. Vanderhoof JA, Whitney DB, Antonson DL, Hanner TL, Lupo JV, and Young RJ. Lactobacillus GG in the prevention of antibiotic-associated diarrhea in children. J. Pediatr. 1999; 135: 564–568. 165. Winston DJ, Ho WG, Bruckner DA, et al. Beta-lactam antibiotic therapy in febrile granulocytopenic patients. A randomized trial comparing cefoperazone plus piperacillin, ceftazidime plus piperacillin, and imipenem alone. Ann. Intern. Med. 1991; 115: 849– 859. 166. Witsell DL, Garrett G, Yarbrough WG, et al. Effect of Lactobacillus acidophilus on antibiotic-associated gastrointestinal morbidity: a prospective randomized trial. J. Otolarynogol. 1995; 24: 231–233. 167. Wunderlich PF, Braun L, Fumagalli I, et al. Double-blind report on the efficacy of lactic acid-producing Enterococcus SF68 in the prevention of antibiotic-associated diarrhoea and in the treatment of acute diarrhoea. J. Int. Med. Res. 1989; 17: 333–338. 168. Barbut F and Petit JC. Epidemiology of Clostridium difficile-associated infections. Clin. Microbiol. Infect. 2001; 7: 405–410. 169. Barbut F, Richard A, Hamadi K, Chomette V, Burghoffer B, and Petit JC. Epidemiology of recurrences or reinfections of Clostridium difficile-associated diarrhea. J. Clin. Microbiol. 2000; 38: 2386–2388. 170. Lawrence SJ, Korzenik JR, and Mundy LM. Probiotics for recurrent Clostridium dificile disease. J. Med. Microbiol. 2005; 54: 905–906.

REFERENCES

361

171. McFarland LV, Surawicz CM, Greenberg RN, et al. A randomized placebo-controlled trial of Saccharomyces boulardii in combination with standard antibiotics for Clostridium difficile disease. JAMA 1994; 271: 1913–1918. 172. McFarland LV, Surawicz CM, Rubin M, et al. Recurrent Clostridium difficile disease: epidemiology and clinical characteristics. Infect. Control Hosp. Epidemiol. 1999; 20: 43–50. 173. Plummer S, Weaver MA, Harris JC, et al. Clostridium difficile pilot study: effects of probiotic supplementation on the incidence of Clostridium difficile diarrhea. Int. Microbiol. 2004; 7: 59–62. 174. Surawicz CM, McFarland LV, Greenberg RN, et al. The search for a better treatment for recurrent Clostridium difficile disease: use of high dose vancomycin combined with Saccharomyces boulardii. Clin. Infect. Dis. 2000; 31: 1012–1017. 175. Wullt M, Hagslatt ML, and Odenholt I. Lactobacillus plantarum 299v for the treatment of recurrent Clostridium difficile-associated diarrhoea: a double-blind, placebo-controlled trial. Scand. J. Infect. Dis. 2003; 35: 365–367. 176. Delia P, Sansotta G, Donato V, Frosina P, Messina G, De Renzis C, and Famularo G. Use of probiotics for prevention of radiation-induced diarrhea. World J. Gastroenterol. 2007; 13: 912–915. 177. Donner CS, Pathophysiology and therapy of chronic radiation-induced injury to the colon. Dig. Dis. 1998; 16: 253–261. 178. Adachi JA, Ericsson CD, Jiang ZD, et al. Azithromycin found to be comparable to levoflozacin for the treatment of US travelers with acute diarrhea acquired in Mexico. Clin. Infect. Dis. 2003; 37: 1165–1171. 179. Black F, Anderson P, Orskov J, Gaarslev K, and Laulund S. Prophylactic efficacy of Lactobacilli on travelers’ diarrhea. Travel Med. 1989; 7: 333–335. 180. Cheng AC and Thielman NM. Update on traveler’s diarrhea. Curr. Infect. Dis. Rep. 2002; 4: 70–77. 181. Clarke SC, Diarrhoeagenic Escherichia colian emerging problem? Diagn. Microbiol. Infect. Dis. 2001; 41: 93–98. 182. Hilton E, Kolakowski P, Singer C, and Smith M. Efficacy of Lactobacillus GG as a diarrheal preventive in travelers. J. Travel. Med. 1997; 4: 41–43. 183. Katelaris PH, Salam I, and Farthing MJ. Lactobacilli to prevent traveler’s diarrhea? N. Engl. J. Med. 1995; 333: 1360–1361. 184. Kollaritsch H, Kremsner P, Wiedermann G, and Scheiner O. Prevention of traveler’s diarrhea: comparison of different nonantibiotic preparations. Travel Med. Int. 1989: 9–17. 185. Kollaritsch H, Holst H, Grobara P, and Wiedermann G. Prophylaxe der reisediarrhoe mit Saccharomyces boulardii [Prevention of traveler’s diarrhea with Saccharomyces boulardii. Results of a placebo controlled double-blind study]. Fortschr. Med. 1993; 111: 152–156. 186. McFarland LV. Meta-analysis of probiotics for the prevention of traveler’s diarrhea. Travel Med. Infect. Dis. 2007; 5(2): 97–105. 187. Oksanen PJ, Salminen S, Saxelin M, et al. Prevention of travelers diarrhea by lactobacillus GG. Ann. Med. 1990; 22: 53–56. 188. Pozo-Olano JD, Warram Jr. JH, Gomez RG, and Cavazos MG. Effect of a Lactobacilli preparation on traveler’s diarrhea. A randomized, double blind clinical trial. Gastroenterology 1978; 74: 829–830.

362


189. Sanders JW and Tribble DR. Diarrhea in the returned traveler. Curr Gastroenterol. Rep. 2001; 3: 304–314. 190. Bleichner G, Blehaut H, Mentec H, and Moyse D. Saccharomyces boulardii prevents diarrhea in critically ill tube-fed patients. A multicenter, randomized, double-blind placebo-controlled trial. Intensive. Care Med. 1997; 23: 517–523. 191. Heimburger DC, Sockwell DG, and Geels WJ. Diarrhea with enteral feeding: prospective reappraisal of putative causes. Nutrition 1994; 10: 392–396. 192. Hill SA, Nielsen MS, and Lennard-Jones JE. Nutritional support in intensive care units in England and Wales: a survey. Eur. J. Clin. Nutr. 1995; 49: 371–378. 193. Silk DBA, Cottam TK, Nielsen MS, Elcoat C, Furness KM, Howard JP, Lennard-Jones JE, and Plester CE. Organization of Nutritional Support in Hospitals. British Association Parenteral & Enteral Nutrition Working Party Report. BAPEN, Maidenhead, 1994. 194. Smith CE, Marien L, Brogdon C, Faust-Wilson P, Lohr G, Gerald KB, and Pingleton S. Diarrhea associated with tube feeding in mechanically ventilated critically ill patients. Nurs. Res. 1990; 39: 148–152. 195. Chadwick VS, Chen W, Shu D, et al. Activation of the mucosal immune system in irritable bowel syndrome. Gastroenterology 2002; 122: 1778–1783. 196. Drossman DA, Camilleri M, Mayer EA, and Whitehead WE. AGA technical review on irritable bowel syndrome. Gastroenterology 2002; 123: 2108–2131. 197. Guyonnet D, Chassany O, Ducrotte P, Picard C, Mouret M, Mercier CH, and Matuchansky C. Effects of fermented milk containing Bifidobacterium animalis DN-173 010 on the health-related quality of life and symptoms in irritable bowel syndrome in adults in primary care: a multicentre, randomized, double-blind, controlled trial. Aliment. Pharmacol. Ther. 2007; 26: 475–486. 198. Hillila MT and Farkkila MA. Prevalence of irritable bowel syndrome according to different diagnostic criteria in a nonselected adult population. Aliment. Pharmacol. Ther. 2004; 20: 339–345. 199. Kajander K, Hatakka K, Poussa T, Farkkila M, and Korpela R. A probiotic mixture alleviates symptom in irritable bowel syndrome patients: a controlled 6-month intervention. Aliment. Pharmacol. Ther. 2005; 222: 387–394. 200. Kim HJ, Vazquez Roque MI, Camilleri M, et al. A randomized controlled trial of a probiotic combination VSL.3 and placebo in irritable bowel syndrome with bloating. Neurogastroenterol. Motil. 2005; 17: 687–696. 201. King TS, Elia M, and Hunter JO. Abnormal colonic fermentation in irritable bowel syndrome. Lancet 1998; 352: 1187–1189. 202. Koebnick C, Wagner I, Leitzmann P, Stern U, and Zunft HJF. Probiotic beverage containing Lactobacillus casei Shirota improves gastrointestinal symptoms in patients with chronic constipation. Can. J. Gastroenterol. 2003; 17: 655–659. 203. Linskens RK, Huijsdens XW, Savelkoul PH, Vandenbroucke-Grauls CM, Meuwissen SG, The bacterial flora in inflammatory bowel disease: current insights in pathogenesis and the influence of antibiotics and probiotics. Scand. J. Gastroenterol. Suppl. 2001; 36: 29–40. 204. Niedzielin K, Kordecki H, and Birkenfeld B. A controlled, double-blind, randomized study on the efficacy of Lactobacillus plantarum 299v in patients with irritable bowel syndrome. Eur. J. Gastroenterol. Hepatol. 2001; 13: 1143–1147.

REFERENCES

363

205. Nobaek S, Johansson ML, Molin G, Ahrne S, and Jeppsson B. Alteration of intestinal microflora is associated with reduction in abdominal bloating and pain in patients with irritable bowel syndrome. Am. J. Gastroenterol. 2000; 95: 1231–1238. 206. O’Sullivan MA and O’Morain CA. Bacterial supplementation in the irritable bowel syndrome. A randomized double-blind placebo-controlled crossover study. Dig. Liver Dis. 2000; 32: 294–301. 207. Sen S, Mullan MM, Parker TJ, Woolner JT, Tarry SA, and Hunter JO. Effect of Lactobacillus plantarum 299v on colonic fermentation and symptoms of irritable bowel syndrome. Dig. Dis. Sci. 2002; 47: 2615–2620. 208. Treem WR, Ahsan N, Kastoff G, and Hyams JS. Fecal short-chain fatty acids in patients with diarrhea-predominant irritable bowel syndrome: in vitro studies of carbohydrate fermentation. J. Pediatr. Gastroenterol. Nutr. 1996; 23: 280–286. 209. Bibiloni R, Fedorak RN, Tannock GW, Madsen KL, Gionchetti P, Campieri M, de Simone C, and Sartor RB. VSL# 3 probiotic-mixture induces remission in patients with active ulcerative colitis. Am. J. Gastroenterol. 2005; 100: 1539–1546. 210. Gionchetti P, Amadini C, Rizzello F, Venturi A, Poggioli G, and Campieri M. Probiotics for the treatment of postoperative complications following intestinal surgery. Best Pract. Res. Clin. Gastroenterol. 2003; 17: 821–831. 211. Gionchetti P, Rizzello F, Helwig U, et al. Prophylaxis of pouchitis onset with probiotic therapy: a double-blind, placebo-controlled trial. Gastroenterology 2003; 124: 1202–1209. 212. Gionchetti P, Rizzello F, Venturi A, et al. Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double-blind, placebo-controlled trial. Gastroenterology 2000; 119: 305–309. 213. Guslandi M, Mezzi G, Sorghi M, and Testoni PA. Saccharomyces boulardii in maintenance treatment of Crohn’s disease. Dig. Dis. Sci. 2000; 45: 1462–1464. 214. Kruis W, Schutz E, Fric P, Fixa B, Judmaier G, and Stolte M. Double-blind comparison of an oral Escherichia coli preparation and mesalazine in maintaining remission of ulcerative colitis. Aliment. Pharmacol. Ther. 1997; 11: 853–858. 215. Prantera C, Scribano ML, Falasco G, Andreoli A, and Luzi C. Ineffectiveness of probiotics in preventing recurrence after curative resection for Crohn’s disease: a randomised controlled trial with Lactobacillus GG. Gut 2002; 51: 405–409. 216. Rembacken BJ, Snelling AM, Hawkey PM, Chalmers DM, and Axon AT. Nonpathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomised trial. Lancet 1999; 354: 635–639. 217. Sartor RB, Therapeutic manipulation of the enteric microflora in inflammatory bowel diseases: antibiotics, probiotics, and prebiotics. Gastroenterology 2004; 126: 1620–1633. 218. Schultz M, Timmer A, Herfarth HH, Sartor RB, Vanderhoof JA, and Rath HC. Lactobacillus GG in inducing and maintaining remission of Crohn’s disease. BMC Gastroenterol. 2004; 4: 5–8. 219. Aiba Y, Suzuki N, Kabir AM, et al. Lactic acid-mediated suppression of Helicobacter pylori by the oral administration of Lactobacillus salivarius as a probiotic in a gnotobiotic murine model. Am. J. Gstroenterol. 1998; 93: 2097–2101. 220. Armuzzi A, Cremonini F, Bartolozzi F, et al. The effect of oral administration of Lactobacillus GG on antibiotic-associated gastrointestinal side-effects during Helicobacter pylori eradication therapy. Aliment. Pharmacol. Ther. 2001; 15: 163–169.

364


221. Bell GD, Powell K, Burridge SM, et al. Experience with ’triple’ anti-Helicobacter pylori eradication therapy: side effects and the importance of testing the pre-treatment bacterial isolate for metronidazole resistance. Aliment. Pharmacol. Ther. 1992; 6: 427–435. 222. Boot H, de Jong D, van Heerde P, et al. Role of Helicobacter pylori eradication in high grade MALT lymphoma. Lancet 1995; 346: 448–449. 223. Brenes F, Ruiz B, Correa P, et al. Helicobacter pylori causes hyperproloferation of the gastric epithelium: pre- and posteradication indices of proliferating cell nuclear antigen. Am. J. Gastroenterol. 1993; 88: 1870–1975. 224. Canducci F, Armuzzi A, Cremonini F, et al. A lyophilized and inactivated culture of Lactobacillus acidophilus increases Helicobacter pylori eradication rates. Aliment. Pharmacol. Ther. 2000; 14: 1625–1629. 225. Cao YJ, Qu CM, Yuan Q, et al. Control of intestinal flora alteration induced by eradication therapy of Helicobacter pylori infection in the elders. Chin. J. Gastroenterol. Hepatol. 2005; 14: 195–199. 226. Cremonini F, Di Caro S, Covino M, et al. Effect of different probiotic preparations on antiHelicobacter pylori therapy-related side effects: a parallel group, triple blind, placebocontrolled study. Am. J. Gastroenterol. 2002; 97: 2744–2749. 227. Go MF, Natural history and epidemiology of Helicobacter pylori infection. Aliment. Pharmacol. Ther. 2002; 16 (Suppl. 1): 3–15. 228. Goldman CG, Barrado DA, Balcarce N, Rua EC, Oshiro M, Calcagno ML, Janjetic M, Fuda J, Weill R, Salgueiro MJ, Valencia ME, Zubillaga MB, and Boccio JR. Effect of a probiotic food as an adjunvant to triple therapy for eradication of Helicobacter pylori infection in children. Nutrition 2006; 22: 984–988. 229. Guo JB, Yang PF, Wang MT, et al. The application of clostridium to the eradication of Helicobacter pylori. Chin. J. Celiopathy. 2004; 4: 163–165. 230. Myllyluoma E, Veijola L, Ahlroos T, et al. Probiotic supplementation improves tolerance to Helicobacter pyroli eradication therapya placebo-controlled, double-blind randomized pilot study. Aliment. Pharmacol. Ther. 2005; 21: 1263–1272. 231. Nista EC, Candelli M, Cremonini F, et al. Bacillus clausii therapy to reduce side effects of anti-Helicobacter pylori treatment: randomized, double-blind, placebo controlled trial. Aliment. Pharmacol. Ther. 2004; 20: 1181–1188. 232. Pinchuk IV, Bressollier P, Verneuil B, et al. In vitro anti-Helicobacter pylori activity of the probiotic strain Bacillus subtilis 3 is due to secretion of antibiotics. Antimicrob. Agents Chemother. 2001; 45: 3156–3161. 233. Rauws EA and Tytgat GN. Cure of duodenal ulcer associated with eradication of Helicobacter pylori. Lancet 1990; 335: 1233–1235. 234. Sheu BS, Wu JJ, Lo CY, et al. Impact of supplement with Lactobacillus- and Bifidobacterium-containing yogurt on triple therapy for Helicobacter pylori eradication. Aliment. Pharmacol. Ther. 2002; 16: 1669–1675. 235. Sykora J, Valeckova K, Amlerova J, et al. Effects of a specially designed fermented milk product containing probiotic Lactobacillus casei DN-114 001 and the eradication of H. pylori in children: a prospective randomized double-blind study. J. Clin. Gastroenterol. 2005; 39: 692–698. 236. Anderson ADG, McNaught CE, Jain PK, and MacFie J. Randomized clinical trial of symbiotic therapy in elective surgical patients. Gut 2004; 53: 241–245.

REFERENCES

365

237. Kanazawa H, Nagino M, Kamiya S, Komatsu S, Mayumi T, Takagi K, Asahara T, Nomoto K, Tanaka R, and Nimura Y. Synbiotics reduce postoperative infectious complications: a randomized controlled trial in biliary cancer patients undergoing hepatectomy. Langenbecks Arch. Surg. 2005; 390: 104–113. 238. McNaught CE, Woodcock NP, MacFie J, and Mitchell CJ. A prospective randomized study of the probiotic Lactobacillus platarum 299V on indices of gut barrier function in elective surgical patients. Gut 2005; 51: 827–831. 239. Nagino M, Kamiya J, Uesaka K, Sano T, Yamamoto H, Hayakawa N, Kanai M, and Nimura Y. Complications of hepatectomy for hilar cholangiocarcinoma. World J. Surg. 2001; 27: 1277–1283. 240. Rayes N, Seehofer D, Muller AR, Hansen S, Bengmark S, and Neuhaus P. Influence of probiotics and fiber on the incidence of bacterial infections following major abdominal surgeryresults of a prospective trial. Z. Gastroenterol. 2002; 40: 869–876. 241. Shigeta H, Nagino M, Kamiya J, Uesaka K, Sano T, Yamamoto H, Hayakawa N, Kanai M, and Nimura Y. Bacteremia after hepatectomy: an analysis of single center. 10-year experience with 407 patients. Langenbecks Arch. Surg. 2002; 387: 117–124. 242. Tancrede CH and Andremont AO. Bacterial translocation and Gram-negative bacteremia in patients with hematological malignancies. J. Infect. Dis. 1985; 152: 99–103. 243. De Vrese M, Winkler P, Rautenberg P, Harder T, Noah C, Laue C, Ott S, Hampe J, Schreiber S, Heller K, and Jurgen S. Effect of Lactobacillus gaseri PA 16/8, Bifidobacterium longum SP 07/3, B. bifidum MF 20/5 on common cold episodes: a double blind, randomized, controlled trial. Clin. Nutr. 2005; 24: 481–491. 244. De Vrese M, Winkler P, Rautenberg P, Harder T, Noah C, Laue C, Ott S, Hampe J, Schreiber S, Heller K, and Jurgen S. Probiotic bacteria reduced duration and severity but not the incidence of common cold episodes in a double blind, randomized, controlled trial. Vaccine 2006; 24: 6670–6674. 245. Habermann W, Zimmermann K, Skarabis H, Kunze R, and Rusch V. Influence of a bacterial immunostimulant (human Enterococcus faecalis bacteria) on the recurrence of relapses in patient with chronic bronchitis. Arzneimittelforschung 2001; 51: 931–937. 246. Habermann W, Zimmermann K, Skarabis H, Kunze R, and Rusch V. Reduction of acute relapses in patients with chronic recurrent hypertrophic sinusitis during treatment with a bacterial immunostimulant (Enterocucus faecalis bacteria of human origina medical probiotic). Arzneimittelforschung 2002; 52: 622–627. 247. Hatakka K, Savilahti E, Ponka A, Meurman JH, Poussa T, Nase L, et al. Effect of long term consumption of probiotic milk on infections in children attending day care centers: double blind, randomized trial. BMJ 2001; 322: 1327–1329. 248. Turchet P, Laurenzano M, Auboiron S, and Antoine JM. Effect of fermented milk containing the probiotic Lactobacillus casei DN-114001 on winter infections in freeliving elderly subjects: a randomized, controlled pilot study. Nutr. Health Aging 2003; 7: 75–77. 249. Brouwer ML, Wolt-Plompen SAA, Dubois AE, ven der Heide S, Jansen DF, Hoijer MA, and Holgate ST. The epidemic of allergy and asthma. Nature 1999; 402 (6760 Suppl.): B2–B4. 250. Helin T, Haahtela S, and Haahtela T. No effect of oral treatment with an intestinal bacterial strain, Lactobacillus rhamnosus (ATCC 53103), on birch-pollen allergy: a placebocontrolled double-blind study. Allergy 2002; 57: 243–246. 251. Holgate ST. The epidemic of allergy and asthma. Nature 1999; 402 (6760 Suppl.): B2–B4.

366


252. Isolauri E, Arvola T, Suta Y, Moilanen E, and Salminen S. Probiotics in the management of atopic ecema. Clin. Expt. Allergy 2000; 30: 1604–1610. 253. Isolauri E, Huurre A, Salminen S, and Impivaara O. The allergy epidemic extends beyond the past few decades. Clin. Exp. Allergy 2004 Jul; 34(7): 1007–1010. 254. Kalliomaki M, Kirjavainen P, Eerola E, Kero P, Salminen S, and Isolauri E. Distinct patterns of neonatal gut microflora in infants in whom atopy was and was not developing. J. Allergy Clin. Immunol. 2001 Jan; 107(1): 129–134. 255. Kalliomaki M, Salminen S, Arvilommi H, Kero P, Koskinen P, and Isolauri E. Probiotics in primary prevention of atopic disease: a randomized placebo-controlled trial. Lancet 2001; 357: 1076–1079. 256. Kalliomaki M, Salminen S, Poussa T, Arvilommi H, and Isolauri E. Probiotics and prevention of atopic disease: 4-year follow-up of a randomized placebo-controlled trial. Lancet 2003; 361: 1869–1871. 257. Kalliomaki M, Salminin S, Poussa T, and Isolauri E. Probiotics during the first 7 years of life: a cumulative risk reduction of eczema in a randomized, placebo-controlled trial. J. Allergy Clin. Immunol. 2007; 119: 1019–1021. 258. Kirjavainen PV, Salminen SJ, and Isolauri E. Probiotic bacteria in the management of atopic disease: underscoring the importance of viability. J. Pediatr. Gastroenterol. Nutr. 2003; 36: 223–227. 259. Kukkonen K, Savilahti E, Haahtela T, Juntunen-Backman K, Korpela R, Poussa T, Tuure T, and Kuitunen M. Probiotics and prebiotic galacto-oligosaccharides in the prevention of allergic diseases: a randomized, double-blind, placebo-controlled trial. J. Allergy Clin. Immunol. 2007; 119: 192–198. 260. Matricardi PM, Rosmini F, Riondino S, et al. Exposure to foodborne and orofecal microbes versus airborne viruses in relation to atopy and allergic asthma: epidemiological study. BMJ 2000; 320: 412–417. 261. Paunio M, Heinonen OP, Virtanen M, Leinikki P, Patja A, and Peltola H. Measles history and atopic diseases: a population-based cross-sectional study. JAMA 2000; 283: 343–346. 262. Pekkanen J, Remes ST, Husman T, Lindberg M, Kajosaari M, Koivikko A, and Soininen L. Prevalence of asthma symptoms in video and written questionnaires among children in four regions of Finland. Eur. Respir. J. 1997; 10: 1787–1794. 263. Prescott SL and Bjorksten B. Probiotics for the prevention or treatment of allergic diseases. J. Allergy Clin. Immunol. 2007 Aug; 120(2): 255–262. 264. Rautava S, Kalliomaki M, and Isolauri E. Probiotics during pregnancy and breast-feeding might confer immunomodulatory protection against atopic disease in the infant. J. Allergy Clin. Immunol. 2002 Jan; 109(1): 119–121. 264a. Wickens K, Black PN, Stanley TV, Mitchell E, Fitzharris P, Tannock GW, Purdie G, Crane J, Probiotic Study Group. A differential effect of 2 probiotics in the prevention of eczema and atopy: A double-blind, randomized, placebo-controlled trial. J. Allergy Clin. Immunol. 2008 Aug 31 [Epub ahead of print]. 264b. Huarre A, Laitinen K, Rautava S, Korkeam€aki M, Isolauri E. Impact of maternal atopy and probiotic supplementation during pregnancy on infant sensitization: A double-blind placebo-controlled study. Clin. Exp. Allergy. 2008; 38: 1342–1348. 265. Remes ST, Korppi M, Kajossari M, Koivikko A, Soininen L, and Pekkanen J. Prevalence of allergic rhinitis and atopic dermatitis among children in four regions of Finland. Allergy 1998; 53: 682–689.

REFERENCES

367

266. Rosenfeldt V, Benfeldt E, Valerius NH, Paerregaard A, and Michaelsen KF. Effect of probiotics on gastrointestinal symptoms and small intestinal permeability in children with atopic dermatitis. J. Pediatr. 2004; 145: 612–616. 267. Shaheen SO, Aaby P, Hall AJ, et al. Measles and atopy I Guinea-Bissau. Lancet 1996; 347: 1792–1796. 268. Shirakawa T, Enomoto T, Shimazu S, and Hopkin JM. The inverse association between tuberculin responses and atopic disorder. Science 1997; 275: 77–79. 269. Strachan DP, Hay feve, hyfiene, and household size. BMJ 1989; 299: 1259–1260. 270. Taylor AL, Dunstan JA, and Prescott SL. Probiotic supplementation for the first 6 months of life fails to reduce the risk of atopic dermatitis and increases the risk of allergen sensitization in higher-risk children: a randomized controlled trial. J. Allergy Clin. Immunol. 2007; 119: 184–191. 271. Vichyanond P, Jirapongsananuruk O, Visitsuntorn N, and Tuchinda M. Prevalence of asthma, rhinitis and eczema in children from the Bangkok area using the ISAAC (International Study for Asthma and Allergy in Children) questionnaires. J. Med. Assoc. Thai. 1998; 81: 175–184. 272. Viljanen M, Savilahti E, Haahtela T, Juntunen-Backman K, Korpela R, Poussa T, Tuure T, and Kuitunen M. Probiotics in the treatment of atopic eczema/dermatitis syndrome in infants: a double-blind placebo-controlled trial. Allergy 2005; 60: 494– 500. 273. Weston S, Halbert A, Richmond P, and Prescott SL. Effects of probiotics on atopic dermatitis: a randomized controlled trial. Arch. Dis. Childhood 2005; 90: 892–897. 274. Xiao JZ, Kondo S, Yanagisawa N, Takahashi N, Odamaki T, Iwabuchi N, Miyaji K, Iwatsuki K, Togashi H, Enomoto K, and Enomoto T. Probiotics in the treatment of Japanese cedar pollinosis: a double-bland placebo-controlled trial. Clin. Exp. Allergy 2006; 36: 1425–1435. 275. Aso Y, and Akazan H. Prophylactic effects of a Lactobacillus casei preparation on the recurrence of superficial bladder cancer. Urol. Int. 1992; 49: 125–129. 276. Aso Y, Akaza H, Tsukamoto T, Imai K, and Naito S. Preventive effect of a Lactobacillus casei preparation on the recurrence of superficial bladder cancer in a double-blind trial. Eur. Urol. 1995; 27: 104–109. 277. De Roos N and Katan M. Effects of probiotic bacteria on diarrhea, lipid metabolism, and carcinogenesis: a review of papers published between 1988 and 1998. Am. J. Clin. Nutr. 2000; 71: 405–411. 278. Hill MJ, Draser BS, Hawksworth G, et al. Bacteria and aetiogy of cancer of the large bowel. Lancet 1971; 1: 95–100. 279. Hirayama K, and Rafter J. The role of lactic acid bacteria in colon cancer prevention: mechanistic considerations. Ant. Leeu. 1999; 76: 391–294. 280. Kanazawa K, Konishi F, Mitsuoka T, et al. Factors influencing the development of sigmoid colon cancer. Bacteriology and biochemical studies. Cancer 1996; 77: 1701–1706. 281. McFarland LA, A review of the evidence of health claims for biotherapeutic agents. Microb. Ecol. Health Dis. 2000; 12: 65–76. 282. Moore WE and Moore LH. Intestinal flora of population that have a high risk of colon cancer. Appl. Environ. Microbiol. 1995; 61: 3202–3207. 283. Ohashi Y, Nakai S, Tsukamoto T, Masumori N, Akaza H, Miyanaga N, Kitamura T, Kawabe K, Kotake T, Kuroda M, Naito S, Koga H, Saito Y, Nomata K, Kitagawa M, and

368

284. 285.

286.

287.

288. 289. 290.

291.

292.

293.

294.

295. 296. 297. 298. 299.

300.


Aso Y. Habitual Intake of lactic acid bacteria and risk reduction of bladder cancer. Urol Int. 2002; 68: 273–280. Pryor M, Slattery ML, Robinson LM, and Egger M. Adolescent diet and breast cancer in Utah. Cancer Res. 1989; 49: 2161–2167. Van’t Veer P, Dekker JM, Lamers JWJ, Kok FJ, Schouten EG, Brants HAM, Sturmans F, and Hermus RJJ. Consumption of fermented milk products and breast cancer: a casecontrol study in the Netherlands. Cancer Res. 1989; 49: 4020–4023. Agerbaek M, Gerdes LU, and Richelsen B. Hypocholesterolaemic effect of a new fermented milk product in healthy middle-aged men. Eur. J. Clin. Nutr. 1995; 49: 346–352. De Roos NM, Schouten G, and Katan MB. Yogurt enriched with Lactobacillus acidophilus does not lower blood lipids in healthy men and women with normal to borderline high serum cholesterol levels. Eur. J. Clin. Nutr. 1999; 53: 277–280. De Smet I, De Boever P, and Verstraete W. Cholesterol lowering in pigs through enhanced bacterial bile hydrolase activity. Br. J. Nutr. 1998; 79: 185–194. Gilliland SE, Nelson CR, and Maxwell C. Assimilation of cholesterol by Lactobacillus acidophilus. Appl. Environ. Microbiol. 1985; 49: 377–381. Greany KA, Nettleton JA, Wangen KE, Thomas W, and Kurzer MS. Probiotic consumption does not enhance the cholesterol-lowering effect of soy in postmenopausal women. J. Nutr. 2004; 134: 3277–3283. Hlivak P, Odraska J, Ferencik M, Ebringer L, Jahnova E, and Mikes Z. One-year application of probiotic strain Enterococcus faecium M-74 decreases serum cholesterol levels. Bratisl. Lek. Listy. 2005; 106: 67–72. Kiebling G, Schneider J, and Jahreis G. Long-term consumption of fermented dairy products over 6 months increases HDL cholesterol. Eur. J. Clin. Nutr. 2002; 56: 843–849. Klaver FA and Meer RVD. The assumed assimilation of cholesterol by Lactobacilli and Bifidobacterium bifidum is due to their bile salt-deconjugating activity. Appl. Environ. Microbiol. 1993; 59: 1120–1124. Law MR, Wald NJ, Wu T, Hackshaw A, and Bailey A. Systematic underestimation of association between serum cholesterol concentration and ischaemic heart disease in observational studies: data from BUPA study. Bret. Med. J. 1994; 308: 363–366. Lewis SJ and Burmeister S. A double-blind placebo-controlled study of the effects of Lactobacillus acidophilus on plasma lipids. Eur. J. Clin. Nutr. 2005; 59: 776–780. Lin SY, Ayres JW, Winkler W, and Sandine WE. Lactobacillus effects on cholesterol: in vitro and in vivo results. J. Dairy Sci. 1989; 72: 2885–2899. Manson JE, Tosteson H, Ridker PM, Satterield S, Hebert P, and O’Connor GT. The primary prevention of myocardial infaction. N. Engl. J. Med. 1992; 326: 1406–1416. Pereira DI and Gibson GR. Effects of consumption of probiotics and prebiotics on serum lipid levels in humans. Crit. Rev. Biochem. Mol. Biol. 2002; 37(4): 259–281. Richelsen B, Kristensen K, and Pedersen SB. Long-term (6 months) effect of a new fermented milk product on the level of plasma lipoproteinsa placebo-controlled and double blind study. Eur. J. Clin. Nutr. 1996; 50: 811–815. Schaafsma G, Meuling WJ, Dokkum W, and Bouley C. Effects of a milk product, fermented by Lactobacillus acidophilus and with fructo-oligosaccharides added, on blood lipids in male volunteers. Eur. J. Clin. Nutr. 1998; 52: 436–440.

REFERENCES

369

301. Simons LA, Armansec SG, and Conway P. Effect of Lactobacillus fermentum on serum lipids in subjects with elevated serum. Nutr. Met. Cardio. Dis. 2006; 16: 531–535. 302. De Vrese M, Rautenberg P, Laue C, Koopmans M, Herremans T, and Schrezenmeir J. Probiotic bacteria stimulate virus-specific neutralizing antibodies following a booster polio vaccination. Eur. J. Nutr. 2005; 44: 406–413. 303. Isolauri E, Joensuu J, Suomalainen H, Luomala M, and Nesikari T. Improved immunogenicity of oral DXRRV reassortant rotavirus vaccine by Lactobacillus casei GG. Vaccine 1995; 13: 310–312. 304. Kukkonen K, Nieminen T, Poussa T, Savilahti E, and Kuitunen M. Effect of probiotics on vaccine antibody responses in infancya randomized placebo-controlled double-blind trial. Pediatr. Allergy Immunol. 2006; 17: 416–421. 305. Abe F, Ishibashi N, and Shimamura S. Effect of administration of Bifidobacteria and Lactic Acid Bacteria to newborn calves and piglets. J. Dairy Sci. 1995; 78: 2838–2846. 306. Adams DC, Gaylean ML, and Kiesling HE. Influence of viable yeast culture, sodium bicarbonate and monensin on liquid dilution rate, rumen fermentation and feedlot performance of growing steers and digestibility in lambs. J. Anim. Sci. 1981; 53(3): 780–789. 307. Allison BC and McGraw RL. Efficacy of Vita-ferm formula for stocker calves. Anim. Sci. Newsletter A&T and NC State Uni. 1989, November, pp. 12–18. 308. Anderson KL, Nagaraja TG, Morril JL, Avery TB, Galitzer SJ, and Boyer JE. Ruminal microbial development in conventionally or early-weaned calves. J. Anim. Sci. 1987; 64: 1215–1226. 309. Barrow PA, Brooker BE, Fuller R, and Newport MJ. The attachment of bacteria to the epithelium of the pig and its importance in the microecology of the intestine. J. Appl. Bacteriol. 1980; 48: 147–154. 310. Baillon M-LA Marshall-Jones ZV, and Butterwick RF. Effects of probiotic Lactobacillus acidophilus strain DSM13241 in healthy adult dogs. Am. J. Vet. Res. 2004; 65(3): 338– 343. 311. Benyacoub J, Gail L, Czarnecki-Maulden GL, Cavadini C, Sauthier T, Anderson RE, Schiffrin EJ, and von der Weid T. Supplementation of food with Enterococcus faecium (SF68) stimulates immune functions in young dogs. J. Nutr. 2003; 133: 1158–1162. 312. Belavi T, Ucan US, Coscedilun B, Kurtogbreveu V, Idot, and Cetingul S. Effect of dietary probiotic on performance and humoral immune response in layer hens. Br. Poult. Sci. 2001; 42(4): 456–461. 313. Biagi G, Cipollini I, Pompei A, Zaghini G, and Matteuzzi D. Effect of a Lactobacillus animalis strain on composition and metabolism of the intestinal microflora in adult dogs. Vet. Microbiol. 2007; 124(1–2): 160–165. 314. Beharka AA, Nagaraja TG, and Morrill JL. Performance and ruminal function development of young calves fed diets with Aspergillus oryzae fermentation extract. J. Dairy Sci. 1991; 74: 4326–4336. 315. Biourge V, Vallet C, Levesque A, Sergheraert R, Chevalier S, and Jean-Luc Roberton J-L. The use of probiotics in the diet of dogs. J. Nutr. 1998; 128: 2730S–2732S. 316. Bontempo1 V, Nutrition and health of dogs and cats: evolution of pet food. Vet. Res. Commun. 2005; 29(2): 45–50. 317. Burgstaller G, Ferstl R, and Alps H. Addition of lactic acid bacteria (Streptococcus faecium SF-68) to a milk replacer for calf feeding. Zuechtungskunde 1984; 56(2–3): 156– 162.

370


318. Burgstaller G, Ferstl R, and Alps H. Lactic acid bacteria (Streptococcus faecium M 74) in combination with avoparcin in milk replacers for fattening calves. Zuechtungskunde 1985; 57(4): 278–283. 319. Bryant MP, Small N, Bouma C, and Robinson I. Studies on the composition of the ruminal flora and vauna of young calves. J. Dairy Sci. 1958; 41(12): 1747–1767. 320. Canzi E, Zanchi R, Camaschella P, Cresci A, Greppi GF, Orpianesi C, Serratoni M, and Ferrari A. Modulation by lactic-acid bacteria of the intestinal ecosystem and plasma cholesterol in rabbits fed a casein diet. Nutr. Res. 2000; 20(9): 1329–1340. 321. Carlos G, Gonzalez SN, and Oliver G. Some probiotic properties of chicken Lactobacilli. Can. J. Microbiol. 1999; 45: 981–987. 322. Cavazzoni V, Adami A, and Castrovilli C. Performance of broiler chickens supplemented with Bacillus coagulans as probiotic. Br. Poult. Sci. 1998; 39: 526–529. 323. Collington GK, Parker DS, and Armstron DG. The influence of inclusion of either an antibiotic or a probiotic in the diet on the development of digestive enzyme activity in the pig. Br. J. Nutr. 1990; 64(1): 59–70. 324. Cruywagen CW, Jordaan I, and Venter L. Effect of Lactobacillus acidophilus supplementation of milk replacer on preweaning performance of calves. J. Dairy Sci. 1996; 79: 486–486. 325. Dawson KA, Newman KE, and Boling JA. Effects of microbial supplements containing yeast and Lactobacilli on roughe-fed ruminal microbial activities. J. Anim. Sci. 1990; 68: 3392–3398. 326. De Mitchell I and Kenworhty R. Investigations on a metabolite from Lactobacillus bulgaricus which neutralizes the effect of enterotoxin from Escherichia coli pathogenic for pigs. J. Appl. Bacteriol. 1976; 41: 163–174. 327. Dilmi-Bouras A and Sadoun D. Survival of starters of yogurt in the digestive tract of rabbits. Lait 2002; 82: 247–253. 328. Djouvinov D, Boicheva S, Simeonova T, and Vlaikova T. Effect of feeding Lactina probiotic on performance, some blood parameters and caecal microflora of mule ducklings. Trakia J. Sci. 2005; 3(2): 22–28. 329. Elam NA, Gleghorn JF, Rivera JD, Gaylean MJ, Defoor PJ, Brashears MM, and Younts-Dahl SM. Effects of live cultures of Lactobacillus acidophilus and Propionibacterium freudenreichii on performance of finishing beef steers. J. Anim. Sci. 2003; 81: 2686–2698. 330. Endo T and Nakano M. Influence of a probiotic on productivity, meat components, lipid metabolism, caecal flora and metabolites, and raising environment in broiler production. Anim. Sci. J. 1999; 70(4): 207–218. 331. Farnell MA, Donoghue AM, Solios de los Santos F, Blore PJ, Hargis BM, and Donoghue DJ. Up-regulation of oxidative burst and degranulation in chicken heterophils stimulated with probiotic bacteria. Poult. Sci. 2006; 85: 1900–1906. 332. Fleige S.Lactulose in combination with Enterococcus faecium: protective role in calves. Thesis submitted for the Doctoral Degree of Natural Science, Munich University of Technology, 2007. 333. Fritts CA, Kersn JH, Motl MA, Kroger EC, Yan E, Si J, Jiang Q, Campos MM, Waldroup AL, and Waldroup PW. Bacillus subtilis C-3102 (Calsporin) improves live performance and microbiological status of broiler chickens. J. Appl. Poult. Res. 2000; 9: 149–155.

REFERENCES

371

334. Gilliland SE, Nelson CR, and Maxwell C. Assimilation of cholesterol by Lactobacillus acidophilus. Appl. Environ. Microbiol. 1985; 49(2): 377–381. 335. Gomez-Basauri J, de Ondarza MB, and Siciliano-Jones J. Intake and milk production of dairy cows fed lactic acid bacteria and mannonoligosaccharide. J. Dairy Sci. 2001; 84(Suppl. 1): 283. 336. Harper AF, Kornegay ET, Bryant KL, and Thomas HR. Efficacy of virginiamycin and a commercially-available Lactobacillus probiotic in swine diets. Anim. Feed Sci. Technol. 1983; 8: 69–76. 337. Higginbotham GE, Collar CA, Aseltine MS, and Bath DL. Effect of yeast culture and Aspergillus oryzae extract on milk yield in a commercial dairy herd. J. Dairy Sci. 1994; 77: 343–348. 338. Higginbotham GE, Santos JEP, Juchem SO, and DePeters EJ. Effect of feeding Aspergillus oryzae extract on milk production and rumen parameters. Livestock Prod. Sci. 2004; 86: 55–59. 339. Hofacre CL, Froyman R, Gautrias B, George B, Goodwin MA, and Brown J. Use of Aviguard and other intestinal bioproducts in experimental Clostridium perfringensassociated necrotizing enteritis in broiler chickens. Avian Dis. 1998; 42: 579–584. 340. Huber JT. Probiotics in cattles. In: Fuller R editor. Probiotics 2: Applications and Practical Aspects. Chapman and Hall, London, 1997, pp. 162–186. 341. Jackson JE, Lambert BD, Cadle JM, Kaiser GE, and Stafford JA. The effect of Aspergillus oryzae on performance of swine. Texas J. Agric. Nat. Res. 2006; 19: 1–7. 342. Jenny BF, Vandijik HJ, and Collins JA. Performance and fecal flora of calves fed a Bacillus subtilis concentrate. J. Dairy Sci. 1991; 74: 1968–1973. 343. Jin LZ, Ho YW, Abdullah N, and Jalaludin S. Growth performance, intestinal microbial populations, and serum cholesterol of broilers fed diets containing Lactobacillus cultures. Poult. Sci. 1998; 77(9): 1259–1265. 344. Jiraphocakul S, Sullivan TW, and Shahani KM. Influence of a dried Bacillus subtilis culture and antibiotics on performance and intestinal microflora in turkeys. Poult. Sci. 1990; 69(11): 1966–1973. 345. Jonsson E and Olsson I. The effect on performance, health and faecal microflora of feeding Lactobacillus strains to neonatal calves. Swedish J. Agric. Res. 1985; 15(2): 71–76. 346. Kabir SML, Rahman MM, Rahman MB, Rahman MM, and Ahmed SU. The dynamics of probiotics on growth performance and immune response in broilers. Int. J. Poult. Sci. 2004; 3(5): 361–364. 347. Kim SL, Standorf D, Roman-Rosario H, Yokoyama MT, and Rust SR. Potential use of propionibacterium acidipropionici, strain DH42 as a direct-fed microbial for cattle. Michigan State University Beef Cattle, Sheep and Forage System Research and Demonstration Report 2001, pp. 45–55. Downloaded from http://beef.ans.msu.edu/Extension/ Publications/Beef__Sheep_and_Forage_Researc/beef__sheep_and_forage_researc.html on 20th December 2007. 348. Kornegay ET and Risley CR. Nutrient digestibilities of a corn–soybean meal diet as influenced by Bacillus products fed to finishing swine. J. Anim. Sci. 1996; 74: 799–805. 349. Krehbiel CR, Rust SR, Zhang G, and Gilliland SE. Bacterial direct-fed microbials in ruminant diets: performance response and mode of action. J. Anim. Sci. 2003; 81(Suppl. 2): E120–E132.

372


350. Kyriakis SC, Tsiloyiannis VK, Vlemmas J, Sarris K, Tsinas AC, Alexopoulos C, and Jansegers L. The effect of probiotic LSP 122 on the control of postweaning diarrhoea syndrome of piglets. Res. Vet. Sci. 1999; 67: 223–228. 351. Lee YK, Lim CY, Teng WL, Ouwehand AC, Tuomola EM, and Salminen S. Quantitative approach in the study of adhesion of lactic acid bacteria to intestinal cells and their competition with Enterobacteria. Appl. Environ. Microbiol. 2000; 66(9): 3692–3697. 352. Lee YK, Nomoto K, Salminen S, and Gorbach SL. Handbook of Probiotics. John Wiley & Sons, NY, 1999. 353. Lessard M and Brisson GJ. Effect of a Lactobacillus fermentation product on growth, immune response and fecal enzyme activity in weaned pigs. Can. J. Anim. Sci. 1987; 67 (2): 509–516. 354. Lin ASH, Teo AYL, and Tan HM. Antimicrobial compounds from Bacillus subtilis for use against animal and human pathogens. US Patent No: 7,247,299B2, 2007. 355. Losada MA and Olleros T. Towards a healthier diet for the colon: the influence of fructooligosaccharides and Lactobacilli on intestinal health. Nutr. Res. 2002; 22: 71–84. 356. Maia OB, Duarte R, Silva AM, Cara DC, and Nicoli JR. Evaluation of the components of a commercial probiotic in gnotobiotic mice experimentally challenged with Salmonella enterica subsp. enterica ser. Typhimurium. Vet. Microbiol. 2001; 79: 183–189. 357. Marshall-Jones ZV, Baillon M-LA Julie M, Croft JM, and Butterwick RF. Effects of Lactobacillus acidophilus DSM13241 as a probiotic in healthy adult cats. Am. J. Vet. Res. 2006; 67(6): 1005–1012. 358. Matarese LE, Seidner DL, and Steiger E. The role of probiotics in gastrointestinal disease. Nutr. Clin. Practice 2003; 18(6): 507–516. 359. Morrill JL, Morrill JM, Feyerharm AM, and Laster JF. Plasma proteins and probiotic as ingredients in milk replacer. J. Dairy Sci. 1995; 78: 902–907. 360. Myers D and Probiotics. J. Exotic Pet Med. 2007; 16(3): 195–197. 361. Nahashon SN, Nakaue HS, Snyder SP, and Mirosh LW. Performance of single comb White Leghorn layers fed corn–soybean meal and barley–corn–soybean meal diets supplemented with a direct-fed microbial. Poult. Sci. 1994; 73(11): 1712–1723. 362. Nahashon SN, Nakaue HS, and Mirosh LW. Performance of single Comb White Leghorn fed a diet supplemented with a live microbial during the growth and egg laying phases. Anim. Feed Sci. Technol. 1996; 57(1–2): 25–38. 363. Netherwood T, Gilbert HJ, Parker DS, and O’Donnell AG. Probiotics shown to change bacterial community structure in the avian gastrointestinal tract. Appl. Environ, Microbiol. 1999; 65(11): 5134–5138. 364. Nicodemus N, Carabano R, Garcia J, and de Blas JC. Performance response of doe rabbits to Toyocerin (Bacillus cereus var. toyoi) supplementation. World Rabbit Sci. 2004; 12(2): 109–118. 365. Nieto N, Cabarello AG, and Martinez A. Comparative study of the ruminal protozoal fauna in calves under different methods of rearing. Revista de Salud Anim. 1985; 7(3): 281–286. 366. Nocek JE and Kautz WP. Direct-fed microbial supplementation on ruminal digestion, health, and performance of pre-postpartum dairy cattle. J. Dairy Sci. 2006; 89: 260–266. 367. Ogawa M, Shimizu K, Nomoto K, Takahashi M, Watanuki M, Tanaka R, Tanaka T, Hamabata T, Yamasaki S, and Takeda Y. Protective effect of Lactobacillus casei strain Shirota on Shiga toxin-producing Escherichia coli O157:H7 infection in infant rabbits. Infect. Immun. 2001; 69(2): 1101–1108.

REFERENCES

373

368. Ozawa K, Yabu-uchi K, Yamanaka K, Yamashita Y, Nomura S, and Oku I. Effect of Streptococcus faecalis BIO-4R on intestinal flora of weanling piglets and calves. Appl. Environ. Microbiol. 1983; 45(5): 1513–1518. 369. Ozcan M, Arslan M, Matur E, Cotelioglu U, IAkyazi I, and Erarslan E. The effects of Enterococcus faecium Cernelle 68 (SF 68) on output properties and some haematological parameters in broilers. Med. Wet. 2003; 59(6): 496–500. 370. Panda AK, Reddy MR, Rama Rao SV, and Praharaj NK. Production performance, serum/yolk cholesterol and immune competence of white Leghorn layers as influenced by dietary supplementation with probiotic. Trop. Anim. Health Prod. 2003; 35(1): 85–94. 371. Patterson JA and Burkholder KM. Application of prebiotics and probiotics in poultry production. Poult. Sci. 2003; 82: 627–631. 372. Pollmann DS, Danielson DM, and Peo Jr ER. Effects of microbial feed additives on performance of starter and growing-finishing pigs. J. Anim. Sci. 1980a; 51(3): 577–581. 373. Pollmann DS, Danielson DM, Wren WB, Peo Jr ER, and Shahani KM. Influence of Lactobacillus acidophilus inoculum on gnotobiotic and conventional pigs. J. Anim. Sci. 1980b; 51(3): 629–637. 374. Pollmann DS, Danielson DM, and Peo Jr ER. Effects of Lactobacillus acidophilus on starter pigs fed a diet supplemented with lactose. J. Anim. Sci. 1980c; 51(3): 638–644. 375. Pollmann DS, Kennedy GA, Koch BA, and Allee GL. Influence of nonviable Lactobacillus fermentation product on artificially reared pigs. Nutr. Rep. Int. 1984; 29(4): 977–982. 376. Pollamann M, Nordhoff M, Pospischil A, Tedin K, and Wieler LH. Effects of a probiotic strain of Enterococcus faecium on the rate of natural chlamydia infection in Swine. Infect. Immun. 2005; 73(7): 4346–4353. 377. Rastall RA and Maitin V. Prebiotics and synbiotics: towards the next generation. Curr. Opin. Biotechnol. 2002; 13: 490–496. 378. Ratcliffe B, Cole CB, Fuller R, and Newport MJ. The effect of yogurt and milk fermented with a porcine intestinal strain of Lactobacillus reuteri on the performance and gastrointestinal flora of pigs weaned at 2 days of age. Food Microbiol. 1986; 3: 203–211. 379. Rinkinen M, Jalava K, Westermarck E, Salminen S, and Ouwehand AC. Interaction between probiotic lactic acid bacteria and canine enteric pathogens: a risk factor for intestinal Enterococcus faecium colonization? Vet. Microbiol. 2003; 92(1–2): 111–119. 380. Russell JB and Rychlik JL. Factors that alter rumen microbial ecology. Science 2001; 292 (5519): 1119–1122. 381. Rust SR, Metz K, and Ware DR. Effects of Bovamine rumen culture on the performance and carcass characteristics of feedlot steers. Michigan State University Beef Cattle, Sheep and Forage System Research and Demonstration Report 2000, pp. 22–26. Downloaded from http://beef.ans.msu.edu/Extension/Publications/Beef__Sheep_and_Forage_Researc/ beef__sheep_and_forage_researc.html on 20 December 2007. 382. Samanya M and Yamaguchi K. Histological alterations of intestinal villi in chickens fed dried Bacillus subtilis var. natto. Comp. Biochem. Physiol. Part A 2002; 133: 95–104. 383. Santoso U, Tanaka K, and Ohtani S. Effect of dried Bacillus subtilis culture on growth, body composition and hepatic lipogenic enzyme activity in female broiler chicks. Br. J. Nutr. 1995; 74(4): 523–529.

374


384. Santoso U, Tanaka K, Ohtani S, and Sakaida M. Effect of fermented product from Bacillus subtilis on feed conversion efficiency, lipid accumulation and ammonia production in broiler chicks. Asia-Australasian J. Anim. Sci. 2001; 14(3): 333–337. 385. Sauter SN, Benyacoub J, Allenspach K, Gaschen F, Ontsouka E, Reuteler G, Cavadini C, Knorr R, and Blum JW. Effects of probiotic bacteria in dogs with food responsive diarrhoea treated with an elimination diet. J. Anim. Physiol. Anim. Nutr. 2006; 90(7–8): 269–277. 386. Scharek L, Guth J, Reiter K, Weyrauch KD, Taras D, Schwwerk P, Schierack P, Schmidt MFG, Wieler LH, and Tedin K. Influence of a probiotic Enterococcus faecium strain on development of the immune system of sows and piglets. Vet. Immunol. Immunopathol. 2005; 105: 151–161. 387. Scharek L, Guth J, Filter M, and Schmidt MFG. Influence of the probiotic bacteria Enterococcus faecium NCIMB 10415 (SF68) and Bacillus cereus var. toyoi NCIMB 40112 on the development of serum IgG and fecal IgA of sows and piglets. Arch. Anim. Nutr. 2007; 61(4): 223–234. 388. Schwab CG, Moore JJ, Hoyt PM, and Pretience JL. Performance and fecal flora of calves fed a nonviable Lactobacillus bulgiaricus fermentation product. J. Dairy Sci. 1980; 63: 1412–1423. 389. Soder KJ and Holden LA. Dry matter intake and milk yield and composition of cows fed yeast prepartum and postpartum. J. Dairy Sci. 1999; 82: 605–610. 390. Strompfova V, Marcinakova M, Simonova M, Bogovic-Matijasic B, and Laukova A. Application of potential probiotic Lactobacillus fermentum AD1 strain in healthy dogs. Anaerobe 2006; 12(2): 75–79. 391. Teo A and Tan HM. Inhibition of Clostridium perfringens by a novel strain of Bacillus subtilis isolated from the gastrointestinal tracts of healthy chickens. Appl. Environ. Microbiol. 2005; 71: 4185–4190. 392. Teo A and Tan HM. Effect of Bacillus subtilis PB6 (CloSTAT) on broilers infected with a pathogenic strain of Escherichia coli. J. Appl. Poult. Res. 2006; 15: 229–235. 393. Teo A and Tan HM. Evaluation of the performance and intestinal gut microflora of broilers fed on corn-soydiets supplemented with Bacillus subtilis PB6 (CloSTAT). J. Appl. Poult. Res. 2007; 16: 296–303. 394. Thocino A, Xiccato G, Carraro L, and Jimenez G. Effect of diet supplementation with Toyocerin (Bacillus cereus var. toyoi) on performance and health of growing rabbits. World Rabbit Sci. 2005; 13(1): 17–28. 395. Timmerman H. Probiotics reduce costly problems in calves. Feed Mix. 2007; 15(1): 1517. 396. Underdahl NR. The effect of feeding Streptococcus faecium upon Escherichia coli induced diarrhea in gnotobiotic pigs. Prog. Food Nutr. Sci. 1983; 7(3–4): 5–12. 397. Vahjen W and M€anner K. The effect of a probiotic Enterococcus faecium product in diets of healthy dogs on bacteriological counts of Salmonella spp., Campylobacter spp., and Clostridium spp. in faeces. Arch. Anim. Nutr. 2003; 57(3): 229–233. 398. Vasconcelos JT, Elam NA, Brashears MM, and Gaylean ML. Effects of increasing dose of live cultures of Lactobacillus acidophilus (Strain NP51) combined with a single dose of Propionibacterium freudenreichii (Strain NP24) on performance and carcass characteristics of finishing beef steers. J. Anim. Sci. 2008; 86(3): 756–762. 399. Wallace RJ. Ruminal microbiology, biotechnology, and ruminant nutrition: progress and problems. J. Anim. Sci. 1994; 72: 2992–3003.

REFERENCES

375

400. Wallace RJ and Newbold CJ. Probiotics for ruminants. In: Fuller R, editors. Probiotics: The Scientific Basis. Chapman and Hall, London, 1992, pp. 317–353. 401. Walter J. The microecology of Lactobacilli in the gastrointestinal tract. In: Tannock G, editor. Probiotics and Prebiotics: Scientific Aspects. Caister Academic Press, UK, 2005. 402. Wiedmeier RD, Arambel MJ, and Walters JL. Effect of yeast culture and Aspergillus oryzae fermentation extract on ruminal characteristics and nutrient digestibility. J. Dairy Sci. 1987; 70: 2063–2068. 403. Weese JS and Arroyo L. Bacteriological evaluation of dog and cat diets that claim to contain probiotics. Can. Vet. J. 2003; 44(3): 212–215. 404. Yeo J and Kim KI. Effect of feeding diets containing an antibiotic, a probiotic, or yucca extract on growth and intestinal urease activity in broiler chicks. Poult. Sci. 1997; 76(2): 381–385. 405. Yu B and Tsen HY. Lactobacillus cells in the rabbit digestive tract and the factors affecting their distribution. J. Appl. Bacteriol. 1993; 75(3): 269–275. 406. Zani JL, Weykamp da Cruz F, Freitas dos Santos A, and Gil-Turnes C. Effect of probiotic CenBiot on the control of diarrhea and feed efficiency in pigs. J. Appl. Microbiol. 1998; 84(1): 68–71. 407. Zhao T, Doyle MP, Harmon BG, Brown CA, Mueller PO, and Parks AH. Reduction of carriage of enterohemorrhagic Escherichia coli O157:H7 in cattle by inoculation with probiotic bacteria. J. Clin. Microbiol. 1998; 36(3): 641–647. 408. Zink R, Roniero R, Rochat F, Cavadini C, Der Weid T, Schiffrin E, Benyacoub J, Rousseau V, and Perez P. Probiotics for pet food applications. US Patent No: 7,189,390, 2007. 409. Zulkifli I, Abdullah N, Azrin NM, and Ho YW. Growth performance and immune response of two commercial broiler strains fed diets containing. Br. Poult. Sci. 2000; 41(5): 593–597. 410. USDA. Pet Food Update. Foreign Agricultural Service, United States Department of Agriculture, October 2007 (http://www.fas.usda.gov/scriptsw/attacherep/default.asp).

5 MECHANISMS OF PROBIOTICS

5.1 ADHESION TO INTESTINAL MUCUS AND EPITHELIUM BY PROBIOTICS

Sampo Lahtinen and Arthur Ouwehand Health & Nutrition, Danisco, Finland

Adhesion of probiotics to intestinal mucus and epithelial cells has long been considered one of the most important selection criteria for probiotic microorganisms. Adhesion to the intestinal mucosa may prevent probiotic cells from being washed out; and therefore, enabling temporary colonization, immune modulation, and competitive exclusion of pathogens. The question whether externally administered probiotics really adhere to epithelial cells or to mucus in vivo has been somewhat controversial (7). Although the evidence of the adhesion of probiotics to mucus in vivo is still limited, recent studies indicate that such adhesion may indeed occur and may thus serve as a mechanism for probiotic action. A number of different methods have been used in the adhesion assays of probiotics (8, 74). The most common are the tests assessing the adhesion to epithelial cell lines and to intestinal mucus. In addition, assessment of the adhesion to resected colonic tissue has been demonstrated (58). This method takes into account epithelial cells and intestinal mucosa as well as the endogenous bacteria attached to mucosa.


377

378

MECHANISMS OF PROBIOTICS

TABLE 5.1

Adhesion of Probiotics to Gastrointestinal Epithelial Cell Lines

Probiotics

Study Design

Result

Lactobacillus isolates from various sources Lactobacillus GG and other dairy strains Human Lactobacillus isolates Thirteen human strains of Bifidobacterium L. acidophilus LA1 and three other strains Commercial probiotic and dairy strains Thirteen B. longum isolates

Adhesion and detection of adherent bacteria from birds Adhesion to Caco-2 cell cultures

Adherence to epithelial cells; species specific

(20)

Lactobacillus GG more adherent than other tested dairy strains Adhesion strain specific; dependent on age of the cell culture Adhesion calcium independent

(18)

Adhesion to Caco-2 cell cultures Adhesion to Caco-2 cells and mucus from HT-29-MTX cells Adhesion to Caco-2 and HT-29-MTX cell cultures Adhesion to Caco-2 cell cultures

Adhesion to Caco-2, HT-29 and KATO III cell cultures Five commercial Adhesion to Caco-2, probiotic strains HT-29 and HT-29-MTX cells Various lactobacilli Adhesion to Caco-2 cell and bifidobacteria cultures; induction of cytokine production Eight Adhesion to Caco-2 cell Bifidobacterium cultures and determination strains of global expression profiles

5.1.1

References

(12)

(5)

Adhesion calcium independent

(6)

Adhesion strain specific

(45, 72)

Adhesion correlated with (17) autoaggregation properties All strains showed strong adhesion

(21)

Adhesion does not affect cytokine production by epithelial cells Caco-2 cells respond differentially to E. coli and Bifidobacterium; response independent from adhesion

(49)

(64)

Adhesion to Gastrointestinal Epithelial Cell Lines

A classic method for assessing adhesive properties of probiotic bacteria is the use of cultures of intestinal epithelial cells, mostly Caco-2, HT-29, or mucus-secreting HT-29-MTX cells (Table 5.1). 5.1.2

Adhesion to Intestinal Mucus

The ability to adhere to intestinal mucosa has been suggested as a potential mechanism for temporary colonization, and the adhesion to mucus is commonly used in in vitro adhesion assays (Table 5.2).

ADHESION TO INTESTINAL MUCUS AND EPITHELIUM BY PROBIOTICS

TABLE 5.2

379

Adhesion of Probiotics to Intestinal Mucus

Probiotics

Study Design

Result

Reference

Commercial probiotic strains

Probiotics more adherent to adult mucus compared to infant mucus Adhesion variable (2–43%); hydrophobicity does not correlate with adhesion Adhesion strain specific; host specificity may play a role In vitro adhesion to mucus Bb-12 most adherent; isolated from three age adhesion highest groups to adult mucus In vitro adhesion to human, No host specificity canine, possum, bird, observed, strain selection and fish mucus more important

In vitro adhesion to mucus from healthy infants and adults Commercial probiotics, In vitro adhesion to mucus from healthy adults; dairy strains, fecal analysis of cell surface isolates hydrophobicity Bifidobacteria from In vitro adhesion to human human and animal and bovine mucus hosts

(41)

Bifidobacterium lactis Bb-12 and other strains Commercial probiotics and fecal isolates

(46)

5.1.3

(55)

(28)

(65)

Colonization of Probiotics in Human Intestine as Assessed by Biopsies

Adhesion to intestinal mucus or epithelial cells is thought to be a prerequisite for temporary colonization of probiotics in the intestine. While colonization of externally administered probiotics in humans is thus far not well documented, increasing evidence suggests that temporary colonization of probiotics is possible (Table 5.3). 5.1.4

Comparisons Between In Vitro and In Vivo Results

The validity of in vitro adhesion tests and the correlation to in vivo colonization have been assessed in several studies. Indirect evidence suggests that adhesion to intestinal cells and mucus is associated with temporary colonization. However, in vitro and in vivo results do not always correlate (Table 5.4). 5.1.5

Adhesins

Several bacterial components, including cell wall proteins, carbohydrates, and lipoteichoic acids, have been suggested to be involved in the adhesion of probiotics to intestinal contents (Table 5.5). 5.1.6

Factors Affecting the Adhesion Properties of Probiotics

Adhesion properties of probiotics are strain specific, and the factors such as cell wall properties and composition (26) and possibly also host specificity are the most

380


TABLE 5.3 Colonization of Probiotics in Human Intestine as Assessed by Biopsies Probiotics

Study design

Result

Nineteen strains of Lactobacillus

Strains administered in combination to 13 volunteers

L. rhamnosus GG

Strain administered to volunteers, followed by colonic biopsies between 7 and 14 days postadministration Strain administered to seven volunteers, followed by colonic biopsies at 2 days postadministration

At 11 days postadministration, 5/19 strains were isolated from biopsies LGG detected in biopsies after administration; temporary colonization

L. paracasei B21060

Most volunteers had at least one positive biopsy sample

Reference (37)

(2, 3)

(48)

important determinants of adhesion properties. However, several other factors have also been reported to affect the adhesion properties (Table 5.6). 5.1.7

Adhesive and Inhibitory Properties of Nonviable Probiotics

Studies on inactivated probiotics have suggested that nonviable probiotic bacteria may also be capable of adhesion. This is because adhesion properties are related to specific TABLE 5.4

Comparisons Between In Vitro and In Vivo Results

Probiotics

Study Design

Result

Twelve strains of Bifidobacterium

In vitro adherence to Caco-2 cells compared to in vivo human study Strains selected based on in vitro assays and administered to human volunteers In vitro and in vivo (human) properties of aggregating and nonaggregating variants compared In vitro properties compared to colonization in mice

Good in vitro adhesion was observed for strains capable of colonization

(16)

Survival and temporary colonization related to in vitro adhesion

(35)

Only wild-type aggregating L. crispatus associated with in vitro adhesion and in vivo colonization

(10)

Strains showed similar in vitro properties but different in vivo colonization

(34)

Forty-seven Lactobacillus strains Wild-type and mutant L. crispatus

L. johnsonii and L. paracasei

Reference

381


TABLE 5.5

Adhesins Associated with Probiotic Adhesion

Adhesin

Probiotics

Target of Adhesion

Proteins

L. fermentum 104-R

Porcine mucin, mucus and epithelium Intestinal cell lines and mucus Intestinal epithelial cell line (Caco-2) Mannose and HT-29 cells Intestinal 407 cells

L. acidophilus BG2FO4 Human Lactobacillus isolates L. plantarum L. acidophilus and L. agilis Commercial probiotic strains L. reuteri 1063 L. brevis L. johnsonii La1 L. acidophilus NCFM L. acidophilus M92 L. reuteri 100-23 L. reuteri 104-R (formerly L. fermentum) 31 L. plantarum strains

Lactobacillus isolates from pigs

Lipoteichoic acids

Bifidobacterium bifidum Various Lactobacillus strains

L. johnsonii La1 Carbohydrates

L. fermentum 104-R Human Lactobacillus isolates

Mucus isolated from healthy volunteers Mucus and mucin from pigs and hens Intestinal cell lines and fibronectin Intestinal cell lines and mucus Intestinal epithelial cell line (Caco-2) Intestinal epithelium from mice Mouse intestine (in vivo) Intestinal epithelial cell line (Caco-2) Porcine mucin, reconstituted basement membranes and Caco-2 cells Pig and human intestinal cells and collagen, laminin, and fibronectin Isolated colonocytes Hemagglutination inhibition by strains adherent to murine gastric epithelium Intestinal epithelial cell line (Caco-2) Porcine gastric squamous epithelium Intestinal epithelial cell line (Caco-2)

References (31, 66) (14) (24) (1, 62) (40) (71)

(67) (33) (4, 22) (9) (19) (73) (47) (70)

(36)

(50) (69)

(23) (31) (24)

382


TABLE 5.6

Factors Affecting the Adhesion Properties of Probiotics

Factor Low pH

Presence of bile Growth phase

Study Design Adhesion of probiotics to Caco-2 epithelial cells Adhesion of probiotics to mucus Adhesion of L. fermentum to keratinizing gastric epithelium in mice Adhesion of probiotics to Caco-2 epithelial cells

Growth medium

Adhesion of potential probiotic strains to ileostomy glycoproteins Acquired acid Adhesion of acidresistance resistant variants of Bifidobacterium to mucus Acquired bile Adhesion of bileresistance resistant variants of Bifidobacterium to mucus Endogenous Adhesion to mucus in the microbiota presence of fecal or mucosal microbiota Presence of other Adhesion of probiotic probiotic strains combinations to ileostomy glycoproteins Adhesion of probiotics to porcine intestinal epithelial IPEC-J2 cells Digestive Adhesion of probiotics enzymes to mucus Adhesion of Propionibacterium acidipropionici to intestinal cells Binding of Adhesion of Lactobacillus mycotoxins GG to Caco-2 epithelial cells Presence of Adhesion of commercial lignans probiotics to mucus

Effect Increased adhesion Changes in adhesion strain dependent Reduced adhesion Adherence higher during stationary phase compared to exponential phase Decreased adhesion during logarithmic phase, increased during stationary phase Culture medium affects adhesion

References (8, 24) (64) (25, 52) (68)

(8)

(60)

Acquired acid resistance may in some cases increase adhesion

(15)

Acquired bile resistance may increase adhesion

(25)

Endogenous microbiota does not affect adhesion to mucus in vitro Combinations of probiotics may have synergistic effects on adhesion Probiotic strains may reduce adhesion of other strains by competing for same adhesion sites Reduced adhesion in most cases No effect on adhesion

Decreased adhesion when cell is bound to mycotoxin Increased adhesion in some strains

(51, 56)

(54)

(44)

(52) (76)

(39)

(43)

383


TABLE 5.6 (Continued) Factor

Study Design

Presence of calcium

Effect

Adhesion calcium independent in some cases and calcium dependent in others Adhesion of probiotics to Adhesion of most strains increased by porcine intestinal the presence of calcium epithelial IPEC-J2 cells Adhesion of probiotics to Adhesion not affected by Mgþþ and Znþþ ions porcine intestinal epithelial IPEC-J2 cells Adhesion of probiotics and human isolates to Caco-2 epithelial cells

Presence of Mgþþ and Znþþ ions

References (5, 6, 12, 14)

(44)

(44)

cell surface properties rather than metabolic activity or cell division. Different inactivation methods may cause strain-specific changes in the adhesion properties of the cells. For example, heating may improve the adhesion of certain probiotic strains, but may be detrimental to the adhesive properties of other strains (Table 5.7). 5.1.8

Role of Age and Diseases on Adhesion

Aberrant gastrointestinal microbiota has been linked to a number of gastrointestinal and other diseases. In addition, age-related differences in the composition of gastrointestinal microbiota have been suggested, especially in the case of bifidobacteria. In TABLE 5.7 Probiotics L. acidophilus

Adhesive and Inhibitory Properties of Nonviable Probiotics Study Design

Result

In vitro adhesion to Viable and nonviable human intestinal cells cells equally adherent No major changes in L. fermentum Adhesion of sonicated the adhesion compared 104-R cells to porcine gastric to untreated controls squamous epithelium Heat-killed probiotic is L. acidophilus Adhesion of heat-killed highly adherent to LB probiotic to epithelial epithelial cell cultures cell cultures; pathogen and inhibits pathogen inhibition adhesion Changes in adhesion Commercial Effects of different dependent on the probiotic inactivation methods method of inactivation strains on the adhesion to mucus in vitro Viable probiotics most Streptococcus Inhibition of E. coli effective, antibiotic-killed thermophilus and infection on epithelial cells also effective, L. acidophilus cell line by viable or heat-killed cells ineffective killed probiotics

References (32) (31)

(11, 13)

(61)

(63)

384


TABLE 5.8

Role of Age and Diseases on Adhesion

Probiotics

Study Design

Result

Bifidobacteria isolated from healthy seniors and adults Commercial bifidobacteria

In vitro adhesion to human mucus

Bifidobacteria from allergic infants

In vitro adhesion to mucus from healthy volunteers

Commercial probiotics

In vitro adhesion to mucus and resected colonic tissue from patients with major intestinal disorders In vitro adhesion to mucus from infants with rotavirus infection Administration of probiotic to patients with ulcerative colitis Administration of probiotic to critically ill patients

Reduced adhesion of bifidobacteria from seniors compared to adults Reduced adhesion to mucus from elderly subjects compared to mucus from adults and infants Reduced adhesion to mucus from allergic infants compared to mucus from healthy infants Adhesion is disease dependent

Commercial probiotics

Bifidobacterium infantis L. plantarum 299v

In vitro adhesion to mucus from infants, adults, and elderly

References (30)

(53)

(27, 29)

(57, 59)

Rotavirus infection does not affect adhesion

(38)

Probiotic strain recovered from biopsies, suggests temporary colonization Probiotic strain recovered from 3/9 biopsies, suggesting temporary colonization

(75)

(42)

certain cases, the adherence properties of the intestinal mucus may be altered during the disease. The ability of certain probiotics to colonize subjects with a disease has also been assessed (Table 5.8). 5.2 COMBINED PROBIOTICS AND PATHOGEN ADHESION AND AGGREGATION

M. Carmen Collado and Seppo Salminen Functional Foods Forum, University of Turku, Finland

The human intestinal microbiota constitutes a complex ecosystem that plays an important role in health and diseases in which various pathogens alter the intestinal

COMBINED PROBIOTICS AND PATHOGEN ADHESION AND AGGREGATION

385

bacterial homeostasis. There are also food probiotic bacteria that exhibit specific beneficial properties through microbiota modulation. The protective role of probiotic bacteria against gastrointestinal pathogens and the underlying mechanisms have received special attention. Pathogen inhibition by lactic acid bacteria might provide significant human health protection against pathogens either as a natural barrier against exposure in the gastrointestinal tract or as a method to decontaminate drinking water or food. This would enhance human health and have a positive economic impact especially in developing countries where the people suffer from frequent gastrointestinal infections. The development of adjuvant or alternative therapies based on bacterial replacement is considered important due to the rapid emergence of antibiotic-resistant pathogenic strains and the adverse consequences of antibiotic therapies on the protective microbiota (100). Probiotic strains have shown to exert a protective effect at least against traveler’s diarrhea, rotavirus diarrhea, and antibiotic-associated diarrhea (89, 109, 116). The possible mechanisms underlying these antagonistic effects include competition for adhesion sites and nutritional sources, secretion of antimicrobial substances, toxin inactivation, and immune stimulation (99). Probiotics exhibit antagonistic effects against pathogens belonging to the genera Listeria, Clostridium, Salmonella, Shigella, Escherichia, Helicobacter, Campylobacter, and Candida (91, 107, 120, 141, 143). There are an increasing number of scientific reports on the effects of combined probiotics on the health of the host (98, 106, 115, 123, 125, 137). The best known probiotic combination consists of a mixture of eight lactic acid bacterial species (VSL # 3) and is reported to be effective in several human diseases (82, 86, 104, 106, 117). Combinations of well-known probiotics strains such as L. rhamnosus GG and B. lactis Bb12 (90, 92, 93, 127). 5.2.1

Aggregation

In order to manifest beneficial effects, probiotic bacteria need to achieve an adequate mass through aggregation. Consequently, the ability of probiotics to aggregate is a desirable property. Organisms with the ability to coaggregate with other bacteria such as pathogens may have an advantage over noncoaggregating organisms that are more easily removed from the intestinal environment. 5.2.2

Adhesion

Adherence to the intestinal epithelium and mucus is associated with stimulation of the immune system (80, 114), and adhesion to the intestinal mucosa is also crucial for transient colonization (114), an important prerequisite for probiotics to control the balance of the intestinal microbiota. Intestinal mucus has a dual role; it protects the mucosa from certain microorganisms while providing an initial binding site, nutrient source, and matrix on which bacteria can proliferate. Further, adherence of bacteria to intestinal epithelium is required for both colonization and infection of the gastrointestinal tract by many pathogens (101). Adhesion is a complex process involving

386


nonspecific (hydrophobicity) and specific ligand–receptor mechanisms. Adherence of bacterial cells is usually related to cell surface characteristics (84, 87). Many authors have reported that the coaggregation abilities of Lactobacillus species might enable it to form a barrier that prevents colonization by pathogenic bacteria (85, 137, 139, 140). 5.2.3

Assay for Adhesion

Cell adhesion is a complex process involving contact between the bacterial cell membrane and interacting surfaces. The ability to adhere to epithelial cells and mucosal surfaces has been suggested to be an important property of many bacterial strains used as probiotics. Several researchers have reported investigations on composition, structure, and forces of interaction related to bacterial adhesion to intestinal epithelial cells (97, 130, 132) and mucus (90, 129, 137). The bacterial adhesion to hydrocarbons test (BATH) has been extensively used for measuring cell surface hydrophobicity in lactic acid bacteria (119, 148) and bifidobacteria (87, 107, 132). Usually, bacterial adhesion to hydrocarbons test or microbial adhesion to hydrocarbons test (MATH has been analyzed (112). Affinity to hydrocarbons (hydrophobicity) was reported as adhesion before and after extraction with organic solvents, respectively. In general, hydrophobicity results demonstrated a great heterogeneity among probiotic strains in adhesion to hydrocarbons, although generally lactobacilli strains showed the highest adhesion percentages (96). Many studies on the microbial cell surface chemistry showed that the presence of (glycol-) proteinaceous material at the cell surface results in higher hydrophobicity, whereas hydrophilic surfaces are associated with the presence of polysaccharides (108, 130, 136). 5.2.4

Assay for Aggregation

Bacterial aggregation is related to cell-to-cell adherence (85, 97, 146) between bacteria of the same strain (autoaggregation) or between genetically different strains (coaggregation) and is of considerable importance in several ecological niches, especially in the human gut where probiotics have to be active (113). Bacterial aggregation was analyzed largely in oral, dental, and biofilm environments (79, 121, 122, 124, 134) but there are only a few studies using probiotic strains and pathogens (85, 94, 96, 133, 139, 140). Coaggregation with potential gut pathogens may contribute to the probiotic properties ascribed to specific probiotic strains. Since detection of bacterial aggregation between probiotics and pathogens is important for human health, such studies are a priority to characterize and assess different methods. In general, specific probiotic strains show higher autoaggregation abilities than pathogen strains (96). A positive relationship between autoaggregation and adhesion ability has been reported for some bifidobacterial species (97, 132) and also, there is a correlation between adhesion ability and hydrophobicity in some lactobacilli (96, 97, 149). However, these correlations have not been found by other authors (148). Nevertheless, these studies indicated that specific strains have highest percentages of adhesion to hydrocarbons and also showed higher autoaggregation abilities (Fig. 5.1). For bifidobacterial strains, a positive correlation was observed between aggregation ability and hydrophobicity (Fig. 5.1).


387

(a) 80 70

BATH % xylene

60 50 40 30 20 10 0 0

10

20

30

40

50

60

70

80

% autoaggregation (20 h) (b) 80 70

BATH % xylene

60 50 40 30 20 10 0 0

5

10

15

20

25

30

35

% autoaggregation (20 h) (c) 80

BATH % xylene

70 60 50 40 30 20 10 0

2

4

6

8

10

12

14

16

18

% autoaggregation (20 h)

FIGURE 5.1 Autoaggregation index of the probiotic and pathogenic strains as a function of adhesion to xylene (n 3). (A) Specific probiotic strains, (B) model pathogens, and (C) common Bifidobacterium strains (adapted from Refs 94 and 96).

388


Coaggregation phenomenon has been observed in bacteria from the human oral cavity, urogenital tract, mammalian gut, and potable water supply systems (134). It has been suggested that bacteriocin-producing lactic acid bacteria, which coaggregate with pathogens, may constitute an important host defense mechanism (133, 142). Several reports have suggested that the cellular aggregation could be important in promoting the colonization of beneficial lactobacilli in the gastrointestinal or vaginal tract (88, 113). Recent reports (96) showed coaggregation between commercial probiotic strains and potential pathogens such as B. vulgatus, C. histolyticum, and St. aureus. Based on the aggregation abilities, bacteria could be divided into three distinct groups. The first group showed high aggregation abilities, the second lower aggregation, and the third high coaggregation and low autoaggregation abilities (Fig. 5.2). The findings suggest that the ability to autoaggregate, together with cell surface hydrophobicity as measured by BATH and coaggregation abilities with pathogen strains, can be used for preliminary screening in order to identify potentially probiotic bacteria suitable for human or animal use. Focused effort is needed to identify and characterize bacterial cell wall components, compositions, and properties to understand their role in adhesion to hydrocarbons, autoaggregation, and relation to coaggregation mechanisms.

60

60

50

50

40

40

30

30

20

20

10

10

0

0 0

5

10

15

20

25

30

35

0

5

10

15

20

25

30

% coaggregation C. histolyticum

% coaggregation B. vulgatus 60

60 50

50

40

40

30

30

20

20

10

10

0

0 0

5

10

15

20

% coaggregation St. aureus

25

30

0

5

10

15

20

25

30

35

% coaggregation E. sakazakii

FIGURE 5.2 Coaggregation abilities (4 h incubation at 20 C) of probiotic strains (n 3). (*) Higher aggregation and coaggregation, ( ) lower aggregation and coaggregation, and (!) lower aggregation and higher coaggregation (adapted from Ref 96).


5.2.5

389

Factors that Determine Adhesion

Adhesion to intestinal mucosa is regarded as a prerequisite for probiotic microorganisms. Adhesion allows the colonization, although transient, of the human intestinal tract (78) and it has been related to many of the health benefits attributed to specific probiotics. Thus, the ability to adhere to epithelial cells and mucosal surfaces has been suggested to be an important property of many probiotic bacterial strains (90, 95, 126, 128) and combination of probiotics. Several researchers have reported on the roles of composition, structure, and forces of interaction in bacterial adhesion to intestinal epithelial cells (97, 132) and mucus (90, 145). It has been shown that some lactobacilli and bifidobacteria share carbohydrate-binding specificities with some pathogens (81, 102, 110) providing the rationale for the use of these microorganisms to prevent infection at an early stage, by inhibiting the adhesion of these pathogens. The adhesion mechanisms involved passive forces, electrostatic and hydrophobic interactions, lipoteichoic acids, and specific structures such as polysaccharides and lectins. In general, it is assumed that probiotic strains are able to inhibit the attachment of pathogenic bacteria by means of steric hindrance at enterocyte pathogen receptors. It has been suggested that proteinaceous components are involved in the adhesion of probiotic strains to intestinal cells (81, 90, 102, 111). 5.2.6

In Vitro Models

The difficulties involved in studying bacterial adhesion in vivo, specifically in humans, have led to the development of in vitro model systems for the preliminary selection of potentially adherent strains. Many different intestinal mucosa models have been used to assess the adhesive ability of probiotics; among them the adhesion to human intestinal mucus has been widely used (90, 92, 95, 111, 118, 127, 135, 145). Good correlations have been previously reported between this mucus model and the enterocyte-like Caco2 model (77, 128, 146). These intestinal models have also been used to demonstrate that probiotic bacteria can competitively inhibit the adhesion of pathogenic microorganisms and displace the previously adhered pathogens, such as Salmonella, Escherichia coli, Listeria monocytogenes, Staphylococcus aureus, Bacteroides vulgatus, Clostridium difficile, and C. perfringens (81, 83, 90, 92, 95, 110, 111). The adhesion levels of the probiotic and pathogens strains showed a great variability depending on the strain, species, and genus (90, 92, 93, 110, 111). These results suggest that they have the capacity to adhere to the intestinal mucus, which could assist the pathogens in the invasion into the human intestinal mucosa. It has been cautioned that the in vitro studies should always be corroborated by studies in animal model and human trial (83, 92, 95). The ability to inhibit the adhesion of pathogen appears to depend on both the probiotic and the pathogen strains, with a high specificity (92, 95, 96, 110, 111, 120, 144). These results, in accordance with previous reports (90, 110, 120), indicate that the displacement was not related to the adhesion ability of the strains. In addition, the displacement and competition profiles are very different from those observed for the inhibition of pathogens. These results appear to confirm that different mechanisms are implied in the processes of pathogen inhibition.

390


5.2.7

Probiotics in Combination

Since the beneficial effects of probiotics are strain dependent, it has been suggested that combinations of different probiotic strains may be more effective than monostrain probiotics (143). However, the impact can be counteractive, if strains are not selected in a scientifically sound manner. Recently, it has been shown that a combination of probiotic strains may complement or improve health benefits given by individual strains (82, 86, 105–107, 115, 117, 123). The adhesion properties of single bacteria to the intestinal mucus could be improved when a combination of probiotics is used. Furthermore, adhesion in vivo could be influenced by both the normal microbiota and the specific probiotics included in each food preparation. In in vitro trials, the probiotic properties have mainly been tested alone or in combination with yogurt bacteria such as L. delbrueckii and L. acidophilus (127) but rarely combined with other probiotics (93, 127). Figure 5.3a and b demonstrates the influence of other probiotic strains in the adhesion of probiotics. This influence may be positive (enhance the adhesion) or negative (decrease). In addition, a recent report (138) describes how the presence of exopolysaccharides produced by probiotic bacteria can modify the bacterial adhesion to intestinal mucus.

(a) 100

80

% adhesion

*

*

60

*

*

*

80

% adhesion

(b) 100

*

*

40

*

60

*

40

*

0

0

9 5 -JS G-9 05-JS 05-99 JS-99 05-99 GG C70 7 7 7 G GG -L GG S-LC -LC G-LC GG G -J G G GG

LC

5 9 -JS G-99 S-99 G-99 70 5-GG 5-JS 5-9 70 C70 5-GG 05-G 05-J 70 S-G 7 L LC 0 C7 LC 5-J 7 LC L 70 LC LC

(d) 200

20

* 0

150

% adhesion

% adhesion

*

20

20

(c)

*

-20

-40

* *

-60

*

*

*

* *

*

* *

100

50

* *

0

-80

99

5 G -JS C705 G-JS C705 C705 70 -G 99 L 99 9-LC -L -L -G GJS 99 9-JS 9 G-G 9 -G 99 99

5 9 5 G -99 5-99 5-99 JS S-G 70 70 JS-9 70 J LC S-GG C70 -LC LC GJ -L JS G-G JS -G JS JS

FIGURE 5.3 Changes in adhesion percentages of (a) L. rhamnosus GG (b) L. rhamnosus LC705 (c) B. breve 99, and (d) P. freudenrenchii JS in double, triple and quadruple combination (adapted from Ref. 93).

PRODUCTION OF ANTIMICROBIAL SUBSTANCES

391

Thus, it is necessary to further research on the influence of coculture and metabolic productions in the adhesion of probiotic strains in order to find the best combinations to be included in functional food products (92, 93). 5.2.8

Conclusion

The studies so far demonstrate that it is possible to characterize specific probiotic combinations that increase the beneficial health effects beyond single strains. Such demonstrations include the inhibition of pathogen adhesion properties and their influence in their colonization. We suggest that combinations of different probiotics strains may be more effective in vivo than single probiotic strains especially in adult and elderly populations and in subjects with complicated microbiota aberrancies. Several reports also exist to support this hypothesis (92, 105, 123, 131, 143, 150). Taken together, the results show a very high specificity in the inhibition of the adhesion and displacement of enteropathogens by different probiotic strain combinations, indicating the need of a case-by-case characterization of these combinations. It must also be considered that at the end in vivo studies are always necessary to confirm the potential health effects prior to introducing such combinations to clinical intervention studies. The presented new strategy and methodology allow the development of new specific probiotic combinations for the treatment or prevention of specific diseases caused by known pathogens or microbiota deviations. It can therefore be hypothesized that a specific combination of these microorganisms may have the potential to increase the efficacy of future probiotic preparations. As a basis, careful characterization and assessment of microbiota aberrancies are required. Thereafter, adhering organisms and their suitability to counteract the microbiota aberrancy in question has to be assessed. In the best cases, the selected strains may complement each other’s probiotic effect and even work synergistically and such combinations can then be further characterized in human intervention studies in target populations. 5.3 PRODUCTION OF ANTIMICROBIAL SUBSTANCES

Satu Vesterlund Functional Foods Forum, University of Turku, Turku, Finland

Although health aspects of fermented milks appeared in the early 1900s because of Metchnikoff observations (174), lactic acid bacteria (LAB) have been used in the preservation of milk and vegetables for centuries (179). Today, a wide variety of strains including LAB, propionic acid bacteria (PAB), and bifidobacteria are industrially used as starter cultures, cocultures, or bioprotective cultures to improve preservation, flavors, and texture of milk, vegetable, meat, and cereal products. The scientific basis of improved preservation is based on fermentation in which the pH value is lowered, the amount of available carbohydrates is reduced, and many antimicrobial compounds are produced by fermenting bacteria. The widespread ability of LAB, PAB, and

392


bifidobacteria to produce antimicrobial substances such as organic acids, hydrogen peroxide, and bacteriocins implies an important biological role for bacteria and has been one of the key elements in the selection of these bacteria for probiotic use (164). The aim of this chapter is to discuss the production, activity, and mode of action of different antimicrobial substances produced by probiotics. 5.3.1

Organic Acids

Organic acids are produced by all LAB upon fermentation of hexose. The levels and types of organic acids produced depend on the species and growth conditions of the bacteria. Homofermentative LAB use the glycolytic pathway to produce two pyruvates, which are further converted to lactate. Theoretically, the yield is 2 mol of lactic acid and net gain of 2 ATP per mole of glucose. When there is a lack of sugar or oxygen, heterofermentative LAB such as leuconostocs and group III lactobacilli as well as homofermentative LAB use the pentose phosphate pathway to produce 1 mol each of lactic acid, acetic acid/ethanol, CO2, and ATP per mole of glucose consumed. The undissociated, more hydrophobic form of the acid diffuses over the cell membrane and dissociates inside the cell, releasing Hþ ions that acidify the cytoplasm (166). Acetic acid and propionic acid have higher pKa values than lactic acid (4.87, 4.75, and 3.08, respectively) and therefore have a higher proportion of undissociated acid at a certain pH (165). Acetic acid is more inhibitory than lactic acid and can inhibit yeasts, molds, and bacteria (156). In addition to the pH effect, the undissociated acid collapses the electrochemical proton gradient, causing bacteriostasis and finally death of susceptible bacteria (166). Moreover, lactic acid has been shown to permeabilize the outer membrane of Gram-negative bacteria by liberation of its lipopolysaccharides, leading to loss of viability (151). Thus by permeabilization, the action of lactic acid may facilitate the action of other antimicrobial factors. The effect of organic acids against bacteria, yeasts, and molds is well documented (156, 157). 5.3.2

Hydrogen Peroxide

In the presence of flavoprotein oxidases and oxygen, bacteria are able to produce hydrogen peroxide (H2O2). The antimicrobial effect of hydrogen peroxide is attributed to a strong oxidizing effect on the bacterial cell. Under certain natural conditions as in milk, the effect of hydrogen peroxide may be enhanced by the lactoperoxidase system resulting in the production of hypothiocyanate (OSCN) or higher oxyacids (O2SCN and O3SCN) (161). The exposure of bacteria to OSCN has been shown to damage metabolic enzymes of bacteria by oxidizing sulfhydryl groups of enzymes such as glyceraldehyde-3-phosphate dehydrogenase (158) or disrupt bacterial membranes (170). The production of hydrogen peroxide by lactobacilli is supposed to be a nonspecific antimicrobial defense mechanism of the normal vaginal ecosystem (175). This is seen in a number of H2O2-generating lactobacilli when they are present in the vagina of most normal women but are absent from most women with bacterial vaginosis (167, 172). In addition, L. crispatus and L. jensenii, the most common lactobacilli

PRODUCTION OF ANTIMICROBIAL SUBSTANCES

393

in the female genital tract, have been shown to inhibit gonococci by producing H2O2 (177). However, it is argued that H2O2 can accumulate and be inhibitory to some microorganisms as in the presence of catalase produced by other bacteria, H2O2 breaks down (177). 5.3.3

Carbon Dioxide

Carbon dioxide (CO2) is mainly formed from heterolactic fermentation. CO2 can directly create an anaerobic environment and is toxic to some aerobic food microorganisms through its action on cell membranes. The antimicrobial activity of the carbon dioxide molecule is thought to be due to the inhibition of enzymatic decarboxylation and accumulation of carbon dioxide in the membrane lipid bilayers causing dysfunction in membrane permeability (173). As CO2 can effectively inhibit the growth of many food spoilage microorganisms, especially Gram-negative psychrotrophic bacteria (162), the effect has been commercially applied to many refrigerated products as modified atmosphere packaging. 5.3.4

Bacteriocins

Bacteriocins are defined as proteinaceous, antibacterial substances synthesized by many different bacterial species in order to kill or inhibit growth of other bacteria. They are heterogeneous group of proteins that vary in spectrum of activity, mode of action, molecular weight, genetic origin, and biochemical properties. Bacteriocins are often confused with antibiotics in the literature, but they differ from antibiotics in several ways: (a) they are ribosomally synthesized, (b) host cells are immune to them due to the production of immunity proteins, (c) their mode of action is different, and (d) they can have narrow killing spectrum (160). Typically, bacteriocins are produced by Gramnegative bacteria and they have wide spectrum of activity as compared to those produced by Gram-positive bacteria. Bacteriocins produced by Gram-positive bacteria, usually LAB, inhibit strains of the same or closely related species (168). Bacteriocins produced by LAB are classified into three major classes: (I) lantibiotics, (II) small heat-stable peptides, and (III) large heat-labile proteins (171). A fourth class of complex bacteriocins with lipid or carbohydrate moieties has been suggested, but the information related to this class is very limited and is supposed to include partially purified bacteriocins (171). Class I comprises bacteriocins, which are posttranslationally modified to contain unusual amino acids not normally found in the nature (e.g., lanthionine and b-methyllanthionine). The group is further divided into two subgroups: elongated, amphipathic, pore-forming type A lantibiotics and rigid, globular peptides of the type B category (154). Class II includes unmodified bacteriocins that are subdivided into three subclasses, namely, class IIa (Listeriaactive or pediocin-like bacteriocins), class IIb (two-peptide bacteriocins), and IIc (other bacteriocins) (168). Class III includes large bacteriocins whose mode of action is poorly described. The best characterized bacteriocin is nisin, which belongs to class I, and is produced by several Lactococcus lactis strains. Nisin has a broad spectrum of activity against

394


Gram-positive bacteria including most LAB, Staphylococcus aureus, Listeria monocytogenes, vegetative cells of Bacillus ssp., and Clostridium spp. as well as preventing outgrowth of spores in Bacillus and Clostridium species (171). The cytoplasmic membrane of susceptible bacteria is the target for nisin activity as nisin has been shown to bind the membrane-bound cell wall precursor lipid II (154, 168). Binding to lipid II results in two modes of action, that is, pore formation and inhibition of cell wall synthesis. The latter is, however, a comparatively slow process and pore formation, which results in the rapid efflux of small cytoplasmic compounds such as amino acids, potassium, inorganic phosphate, and ATP, is still considered the primary mode of action (154). Bacteriocins of LAB have attracted interest for use as natural preservatives in food or in probiotic applications. For these purposes, it is an advantage that the bacteriocins have a broad spectrum of activity, that is, inhibit many pathogens. However, many bacteriocins of LAB have a narrow spectrum of activity and they are not effective against Gram-negative bacteria. Thus, the combination of bacteriocins with other preservation mechanisms has been proposed to extend its inhibitory activity to Gramnegative species (152). Also interpretation of spectra of inhibitory activity can sometimes be difficult as many of the producer strains can release more than one bacteriocin. In probiotic applications, bacteriocins should be active in the intestinal conditions and this can be difficult due to the proteinaceous nature of bacteriocins. For example, current evidence has shown that nisin is degraded or inactivated in intestinal conditions (155). 5.3.5

Low Molecular Weight Antimicrobial Compounds

Reuterin is the most intensively studied low molecular mass inhibitory compound of probiotics. It is produced by Lactobacillus reuteri, an inhabitant of the gastrointestinal tract of humans and animals. Reuterin is produced during stationary phase by anaerobic growth on a mixture of glucose and glycerol or glyceraldehydes (153). During log growth phase, reuterin is not produced due to the reducing power of glucose metabolism. When the cells enter into the stationary phase of growth, reuterin starts to accumulate. Moreover, reuterin accumulates when contacted with the target cells (159). Reuterin has a wide antimicrobial spectrum affecting both Gram-positive and Gram-negative bacteria as well as yeasts, fungi, and protozoa (153, 159, 178). The broad spectrum of activity is explained by its mechanism of action as it has been shown to inhibit ribonucleotide reductase, thereby interfering DNA synthesis (163). 5.3.6

Other Antimicrobial Agents

Probiotic bacteria can also produce antimicrobial substances such as diacetyl, acetaldehyde, and ethanol. Diacetyl is a product of citrate metabolism and is responsible for the aroma and flavor of butter. Gram-negative bacteria, yeasts, and molds are more sensitive to diacetyl than Gram-positive bacteria and its mode of action is believed to be due to interference with the utilization of arginine (169). The contribution of acetaldehyde to biopreservation is minor since the flavor

IMMUNE EFFECTS OF PROBIOTIC BACTERIA

395

threshold is much lower than the levels that are considered necessary to achieve inhibition of microorganisms (157). In addition, the levels of diacetyl, acetaldehyde, and ethanol produced are so low that the contribution to antimicrobial effect is minimal. 5.4 IMMUNE EFFECTS OF PROBIOTIC BACTERIA

Mimi Tang Department of Allergy and Immunology, Royal Children’s Hospital, Australia

5.4.1

The Neonatal Intestinal Microbiota

The largest microbial exposure in early life occurs through the acquisition of an intestinal microbiota. Newborns have their first exposure to bacteria in the birthing process. Prior to this, the intestinal tract is sterile. The process of colonization and the types of organisms that become established are influenced by many factors including mode of delivery (vaginal or caesarean section), mother’s diet including use of probiotics, and whether the infant is bottle or breast-fed. The newborn microbiota changes rapidly in the first weeks of life, but stabilizes within months and by 2 years reflects adult patterns. Bifidobacteria are the dominant bacterial group in the infant intestine by 1 week of age. Studies using molecular methods show that they compose up to 60–90% of the intestinal microbiota in breast-fed infants. Lower counts of bifidobacteria are found in formula-fed infants (188) and adults; bacteroides are the most prevalent organisms with lesser number of bifidobacteria, lactobacilli, staphylococci, enterobacteria, streptococci, and clostridia species. 5.4.2

The Importance of the Intestinal Microbiota in Immune Development

Intestinal microbes have important effects on the intestinal mucosal barrier function and on intestinal maturation and are necessary for full development of the body’s largest collection of lymphoid tissue, the gut-associated lymphoid tissue. It has been shown in mouse models that the first bacteria to colonize the newborn intestine (“pioneer bacteria”) can modulate gene expression in host intestinal epithelial cells (192). This results in an altered intestinal microenvironment that influences the nature of subsequent intestinal colonization. The initial neonatal colonization is also important in stimulating normal immune development. Absence or an inadequacy of early microbial stimuli has been shown to cause defects in intestinal barrier function, reduced inflammatory responses, defective IgA responses, and deficient oral tolerance induction. Mice raised in a germ-free environment fail to develop oral tolerance and have a persistent Th2-dependent antibody response (214). This immune deviation can be corrected by reconstitution of intestinal microbiota, but only if this occurs during the neonatal period (214). These findings suggest that early microbial exposure and a healthy intestinal microflora are crucial in providing immune stimulation for normal immune development (182).

396


5.4.3 Interaction of Commensal and Pathogenic Bacteria with the Intestinal Immune System There is a constant interaction between bacteria in the intestinal lumen and the epithelial and immune cells within the gut, and this continuous interaction is central to the maintenance of immune homeostasis. Bacterial and food antigens are continuously sampled by specialized epithelial cells overlying the dome area of the follicles and by dendritic cells (DCs) that send dendrite processes into the gut lumen between the epithelial cell tight junctions. These cells represent the first cells of the mucosal immune system to encounter commensal and pathogenic bacteria. The immune system here has important opposing roles of responding to pathogens while maintaining suppressed responses against commensal microbial antigens. To sense microbes within the gastrointestinal ecosystem, the gastrointestinal epithelium and dendritic cells in the gut-associated lymphatic tissue are equipped with pattern recognition receptors (PRRs) that recognize specific conserved molecular patterns on pathogens (215). Interestingly, these molecular patterns are not unique to bacterial pathogens, but are shared by entire classes of bacteria, both commensal and pathogen, and also viruses. There are a number of families of PRRs, including the TLRs that are usually expressed on the cell surface and the nucleotide binding oligomerization domain-like receptor (NLR) family, which are expressed in the cytosol (186, 215). Signaling through TLR or NLR molecules typically leads to proinflammatory gene expression (183). Interaction of bacterial components with PRR on DCs leads to upregulation of cell surface costimulatory molecules, such as CD80 and CD86, and DC migration to lymph nodes where they activate and influence the differentiation of na€ıve T cells toward T regulatory or T helper (h) cell pathways. DCs that produce interleukin (IL)-12 can promote Th1 responses, while production of IL-4 preferably promotes Th2 responses, and IL-10 or TGF-b promotes induction of T regulatory cells. Therefore, DCs play a key role in guiding the regulation of immune responsiveness or tolerance. Interactions between commensal bacteria and DCs result in antiinflammatory or tolerogenic immune responses, while pathogenic bacteria induce active immune responses. 5.4.4

Probiotic Effects on Immune Responses

Specific probiotics can assist in maintaining gut immune homeostasis by directly modulating immune responses, enhancing epithelial barrier function, and inhibiting pathogen growth. Probiotics interact with the mucosal immune system via the same pathways as commensal bacteria, specifically via interaction with epithelial cells and DCs, to influence both innate and adaptive immune responses. Probiotic effects on immune responses appear to be immune regulating rather than immune activating. In vitro and in vivo studies in mice and humans have shown that probiotics may predominantly modulate DC and T regulatory cell activity rather than T helper responses per se (203).

IMMUNE EFFECTS OF PROBIOTIC BACTERIA

5.4.5

397

Probiotic Effects on Epithelial Cells

The close association between gut barrier integrity and immune response has been demonstrated in a suckling rat model, where Lactobacillus rhamnosus GG (LGG) reversed the increased intestinal permeability induced by cow’s milk (195). Probiotics may modulate epithelial barrier function through interactions with TLR2 (197). Probiotic bacteria have been shown to modulate epithelial cell signal transduction pathways and cytokine production, thereby suppressing systemic inflammatory responses (200, 206, 210). Other nonpathogenic enteric bacteria are known to have an immunosuppressive effect on intestinal epithelial cells by inhibiting the transcription factor NF-kB pathway (205) 5.4.6

Probiotic Effects on DCs

Given the central role of DCs in directing the T cell response toward T regulatory, Th1, or Th2 pathways, probiotics are likely to modulate immune responses via these, in a species- and strain-dependent manner (189). Individual bacterial strains were shown to differentially modulate IL-10 and IL-12 production and the expression of costimulatory and maturation markers by DCs. The bifidobacteria strains showed markedly enhanced IL-10 production by both myeloid DCs and plasmacytoid DCs. In that study, Lactobacillus strains downregulated or had no effect upon IL-10 production. The bifidobacteria strains also showed downregulation of costimulatory molecules CD80 and CD40, and in some cases reduced IFN-g production that was IL-10 dependent. Nevertheless, specific Lactobacillus strains were shown to induce T regulatory cells and tolerance by generating semimature DCs with upregulation of costimulatory molecules but low production of proinflammatory cytokines (189). 5.4.7 Probiotic Effects on Adaptive Immune Responses: T Helper Cells and T Regulatory Cells As for DC effects, the effects of probiotics on T helper and T regulatory responses are species specific. Some Lactobacillus strains have been shown to stimulate Th1 cytokine production while others have increased Th2 responses or induced a mixed Th1/Th2 response. The cytokine patterns induced by intestinal bifidobacteria have also been shown to be strain specific and different Bifidobacterium strains may induce distinct and even opposing responses (190). In infants with cow’s milk allergy and eczema, treatment with LGG was reported to increase PBMC production of IFN-g, while a mixture of four probiotics that included LGG had no effect on IFN-g and increased IL-4 production (208). In animal models of autoimmune arthritis, some probiotic bacteria have been reported to inhibit Th1 responses providing beneficial effects while others have been demonstrated to aggravate disease by inducing Th1 cytokine responses (201). Probiotic bacteria have been shown to enhance IgA immune responses to oral and parenteral vaccines (191, 194, 204). A mixture of probiotic bacteria given to infants for the first 6 months of life was also shown to increase IgG responses to parenteral HIB vaccine (199).

398


Probiotic bacteria have also been demonstrated to induce regulatory cytokine production and T regulatory cells in vitro in animal models of disease and in human clinical trials. Several Lactobacillus strains have been shown to inhibit T cell proliferation, induce IL-10 and TGF-b production, and modify Th1 and Th2 cytokine production in vitro in various models of autoimmune inflammatory disease (201, 207, 212, 213, 217). In some animal models and human clinical trials, beneficial clinical effects associated with probiotic treatment have been attributed to increased IL-10 and/or TGF-b production and increased CD4þ T regulatory cells (185, 209). Of note, some probiotic bacteria, for example, B. lactis, have been shown to inhibit TGF-b production in vivo (193). These findings together demonstrate that probiotic bacteria can have varied effects on both innate and adaptive immune responses. Interactions with DCs in particular may be important for probiotic effects on immune responses. DCs may be modulated by probiotic bacteria to induce T regulatory/tolerogenic responses or T helper immune responses. Selection of probiotic bacteria for clinical applications should take into account the specific effects on immune responses, underlining the importance of preclinical testing in specific target functions and populations. 5.4.8

Delivery of Probiotic Bacteria

Beneficial effects of probiotic bacteria are dependent upon ingestion in the live form. Bacteria must survive the host’s digestive process, colonize the intestine, and attach to and adhere to gut epithelium to mediate their effects in vivo. Moreover, heatinactivated probiotic bacteria have been reported to cause adverse gastrointestinal symptoms and diarrhea requiring discontinuation of therapy (198). Probiotics produce bacteriocins, hydrogen peroxide, and biosurfactants to aid their survival in the intestinal tract. They may also upregulate mucin encoding genes that stimulate the production of mucus to form a protective barrier. An effective probiotic will adapt to healthy flora and not displace native bacteria. The best studied probiotic is LGG. Orally administered LGG survives passage in the gastrointestinal tract and adheres to intestinal mucus and epithelial cells. It can persist in the intestine for a week after oral administration ends when fecal recovery is used as a marker of colonization (187). LGG persists for longer than this in infants and in infants with rotavirus diarrhea (196, 211). Studies using colonic biopsies in adults show that LGG colonization continues for longer than that indicated by fecal recovery studies (180). Lactic acid-producing organisms can lower intestinal pH, which favors the growth of more beneficial organisms. LGG has been shown to alter the intestinal microecology by creating an environment that promotes bifidobacterial growth (181) and has been shown to increase total levels of anaerobic bacteria, particularly bifidobacteria, bacteroides, and clostridia. LGG does not displace other species of lactobacilli or increase total counts of lactobacilli. Colonization is transient and LGG is no longer cultured from the stool by 7–10 days after discontinuation of its use.

ALTERATION OF MICROECOLOGY IN HUMAN INTESTINE

5.4.9

399

The Specificity of Probiotic Effects

It is clear that different probiotic species and strains can have very different effects both in vivo and in vitro. The clinical or laboratory effects of one probiotic cannot be assumed for another probiotic species, or even for different strains of the same species. For example, in a double-blind placebo-controlled trial comparing LGG and a mixture of four probiotic strains (LGG, L. ramnosus LC705, Bifidobacterium breve Bbi99, Propionibacterium JS) for the treatment of infant eczema, beneficial effects were observed only for LGG and not the probiotic mix (216). Furthermore, LGG has been shown to enhance IgA responses against rotavirus, which are not found with different strains of the same species (202). In vitro, Lactobacillus species vary in their capacity to induce IL-12 production by murine dendritic cells. For example, a strain of Lactobacillus reuteri was found to specifically inhibit Lactobacillus casei-induced IL-12, IL-6, and TNF-a production by murine dendritic cells and to inhibit Lactobacillus casei-induced upregulation of dendritic cell costimulatory markers (184). 5.4.10

Summary

As a class of bacteria, probiotics appear to have predominantly immune modulating effects on DC and T regulatory activity rather than directly influencing Th1 or Th2 activity. Their potential application in the clinical setting holds great promise and selection of specific probiotic species and strains will be dictated by the spectrum of species-specific effects.

5.5 ALTERATION OF MICROECOLOGY IN HUMAN INTESTINE 5.5.1

Impact on Human Health: in Infants and the Elderly

Seppo Salminen and Reetta Satokari Functional Foods Forum, University of Turku, Finland

The indigenous microbiota of an infant gastrointestinal tract is created through contact with the microbiota of the parents and the infant’s immediate environment. Natureinduced initial colonization is optimally enhanced by oligosaccharides in breast milk and the microbiota of the mother. This process directs the later microbiota succession and health of the infant throughout the rest of his/her life (238). It also has an impact on the type of microbiota the individual will harbor at the time of aging. Thus, understanding and positive guidance of the process through dietary means is an important target when facilitating the different stages of the colonization starting from the mother to infant microbiota transfer during birth, breast feeding and weaning, and maintenance of healthy microbiota during the first years of life and throughout the lifetime and especially old age.

400


5.5.1.1

Stepwise Establishment of Microbiota

1. Source of Microbiota. The basis of the healthy infant gut microbiota is created by the mother during pregnancy and microbiota transfer at birth. The microbiota of a newborn develops rapidly after birth and it is initially dependent on the mother’s microbiota, mode of delivery, gestational age, and birth environment (218, 238). The microbiota of the mother is determined by genetic and environmental factors. Recently, it has been demonstrated that stress and dietary habits during later stage of pregnancy and prior to birth may have a significant impact on the microbiota at the time of delivery and thus influence the quality and quantity of the first colonizers of the newborn. It has been shown that a probiotic strain can be transferred from mother to child during birth and that maternal consumption of probiotics influences the transfer and establishment of neonatal microbiota (224, 251). Subsequently, feeding practices including formula feeding and breast feeding and the nursing environment of the infant influence the microbiota, at the level of both species composition and number of bacteria. The stepwise establishment of the gut microbiota is usually characterized by early colonization at birth and during the first 1 or 2 weeks of life with facultative anaerobes such as the enterobacteria, coliforms, lactobacilli, and streptococci, followed by anaerobic genera such as Bifidobacterium, Bacteroides, Clostridium, and Eubacterium (238, 243). The classical view on the infant intestinal microbiota is that breast-fed infants are more frequently colonized with bifidobacteria and have higher counts of fecal bifidobacteria than formula-fed infants. This has also been supported by new molecular methods indicating that bifidobacteria can range from 60% up to 90% of the total fecal microbiota in breast-fed infants while lactic acid-producing bacteria may account for less than 1% of the total microbiota. However, many papers report equally high fecal counts of bifidobacteria in breast-fed and formula-fed infants (235, 245). In general, the microbiota of formula-fed infants seems more complex and more often colonized also by other bacteria (224, 239). The differences between the breast-fed and formula-fed infants at bacterial groups’ level decreased along with the development and improved composition of infant formulas (244, 247). The most commonly found species of bifidobacteria in infants are Bifidobacterium bifidum, B. breve, B. infantis, and B. longum. Recent molecular studies indicate that there might be a significant difference in the species composition of bifidobacteria between breast-fed and formula-fed infants (220), between infants of allergic, atopic mothers, and nonallergic mothers (221), and between allergic and nonallergic children (241). The relevance of specific species to infant health is still unclear and warrants for further investigations. The most common lactobacilli in infant feces are lactobacilli belonging to the Lactobacillus acidophilus group (L. acidophilus, L. gasseri, and L. johnsonii) irrespective of the type of feeding (240, 249). The practice of breast feeding for 4–6 months has been considered to assist in the development of healthy gut microbiota. Major changes in the microbiota


401

composition that occur during breast feeding are related to breast milk components, especially oligosaccharides that act as a selective agent for the infant microbiota and stimulate the growth of bifidobacteria. Recent pilot study by Rinne et al. (247) on 6-month-old infants showed that infants receiving formula supplemented with prebiotic oligosaccharides developed Bifidobacterium microbiota resembling that of breast-fed in terms of both bacterial counts and species diversity. Further, breast milk contains bacteria, notably also bifidobacteria, and thus serves as a constant inoculum for the infant (221, 224, 237). However, the data concerning the breast milk microbiota are scarce and this form of exposure needs to be further assessed. Breast feeding also provides an optimal environment for exchange of microbes between mother and infant via the skin contact and exposure to microbiota present in the immediate environment. As a result, every individual has a unique characteristic microbiota during later phases of breast feeding. Also formula-fed infants acquire their individually specific microbiota through various contacts with the environment. Thus, the intestinal microbiota as a defined entity does not exist as this microbial population rather comprises a dynamic mixture of microbes typical to each individual. Weaning will break the contact and constant supply of oligosaccharides and microbes from the mother and introduction of solid foods as well as possible antimicrobial drug treatment period further influences the microbiota development. By the age of 1 year, the infant microbiota starts to resemble that of an adult. 2. Basis for Healthy Gut. The desired outcome of the infant gut colonization process is a complex microbial community that provides the barrier against foreign microbes and some harmful components in the diet. In addition, the colonization process creates the basis for the establishment of a “noninflammatory” status of the gut. Such an environment in infants is hallmarked with a large Gram-positive bacterial population with a significant number of bifidobacteria in a species composition typical to the healthy infant (mainly B. Bifidum, B. longum, B. breve, and B. infantis). Lactic acid bacteria may have a role in providing the right conditions for bifidobacteria to dominate. The collective composition of the colonizing strains in infancy also provides the basis for healthy gut microbiota later in life as the development of the diseasefree state of the gut lies in the host–microbe interaction in infancy. As the disturbed succession during early infancy has been linked to the risk of developing infectious, inflammatory, and allergic diseases later in life, it is still of great interest to further characterize both composition and succession of microbiota during infancy. Some deviations of the infant microbiota related to diseases are compiled in Table 5.9. 5.5.1.2 Methodological Improvements in Microbiota Assessment Our understanding of the intestinal microbiota has improved stage by stage along with the methodological improvements in the microbiota characterization. While early studies relied on cultivation, and only organisms that grew on laboratory media could be studied, today molecular biological techniques allow us to study the microbiota more

402


TABLE 5.9 Characteristics of Infant Microbiota: Deviations Associated with Diseases or Disease Risk Subject Group

Microbiota at 0–12 Months

Autistic children Higher number of clostridia Wheezing High Clostridium infants Infants at risk Low bifidobacteria, high of diarrhea Clostridium, less diverse microbiota Allergic infants At 6 months lower bifidobacteria and higher clostridia

Microbiota at 24 Months Higher number of clostridia Less diverse microbiota Less diverse microbiota

References (252) (245, 256) (231)

(233, 234, 245, 254) Less lactobacilli, high number of aerobic bacteria, high coliforms, higher Staphylococcus aureus counts (232, 245, 254) Differences similar but Early microbiota (already Infants later at 2–3 weeks or 1 month), not so pronounced, developing but still present even allergic disease less bifidobacteria, and at 5 years of age different species (including the higher composition, often higher number of Bifidobacterium number of B. adolescentis in adolescentis, higher allergic infants) clostridia (222, 232, 245) High number of Normal infants At 6 months high aerobic bacteria, high bifidobacteria, low diversity, number of clostridia (especially unculturable bacteria in breast-fed infants) increase

comprehensively also in a culture-independent way (249). In the first phase, molecular techniques such as amplified ribosomal DNA restriction analysis (ARDRA), randomly amplified polymorphic DNA (RAPD), pulsed field gel electrophoresis (PFGE), and ribotyping were used to characterize cultivated colonies. Later, community profiling techniques such as PCR coupled to temperature and denaturing gradient gel electrophoresis (PCR–TGGE and PCR–DGGE, respectively) and sequencing of amplified small subunit ribosomal RNA (SSU rRNA) gene products were introduced to perform culture-independent analysis. Specific primers and probes in qPCR and fluorescent in situ hybridization (FISH), respectively, are widely used for the quantitative analysis of specific species/groups of bacteria. The major recent methodological improvement is the development of highdensity microarrays for the analysis of human microbiota (243, 246). The arrays consist of thousands of SSU rRNA gene-targeted oligonucleotide probes designed to have selected specificity to different taxonomic groups or species. The methods of


403

array design and analysis are imperfect and still evolving, but it is already evident that they provide us with a powerful high-throughput tool. It is anticipated that in future we will be able to analyze the microbiota composition in great detail at species or even strain level by using arrays. Large-scale studies with detailed microbiota descriptions will become possible and this will tremendously increase our knowledge about the human intestinal microbiota. 5.5.1.3 Microbiota After Infancy Following the first 6 months of life, the microbiota succession diverts toward a more diverse community after weaning (238, 243, 255). The differences between breast-fed and formula-fed infants disappear gradually due to the increase in the number of enterobacteria and enterococci and the succession of Bacteroides, Clostridium, and anaerobic cocci including peptococci, peptostreptococci in the former group (253). Increases in E. coli and enterococci have been reported after weaning. The levels of bacteroides and anaerobic Gram-positive cocci also appear to increase gradually during and following weaning, whereas enterobacteria decrease (236, 255). A small study reports the microbiota follow-up for two infants for a period of 2 years using molecular methods. At 6 months, the T-RFLP profiles were dominated by Bacteroides and Clostridium. Between 6 and 12 months, more members of clostridia (C. coccoides–Eub. rectale group [Clostridium cluster XIV]) appeared in the feces of the infants. At 1 year, there was a new shift in the microbiota and it became more diverse with Bacteroides, Vellionella, and Fusobacterium prausnitzii increasing. Contrary to that Guerin-Danan and coworkers (223) report that in 10–18-month infants bifidobacteria predominates, followed by Bacteroides, enterobacteria, and enterococci. In the comprehensive study of Palmer et al. (243), the microbiota development of 14 healthy infants was followed throughout the first year of life by using 16S-based microarray combined with sequencing. In consistence with earlier studies, the colonization started with aerobic organisms followed by strict anaerobes. Strikingly, the observed Bifidobacterium levels were very low in this study and constituted only a minor part of the infant microbiota. Thus, there seem to be also geographical and demographic differences in the prevalence of bifidobacteria and in microbiota composition in general. Several abrupt shifts occurred in the population structure, but these could not be linked to any specific age or event, although the transition to an adult-like profile often followed the introduction of solid foods (243). At the age of 1–2 years, microbiota resembles that of adults (236, 243). However, it has been reported that children (16 months to 7 years) still harbor higher levels of bifidobacteria and enterobacteria than adults (229). Along with the maturation of gut and normal mucus production also mucin-degrading bacteria colonize the gut. Akkermansia muciniphila-like bacteria start to colonize infants at the age of few months and by the age of 1 year reach a level close to that observed in adults (219). 5.5.1.4 Host–Microbe Cross Talk Components of the human intestinal microbiota or organisms entering the intestine may have harmful or beneficial effects on human health and a complex community is required for the individual balance. Abundant evidence exists to document that specific strains of the healthy gut

404


microbiota exhibit powerful antipathogenic and anti-inflammatory capabilities and are consequently involved with enhanced colonization resistance in the intestine. Following weaning, the healthy microbiota is gradually created. In the gastrointestinal tract, there is a constant challenge by diverse antigens such as microbial antigens, foods, and allergens. Such priming of gut-associated lymphoid tissue is important for two opposing functions: mounting a response to pathogens and maintaining hyporesponsiveness to innocuous antigens. An important question is how the inflammation is kept under control during weaning and how the microbiota is altered during the adaptive process. The strains of the healthy gut microbiota are likely to provide the host with an anti-inflammatory stimulus directing the host–microbe interaction toward a healthy gut. The host–microbe cross talk during and after breast feeding seems important in this respect. At this stage, the bifidobacteria-dominated environment may provide the child a more anti-inflammatory stimulus than bacteria from adults, which have been shown to be more proinflammatory (226, 227, 242). 5.5.1.5 Microbiota in the Elderly Earlier culture-based methods assessing the human intestinal microbiota demonstrated changes in composition in the old age (239). Culture-based studies reported the decline of bifidobacteria in concentration in the elderly (218) and some support for the conception is offered by recent studies using molecular methods (230). Bifidobacteria are regarded as key members of healthy and protective intestinal microbiota of life (248) and the decline in their number and species diversity may contribute to the often decreased gut health in elderly. Further, Bacteroides decrease, while facultative anaerobes, fusobacteria, clostridia, and eubacteria increase (257). Also significant intestinal microbiota alterations have been reported among the elderly with potentially important clinical consequences related to bowel regularity and intestinal infections (228–230). Table 5.10 lists some characteristics of intestinal microbiota among elderly. The defining factors in microbiota composition and fluctuation in old age are largely unknown. Decreased secretion of mucus (a major source of nutrients for gut microbes) is a very probable factor causing changes in the microbiota. This is supported by the recent finding that mucin-degrading bacterium Akkermansia muciniphila or A. muciniphila-like bacteria decrease significantly in elderly (219). TABLE 5.10 Characteristics of Intestinal Microbiota Among Elderly Subject in Different Intestinal Conditions Subjects

Potential Microbiota Deviations

General Microbiota Characteristics

Normal elderly

Lower number of bifidobacteria, higher number of staphylococci Lower number of lactic acid bacteria and bifidobacteria

Less diversity, decreased barrier

Elderly with constipation Elderly with diarrhea

Higher number of clostridia, different clostridial species composition

Lowered diversity, reduced acid production, altered bifidobacterial species composition Less diversity, altered metabolic activity


405

5.5.1.6 Maintenance of Healthy Microbiota Creating a healthy gut microbiota during early life must be followed by proper maintenance and enhancement of the individual balance. During times of disease or following detectable deviations in initial microbiota development, the gut microbiota can be directed into healthy balance by dietary means, for instance, by using probiotics or prebiotics. Probiotics are members of the healthy gut microbiota and assist in mimicking the healthy microbiota of both infants and adults. Each probiotic strain has its specific effects, which have to be evaluated prior to application. A recent brief overview of the effects of probiotics on microbial diseases in humans was given by Woodmansey (257). Prebiotics act through promotion of specific microbes with potential to maintain health. The prerequisite of prebiotic activity is that bacteria to be stimulated are already present in the gut. Most prebiotic components have been shown to enhance the Bifidobacterium microbiota, but different prebiotic oligosaccharides have different microbiota modifying properties, and the prebiotic effects should be defined more clearly. First, the bifidogenic change alone cannot be considered as a prebiotic effect. It has been reported that some fructooligosaccharides also enhance the levels of unknown microbes in human gut, thus potentially facilitating undesirable effects. Second, the desired Bifidobacterium strains should be present in the gut for the prebiotic effect. Finally, a clinical benefit has to be documented before a prebiotic effect can be verified. There is a need for the development of novel specific prebiotics with defined microbiota and health effects. The mother-to-infant transfer of both microbes and oligosaccharides could be considered as a model for the development of future functional foods. Carefully designed combinations of probiotics and prebiotics would offer optimal means for creating and maintaining a healthy microbiota. 5.5.1.7 Conclusion The healthy human microbiota is metabolically active and acts as a defense mechanism for our body. Deviations in its composition are related to multiple disease states not only within the intestine but also beyond the gastrointestinal tract. Infant microbiota and the first colonization steps are thought to have crucial role in the health later. Especially, bifidobacteria seem to have a key role in this process. The mother–infant contact has an important impact on initial development. The mother provides the first inoculum at birth, promotes the bifidogenic environment through (prebiotic) oligosaccharides in breast milk, and introduces environmental bacteria through her skin and other contact with the infant. Taken together, this guides the development of individually optimized microbiota under the existing environmental conditions for each infant. The process may also influence the microbiota diversity and development during old age. The future target is to further clarify both the composition and the succession of microbial communities from early infancy to weaning and during the first years of life in order to understand how the specific composition and characteristics of the microbiota of each individual develop. In a similar manner, we need to characterize more carefully the microbiota changes, temporal alterations, and decreasing diversity in old age. Such knowledge would greatly assist in finding out the ways to support the healthy microbiota development and maintenance from birth to old age and

406


understand the role of specific probiotics and prebiotics in the dietary management especially in the case of health-related microbiota deviations. 5.5.2 Impact on Animal Health: Designer Probiotics for the Management of Intestinal Health and Colibacillosis in Weaner Pigs

James J.C. Chin and Toni A. Chapman Immunology and Molecular Diagnostic Research Unit (IMDRU), Elizabeth Macarthur Agricultural Institute, NSW Department of Primary Industries, Australia

Escherichia coli is a naturally ubiquitous group of Gram-negative facultative anaerobic rod-shaped and sometimes flagellated bacteria capable of fermenting lactose, which are normal enteric residents of the gastrointestinal tract (GIT) of vertebrates and even some invertebrates. Most E. coli are fairly resilient to stomach acidity and generally survive to colonize the duodenum, jejunum, ileum, and colon, with the greatest number of commensals preferentially located in the small intestine. E. coli are normally shed in the feces and this association has been used as an environmental estimate of fecal coliform contamination (260), particularly for evaluation of sanitary quality of water or as a general indicator of sanitary conditions in the food processing environment. 5.5.2.1 The Farrowing Environment The GIT of newborn mammals is sterile. Within a short period of time, uptake of microorganisms from the mother through skin contact and breast feeding (263) very quickly results in the introduction of bacteria capable of colonizing the microenvironment of both the small and large intestines (283). With the current intensive farming practices, farrowing sows are confined to crates (308) that limit movement so that neonate suckers may access teats more readily. Since all animals are grounded in the crates, there is a very high incidence of fecal contamination of the lower belly and teats. Consequently, newborn piglets become rapidly colonized with maternal fecal microbiota (295). Although the dynamics of fecal colonization of the neonatal GIT is under investigation in our laboratory, it is nevertheless intuitively evident that pathogenic strains, if present, would be competing on an equal footing with commensal biotypes. The ultimate balance of successful colonizers in different intestinal compartments would establish “niche-adapted” diverse communities (276) with varying abilities to function as competitive excluders. 5.5.2.2 The Weaning Environment In most intensive pig production systems, piglets are weaned usually between 21 and 28 days of age. Weaning is stressful because young piglets are separated from their mothers, mixed with piglets from other litters, and experience change in environment and diets (267). Weaning stress has been found to activate the enteric neuronal network in pigs that is accompanied by coactivation of the prostanoid pathway. This is associated with increased expression of intestinal corticotropin releasing factor receptors that trigger mucosal dysfunctions such as a reduction in transepithelial electrical resistance (TER) and increased intestinal permeability (289). Nutritional stress is a major factor in predisposing weaners to


407

enteric infection because piglets have been accustomed to sow milk at hourly intervals in relatively small proportions. At weaning, there is a drastic change to more granular and particulate formulations such as whey, yeast, fish meal, soybean meal, fat, and oil. If provided ad libitum, overzealous eating can cause indigestion and malabsorbtion during the early days of weaning, predisposing animals to enteric infection. Much of this is attributed to transient and long-lasting modifications of the piglet intestine (266) and the impact of stress and feeding behavior on the hypothalamic–pituitary–adrenal (HAP) axis (268). 5.5.2.3 Colibacillosis in Pigs Pathogenic E. coli is mainly responsible for colibacillosis diarrhea in newborn, preweaning, and postweaning pigs. These pathogenic strains are grouped as enteropathogenic E. coli (EPECs) but display a number of unique phenotypes such as the production of toxins that qualify them as members of two subgroups—enterotoxigenic E. coli (ETECs) and verotoxigenic E. coli or (VTECs). Diarrheagenic porcine ETECs elaborate a high molecular weight heat-labile enterotoxin (LT) and smaller sized heat-stable enterotoxins (STa/STb), while VTECs produce verotoxin (VTe) that causes edema disease. VTe is synonymous with Shiga toxin 2e (Stx2e) and VTEC strains are also known as Shiga toxigenic E. coli (STECs). Although rare, some strains of E. coli responsible for postweaning diarrhea (PWD) secrete both entero- and verotoxins and are referred to as ETECs and VTECs, respectively (290). Traditionally, porcine ETECs and VTECs are identified by serological typing based on specific antibodies directed against the O antigen, determined by the chemistry of the polysugar side chain bound to the core of the lipopolysaccharide in the outer membrane (181 recognized types), K or acid polysaccharide capsular antigen (60 recognized types), and H or flagellar antigen (53 recognized types). As most of these antibody reagents were produced and crossabsorbed against pathogenic isolates, many commensal strains remain untypable and these generally are designated ONT (O-antigen nontypable). Antibody-based methods of serotyping (284) have been made more efficient through miniaturized antibody arrays (259), but even these may soon be replaced by molecular serotyping technology (261). Throughout the world, there are only a number of specific serogroups associated with colibacillosis in pigs. These are O8, O64, O138, O139, O141, O147, O149, and O157 (265). Apart from the toxin repertoire, a third feature associated with identification of porcine ETEC/STEC strains is the presence of fimbrial adhesins. Fimbriae are colonization factors that facilitate attachment of E. coli to the lumenal surface of enterocytes. There are five major fimbrial adhesin types— F4 (K88, fae), F5 (K99, fanA), F6 (P987, fasA), F18 (fedA), and F41 (fimF41a). The ownership of genes encoding enterotoxins, verotoxins, and fimbrial types can now be determined by PCR (265). While the restricted number of virulence genes (VGs) associated with diarrheagenic E. coli is an advantage for genotyping clonal groupings in outbreaks, they do not provide sufficient signal to noise discrimination to distinguish more subtle differences in gene carriage that can describe the signatures of individual pathogenic and commensal strains with greater precision and accuracy.

408


5.5.2.4 Control of Colibacillosis Unlike free-range farming, intensive animal industries for growing poultry, pigs, and feedlot cattle create conditions conducive to increase in ill-thrift and reduced growth performance. From therapeutic antibiotic treatment of sick animals in the 1950s, production systems have incorporated antibiotics such as tylosin, avilamycin, tetracycline, and penicillin into stock feed. These supplements were initially used prophylactically for individual healthy animals believed to be at risk of infection. Some of these antibiotics are used presently as growth promotants to increase growth rates and improve efficiency of feed conversion. Using NAHMS swine data, antibiotic growth promotants (AGPs) improve average daily gain by 0.5% and feed conversion ratio by 1.1% and reduce mortality rates by 0.22%. In the United States, these productivity improvements translate into a profitability gain of US$ 0.59 per pig marketed or an improvement of 9% in net profits associated with growth promotion antibiotics (288). Unfortunately, indiscriminate use of AGPs has caused significant development of antimicrobial resistance in bacteria associated with farm animals and increasing the risk of these resistance genes to be acquired by human pathogens via the food chain (277). So great is the perception of this risk that the European Union has banned all AGPs from being used in animal production systems from 2006 (http://www.ucsusa.org/food_and_environment/antibiotics_and_food/ european-union-ban.html). Alternative strategies to control production from disease have focused on dietary strategies such as acidification, immunization (258), and the use of probiotics (287). 5.5.2.5 Mechanism of Action Parker’s (292) and Fuller’s (278) definitions of probiotics (see Section 1.1) have unknowingly incorporated a basic concept underwriting one of the key aspects of probiotic functionality and mechanism of action (298), that is, the ability to alter microbial balance. Upon closer scrutiny, balance is probably an inappropriate choice to describe microbial dynamics in the GIT because even minor changes in diet and environmental/community/social stressors can modify balance (293, 294). Since balance of good versus bad bacteria is too simple a concept, it may be more realistic to interpret balance as a continuum of shifting community dynamics of microflora in various microniches of each gastrointestinal compartment. Inherent in this notion of shifting balances in microbial community dynamics is our understanding of the role of probiotics in competitive exclusion (CE). Because community dynamics is changing, it is impossible to establish a persistent autochthonous commensal community, coexisting in static equilibrium with a minority of orally administered probiotic bacteria in any one intestinal microniche. How then can a snapshot be taken of shifting balances in the microbial community if a significant component of that community is not culturable and therefore impossible to enumerate to demonstrate an impact of probiotics on that balance? To address this issue, we have explored the use of culture-independent gene signatures of pathogenic and commensal E. coli strains on a clonal and population basis to generate snapshot profiles of the impact of probiotic administration on microbial community dynamics. Indeed, while it has been demonstrated very clearly in vitro that probiotic LAB strains can modulate Toll receptors and influence immune responses (271), it may be pertinent to consider that changing microbial community dynamics, particularly in the small intestine, can


409

also play an important role in vivo in modifying both active immunity and tolerance in the host animal (272). 5.5.2.6 Pathogenic and Commensal E. coli—the Concept of Gene Signatures Competitive exclusion is an important mechanism of action of probiotic bacteria but it is by no means an exclusive phenomenon. Microbial communities in the lumen that are in peristaltic transit, those in the mucus substratum or attached to receptors on the epithelial face of enterocytes in different compartments of the GIT, are continuously engaged in competition with each other. The role of E. coli in the pig gut provides an ideal model to evaluate the dynamics of such clonal interactions within a single species community and the possible impact of nutrition and probiotic supplements as well as host immunity (innate and acquired) in changing the composition of this population. At least six E. coli strains and their genomes have been fully sequenced. This information base has been a motivating force in both phylogenetic and pathogenomic studies of E. coli. E. coli are phylogenetically grouped as A, B1, B2, and D phylotypes based on multilocus enzyme electrophoresis (MLEE) and multilocus sequence typing (MLST). Commensals belong to phylotype A and B1 while most pathogens belong to B2 and D, respectively. Functionally, pathogenic E. coli are grouped as diarrheagenic (DEC) or extraintestinal pathogenic E. coli (ExPEC). Diarrheagenic members have been subclassified as enteropathogenic (EPEC), EHEC (enterohemorrhagic), and atypical EPEC or ATEC. EPECs are a major cause of infant diarrhea in underdeveloped countries while EHECs cause bloody diarrhea and hemolytic uremic syndrome (HUS). The EPEC attaching and effacing gene (eae) is located within a specific chromosomal locus known as the locus for enterocytes effacement (LEE) pathogenicity island and encodes an attachment factor intimin that is shared between almost all EPEC and EHEC strains. EHECs are distinguished from EPECs by the presence of Shiga toxin genes (stx). A distinguishing feature of EPECs is the presence of an EPEC adherence factor plasmid (EAF) that also encodes a type IV bundle-forming pilus (Bfp) gene (bfp) and plasmid-encoded regulator gene per. Colonies expressing Bfp not only adhere to each other, but also form compact microcolonies that locally adhere (LA) to HEp-2 epithelial cells as part of the pathology of colonization and invasion (LEEþ). ATECs are EPECs that are LEEþ, stx, EAF, and bfp. Although strains that are LAþ show a close association with ownership of Bfp, a number of bfp EPEC strains are still capable of local adherence. Recent studies to examine this property with ATEC O26:H11 have revealed that LA is mediated via a novel afimbrial adhesin located in a new locus designated as the locus of diffuse adherence (lda) with homologies to the plasmid-encoded porcine K88 fae and ETEC CS31A clp fimbrial operons (296). Additional polymorphisms associated with 11 bfp and 20 per alleles have been used to subtype 12 EAF plasmids associated with various EPEC clones (286). Together with preferred insertions of the LEE, loci at the selC or pheU site demonstrate the versatility of horizontal gene transfer acquisitions and loss as part of the evolving phylogeny of DECs. ExPECs are primarily responsible for extraintestinal disease and classified pathotypically as UPECs (uropathogenic E. coli that cause urinary tract infections (UTIs),

410


pyelonephritis and cystitis, sepsis/bacteremia, and neonatal meningitis (NMEC). Many of the VGs of UPECs have been derived from studies with strains CFT073, J96, and 536. UPEC and EPEC pathotypes appear to maintain a high degree of synthetically preserved and vertically evolved core genes. Punctuating this backbone are many pathogenicity islands acquired by different horizontal transfer events, but UPECs do not contain genes for the type III secretion system. These islands contain strain-specific VGs including fimbrial adhesins (pap), hemolysin (hlyBACD), secreted autotransporters (sat, vat), and phase-switch recombinases. Strains vary in other virulence genes: J96 has cnf-1 (cytotoxic necrotizing factor), hra (heat resistant agglutinin), and no aerobactin genes while CFT073 only has the former (305). 5.5.2.7 Mosaicism and Genome Plasticity in Porcine E. coli (Clone Gene Signatures) Genome plasticity and diversity (264) in pathogenic and commensal E. coli have arisen because of horizontal gene transfers and mutations into a “core” gene pool responsible for essential cellular functions and a “flexible” gene pool made up of ectochromosomal DNA (ECDNA) that encode adaptive functionalities such as pathogenicity, antibiotic/antiseptic/metal resistances, and fitness traits. Core and flex genes are generally located downstream of tDNA loci (DNA encoding transfer RNA). Contrary to expectations, only a limited number of tDNA loci remain hotspots for ECDNA insertions and members of different phylogenetic groups display different preferential patterns of tDNA loci polymorphisms (279). In view of the mosaic nature of the E. coli genome and assuming that gene acquisitions are not confined solely to only pathogenic strains and could also occur in commensals, we assembled a 58 virulence gene panel selected from virulence factors known to be associated with DEC(diarrheagenic) and ExPEC/UPEC/NMEC pathotypes (270). With the aid of uniand multiplex PCR assays, the VG distribution was determined for 23 commensal strains (275) and 52 clinical isolates (20 neonatals and 32 weaners) (270). The primary intention of this investigation was to test the hypothesis that virulence gene ownership is not specific and exclusive to different E. coli pathotypes and commensal strains. The second hypothesis was that the presence as well as the absence of combinations of VGs can be applied to genotype both pathogenic and commensal isolates. If this was the case, then combinatorial sorting of various virulence gene combinations could be used to assign groupings for E. coli isolates from healthy pigs as well as diarrheic swine. As shown in Fig. 5.4, gene signature combinations for each clone when plotted after multiple regression to two principal coordinates (PCOs) successfully displayed the spatial distribution of clinical and commensal isolates. Commensal clones were more tightly clustered but the separation was not absolute as a small number of commensal isolates were rastered left toward the clinical zone. However, a proportion of clinical clones were also positioned in the commensal zone. Sporadic introgression of occasional clinical and healthy E. coli clone genotypes into pathogenic and commensal signature zones reflects the dynamic nature of gene acquisitions and loss in this group of enterobacteriaceae and supports the contention that pathogenicity ultimately resides in a clone not just being able to acquire virulence genes, but to be


411

2.5 2 1.5 1

PCO2

0.5 0 -0.5 -1 -1.5 -2 -2.5 -1.5

-1

-0.5

0

0.5

1

1.5

2

PCO1

FIGURE 5.4 Clone gene signatures of commensal and clinical E. coli.— Principal coordinate analysis of single clones isolated from individual healthy pigs and diarrheic swine. Twenty-three commensal clones (from healthy pigs) and 52 clinical clones (from diarrheic swine) are represented by open circles and solid squares, respectively. The data matrix scoring system of 1 and 0 for presence and absence of 58 virulence genes was converted by regression to two dimensions using multiple linear equations (270). This was then plotted to display the spatial relationships between clones. Some of the clones depicted below may overlap if they possess identical virulence gene profiles, and such overlapping clones have been marginally displaced for visualization purposes by digital jittering.

able to express the right combination at the most optimal time in the best suited environmental niche. The significance of this discovery led us to question whether commensals and ETECs also carried ExPEC virulence genes. We expanded and rescreened 158 porcine intestinal isolates and 47 ETECs for 36 extraintestinal virulence genes and discovered in these the presence of fimH (D-mannose-specific adhesin, type 1 fimbriae), traT (ColV plasmid gene encoding serum resistance), fyuA (Yersinia siderophore receptor), hlyA (alpha-hemolysin), kpsMtII (group 2 polysaccharide synthesis), kpsMt k5 (nonK1 and non-K2 group II kpsMii), iha (nonhemagglutinin adhesin), and ompT (outer membrane protein T). One or more of these ExPEC genes were present at various frequencies in all commensal isolates (from 0.6% in the case of hlyA to 84.8% for fimH). Amongst ETECs, fimH was completely absent in all O149 serogroups but always present in O141 (307). These results justify the use of combinatorial gene signatures to track the clinical and commensal status of E. coli isolated from pigs. At the same time when this was published, others had reported that virulence genecarrying E. coli strains are a normal part of intestinal bacterial populations and high number of these that carry hemolysin cannot always be correlated with disease (297). This conclusion was reached with only a restricted panel of porcine ETEC-specific

412


Commensal E. coli

aah

Clinical E. coli

cdt

chuA east 1 F4 1 PAI sfa/focDE

faeG fim H fyuA

hlyA

iha

iutA

KpsMTII K5 omp T saa stx2 TSPE4.C2 traT

yjaA

aidA orfC bmaE cdtB cvaC eaeA fanC ehxA fasA fedA ireA iroNE.coli iss kpsMTII K1 kpsMTII LT paa papA papC papGI STa STb

FIGURE 5.5 Venn diagram depicting virulence clone gene signatures identified in commensal and clinical E. coli clones isolated from pigs. VGs located in the overlapping zone of both circles represent virulence genes that have been found in clone isolates from both commensals and ETECs.

genes and does not reflect the diverse repertoire of virulence genes that can be present in both commensals and pathogens. It is important to ascribe biological relevance of VGs because presence or absence of individual virulence genes only facilitates genotyping, while the presence or absence of specific gene combinations defines the pathotype and virulence. Commensal and ETEC clones not only possess a number of VGs unique to their phenotype but also share some others in common (Fig. 5.5). It is the number of genes that are shared by different pathogenic clones that is responsible for attaining either a tight cluster in the clinical zone or shifting each pathogenic clone toward the commensal signature cluster. 5.5.2.8 Population Gene Signatures in Epidemiological Study If virulence gene signatures of clones permit each commensal and clinical isolate to be spatially and separately clustered, then it should also be possible to group healthy and diarrheic swine based on their ownership of prevalent/dominant commensal or clinical clones within a population of E. coli from each respective host. In short, clinical pigs with diarrhea will tend to shed more ETECs than commensals while E. coli found in the feces of healthy animals would be dominated by commensal clones. The approach undertaken to test this concept was to deploy a rectal swab sampling technique followed by dispersal and immobilization of bacteria on a hydrophobic grid membrane filter (HGMF) (Fig. 5.6). E. coli colonies on the filter were then enriched by transfer of filter grids onto MacConkey agar medium. With appropriate dilution it was possible to


413

FIGURE 5.6 Processing of rectal swab samples for enrichment of E. coli on hydrophobic grid membrane filters before enumeration, differentiation, replication, and harvesting for assessment of population gene signatures.

display 200–300 colonies on each filter, which can then be immortalized by freezing or replica plating. Otherwise, the entire population of 200–300 E. coli colonies from a representative filter can be harvested and total DNA can be extracted. Each of these samples would then represent an entire E. coli population of the respective host and the composite DNA serve as a template for profiling population VG signatures.

414

MECHANISMS OF PROBIOTICS 2.5 2 1.5

I

1

PCO2

II 0.5

IIIA

0 -0.5 -1

IIIB

-1.5

-2

-2

-1.5

-1

-0.5

0

0.5

1

1.5

2

2.5

3

3.5

PCO1

FIGURE 5.7 Population gene signatures of individual animals based on virulence gene profiling of DNA extracted from enriched E. coli clones (200–300 cfu) per HGMF. Healthy (nondiarrheic) pigs (n ¼ 12) are represented by open squares; subclinical animals (n ¼ 15) exposed to diarrheic swine but not displaying any clinical signs of colibacillosis at time of sampling are represented by open triangles; clinical pigs (n ¼ 12) with at least three episodes of watery diarrhea per day are represented by closed circles. In the population gene signature analysis, only a subset of 35 out of a total of 58 genes nominated in Figure 5.4 was assayed. The abbreviations and names of all of these genes are listed in Table 5.11.

Figure 5.7 shows results of VG signatures of composite DNA from 12 healthy, 15 subclinical, and 12 diarrheic swine. Healthy animals were pigs that did not show any clinical signs of colibacillosis (open squares), while diarrheic swine represented animals that had produced more than two to three episodes of watery stools per day (solid circles). Subclinical animals were pigs that had been mingled with ETEC secretors but had, at the time of sampling, not displayed any signs of diarrhea (open triangles). Three primary clusters can be discerned even with such a small subset of animals analyzed. Pigs with diarrhea were grouped mainly in zone I while healthy animals were separated into two subclusters—zones IIIA and IIIB. The two major clusters, zones 1 and 2, were separated because of differences in virulence gene composition. Zone III animals were identifiable primarily by the absence of combinations of VGs in contrast to animals represented in zone 1. The most interesting observation was that subclinical animals were tightly bunched in zone II and these were marked by VG combinations intermediate between healthy and subclinical pigs.


415

There were two “clinical” pigs (solid circles) located in zone II and another two in zone IIIB. These cases probably represent differences in levels of gene expression and variations in the immune status of the pigs. Smaller and weaker animals in sibling cohorts are usually more susceptible to lower doses of ETECs with earlier onset of diarrhea. The clustering of subclinical pigs provides a very useful epidemiological tool to rapidly assess the clinical status of animals on farm before making decisions about preemptive treatments to prevent diarrhea. Composite DNA extracted from an enriched population of E. coli is a more statistically reliable sample for epidemiological analysis than that obtained by separate clonal replicates from each animal even though the population signature approach is limited because it provides a once-off snapshot of the complexity of interactive microbial dynamics. Nonetheless, VG signatures of populations provide a rapid method for establishing the bacteriological status of the animal without the time demands of more traditional single clone isolation, characterization, and phenotypic/ genotypic analysis (282). Indeed, population signatures from individual animals can also be pooled to represent herds from different production units in pig farming systems. Pooling not only reduces the cost of analysis but also facilitates temporal monitoring of subclinical disease and timely therapeutic intervention before an outbreak (unpublished results). Population signatures of different gene sets such as antimicrobial genes can also be used to monitor on-farm use of antibiotics (269, 299), paving the way to novel epidemiological surveillance applications with population gene signatures. 5.5.2.9 Designer Lactic Acid Bacteria as Probiotics The sustained use of AGPs in intensive animal industries has established a background of antimicrobial resistance in the microbial community of the GITof pigs in piggeries throughout the world. In the United States, and also in Australia (281, 269), more than 75% of farming operations deploy antibiotics prophylactically to control infections due to postweaning diarrhea and edema disease (303). With increasing public scrutiny and concerns over the risk of antibiotic resistance genes transferring to human pathogens via the food chain, zero tolerance may be mandated despite several internationally prescribed principles of self-regulation (307). In the course of evolution of social behavior within the E. coli community (274), survival is dependent to a large extent on the ability of a proportion of the established clonal community to ward off invaders through the production of colicins (275). Stahl (301) showed that purified ColE1 and ColN were effective in suppressing the growth of fimbriated porcine ETECs (F4 and F18). Lactic acid bacteria are phylogenetically diverse group of Gram-positive, nonsporulating cocci- or rod-shaped lactic acid-producing microorganisms. LAB produce three classes of bacteriocins: (I) lantibiotics that are greatly posttranslationally modified, for example, nisin; (II) nonlantibiotic heat-stable single and bipeptide bacteriocins similar to colicin V that have not been extensively modified posttranslationally; and (III) nonlantibiotic heat-labile proteins (304). Instead of utilizing probiotic formulation off the shelf (285, 302), we investigated the practicalities of producing designer LAB with specific targeted antagonism against predominantly Australian ETEC isolates O141, O149, and O8G7 by screening

416


more than 100 internationally and commercially available GRAS (generally regarded as safe) LAB strains. The screening strategy employed a microtiter protocol known as kinetic inhibition microtiter assay (KIMA), where the ETEC bacteria are embedded in an agarose–brain heart infusion broth (BHIB) medium, subsequently overlaid with culture supernatant harvested from end of log-phase LAB strains grown in MRS broth. The reason for exploring LAB rather than E. coli was because bacteriocin production of LAB is predominantly constitutive while colicin production occurs in only a proportion of the clonal community in response to SOS-induced stress that can be simulated artificially in vitro through the use of growth modulating agents such as mitomycin C. The growth of the ETEC was determined temporally (hence a kinetic assay) against control MRS (bacteriocin-free) and BHIB (colicin-free) supernatants. Figure 5.8 shows the growth inhibition kinetics of four of the GRAS strains with the

0.5

0.4

0.3

Turbidity (A 620nm)

0.2

0.1

0.0 0.6 0.5 0.4 0.3 0.2 0.1 0.0 0

1

2

3

4

5

Time (h)

FIGURE 5.8 Kinetic inhibition microtiter assay—time course assessment of growth kinetics of targeted ETECs (O141 upper and O149 lower panels) grown in nutrient agarose and overlaid with culture supernatant (CS). From top to bottom, each symbol set designates the growth curve of targeted bacteria in the presence of BHIB (solid triangles), MRS broth (solid squares), and CS from stationary phase cultures of L. acidophilus (open triangles), L. plantarum (closed circles), L. casei (crosses), and L. salivarus (open diamonds) grown in MRS for 36–48 h.


417

most to least inhibitory activity displayed by L. salivarus, L. casei, L. plantarum, and L. acidophilus, respectively. These four strains were selected as a prototype combinatorial formulation (Top4) for further evaluation in pig trials. Top4 has been commercially registered as ColiGuard. 5.5.2.10 Population Gene Signatures as a Measure of Probiotic Bioefficacy To optimize conditions for trial of probiotics, rectal swabs (n ¼ 50) were collected from a large number of pig farms (n ¼ 9) in New South Wales and the population gene signature for subclinical endemic ETEC (according to Fig. 5.7) determined. Based on these results, one test farm with a high incidence of subclinical pigs was selected for evaluation of Top4 as a probiotic. A subset of 98 pigs on this farm was weaned at 21 days and 48 of these were immediately fed weaner mash supplemented with ColiGuard (109 cfu/g each pig) daily for 10 days. The remaining 50 pigs were not supplemented and served as controls. All pigs consumed on the average approximately 300 g of feed per day. Rectal swab samples were collected from all animals after Top4 supplementation and processed on HGMF as shown in Fig. 5.6. Population signatures were collated and the average change in frequency of occurrence for each of 35 virulence genes (Table 5.11) was assessed. The underlying assumption behind any justification for a gene signature shift is the null hypothesis; that is, if Top4 were ineffective against ETECs, then it would not act antagonistically against them. Under these conditions, there would be little or no change in the frequency of each VG. However, if the E. coli community were to be perturbed to the disadvantage of ETECs, then they would be excluded and purged in the feces. These changes in E. coli population structure would be reflected in specific gene shifts as shown in Fig. 5.9. Insignificant shifts were registered for 16 out of 35 VGs. Two significant gene shift patterns can be identified for the remaining 19 genes. Eleven of the significantly shifted genes were excreted at higher frequencies in ColiGuard-treated animals compared to controls and the remaining eight VGs were found at reduced frequencies in the feces of these animals (Table 5.12 and Fig. 5.9). Closer examination of the VGs in each of the two significantly shifted population signatures shows a partitioning of bmaE, cvaC, eaeA, F18, hlyA, iha, kpsMTII, paa, saa, stx2, and traT from cnf1, east1, fimH, fyuA, ironE.coli, iss, K5, and STb. When population gene signatures are compared to clone gene signatures on a single gene basis, it is clear that VGs that contribute to significant shifts in population signatures cannot be used to exactly match VG combinations that characterize clone signatures of commensals and ETECs (compare with Fig. 5.5). The deployment of singly shifted VGs in population signatures is not intended to provide a rationale for how ETEC clones within the community microflora of subclinical animals are disengaged from their intended role of causing disease. The shifts in individual gene frequencies seen in population signatures simply reflect perturbation of the population structure. Although Top4 (ColiGuard) may most likely exert its impact directly against ETECs, one should consider another alternative mechanism. Instead of direct antagonism of ColiGuard against the E. coli community, the presence of bioactive LAB in the GIT can provide SOS (e.g., stress-induced by competition and nutrient deprivation) (280) signals to perturb E. coli community dynamics and increase the production

418


TABLE 5.11 Signatures

List of 35 Virulence Genes Used for Establishing Population Gene

Virulence Genes Adhesins aah aidA AIDAc (orfC) bmaE eaeA faeG fedA fimH focG iha paa saa Toxins cdt cnf1 cvaC east1 ehxA hlyA LT STa STb stx2 univcnf Capsule synthesis kpsMT II

Description/Function Autotransporter adhesin heptosyltransferase encoding the AAH protein that modifies the AIDA-I adhesin Adhesin involved in diffuse adherence, consists of AIDA-I (orf B) and AIDAc (orf Bc) AIDA-I adhesion M-agglutinin subunit Intimin F4 fimbrial adhesin F18 fimbrial adhesin D-Mannose-specific adhesin, type 1 fimbriae Pilus tip molecule, F1C fimbriae (sialic acid specific) Novel nonhemagglutinin adhesin (from O157:H7 and FT073) Porcine A/E-associated gene STEC autoagglutinating adhesion Cytolethal distending toxin Cytotoxic necrotizing factor 1 Colicin V; conjugative plasmids (traT, iss, and antimicrobial resistance) EaggEC heat-stable enterotoxin Enterohemolysin a-Hemolysin Heat-labile toxin Heat-stable enterotoxin a Heat-stable enterotoxin b Shiga toxin II Universal primer for cytotoxic necrotizing factor 1

kpsMT “K5”

Group II capsular polysaccharide synthesis (e.g., K1, K5, and K12) Specific for non-K1 and non-K2 group II kpsMT

Siderophores fyuA ireA iroNE.coli iutA

Yersinia siderophore receptor (ferric yersiniabactin uptake) Iron-regulated element, a siderophore receptor Novel catecholate siderophore Ferric aerobactin receptor (iron uptake: transport)

Additional virulence genes chuA iss ompT traT TspE4.C2 yjaA

Gene required for heme transport in EHEC O157:H7 Serum survival gene Outer membrane protein A and T (protease) Surface exclusion, serum survival Anonymous DNA fragment Identified in E. coli K12, function currently unknown

419

ALTERATION OF MICROECOLOGY IN HUMAN INTESTINE 100%

*

*

Frequency of gene shifted

90% 80%

* *

*

*

70%

*

*

60%

* *

50%

*

*

*

*

*

40% 30% 20% 10%

*

* *

*

0%

Virulence gene

FIGURE 5.9 Demonstration of shifts in the population gene signatures of virulence genes profiled from enriched E. coli clones (200–300 per pig per HGMF grid). Data set represents profiles obtained from 48 pigs supplemented with lactic acid bacteria formulation (Top4) for a period of 10 days after weaning (solid bars) compared to 50 control animals that were not administered with LAB (open bars). LAB-treated and control pigs were housed in different pens in the same shed. Significant differences in the frequency of each VG between treatment groups are asterisked (p < 0.05). Only 19 out of 35 VGs were significantly shifted (all shown in the figure) while only 7 out of 17 nonsignificantly shifted genes are represented.

of E. coli-specific colicins that would also purge pathogenic ETECs in subclinical animals. Irrespective of these two proposed mechanisms, the shift in gene signature of fecal E. coli demonstrates a modulating effect of ColiGuard on the enteric community of E. coli. A major benefit of E. coli population signatures for the pig industry is to provide a facile tool for monitoring treatment programs intended to control or eradicate colibacillosis. Administration of ColiGuard to weaners on a farm characterized by population gene signatures of subclinical pigs with endemic colibacillosis was able to significantly shift individual VGs. It can be concluded that Top4 not only reshaped the enteric E. coli population gene signatures but also confirmed the effectiveness of this treatment by increasing the growth weight of probiotic supplemented weaners. 5.5.2.11 Creation of Enteric Microbial Communities for Sustainable Intestinal Health (Probiosis) One of the proposed alternatives to AGPs for the control of ND and PWD is maternal vaccination with autogenous ETEC strains. While maternal antibodies can undoubtedly provide transient protection for the neonate, the lack of fimbriae and O antigen-specific antibodies in bacterin vaccines opens up the real possibility that common antigens such as membrane porins and heat-shock proteins in

420


TABLE 5.12 List of Virulence Genes that Were Either Affected or Remained Unaffected in the Feces of Weaners Following Probiotic (Top4) Supplementation Significant Genes Shifts

Insignificant Gene Shifts aah aidA ehxA iutA ompT STa yjaA AIDAc(orf C ) faeG (F4) focG cdt unicnf LT ireA chuA TspE4.C2

Increased Fecal Frequency

Decreased Fecal Frequency

bmaE cvaC eaeA fedA (F18) hlyA iha KpsMTII paa saa stx2 traT

cnf1 east1 fimH fyuA iroNE. coli iss KpsMTII K5 STb

the vaccine strain can elicit maternal antibodies with the ability to interfere with effective colonization by beneficial commensals and niche-specific E. coli. The implication behind maternal antibodies reshaping community dynamics of E. coli in the newborn is only being unraveled with the use of gene signatures and comparative diversity and typing analysis of colonizing commensal E. coli strains (e.g., SNPs, MLST, subtraction PCR libraries) (unpublished data). In future, VG profiling will be further enhanced by other sequences obtained by subtractive hybridization (300) to identify housekeeping and fitness genes that are unique to commensal populations. These genes will be added to the binary data set used currently for VG profiling and hence further increase the resolving power of gene signatures. Indeed, it appears that E. coli strains from different intestinal compartments of healthy grower pigs possess unique colicin and microcin gene signatures distinct from ETECs (291). These results support the notion that early neonatal intervention with a cocktail of nicheadapted E. coli can provide a sound basis for the use of E. coli strains as probiotics for promoting intestinal health (probiosis). Complementation of this strategy with LAB delivery to weaners will probably form the basis of new management strategies for AGP-free rearing of pigs in intensive production systems (267). ACKNOWLEDGMENTS The authors acknowledge the cumulative contributions (2001–2007) of graduate students at IMDRU, including S. Dixit, X.-Y. Wu, J. Patterson, and P. Njuguna. The

REFERENCES

421

expertise and input of Bernadette Turner merits special mention for well-performed technical work. This program was funded substantively by a Commonwealth Research and Development Start Grant awarded to International Animal Health (C. Lawlor and K. Healey) in conjunction with CSIRO and NSW DPI. ColiGuard probiotic strains were provided by International Animal Health, Sydney, Australia. REFERENCES 1. Adlerberth I, Ahrne S, Johansson ML, Molin G, Hanson LA, and Wold AE. A mannosespecific adherence mechanism in Lactobacillus plantarum conferring binding to the human colonic cell line HT-29. Appl. Environ. Microbiol. 1996; 62: 2244–2251. 2. Alander M, Korpela R, Saxelin M, Vilpponen-Salmela T, Mattila-Sandholm T, and von Wright A. Recovery of Lactobacillus rhamnosus GG from human colonic biopsies. Lett. Appl. Microbiol. 1997; 24: 61–64. 3. Alander M, Satokari R, Korpela R, Saxelin M, Vilpponen-Salmela T, Mattila-Sandholm T, and von Wright A. Persistence of colonization of human colonic mucosa by a probiotic strain, Lactobacillus rhamnosus GG, after oral consumption. Appl. Environ. Microbiol. 1999; 65: 351–354. 4. Bergonzelli GE, Granato D, Pridmore RD, Marvin-Guy LF, Donnicola D, and Corthesy-Theulaz IE. GroEL of Lactobacillus johnsonii La1 (NCC 533) is cell surface associated: potential role in interactions with the host and the gastric pathogen Helicobacter pylori. Infect. Immun. 2006; 74: 425–434. 5. Bernet MF, Brassart D, Neeser JR, and Servin AL. Adhesion of human bifidobacterial strains to cultured human intestinal epithelial cells and inhibition of enteropathogen–cell interactions. Appl. Environ. Microbiol. 1993; 59: 4121–4128. 6. Bernet MF, Brassart D, Neeser JR, and Servin AL. Lactobacillus acidophilus LA 1 binds to cultured human intestinal cell lines and inhibits cell attachment and cell invasion by enterovirulent bacteria. Gut 1994; 35: 483–489. 7. Bezkorovainy A. Probiotics: determinants of survival and growth in the gut. Am. J. Clin. Nutr. 2001; 73: 399S–405S. 8. Blum S, Reniero R, Schiffrin EJ, Crittenden R, Mattila-Sandholm T, von Wright A, Saarela M, Saxelin M, Collins K, and Morelli L. Adhesion studies for probiotics: need for validation and refinement. Trends Food Sci. Technol. 1999; 10: 405–410. 9. Buck BL, Altermann E, Svingerud T, and Klaenhammer TR. Functional analysis of putative adhesion factors in Lactobacillus acidophilus NCFM. Appl. Environ. Microbiol. 2005; 71: 8344–8351. 10. Cesena C, Morelli L, Alander M, Siljander T, Tuomola E, Salminen S, MattilaSandholm T, Vilpponen-Salmela T, and von Wright A. Lactobacillus crispatus and its nonaggregating mutant in human colonization trials. J. Dairy Sci. 2001; 84: 1001–1010. 11. Chauviere G, Coconnier MH, Kerneis S, Darfeuille-Michaud A, Joly B, and Servin AL. Competitive exclusion of diarrheagenic Escherichia coli (ETEC) from human enterocytelike Caco-2 cells by heat-killed Lactobacillus. FEMS Microbiol. Lett. 1992; 70: 213–217. 12. Chauviere G, Coconnier MH, Kerneis S, Fourniat J, and Servin AL. Adhesion of human Lactobacillus acidophilus strain LB to human enterocyte-like Caco-2 cells. J. Gen. Microbiol. 1992; 138(Part 8): 1689–1696.

422


13. Coconnier MH, Bernet MF, Chauviere G, and Servin AL. Adhering heat-killed human Lactobacillus acidophilus, strain LB, inhibits the process of pathogenicity of diarrhoeagenic bacteria in cultured human intestinal cells. J. Diarrhoeal Dis. Res. 1993; 11: 235– 242. 14. Coconnier MH, Klaenhammer TR, Kerneis S, Bernet MF, and Servin AL. Proteinmediated adhesion of Lactobacillus acidophilus BG2FO4 on human enterocyte and mucus-secreting cell lines in culture. Appl. Environ. Microbiol. 1992; 58: 2034–2039. 15. Collado MC, Gueimonde M, Sanz Y, and Salminen S. Adhesion properties and competitive pathogen exclusion ability of bifidobacteria with acquired acid resistance. J. Food Prot. 2006; 69: 1675–1679. 16. Crociani J, Grill JP, Huppert M, and Ballongue J. Adhesion of different bifidobacteria strains to human enterocyte-like Caco-2 cells and comparison with in vivo study. Lett. Appl. Microbiol. 1995; 21: 146–148. 17. Del Re B, Sgorbati B, Miglioli M, and Palenzona D. Adhesion, autoaggregation and hydrophobicity of 13 strains of Bifidobacterium longum. Lett. Appl. Microbiol. 2000; 31: 438–442. 18. Elo S, Saxelin M, and Salminen S. Attachment of Lactobacillus casei strain GG to human colon carcinoma cell line Caco-2: comparison with other dairy strains. Lett. Appl. Microbiol. 1991; 13: 154–156. 19. Frece J, Kos B, Svetec IK, Zgaga Z, Mrsa V, and Suskovic J. Importance of S-layer proteins in probiotic activity of Lactobacillus acidophilus M92. J. Appl. Microbiol. 2005; 98: 285–292. 20. Fuller R and Brooker BE. Lactobacilli which attach to the crop epithelium of the fowl. Am. J. Clin. Nutr. 1974; 27: 1305–1312. 21. Gopal PK, Prasad J, Smart J, and Gill HS. In vitro adherence properties of Lactobacillus rhamnosus DR20 and Bifidobacterium lactis DR10 strains and their antagonistic activity against an enterotoxigenic Escherichia coli. Int. J. Food Microbiol. 2001; 67: 207–216. 22. Granato D, Bergonzelli GE, Pridmore RD, Marvin L, Rouvet M, and Corthesy-Theulaz IE. Cell surface-associated elongation factor Tu mediates the attachment of Lactobacillus johnsonii NCC533 (La1) to human intestinal cells and mucins. Infect. Immun. 2004; 72: 2160–2169. 23. Granato D, Perotti F, Masserey I, Rouvet M, Golliard M, Servin A, and Brassart D. Cell surface-associated lipoteichoic acid acts as an adhesion factor for attachment of Lactobacillus johnsonii La1 to human enterocyte-like Caco-2 cells. Appl. Environ. Microbiol. 1999; 65: 1071–1077. 24. Greene JD and Klaenhammer TR. Factors involved in adherence of lactobacilli to human Caco-2 cells. Appl. Environ. Microbiol. 1994; 60: 4487–4494. 25. Gueimonde M, Noriega L, Margolles A, de los Reyes-Gavilan CG, and Salminen S. Ability of Bifidobacterium strains with acquired resistance to bile to adhere to human intestinal mucus. Int. J. Food Microbiol. 2005; 101: 341–346. 26. Gusils C, Cuozzo S, Sesma F, and Gonzalez S. Examination of adhesive determinants in three species of Lactobacillus isolated from chicken. Can. J. Microbiol. 2002; 48: 34–42. 27. He F, Isolauri E, Morita H, Hosoda M, Hashimoto H, Fuse T, Mizumachi K, Kurisaki J, Benno Y, Salminen S, and Ouwehand AC. Bifidobacteria isolated from allergic and healthy infants: differences in taxonomy, mucus adhesion and immune modulatory effects. Microecol. Ther. 2002; 29: 103–108.

REFERENCES

423

28. He F, Ouwehand AC, Hashimoto H, Isolauri E, Benno Y, and Salminen S. Adhesion of Bifidobacterium spp. to human intestinal mucus. Microbiol. Immunol. 2001; 45: 59–262. 29. He F, Ouwehand AC, Isolauri E, Hashimoto H, Benno Y, and Salminen S. Comparison of mucosal adhesion and species identification of bifidobacteria isolated from healthy and allergic infants. FEMS Immunol. Med. Microbiol. 2001; 30: 43–47. 30. He F, Ouwehand AC, Isolauri E, Hosoda M, Benno Y, and Salminen S. Differences in composition and mucosal adhesion of bifidobacteria isolated from healthy adults and healthy seniors. Curr. Microbiol. 2001; 43: 351–354. 31. Henriksson A, Szewzyk R, and Conway PL. Characteristics of the adhesive determinants of Lactobacillus fermentum 104. Appl. Environ. Microbiol. 1991; 57: 499–502. 32. Hood SK and Zottola EA. Effect of low pH on the ability of Lactobacillus acidophilus to survive and adhere to human intestinal cells. J. Food Sci. 1988; 53: 1514–1516. 33. Hyn€onen U, Westerlund-Wikstr€om B, Palva A, and Korhonen TK. Identification by flagellum display of an epithelial cell- and fibronectin-binding function in the SlpA surface protein of Lactobacillus brevis. J. Bacteriol. 2002; 184: 3360–3367. 34. Ibnou-Zekri N, Blum S, Schiffrin EJ, and von der Weid T. Divergent patterns of colonization and immune response elicited from two intestinal Lactobacillus strains that display similar properties in vitro. Infect. Immun. 2003; 71: 428–436. 35. Jacobsen CN, Rosenfeldt Nielsen V, Hayford AE, Moller PL, Michaelsen KF, Paerregaard A, Sandstrom B, Tvede M, and Jakobsen M. Screening of probiotic activities of forty-seven strains of Lactobacillus spp. by in vitro techniques and evaluation of the colonization ability of five selected strains in humans. Appl. Environ. Microbiol. 1999; 65: 4949–4956. 36. Jakava-Viljanen M and Palva A. Isolation of surface (S) layer protein carrying Lactobacillus species from porcine intestine and faeces and characterization of their adhesion properties to different host tissues.Vet. Microbiol. 2007, doi: 10.1016/j.vetmic. 2007.04.029. 37. Johansson ML Molin G, Jeppsson B, Nobaek S, Ahrne S, and Bengmark S. Administration of different Lactobacillus strains in fermented oatmeal soup: in vivo colonization of human intestinal mucosa and effect on the indigenous flora. Appl. Environ. Microbiol. 1993; 59: 15–20. 38. Juntunen M, Kirjavainen PV, Ouwehand AC, Salminen SJ, and Isolauri E. Adherence of probiotic bacteria to human intestinal mucus in healthy infants and during rotavirus infection. Clin. Diagn. Lab. Immunol. 2001; 8: 293–296. 39. Kankaanp€a€a P, Tuomola E, El-Nezami H, Ahokas J, and Salminen SJ. Binding of aflatoxin B1 alters the adhesion properties of Lactobacillus rhamnosus strain GG in a Caco-2 model. J. Food Prot. 2000; 63: 412–414. 40. Kapczynski DR, Meinersmann RJ, and Lee MD. Adherence of Lactobacillus to intestinal 407 cells in culture correlates with fibronectin binding. Curr. Microbiol. 2000; 41: 136– 141. 41. Kirjavainen PV, Ouwehand AC, Isolauri E, and Salminen SJ. The ability of probiotic bacteria to bind to human intestinal mucus. FEMS Microbiol. Lett. 1998; 167: 185– 189. 42. Klarin B, Johansson ML, Molin G, Larsson A, and Jeppsson B. Adhesion of the probiotic bacterium Lactobacillus plantarum 299v onto the gut mucosa in critically ill patients: a randomised open trial. Crit. Care 2005; 9: R285–R293.

424


€ 43. Lahtinen SJ, Saarinen NM, Amm€ al€a J, M€akel€a SI, Salminen S, and Ouwehand AC. Interactions between lignans and probiotics. Microb. Ecol. Health Dis. 2002; 14: 106– 109. 44. Larsen N, Nissen P, and Willats WG. The effect of calcium ions on adhesion and competitive exclusion of Lactobacillus ssp. and E. coli O138. Int. J. Food Microbiol. 2007; 114: 113–119. 45. Lehto EM and Salminen S. Adhesion of twelve different Lactobacillus strains to Caco-2 cell cultures. Nutr. Today 1996; 31(Suppl.): 49S–50S. 46. Matsumoto M, Tani H, Ono H, Ohishi H, and Benno Y. Adhesive property of Bifidobacterium lactis LKM512 and predominant bacteria of intestinal microflora to human intestinal mucin. Curr. Microbiol. 2002; 44: 212–215. 47. Miyoshi Y, Okada S, Uchimura T, and Satoh E. A mucus adhesion promoting protein, MapA, mediates the adhesion of Lactobacillus reuteri to Caco-2 human intestinal epithelial cells. Biosci. Biotechnol. Biochem. 2006; 70: 1622–1628. 48. Morelli L, Garbagna N, Rizzello F, Zonenschain D, and Grossi E. In vivo association to human colon of Lactobacillus paracasei B21060: map from biopsies. Digest. Liver Dis. 2006; 38: 894–898. 49. Morita H, He F, Fuse T, Ouwehand AC, Hashimoto H, Hosoda M, Mizumachi K, and Kurisaki J. Adhesion of lactic acid bacteria to Caco-2 cells and their effect on cytokine secretion. Microbiol. Immunol. 2002; 46: 293–297. 50. Op den Camp HJ, Oosterhof A, and Veerkamp JH. Interaction of bifidobacterial lipoteichoic acid with human intestinal epithelial cells. Infect. Immun. 1985; 47: 332–334. 51. Ouwehand A, Parhiala R, Salminen S, Rantala A, Huhtinen H, Sarparanta H, and Salminen E. Influence of the endogenous mucosal microbiota on the adhesion of probiotic bacteria in vitro. Microb. Ecol. Health Dis. 2004; 16: 202–204. 52. Ouwehand A, T€olkk€o S, and Salminen S. The effect of digestive enzymes on the adhesion of probiotic bacteria in vitro. J. Food Sci. 2001; 66: 856–859. 53. Ouwehand AC, Isolauri E, Kirjavainen PV, and Salminen SJ. Adhesion of four Bifidobacterium strains to human intestinal mucus from subjects in different age groups. FEMS Microbiol. Lett. 1999; 172: 61–64. 54. Ouwehand AC, Isolauri E, Kirjavainen PV, Tolkko S, and Salminen SJ. The mucus binding of Bifidobacterium lactis Bb12 is enhanced in the presence of Lactobacillus GG and Lact. delbrueckii subsp. bulgaricus. Lett. Appl. Microbiol. 2000; 30: 10–13. 55. Ouwehand AC, Kirjavainen PV, Gr€onlund M-M, Isolauri E, and Salminen SJ. Adhesion of probiotic micro-organisms to intestinal mucus. Int. Dairy J. 1999; 9: 623–630. 56. Ouwehand AC, Niemi P, and Salminen SJ. The normal faecal microflora does not affect the adhesion of probiotic bacteria in vitro. FEMS Microbiol. Lett. 1999; 177: 35–38. 57. Ouwehand AC, Salminen S, Roberts PJ, Ovaska J, and Salminen E. Disease-dependent adhesion of lactic acid bacteria to the human intestinal mucosa. Clin. Diagn. Lab. Immunol. 2003; 10: 643–646. 58. Ouwehand AC, Salminen S, T€olkk€o S, Roberts P, Ovaska J, and Salminen E. Resected human colonic tissue: new model for characterizing adhesion of lactic acid bacteria. Clin. Diagn. Lab. Immunol. 2002; 9: 184–186. 59. Ouwehand AC, Salminen S, T€olkk€o S, Roberts PJ, Ovaska J, and Salminen E. Dependent adhesion of lactic acid bacteria to colonic tissue in vitro. Microecol. Ther. 2002; 29: 95–102.

REFERENCES

425

60. Ouwehand AC, Tuomola EM, T€olkk€o S, and Salminen S. Assessment of adhesion properties of novel probiotic strains to human intestinal mucus. Int. J. Food Microbiol. 2001; 64: 119–126. 61. Ouwehand AC, T€olkk€o S, Kulmala J, Salminen S, and Salminen E. Adhesion of inactivated probiotic strains to intestinal mucus. Lett. Appl Microbiol. 2000; 31: 82–86. 62. Pretzer G, Snel J, Molenaar D, Wiersma A, Bron PA, Lambert J, de Vos WM, van der Meer R, Smits MA, and Kleerebezem M. Biodiversity-based identification and functional characterization of the mannose-specific adhesin of Lactobacillus plantarum. J. Bacteriol. 2005; 187: 6128–6136. 63. Resta-Lenert S, and Barrett KE. Live probiotics protect intestinal epithelial cells from the effects of infection with enteroinvasive Escherichia coli (EIEC). Gut 2003; 52: 988– 997. 64. Riedel CU, Foata F, Goldstein DR, Blum S, and Eikmanns BJ. Interaction of bifidobacteria with Caco-2 cells—adhesion and impact on expression profiles. Int. J. Food Microbiol. 2006; 110: 62–68. 65. Rinkinen M, Westermarck E, Salminen S, and Ouwehand AC. Absence of host specificity for in vitro adhesion of probiotic lactic acid bacteria to intestinal mucus. Vet. Microbiol. 2003; 97: 55–61. 66. Rojas M, Ascencio F, and Conway PL. Purification and characterization of a surface protein from Lactobacillus fermentum 104R that binds to porcine small intestinal mucus and gastric mucin. Appl. Environ. Microbiol. 2002; 68: 2330–2336. 67. Roos S and Jonsson H. A high-molecular-mass cell-surface protein from Lactobacillus reuteri 1063 adheres to mucus components. Microbiology 2002; 148: 433–442. 68. Savage DC. Growth phase, cellular hydrophobicity, and adhesion in vitro of lactobacilli colonizing the keratinizing gastric epithelium in the mouse. Appl. Environ. Microbiol. 1992; 58: 1992–1995. 69. Sherman LA and Savage DC. Lipoteichoic acids in Lactobacillus strains that colonize the mouse gastric epithelium. Appl. Environ. Microbiol. 1986; 52: 302–304. 70. Tallon R, Arias S, Bressollier P, and Urdaci MC. Strain- and matrix-dependent adhesion of Lactobacillus plantarum is mediated by proteinaceous bacterial compounds. J. Appl. Microbiol. 2007; 102: 442–451. 71. Tuomola EM, Ouwehand AC, and Salminen SJ. Chemical, physical and enzymatic pretreatments of probiotic lactobacilli alter their adhesion to human intestinal mucus glycoproteins. Int. J. Food Microbiol. 2000; 60: 75–81. 72. Tuomola EM and Salminen SJ. Adhesion of some probiotic and dairy Lactobacillus strains to Caco-2 cell cultures. Int. J. Food Microbiol. 1998; 41: 45–51. 73. Walter J, Chagnaud P, Tannock GW, Loach DM, Dal Bello F, Jenkinson HF, Hammes WP, and Hertel C. A high-molecular-mass surface protein (Lsp) and methionine sulfoxide reductase B (MsrB) contribute to the ecological performance of Lactobacillus reuteri in the murine gut. Appl. Environ. Microbiol. 2005; 71: 979–986. 74. Vesterlund S, Paltta J, Karp M, and Ouwehand AC. Measurement of bacterial adhesion—in vitro evaluation of different methods. J. Microbiol. Methods 2005; 60: 225–233. 75. von Wright A, Vilpponen-Salmela T, Llopis MP, Collins K, Kiely B, Shanahan F, and Dunne C. The survival and colonic adhesion of Bifidobacterium infantis in patients with ulcerative colitis. Int. Dairy J. 2002; 12: 197–200.

426


76. Zarate G, Morata de Ambrosini V, Perez Chaia A, and Gonzalez S. Some factors affecting the adherence of probiotic Propionibacterium acidipropionici CRL 1198 to intestinal epithelial cells. Can. J. Microbiol. 2002; 48: 449–457. 77. Aissi EA, Lecocq M, Brassart C, and Buoquelet S. Adhesion of some Bifidobacteria strains to human enterocyte-like cells and binding to mucosal glycoproteins. Microb. Ecol. Health Dis. 2001; 13: 32–39. 78. Alander M, Satokari R, Korpela R, Saxelin M, Vilpponen-Salmela T, Mattila-Sandholm T, and von Wright A. Persistence of colonization of human colonic mucosa by a probiotic strain, Lactobacillus rhamnosus GG, after oral consumption. Appl. Environ. Microbiol. 1999; 65: 351–354. 79. Bachrach G, Ianculovici C, Naor R, and Weiss EI. Fluorescence based measurements of Fusobacterium nucleatum co-aggregation and of fusobacterial attachment to mammalian cells. FEMS Microbiol. Lett. 2005; 248(2): 235–240. 80. Beachey EH. Bacterial adherence: adhesin–receptor interactions mediating the attachment of bacteria to mucosal surfaces. J. Infect. Dis. 1981; 143: 325–345. 81. Bernet MF, Brassart D, Nesser JR, and Servin AL. Adhesion of human bifidobacterial strains to cultured human intestinal epithelial cells and inhibition of enteropathogen–cell interactions. Appl. Environ. Microbiol. 1993; 59: 4121–4128. 82. Bibiloni R, Fedorak RN, Tannock GW, Madsen KL, Gionchetti P, Campieri M, De Simone C, and Sartor RB. VSL#3 probiotic-mixture induces remission in patients with active ulcerative colitis. Am. J. Gastroenterol. 2005; 100(7): 1539–1546. 83. Bibiloni R, Perez PF, and de Antoni GL. Will a high adhering capacity in a probiotic strain guarantee exclusion of pathogens from intestinal epithelia? Anaerobe 1999; 5: 519–524. 84. Bibiloni R, Perez PF, Garrote GL, Disalvo EA, and De Antoni GL. Surface characterization and adhesive properties of bifidobacteria. Methods Enzymol. 2001; 336: 411–427. 85. Boris S, Suarez JE, and Barbes C. Characterization of the aggregation promoting factor from Lactobacillus gasseri, a vaginal isolate. J. Appl. Microbiol. 1997; 83(4): 413–420. 86. Camilleri M. Probiotics and irritable bowel syndrome: rationale, putative mechanisms, and evidence of clinical efficacy. J. Clin. Gastroenterol. 2006; 40(3): 264–269. 87. Canzi E, Guglielmetti S, Mora D, Tamagnini I, and Parini C. Conditions affecting cell surface properties of human intestinal bifidobacteria. Antonie van Leeuwenhoek 2005; 88 (3–4): 207–219. 88. Cesena C, Morelli L, Alander M, Siljander T, Tuomola E, Salminen S, MattilaSandholm T, Vilpponen-Salmela T, and Von Wright A. Lactobacillus crispatus and its nonaggregating mutant in human colonization trials. J. Dairy Sci. 2001; 84: 1001–1010. 89. Chouraqui JP, Van Egroo LD, and Fichot MC. Acidified milk formula supplemented with Bifidobacterium lactis: impact on infant diarrhea in residential care settings. J. Pediatr. Gastroenterol. Nutr. 2004; 38(3): 288–292. 90. Collado MC, Gueimonde M, Hernandez M, Sanz Y, and Salminen S. Adhesion of selected Bifidobacterium strains to human intestinal mucus and its role in enteropathogen exclusion. J. Food Prot. 2005; 68(12): 2672–2678. 91. Collado MC, Hernandez M, and Sanz Y. Production of bacteriocin-like inhibitory compounds by potentially probiotic bifidobacteria. J. Food Prot. 2005; 68(5): 1034– 1040.

REFERENCES

427

92. Collado MC, Meriluoto J, and Salminen S. Development of new probiotics by strains combination: is it possible to improve the adhesion to intestinal mucus? J. Dairy Sci. 2007; 90: 2710–2716. 93. Collado MC, Meriluoto J, and Salminen S. In vitro analysis of probiotic strains combinations to inhibit pathogen adhesion to human intestinal mucus. Food Res. Int. 2007; 40(5): 629–636. 94. Collado MC, Meriluoto J, and Salminen S. Interactions between pathogens and lactic acid bacteria: aggregation and coaggregation abilities. Eur. J. Food Res. Technol. 2008; 226(5): 1065–1073. 95. Collado MC, Meriluoto J, and Salminen S. Measurement of aggregation properties of probiotic strains with pathogens: in vitro evaluation of different methods. J. Microbiol. Methods 2007; 71(1): 71–74. 96. Collado MC, Meriluoto J, and Salminen S. Role of commercial probiotic strains against human pathogen adhesion to intestinal mucus. Lett. Appl. Microbiol. 2007; 45(4): 454– 460. 97. Del Re B, Sgorbati B, Miglioli M, and Palenzona D. Adhesion, autoaggregation and hydrophobicity of 13 strains of Bifidobacterium longum. Lett. Appl. Microbiol. 2000; 31: 438–442. 98. Femia AP, Luceri C, Dolara P, Giannini A, Biggeri A, Salvadori M, Clune Y, Collins KJ, Paglierani M, and Caderni G. Antitumorigenic activity of the prebiotic inulin enriched with oligofructose in combination with the probiotics Lactobacillus rhamnosus and Bifidobacterium lactis on azoxymethane-induced colon carcinogenesis in rats. Carcinogenesis 2002; 23(11): 1953–1960. 99. Fooks LJ, Fuller R, and Gibson GR. Prebiotics, probiotics and human gut microecology. Int. Dairy J. 1999; 9: 53–61. 100. Forestier C, De Champs C, Vatoux C, and Joly B. Probiotic activities of Lactobacillus casei rhamnosus: in vitro adherence to intestinal cells and antimicrobial properties. Res. Microbiol. 2001; 152: 167–173. 101. Freter M, Factors affecting the microecology of the gut. In: Fuller R editor. Probiotics. The Scientific Basis. Chapman and Hall, Glasgow, 1992, pp. 111–145. 102. Fujiwara S, Hashiba H, Hirota T, and Forstner JF. Inhibition of the binding of enterotoxigenic Escherichia coli Pb176 to human intestinal epithelial cell line HCT-8 by an extracellular protein fraction containing BIF of Bifidobacterium longum SBT2928: suggestive evidence of blocking of the binding receptor gangliotetraosylceramide on the cell surface. Int. J. Food Microbiol. 2001; 67: 97–106. 103. Gagnon M, Kheadr EE, Le Blay G, and Fliss I. Invitro inhibition of Escherichia coli O157: H7 by bifidobacterial strains of human origin. Int. J. Food Microbiol. 2004; 92: 69–78. 104. Gaudier E, Michel C, Segain JP, Cherbut C, and Hoebler C. The VSL# 3 probiotic mixture modifies microflora but does not heal chronic dextran–sodium sulfate-induced colitis or reinforce the mucus barrier in mice. J. Nutr. 2005; 135(12): 2753–2761. 105. Gionchetti P, Amadini C, Rizzello F, Venturi A, and Campieri M. Review article: treatment of mild to moderate ulcerative colitis and pouchitis. Aliment. Pharmacol. Ther. 2002; 16(4): 13–19. 106. Gionchetti P, Lammers KM, Rizzello F, and Campieri M. VSL#3: an analysis of basic and clinical contributions in probiotic therapeutics. Gastroenterol. Clin. North Am. 2005; 34(3): 499–513.

428


107. Gomez Zavaglia A, Kociubinski G, Perez P, Disalvo E, and De Antoni G. Effect of bile on the lipid composition and surface properties of bifidobacteria. J. Appl. Microbiol. 2002; 93(5): 794–799. 108. Green JD and Klaenhammer TR. Factors involved in adherence of lactobacilli to human Caco-2 cells. Appl. Environ. Microbiol. 1994; 60: 4487–4494. 109. Guandalini S. Probiotics for children: use in diarrhea. J. Clin. Gastroenterol. 2006; 40(3): 244–248. 110. Gueimonde M, Jalonen L, He F, Hiramatsu M, and Salminen S. Adhesion and competitive inhibition and displacement of human enteropathogens by selected lactobacilli. Food Res. Int. 2006; 39(4): 467–471. 111. Gueimonde M, Noriega L, Margolles A, De los Reyes-Gavilan CG, and Salminen S. Ability of Bifidobacterium strains with acquired resistance to bile to adhere to human intestinal mucus. Int. J. Food Microbiol. 2005; 101: 341–346. 112. Handley PS, Harty DW, Wyatt JE, Brown CR, Doran JP, and Gibbs AC. A comparison of the adhesion, coaggregation and cell-surface hydrophobicity properties of fibrillar and fimbriate strains of Streptococcus salivarius. J. Gen. Microbiol. 1987; 133(11): 3207– 3217. 113. Jankovic I, Ventura M, Meylan V, Rouvet M, Elli M, and Zink R. Contribution of aggregation-promoting factor to maintenance of cell shape in Lactobacillus gasseri 4B2. J. Bacteriol. 2003; 185: 3288–3296. 114. Juntunen M, Kirjavainen PV, Ouwehand AC, Salminen SJ, and Isolauri E. Adherence of probiotic bacteria to human intestinal mucus in healthy infants and during rotavirus infection. Clin. Diagn. Lab. Immunol. 2001; 8(2): 293–296. 115. Kajander K, Hatakka K, Poussa T, Farkkila M, and Korpela R. A probiotic mixture alleviates symptoms in irritable bowel syndrome patients: a controlled 6-month intervention. Aliment. Pharmacol. Ther. 2005; 22(5): 387–394. 116. Katz JA. Probiotics for the prevention of antibiotic-associated diarrhea and Clostridium difficile diarrhea. J. Clin. Gastroenterol. 2006; 40(3): 249–255. 117. Kim HJ, Vazquez Roque MI, Camilleri M, Stephens D, Burton DD, Baxter K, Thomforde G, and Zinsmeister AR. A randomized controlled trial of a probiotic combination VSL#3 and placebo in irritable bowel syndrome with bloating. Neurogastroenterol. Motil. 2005; 17(5): 687–696. 118. Kirjavainen PE, Ouwehand AC, Isolauri E, and Salminen S. The ability of probiotic bacteria to bind to human intestinal mucus. FEMS Microbiol. Lett. 1998; 167: 185–189. 119. Kos B, Suskovic J, Vukovic S, Simpraga M, Frece J, and Matosic S. Adhesion and aggregation ability of probiotic strain Lactobacillus acidophilus M92. J. Appl. Microbiol. 2003; 94: 981–987. 120. Lee Y-J, Yu W-K, and Heo T-R. Identification and screening for antimicrobial activity against Clostridium difficile of Bifidobacterium and Lactobacillus species isolated from healthy infant faeces. Int. J. Antimicrob. Agents 2003; 21: 340–346. 121. Li J and Ellen RP. Coaggregation of Porphyromonas (Bacteroides) gingivalis, other species of bacteroides, and Actinomyces viscosus. Methodological evaluation. J. Microbiol. Methods 1990; 12: 91–96. 122. Malik A, Sakamoto M, Ono T, and Kakii K. Coaggregation between Acinetobacter johnsonii S35 and Microbacterium esteraromaticum strains isolated from sewage activated sludge. J. Biosci. Bioeng. 2003; 96: 10–15.

REFERENCES

429

123. Myllyluoma E, Veijola L, Ahlroos T, Tynkkynen S, Kankuri E, Vapaatalo H, Rautelin H, and Korpela R. Probiotic supplementation improves tolerance to Helicobacter pylori eradication therapy—a placebo-controlled, double-blind randomized pilot study. Aliment. Pharmacol. Ther. 2005; 21(10): 1263–1272. 124. Nagayama M, Sato M, Yamaguchi R, Tokuda C, and Takeuchi H. Evaluation of coaggregation among Streptococcus mitis. Fusobacterium nucleatum and Porphyromonas gingivalis. Lett. Appl. Microbiol. 2001; 33(2): 122–125. 125. Olivares M, Dıaz-Ropero MP, Gomez N, Lara-Villoslada F, Sierra S, Maldonado JA, Martın R, Rodrıguez JM, and Xaus J. The consumption of two new probiotic strains, Lactobacillus gasseri CECT 5714 and Lactobacillus coryniformis CECT 5711, boosts the immune system of healthy humans. Int. Microbiol. 2006; 9(1): 47–52. 126. Ouwehand AC and Salminen S. In vitro adhesion assays for probiotics and their in vivo relevance: a review. Microbial Ecol. Health Dis. 2003; 15: 175–184. 127. Ouwehand AC, Isolauri E, Kirjavainen PV, and Salminen SJ. Adhesion of four Bifidobacterium strains to human intestinal mucus from subjects in different age groups. FEMS Microbiol. Lett. 1999; 172: 61–64. 128. Ouwehand AC, Isolauri E, Kirjavainen PV, Tolkko S, and Salminen SJ. The mucus binding of Bifidobacterium lactis Bb12 is enhanced in the presence of Lactobacillus GG and Lact. delbrueckii subsp. bulgaricus. Lett. Appl. Microbiol. 2000; 30(1): 10–13. 129. Ouwehand AC, Salminen S, and Isolauri E. Probiotics: an overview of beneficial effects. Antonie van Leeuwenhoek 2002; 82: 279–289. 130. Pelletier C, Bouley C, Cayuela C, Bouttier S, Bourlioux P, and Bellon-Fontaine MN. Cell surface characteristics of Lactobacillus casei subsp. casei, Lactobacillus paracasei subsp. paracasei, and Lactobacillus rhamnosus strains. Appl. Environ. Microbiol. 1997; 63: 1725–1731. 131. Perdigon G, Maldonado Galdeano C, Valdez JC, and Medici M. Interaction of lactic acid bacteria with the gut immune system. Eur. J. Clin. Nutr. 2002; 56(4): S21–S26. 132. Perez PF, Minnaard Y, Disalvo EA, and De Antoni GL. Surfaceproperties of bifidobacterial strains of human origin. Appl. Environ. Microbiol. 1998; 64: 21–26. 133. Reid G, McGroarty JA, Angotti R, and Cook RL. Lactobacillus inhibitor production against Escherichia coli and coaggregation ability with uropathogens. Can. J. Microbiol. 1988; 34: 344–351. 134. Rickard AH, Gilbert P, High NJ, Kolenbrander PE, and Handley PS. Bacterial coaggregation: an integral process in the development of multi-species biofilms. Trends Microbiol. 2003; 11: 94–100. 135. Rinkinen M, Westermarck E, Salminen S, and Ouwehand AC. Absence of host specificity for in vitro adhesion of probiotic lactic acid bacteria to intestinal mucus. Vet. Microbiol. 2003; 97: 55–61. 136. Rojas M and Conway PL. Colonization by lactobacilli of piglet small intestinal mucus. J. Appl. Bacteriol. 1996; 81: 474–480. 137. Roselli M, Finamore A, Britti MS, and Mengheri E. Probiotic bacteria Bifidobacterium animalis MB5 and Lactobacillus rhamnosus GG protect intestinal Caco-2 cells from the inflammation-associated response induced by enterotoxigenic Escherichia coli K88. Br. J. Nutr. 2006; 95(6): 1177–1184.

430


138. Ruas-Madiedo P, Gueimonde M, Margolles A, de los Reyes-Gavilan CG, and Salminen S. Exopolysaccharides produced by probiotic strains modify the adhesion of probiotics and enteropathogens to human intestinal mucus. J. Food Prot. 2006; 69(8): 2011–2015. 139. Schachtsiek M, Hammes WP, and Hertel C. Characterization of Lactobacillus coryniformis DSM 20001T surface protein Cpf mediating coaggregation with and aggregation among pathogens. Appl. Environ. Microbiol. 2004; 70(12): 7078–7085. 140. Schellenberg J, Smoragiewicz W, and Karska-Wysocki B. A rapid method combining immunofluorescence and flow cytometry for improved understanding of competitive interactions between lactic acid bacteria (LAB) and methicillin-resistant S. aureus (MRSA) in mixed culture. J. Microbiol. Methods 2006; 65(1): 1–9. 141. Servin AL. Antagonistic activities of lactobacilli and bifidobacteria against microbial pathogens. FEMS Microbiol. Rev. 2004; 28: 405–440. 142. Spencer RJ and Chesson A. The effect of Lactobacillus spp. on the attachment of enterotoxigenic Escherichia coli to isolated porcine enterocytes. J. Appl. Bacteriol. 1994; 77: 215–220. 143. Timmerman HM, Koning CJ, Mulder L, Rombouts FM, and Beynen AC. Monostrain, multistrain and multispecies probiotics—a comparison of functionality and efficacy. Int. J. Food Microbiol. 2004; 96: 219–233. 144. Toure R, Kheardr E, Lacroix C, Moroni O, and Fliss I. Production of antibacterial substances by bifidobacterial isolates from infant stool active against Listeria monocytogenes. J. Appl. Microbiol. 2003; 95: 1058–1069. 145. Tuomola EM, Ouwehand AC, and Salminen S. Chemical, physical and enzymatic pretreatments of probiotic lactobacilli alter their adhesion to human intestinal mucus glycoproteins. Int. J. Food Microbiol. 2000; 60: 75–81. 146. Vandevoorde L, Christiaens H, and Verstraete W. Prevalence of coaggregation among chicken lactobacilli. J. Appl. Bacteriol. 1992; 72: 214–219. 147. Vesterlund S, Paltta J, Karp M, and Ouwehand AC. Measurement of bacterial adhesion— in vitro evaluation of different methods. J. Microbiol. Methods 2005; 60: 225–233. 148. Vinderola CG, Medici M, and Perdigon G. Relationship between interaction sites in the gut hydrophobicity, mucosal immunomodulating capacities and cell wall protein profiles in indigenous and exogenous bacteria. J. Appl. Bacteriol. 2004; 96: 230–243. 149. Wadstr€om T, Anderson K, Sydow M, Axelsson L, Lindgren S, and Gullmar B. Surface properties of lactobacilli isolated from the small intestine of pigs. J. Appl. Bacteriol. 1997; 62: 513–520. 150. Zoppi G, Cinquetti M, Benini A, Bonamini E, and Minelli EB. Modulation of the intestinal ecosystem by probiotics and lactulose in children during treatment with ceftriaxone. Curr. Ther. Res. 2001; 62: 418–435. 151. Alakomi HL, Skytt€a E, Saarela M, Mattila-Sandholm T, Latva-Kala K, and Helander IM. Lactic acid permeabilizes Gram-negative bacteria by disrupting the outer membrane. Appl. Environ. Microbiol. 2000; 66: 2001–2005. 152. Arques JL, Fernandez J, Gaya P, Nunez M, Rodriguez E, and Medina M. Antimicrobial activity of reuterin in combination with nisin against food-borne pathogens. Int. J. Food Microbiol. 2004; 95: 225–229. 153. Axelsson LT, Chung TC, Dobrogosz WJ, and Lindgren SE. Production of a broad spectrum antimicrobial substance by Lactobacillus reuteri. Microb. Ecol. Health Dis. 1989; 2: 131–136.

REFERENCES

431

154. Bauer R and Dicks LM. Mode of action of lipid II-targeting lantibiotics. Int. J. Food Microbiol. 2005; 101: 201–216. 155. Bernbom N, Licht TR, Brogren CH, Jelle B, Johansen AH, Badiola I, Vogensen FK, and Nørrung B. Effects of Lactococcus lactis on composition of intestinal microbiota: role of nisin. Appl. Environ. Microbiol. 2006; 72: 239–244. 156. Blom H and Mortvedt C. Anti-microbial substances produced by food associated microorganisms. Biochem. Soc. Trans. 1991; 19: 694–698. 157. Caplice E and Fitzgerald GF. Food fermentations: role of microorganisms in food production and preservation. Int. J. Food Microbiol. 1999; 50: 131–149. 158. Carlsson J, Iwami Y, and Yamada T. Hydrogen peroxide excretion by oral streptococci and effect of lactoperoxidase thiocyanate–hydrogen peroxide. Infect. Immun. 1983; 40: 70–80. 159. Chung TC, Axelsson LT, Lindgren SE, and Dobrogosz WJ. In vitro studies on reuterin synthesis by Lactobacillus reuteri. Microb. Ecol. Health Dis. 1989; 2: 137–144. 160. Cleveland J, Montville TJ, Nes IF, and Chikindas ML. Bacteriocins: safe, natural antimicrobials for food preservation. Int. J. Food Microbiol. 2001; 71: 1–20. 161. Condon S. Responses of lactic acid bacteria to oxygen. FEMS Microbiol. Rev. 1987; 46: 269–280. 162. Daniels JA, Krishnamurthi R, and SSH R. A review of the effects of carbon dioxide on microbial growth and food quality. J. Food Prot. 1985; 6: 532–537. 163. Dobrogosz WJ, Casas IA, Pagano GA, Talarico TL, Sj€ oberg B-M, and Karlsson M. Lactobacillus reuteri and the enteric microbiota. In: Gruff R, Midtvedt T, and Norin E, editors. The Regulatory and Protective Role of the Normal Microflora. Stockton Press, New York, 1989, pp. 283–292. 164. Dunne C, O’Mahony L, Murphy L, Thornton G, Morrissey D, O’Halloran S, Feeney M, Flynn S, Fitzgerald G, Daly C, Kiely B, O’Sullivan GC, Shanahan F, and Collins JK. In vitro selection criteria for probiotic bacteria of human origin: correlation with in vivo findings. Am. J. Clin. Nutr. 2001; 73: 386S–392S. 165. Eklund T. The antimicrobial effect of dissociated and undissociated sorbic acid at different pH levels. J. Appl. Bacteriol. 1983; 54: 383–389. 166. Eklund T. Organic acids, and esters. In: Gould GW, editor. Mechanisms of Action of Food Preservation Procedures. Elsevier, New York, 1989, pp. 161–200. 167. Eschenbach DA, Davick PR, Williams BL, Klebanoff SJ, Young-Smith K, Critchlow CM, and Holmes KK. Prevalence of hydrogen peroxide-producing Lactobacillus species in normal women and women with bacterial vaginosis. J. Clin. Microbiol. 1989; 27: 251–256. 168. Hechard Y and Sahl HG. Mode of action of modified and unmodified bacteriocins from Gram-positive bacteria. Biochimie 2002; 84: 545–557. 169. Jay JM. Antimicrobial properties of diacetyl. Appl. Environ. Microbiol. 1982; 44: 525–532. 170. Kamau DN, Doores S, and Pruitt K. Enhanced thermal destruction of Listeria monocytogenes and Staphylococcus aureus by the lactoperoxidase system. Appl. Environ. Microbiol. 1990; 56: 2711–2716. 171. Klaenhammer TR. Genetics of bacteriocins produced by lactic acid bacteria. FEMS Microbiol. Rev. 1993; 12: 39–85. 172. Klebanoff SJ, Hillier SL, Eschenbach DA, and Waltersdorph AM. Control of the microbial flora of the vagina by H2O2-generating lactobacilli. J. Infect. Dis. 1991; 164: 94–100.

432


173. Lindgren SE and Dobrogosz WJ. Antagonistic activities of lactic acid bacteria in food and feed fermentations. FEMS Microbiol. Rev. 1990; 87: 149–163. 174. Metchnikoff E. The Prolongation of Life. Optimistic Studies. Butterworth-Heinemann, London, 1907. 175. Reid G and Burton J. Use of Lactobacillus to prevent infection by pathogenic bacteria. Microbes Infect. 2002; 4: 319–324. 176. Ryan CS and Kleinberg I. Bacteria in human mouths involved in the production and utilization of hydrogen peroxide. Arch. Oral Biol. 1995; 40: 753–763. 177. St, Amant DC, Valentin-Bon IE, and Jerse AE. Inhibition of Neisseria gonorrhoeae by Lactobacillus species that are commonly isolated from the female genital tract. Infect. Immun. 2002; 70: 7169–7171. 178. Talarico TL and Dobrogosz WJ. Chemical characterization of an antimicrobial substance produced by Lactobacillus reuteri. Antimicrob. Agents Chemother. 1989; 33: 674– 679. 179. Tamime AY. Fermented milks: a historical food with modern applications—a review. Eur. J. Clin. Nutr. 2002; 56(Suppl. 4): S2–S15. 180. Alander M, Satokari R, Korpela R, et al. Persistence of colonization of human colonic mucosa by Lactobacillus rhamnosus GG, after oral consumption. Appl. Environ. Microbiol. 1999; 65: 351–354. 181. Benno Y, He F, and Hosoda M. Effects of Lactobacillus GG yoghurt on human intestinal microecology in Japanese subjects. Nutr. Today 1996; 31: 9S–11S. 182. Bjorksten B, Sepp E, Julge K, Voor T, and Mikelsaar M. Allergy development and the intestinal microflora during the first year of life. J. Allergy Clin. Immunol. 2001; 108(4): 516–520. 183. Carmody RJ and Chen YH. Nuclear factor-kappaB: activation and regulation during tolllike receptor signaling. Cell. Mol. Immunol. 2007; 4(1): 31–41. 184. Christensen HR, Frokiaer H, and Pestka JJ. Lactobacilli differentially modulate expression of cytokines and maturation surface markers in murine dendritic cells. J. Immunol. 2002; 168(1): 171–178. 185. Di Giacinto C, Marinaro M, Sanchez M, Strober W, and Boirivant M. Probiotics ameliorate recurrent Th1-mediated murine colitis by inducing IL-10 and IL-10dependent TGF-beta-bearing regulatory cells. J. Immunol. 2005; 174(6): 3237–3246. 186. Franchi L, McDonald C, Kanneganti TD, Amer A, and Nunez G. Nucleotide-binding oligomerization domain-like receptors: intracellular pattern recognition molecules for pathogen detection and host defense. J. Immunol. 2006; 177(6): 3507–3513. 187. Goldin BR, Gorbach SL, Saxelin M, Barakat S, Gualtieri L, and Salminen S. Survival of Lactobacillus species (strain GG) in human gastrointestinal tract. Digest. Dis. Sci. 1992; 37(1): 121–128. 188. Harmsen HJ, Wildeboer-Veloo AC, Raangs GC, Wagendorp AA, Klijn N, Bindels JG, et al. Analysis of intestinal flora development in breast-fed and formula-fed infants by using molecular identification and detection methods. J. Pediatr. Gastroenterol. Nutr. 2000; 30(1): 61–67. 189. Hart AL, et al. Modulation of human dendritic cell phenotype and function by probiotic bacteria. Gut 2004; 53(11): 1602–1609. 190. He F, Morita H, Hashimoto H, et al. Intestinal Bifidobacterium species induce varying cytokine production. J. Allergy Clin. Immunol. 2002; 109: 1035–1036.

REFERENCES

433

191. He F, Tuomola E, Arvilommi H, and Salminen S. Modulation of humoral immune response through probiotic intake. FEMS Immunol. Med. Microbiol. 2000; 29: 47–52. 192. Hooper LV, Wong MH, Thelin A, Hansson L, Falk PG, and Gordon JI. Molecular analysis of commensal host–microbial relationships in the intestine. Science 2001; 291 (5505): 881–884. 193. Isolauri E, Arvola T, Sutas Y, Moilanen E, and Salminen S. Probiotics in the management of atopic eczema. Clin. Exp. Allergy 2000; 30(11): 1604–1610. 194. Isolauri E, Joensuu J, Suomalainen H, Luomala M, and Vesikari T. Improved immunogenicity of oral D RRV reassortant rotavirus vaccine by Lactobacillus casei GG. Vaccine 1995; 13: 310–312. 195. Isolauri E, Majamaa H, Arvola T, Rantala I, Virtanen E, and Arvilommi H. Lactobacillus casei strain GG reverses increased intestinal permeability induced by cow milk in suckling rats. Gastroenterology 1993; 105: 1643–1650. 196. Kaila M, Isolauri E, Salminen S, Mikelsaar M, and Sepp E. Colonisation of infants with Lactobacillus GG during acute rotavirus diarrhea. Biosci. Microflora 1998; 17: 149–151. 197. Kalliom€aki MA and Walker WA. Physiologic and pathologic interactions of bacteria with gastrointestinal epithelium. Gastroenterol. Clin. North Am. 2005; 34: 383–399. 198. Kirjavainen PV, Salminen SJ, and Isolauri E. Probiotic bacteria in the management of atopic disease: underscoring the importance of viability. J. Pediatr. Gastroenterol. Nutr. 2003; 36: 223–227. 199. Kukkonen K, Nieminen T, Poussa T, Savilahti E, and Kuitunen M. Effect of probiotics on vaccine antibody responses in infancy—a randomized placebo-controlled doubleblind trial. Pediatr. Allergy Immunol. 2006; 17(6): 416–421. 200. Lammers KM, et al. Effect of probiotic strains on interleukin 8 production by HT29/19A cells. Am. J Gastroenterol. 2002; 97(5): 1182–1186. 201. Maassen CB, et al. Orally administered Lactobacillus strains differentially affect the direction and efficacy of the immune response. Vet. Q. 1998; 20(Suppl. 3): S81–S83. 202. Majamaa H, Isolauri E, Saxelin M, and Vesikari T. Lactic acid bacteria in the treatment of acute rotavirus gastroenteritis. J. Pediatr. Gastroenterol. Nutr. 1995; 20 (3): 333–338. 203. Matsuzaki T, et al. Prevention of onset in an insulin-dependent diabetes mellitus model, NOD mice, by oral feeding of Lactobacillus casei. Acta Pathol. Microbiol. Immunol. Scand. 1997; 105(8): 643–649. 204. Mullie C, Yazourh A, Thibault H, et al. Increased poliovirus-specific intestinal antibody response coincides with promotion of Bifidobacterium longum-infantis and Bifidobacterium breve in infants: a randomized, double-blind, placebo-controlled trial. Pediatr. Res. 2004; 56(5): 791–795. 205. Neish AS, Gewirtz AT, Zeng H, et al. Prokaryotic regulation of epithelial responses by inhibition of IkappaB-alpha ubiquitination. Science 2000; 289(5484): 1560–1563. 206. Neish AS. Bacterial inhibition of eukaryotic pro-inflammatory pathways. Immunol. Res. 2004; 29(1–3): 175–186. 207. Pessi T, Sutas Y, Hurme M, and Isolauri E. Interleukin-10 generation in atopic children following oral Lactobacillus rhamnosus GG. Clin. Exp. Allergy 2000; 30(12): 1804– 1808. 208. Pohjavuori E, et al. Lactobacillus GG effect in increasing IFN-gamma production in infants with cow’s milk allergy. J. Allergy Clin. Immunol. 2004; 114(1): 131–136.

434


209. Rautava S, Kalliomaki M, and Isolauri E. Probiotics during pregnancy and breast-feeding might confer immunomodulatory protection against atopic disease in the infant. J. Allergy Clin. Immunol. 2002; 109: 119–121. 210. Ruiz PA, et al. Innate mechanisms for Bifidobacterium lactis to activate transient proinflammatory host responses in intestinal epithelial cells after the colonization of germfree rats. Immunology 2005; 115(4): 441–450. 211. Sepp E, Mikelsaar M, and Salminen S. Effect of Lactobacillus casei strain GG administration on the gastrointestinal microbiota of newborns. Microb. Ecol. Health Dis. 1993; 6: 309–314. 212. Sheil B, McCarthy J, O’Mahony L, et al. Is the mucosal route of administration essential for probiotic function? Subcutaneous administration is associated with attenuation of murine colitis and arthritis. Gut 2004; 53(5): 694–700. 213. Sturm A, Rilling K, Baumgart DC, et al. Escherichia coli Nissle 1917 distinctively modulates T-cell cycling and expansion via toll-like receptor 2 signaling. Infect. Immun. 2005; 73(3): 1452–1465. 214. Sudo N, Sawamura S, et al. The requirement of intestinal bacterial flora for the development of an IgE production system susceptible to oral tolerance induction. J. Immunol. 1997; 159: 1739–1745. 215. Takeda K and Akira S. Toll-like receptors in innate immunity. Int. Immunol. 2005; 17: 1–14. 216. Viljanen M, Savilahti E, Haahtela T, Juntunen-Backman K, Korpela R, Poussa T, Tuure T, and Kuitunen M. Probiotics in the treatment of atopic eczema/dermatitis syndrome in infants: a double blind placebo-controlled trial. Allergy 2004, doi:10.1111/j.1398-9995. 217. von der Weid T, Bulliard C, and Schiffrin EJ. Induction by a lactic acid bacterium of a population of CD4(þ) T cells with low proliferative capacity that produce transforming growth factor beta and interleukin-10. Clin. Diagn. Lab. Immunol. 2001; 8(4): 695–701. 218. Benno Y and Mitsuoka T. Development of intestinal microflora in humans and animals. Bifidobacteria Microfi. 1986; 5: 13–25. 219. Collado MC, Derrien M, Isolauri E, de Vos WM, and Salminen S. Intestinal integrity and Akkermansia muciniphila: a mucin-degrading member of the intestinal microbiota present in infants, adults and the elderly. Appl. Environ. Microbiol. 2007, doi:10.1128/AEM.01477-07. 220. Gore C, Munro K, Lay C, Bibiloni R, Morris J, Woodstock A, Custovic A, and Tannock GW, Bifidobacterium pseudocatenulatum is associated with atopic eczema: a nested case-control study investigating the fecal microbiota of infants. J. Allergy Clin. Immunol., 2008; 121: 135–140. 221. Gr€onlund MM, Gueimonde M, Laitinen K, Kociubinski G, Salminen S, and Isolauri E. Maternal breast-milk and intestinal bifidobacteria guide the compositional development of the Bifidobacterium microbiota in infants at risk of allergic disease. Clin. Exp. Allergy 2007, doi:10.1111/j.1365-2222.2007.02849.x. 222. Guarner F and Malagelada JR. Gut flora in health and disease. Lancet 2003; 361: 512– 519. 223. Guerin-Danan C, Meslin JC, Chambard A, Charpilienne A, Relano P, Bouley C, Cohen J, and Andrieux C. Food supplementation with milk fermented by Lactobacills casei DN-114 001 protects suckling rats from rotavirus-associated diarrhea. J. Nutr. 2001; 131: 111–117.

REFERENCES

435

224. Gueimonde M, Sakato S, Kalliom€aki M, Isolauri E, Benno Y, and Salminen S. Effect of maternal consumption of Lactobacillus GG on transfer and establishment of fecal bifidobacterial microbiota in neonates. J. Pediatr. Gastroenterol. Nutr. 2006; 42: 166–170. 225. Harmsen HJ, Wildeboer Veloo AC, Raangs GC, Wagendorp AA, Klijn N, Bindels JG, and Welling GW. Analysis of intestinal flora development in breast-fed and formula-fed infants by using molecular identification and detection methods. J. Pediatr. Gastroenterol. Nutr. 2000; 30: 61–67. 226. He F, Morita H, Hashimoto H, Hosoda M, Kurisaki J, Ouwehand AC, Isolauri E, Benno Y, and Salminen S. Intestinal Bifidobacterium species induce varying cytokine production. J. Allergy Clin. Immunol. 2002; 109: 1035–1036. 227. He F, Morita H, Kubota A, Ouwehand AC, Hosoda M, Hiramatsu M, and Kurisaki J. Effect of orally administered non-viable Lactobacillus cells on murine humoral immune responses. Microbiol. Immunol. 2005; 49: 993–997. 228. Hebuterne X. Gut changes attributed to ageing: effects on intestinal microflora. Curr. Opin. Clin. Nutr. Metab. Care 2003; 6: 49–54. 229. Hopkins MJ, Sharp R, and Macfarlane GT. Age and disease related changes in intestinal bacterial populations assessed by cell culture, 16S rRNA abundance, and community cellular fatty acid profiles. Gut 2001; 48: 198–205. 230. Hopkins MJ and Macfarlane GT. Changes in predominant bacterial populations in human faeces with age and with Clostridium difficile infection. J. Med. Microbiol. 2002; 51: 448–454. 231. Juntunen M, Kirjavainen P, Ouwehand AC, Salminen SJ, and Isolauri E. Gut microflora changes and probiotics in children in day care centers. Biosci. Microflora 2003; 22: 99– 107. 232. Kalliom€aki M, Kirjavainen P, Eerola E, et al. Distinct patterns of neonatal gut microflora in infants in whom atopy was and was not developing. J. Allergy Clin. Immunol. 2001; 107: 129–134. 233. Kirjavainen PV, Apostolou E, Arvola T, Salminen SJ, Gibson GR, and Isolauri E. Characterizing the composition of intestinal microflora as a prospective treatment target in infant allergic disease. FEMS Immunol. Med. Microbiol. 2001; 32: 1–7. 234. Kirjavainen PV, Arvola T, Salminen SJ, and Isolauri E. Aberrant composition of gut microbiota of allergic infants: a target of bifidobacterial therapy at weaning? Gut 2002; 51: 51–55. 235. Kleessen B, Bunke H, Tovar K, Noack J, and Sawatzki G. Influence of two infant formulas and human milk on the development of the faecal flora in newborn infants. Acta Pediatr. 1995; 84: 1347–1356. 236. Mackie RI, Sghir A, and Gaskins HR. Developmental microbial ecology of the neonatal gastrointestinal tract. Am. J. Clin. Nutr. 1999; 69(Suppl.): 1035S–1045S. 237. Martin R, Heilig HGHJ, Zoetendal EG, Jimenez E, Fernandez L, Smidt H, and Rodriguez JM. Cultivation-independent assessment of the bacterial diversity of breast milk among healthy women. Res. Microbiol. 2007; 158: 31–37. 238. Mikelsaar M, M€andar R, Sepp E, and Annuk H, Human lactic acid microflora and its role in the welfare of host. In: Salminen S, von Wright A, Ouwehand A, editors. Lactic Acid Bacteria. Marcel Dekker Inc., New York, 2004.

436


239. Mitsuoka T and Hayakawa K. Die faecalflora bei Menschen I. Mitteilung: die zusammensetzung der faecalflora der verschiedenen altersgruppen. ZBL Bakt. Hyg. 1972; 233: 333–42. 240. Morelli LC, Cesena C, de Hae€n, and Gozzini L. Taxonomic Lactobacillus composition of feces from human newborns during the first few days. Microb. Ecol. 1998; 35: 205–212. 241. Ouwehand AC, Isolauri E, He F, Hashimoto H, Benno Y, and Salminen S. Differences in Bifidobacterium flora composition in allergic and healthy infants. J. Allergy Clin. Immunol. 2001; 108: 144–145. 242. Ouwehand A, Isolauri E, and Salminen S. The role of the intestinal microflora for the development of the immune system in early childhood. Eur. J. Nutr. 2002; 41(Suppl. 1): I32–I37. 243. Palmer C, Bik EM, DiGiulio DB, Relman DA, and Brown PO. Development of the human infant intestinal microbiota. PLoS Biol. 2007; 5(7): e177. 244. Penders J, Thijs C, Vink C, Stelma FF, Snijders B, Kummeling I, van den Brandt PA, and Stobberingh EE. Factors influencing the composition of the intestinal microbiota in early infancy. Pediatrics 2006; 118: 511–521. 245. Penders J, Thijs C, van den Brandt PA, Kummeling I, Snijders B, Stelma F, Adams H, van Ree R, and Stobberingh EE. Gut microbiota composition and development of atopic manifestations in infancy: the KOALA Birth Cohort Study. Gut 2007; 56: 661– 667. 246. Rajilic-Stojanovic M, Smidt H, and de Vos WM. Diversity of the human gastrointestional tract microbiota revisited. Environ. Microbiol. 2007; 9: 2125–2136. 247. Rinne M, Gueimonde M, Kalliom€aki M, Hoppu U, Salminen S, and Isolauri E. Similar bifidogenic effects of prebiotic-supplemented partially hydrolyzed infant formula and breastfeeding on infant gut microbiota. FEMS Immunol. Med. Microbiol. 2005; 43: 59– 65. 248. Salminen S, Bouley C, Boutron-Ruault MC, et al. Gastrointestinal physiology and function—targets for functional food development. Br. J. Nutr. 1998; 80(Suppl.): 147– 171. 249. Satokari RM, Vaughan EE, Favier CF, Dore J, Edwards C, and de Vos WM. Diversity of Bifidobacterium and Lactobacillus spp. in breast-fed and formula-fed infants as assessed by 16S rDNA sequence differences. Microb. Ecol. Health Dis. 2002; 14: 97–105. 250. Satokari RM, Vaughan EE, Smidt H, Saarela M, M€att€ o J, and de Vos WM. Molecular approaches for the detection and identification of bifidobacteria and lactobacilli in the human gastrointestinal tract. Syst. Appl. Microbiol. 2003; 26: 572–584. 251. Schultz M, Gottl C, Young RJ, Iwen P, and Vanderhoof JA. Administration of oral probiotic bacteria to pregnant women causes temporary infantile colonization. J. Pediatr. Gastroenterol. Nutr. 2004; 38: 293–297. 252. Song Y, Liu C, and Finegold SM. Real-time PCR quantitation of clostridia in feces of autistic children. Appl. Environ. Microbiol. 2004; 70: 6459–6465. 253. Stark PL and Lee A. The microbial ecology of the large bowel of breast-fed and formulafed infants during the first year of life. J. Med. Microbiol. 1982 189–203. 254. Stsepetova J, Sepp E, Julge K, Vaughan E, Mikelsaar M, and de Vos WM. Molecularly assessed shifts of Bifidobacterium ssp. and less diverse microbial communities are

REFERENCES

255.

256.

257. 258.

259. 260. 261.

262.

263.

264.

265.

266.

267.

268.

437

characteristic of 5-year-old allergic children. FEMS Immunol. Med. Microbiol. 2007; 51: 260–269. Wang M, Ahrne S, Antonsson M, and Molin G. T-RFLP combined with principal components analysis and 16S rRNA sequencing: an effective strategy for comparison of fecal microbiota in infants of different ages. J. Microbiol. Methods 2004; 59: 53– 69. Woodcock A, Moradi M, Smillie FI, Murray CS, Burnie JP, and Custovic A. Clostridium difficile, atopy and wheeze during the first year of life. Pediatr. Allergy Immunol. 2002; 13 (5): 357–360. Woodmansey EJ. Intestinal bacteria and ageing. J. Appl. Microbiol. 2007; 102: 1178– 1186. Alexa P, Hamrik J, Stouracova K, and Salajka E. Oral immunization against enterotoxigenic colibacillosis in weaned piglets by non-pathogenic E. coli strain with K88 (F4) colonizing factors. Vet. Med. Czech. 2005; 50: 315–320. Anjum M, Tucker J, Sprigings K, Woodward M, and Ehricht R. Use of miniaturized protein arrays for E. coli O serotyping. Clin. Vaccine Immunol. 2006; 13: 561–567. America Public Health Association (APHA), Standard Methods for the Examination of Water and Wastewater, 20th ed. APHA, Washington, DC, 1998. Ballmer K, Korczak B, Kuhnert P, Slickers P, Ehricht R, and Hachler H. Fast DNA serotyping of E. coli by use of an oligonucleotide microarray. J. Clin. Microbiol. 2007; 45: 370–379. Beale L, Njuguna P, Chapman T, Al-Jassim R, Trott D, and Chin JC. Fitness genes of commensal and enterotoxigenic E. coli. In: Paterson JE, editor. Manipulating Pig Production XI. Australasian Pig Science Association Book Publication, Australia, 2007, pp. 193. Bertschinger HW, Eng V, and Wegmann P. Relationship between coliform contamination of floor and teats and the incidence of puerperal mastitis in two types of farrowing accommodations. In: Eskesbo I, editor. Proceedings of the Sixth International Congress on Animal Hygiene. Swedish University of Agricultural Science, Skara, Sweden, 1988, pp. 86–88. Bielaszewska M, Dobrindt U, Gartner J, Gallitz I, Hacker J, Karch H, Muller D, Schubert S, Schmidt M, Sorsa L, and Zdziarski J. Aspects of genome plasticity in pathogenic E. coli. Int. J. Med. Microbiol. 2007, . Blanco M, Lazo L, Blanco J, Dahbi G, Mora A, Lopez C, Gonzalez E, and Blanco J. Serotypes, virulence genes, and PFGE patterns of enteropathogenic E. coli isolated from Cuban pigs with diarrhea. Int. Microbiol. 2006; 9: 53–60. Boudry G, Peron V, Le Huerou-Luron I, Lalles J, and Seve B. Weaning induces both transient and long-lasting modifications of absorptive, secretory and barrier properties of piglet intestine. J. Nutr. 2004; 134: 2256–2262. Bruininx E, Binnendijk G, Van der Peet-Schwering C, Schrama J, Den Hartog L, Everts H, and Beynen A. Effect of creep feed consumption on individual feed intake characteristics and performance of group-housed weanling pigs. J. Anim. Sci. 2002; 80: 1413– 1418. Carroll J, Touchette K, Matteri B, Dyer C, and Allee G. Effect of spray-dried plasma and lipopolysaccharide exposure on weaned pigs. II. Effects on the hypothalamic–pituitary– adrenal axis of weaned pigs. J. Anim. Sci. 2002; 80: 502–509.

438


269. Chapman T, Smith AM, Daniels P, Jordan D, Trott D, and Chin JC. Phenotyping Escherichia coli antimicrobial resistances in pigs. In: Paterson JE, editor. Manipulating Pig Production XI. Australasian Pig Science Association, Book Publication, Australia, 2007, pp. 194. 270. Chapman T, Wu XY, Barchia I, Bettelheim K, Driesen S, Trott D, Wilson M, and Chin J. Comparison of virulence gene profiles of E. coli strains isolated from healthy and diarrheic swine. Appl. Environ. Microbiol. 2006; 72: 4782– 4795. 271. Chin JC, Chapman TA. Turner B, and Wu ZY. A re-appraisal of early signaling events and gene activation in a human intestinal epithelial cell line in vitro by probiotics and enteric pathogenic bacteria species. Int. J. Probiotics Prebiotics, in press. 272. Chin JC and Mullbacher A, Immune activation versus hyporesponsiveness and tolerance in the gut: is there a role for probiotics in shaping an unbalanced response against commensals and pathogens? In: Fuller DR and Perdigon G, editors. Gut Flora, Nutrition and Health. Blackwell Science Ltd., 2002, pp. 178–200. 273. Correa MG and Marin J. O-serogroups, eae gene and EAF plasmid in E. coli isolates from cases of bovine mastitis in Brazil. Vet. Microbiol. 2002; 85: 125–132. 274. Crespi B. The evolution of social behavior in microorganisms. Trends Ecol. Evol. 2001; 16: 178–181. 275. Diez-Gonzalez F, Applications of bacteriocins in livestock. Curr. Iss. Intest. Microbiol. 2005; 8: 15–24. 276. Dixit S, Gordon D, Wu XY, Chapman T, Kailasapathy K, and Chin J. Diversity analysis of commensal porcine E. coli – associations between genotypes and habitat in the porcine gastrointestinal tract. Microbiology 2004; 150: 1735–1740. 277. Dixon B. Antibiotics as growth promoters: risks and alternatives. ASM News 2000; 66(No. 5) 278. Fuller R. Probiotics in man and animals. J. Appl. Bacteriol. 1989; 66: 365–378. 279. Germon P, Roche D, Melo S, Mignon-Grasteau S, Dobrindt U, Hacker J, Schouler C, and Moulin-Schouleur M. tENA locus polymorphism and ecto-chromosomal DNA insertion hotspots are related to the phylogenetic group of E. coli strains. Microbiology 2007; 153: 826–837. 280. Janion C, Sikora (nee Wojcik) A, Nowosielska A, and Grzesiuk E. SOS response in starved E. coli. Environ. Mol. Mutagen. 2002; 40: 129–133. 281. Jordan D, Chin J, Trott D, Antimicrobial use in the Australian pig industry: which drugs, how often and why. In: Paterson JE, editor. Manipulating Pig Production XI. Australasian Pig Science Association Book Publication, Australia, 2007, pp. 122. 282. Katouli M, Lund A, Wallgren P, Kuhn I, Soderlind O, and Mollby R. Phenotypic characterization of intestinal E. coli of pigs during suckling, postweaning and fattening periods. Appl. Environ. Microbiol. 1995; 61: 778–783. 283. Kuhn L, Tullus K, and Molby R. Colonization and persistence of E. coli phenotypes in intestines of children aged 0–18 months. Infection 1986; 14: 7–12. 284. Kunin C and Beard M. Serological studies of O antigens of E. coli by means of the hemagglutination test. J. Bacteriol. 1963; 85: 541–548. 285. Kyriakis S, Tsiloyiannis V, Vlemmas J, Sarris K, Tsinas A, Alexopoulos C, and Jansegers L. The effect of probiotic LSP 122 on the control of post-weaning diarrhea syndrome of piglets. Res. Vet. Sci. 1999; 67: 223–228.

REFERENCES

439

286. Lacher D, Strinsland H, Blank T, Donnenberg M, and Whittam T. Molecular evolution of typical EPEC: clonal analysis by multilocus sequence typing and virulence gene allelic profiling. J. Bacteriol. 2007; 189: 342–350. 287. Manner K and Spieler A. Probiotics in piglets—an alternative to traditional growth promoters. Microecol. Ther. 1997; 26: 243–256. 288. Miller G, Algozin K, McNamara P, and Bush E. Productivity and economic effects of antibiotics used for growth promotion in U.S. pork production. J. Agric. Appl. Econ. 2003; 35: 469–482. 289. Moeser A, Klok C, Ryan K, Wooten J, Little D, Cook V, and Blikslager A. Stress signaling pathways activated by weaning mediate intestinal dysfunction in the pig. Am. J. Physiol. Gastrointest. Liver Physiol. 2007; 292: 173–181. 290. Naomani B, Fairbrother J, and Gyles C. Virulence genes of O149 enterotoxigenic E. coli from outbreaks of postweaning diarrhea in pigs. Vet. Microiobiol. 2003; 97: 87–101. 291. Njuguna P. Studies on the manipulation of gastrointestinal tract bacteria. MSc. thesis, 2005, http://www.library.uow.edu.au/adt-NWU/public/adt-NWU20060719.125402/index.html. 292. Parker RB. Probiotics: the other half of the antibiotic story. Anim. Nutr. Health 1974; 29: 4–8. 293. Patterson J, Chapman T, Hegedus E, Barchia I, and Chin J. Selected culturable enteric bacterial populations are modified by diet acidification and the growth promotant tylosin. Letts. Appl. Microbiol. 2005; 41: 119–124. 294. Patterson J, Chandrasekara A, Bao S, Hegedus E, Caterson I, Denyer G, Turner B, Mullbacher A, Chin JC,Prebiotic supplementation with resistant starch alters health indices associated with metabolic changes and intestinal dysbiosis. Int. J. Probiotics Prebiotics, in press. 295. Sansom BF and Gleed PT. The ingestion of sow’s faeces by suckling piglets. Br. J. Nutr. 1981; 46: 451–456. 296. Scaletsky I, Michalski J, Torres A, Dulguer M, and Kaper J. Identification and characterization of the locus for diffuse adherence, which encodes a novel afimbrial adhesin found in atypical EPEC. Infect. Immun. 2005; 73: 4753–4765. 297. Schierack P, Steinruck H, Kleta S, and Vahjen W. Virulence factor gene profiles of E. coli isolates from clinically healthy pigs. Appl. Environ. Microbiol. 2006; 72: 6680–6686. 298. Simon O, Jadamus A, and Vahjen W. Probiotic feed additives – Effectiveness and expected modes of action. J. Anim. Feed Sci. 2001; 10: 51–67. 299. Smith MG, Chapman TA, Jordan D, Chin JC, and Trott D. Resistant phenotypes of enteric microbial communities from Australian pig farms. In: Paterson JE, editor. Manipulating Pig Production XI. Australasian Pig Science Association Book Publication, 2007, pp. 121. 300. Srinivasan U, Zhang L, France A, Ghosh D, Shalaby W, Xie J, Marrs C, and Foxman B. Probe hybridization array typing: a binary typing method for E. coli. J. Clin. Microbiol. 2007; 45: 206–214. 301. Stahl CH, Callaway TR, Lincoln L, Lonergan S, and Genovese K. Inhibitory activities of colicins against E. coli strains responsible for postweaning diarrhea and edema disease in swine. Antimicrob. Agents Chemother. 2004; 48: 3119–3121. 302. Taras D, Vahjen W, Macha M, and Simon O. Performance, diarrhea incidence, and occurrence of E. coli virulence genes during long-term administration of a probiotic Enterococcus faecium strain to sows and piglets. J. Anim. Sci. 2006; 84: 608–607.

440


303. U.S. Department of Agriculture. Reference of swine health and management in the United States. 2002. N338.0801. National Animal Health Monitoring System, Fort Collins, CO, 2001. 304. Van Belkum M and Stiles ME. Nonlantibiotic antibacterial peptides from lactic acid bacteria. Nat. Prod. Rep. 2000; 17: 323–335. 305. Welch R, Burland V, PlunkettIIIG, Redford P, Roesch P, Rasko D, Buckles E, Liou S, Boutin A, Hackett J, Stroud D, Mayhew G, Rose D, Zhou S, Schwartz D, Perna N, Mobley H, Donnenberg M, and Blattner F. Extensive mosaic structure revealed by the complete genome sequence of uropathogenic E. coli. Proc. Natl. Acad. Sci. USA 2002; 99: 17020–17024. 306. World Health Organization. Global principles for the containment of antimicrobial resistance in animals intended for food, 2000, http://www.who.int/cmc-documents/ zoonoses/docs/whocdscsraph2004.pdf. 307. Wu XY, Chapman TA, Trott DJ, Bettelheim KA, Do TN, Driesen S, Walker MJ, and Chin JC. Comparative analysis of virulence genes, genetic diversity and phylogeny between commensal and enterotoxigenic Escherichia coli from weaned pigs. Appl. Environ. Microbiol. 2007; 73: 83–91. 308. www.thepigsite.com/pighealth/article/227/farrowing-house-design.

6 COMMERCIALLY AVAILABLE HUMAN PROBIOTIC MICROORGANISMS

6.1 Lactobacillus acidophilus, LA-5

Camilla Hoppe and Charlotte Nexmann Larsen Health & Nutrition Division, Chr. Hansen A/S, Denmark

Lactobacillus acidophilus, LA-5 originally selected by Chr. Hansen for the production of probiotic dairy products, has been used in dietary supplements and fermented milk products worldwide. LA-5 is clinically well documented. LA-5 has no adverse effects on the taste, appearance, or palatability of the product. Furthermore, it is able to survive in the product until consumption. LA-5 has many probiotic features. It is able to survive passage through the stomach and upper small intestine due to its tolerance of stomach and bile acid and resistance to digestive enzymes (1–5). It is able to adhere to the intestinal mucosa (6, 7), and the survivability of LA-5 in the intestines has been demonstrated showing a good recovery in feces following oral administration (8). 6.1.1

Gastrointestinal Effects

6.1.1.1 Intestinal Microbial Balance Lactobacillus acidophilus belongs to the group of Gram-positive non-sporulating facultative or anaerobic rods, and it is a natural inhabitant of the gut. The main end products of glucose fermentation by Lactobacilli are lactic acid, acetic acid, and H2O2. These metabolites make Handbook of Probiotics and Prebiotics, Second Edition Edited by Yuan Kun Lee and Seppo Salminen Copyright 2009 John Wiley & Sons, Inc.

441

442

COMMERCIALLY AVAILABLE HUMAN PROBIOTIC MICROORGANISMS

the environment less favorable for the growth of potentially pathogenic microorganisms (9). Lactobacilli play a significant role in controlling intestinal pH through the production of acids, which decrease the intestinal pH thereby restricting the growth of many potentially pathogenic and putrefactive bacteria. In vitro, LA-5 caused an increase in acetate and propionate production by colonic bacteria when a stable microbiota had not been established, suggesting that supplementation with LA-5 modifies colonic fermentation (10). LA-5 also produces bacteriocin CH5 that is characterized not only by a particularly wide antibacterial range (11), but also by inhibitory action against certain yeasts and moulds (12). More than 60% inhibition of Salmonella typhimurium was demonstrated by LA-5 (13), and the growth of Campylobacter jejuni decreased as the concentration of cell-free extract fermented with LA-5 increased in vitro (14). In a number of intestinal inflammatory diseases, disturbances of the normal intestinal microbiota seem to play a pivotal role. An increase of bifidobacteria and lactobacilli and a decrease in the number of stools per day (15) as well as an improvement of gastrointestinal disorders (16) were observed in patients with ileal-pouch-anal anastomosis, receiving LA-5 and Bifidobacterium animalis ssp. lactis (BB-12). In patients with collagenous colitis and diarrhea, days per week with liquid feces were reduced from 6 to 1 in patients receiving LA-5 and BB-12, whereas they increased from 4.5 to 6 in the placebo group (p ¼ 0.052) (17). 6.1.1.2 Diarrhea Diarrhea is the most common health problem encountered by visitors traveling to regions with poor hygiene. The condition is characterized by acute diarrhea caused mainly by intake of food or water infected with Escherichia coli, Salmonella, Shigella, or Campylobacter. Several studies have been carried out addressing the issue of probiotic prophylaxis of traveler’s diarrhea (18). In travelers going to Egypt, the intake of LA-5 together with BB-12, Streptococcus thermophilus (STY-31), and Lactobacillus delbrueckii spp. bulgaricus (LBY-27) significantly decreased the occurrence of diarrhea in the test group (43%) compared to the placebo group (71%) (19). Diarrhea is a potential consequence of a disturbed intestinal flora during an oral therapy with antibiotics, possibly leading to an unfortunate amplification of potentially pathogenic bacteria. The triple treatment for Helicobacter pylori is particularly harsh resulting in many adverse effects. H. pylori infected patients experienced less vomiting, constipation, and diarrhea during antibiotic treatment when supplemented with LA-5 and BB-12 containing yogurt compared to placebo yogurt (20, 21). In another study, administration of yogurt with LA-5 and BB-12 significantly reduced the content of H. pylori and gastritis activity in the antrum of the stomach after 6 weeks of therapy (22). Other studies have shown that volunteers treated with ampicillin or clindamycin and those supplemented with LA-5 and BB-12 experienced a faster normalization of the intestinal flora than those receiving placebo (23, 24). 6.1.1.3 Other Gastrointestinal Effects Constipation is very common in developed countries, and supplementation with lactobacillus might improve natural bowel transit time. Elderly patients suffering from chronic constipation were randomized

Lactobacillus acidophilus, LA-5

443

to receive either unfermented milk or fermented milk with LA-5 and BB-12. The probiotic group experienced a significant improvement in frequency of bowel movement, and reported no negative side effects (25). Some probiotic bacteria have been shown to improve lactose digestion by release of b-galactosidase. In lactose intolerant subjects symptoms of lactose intolerance, such as stomachache, flatulence, diarrhea, and constipation have been found to be improved (26) or unchanged (27) by LA-5, BB-12, STY-31, and LBY-27. However, supplementing LA-5 in milk significantly decreased breath hydrogen values in lactose intolerant subjects when comparing with milk alone, indicating improved lactose degradation (28). Also in vitro studies demonstrated that LA-5 enhances lactose fermentation, as lactose concentration decreased and b-galactosidase activity increased in media supplemented with LA-5 (29, 30). 6.1.2

Immunomodulatory Effects

The gut-associated lymphoid tissue (GALT) is the largest organ of the immune system, and numerous probiotic health effects can be related to the modulation of immune functions. Administration of LA-5 has been associated with nonspecific stimulatory effects on the production of cytokines and phagocytic activity as well as more specific immune reactions such as antibody production. 6.1.2.1 Nonspecific Immune Responses In an in vitro study with a murine macrophage-like cell line that was cultured in the presence of cell-free extracts of LA-5, LA-5 enhanced phagocytosis of inert particles or viable Salmonella (31). The induction of signaling compounds for immune reactions, cytokines, can also be affected by LA-5. In vitro, 10 lactic acid bacteria strains were compared as to their ability to induce the release of three cytokines: tumor necrosis factor alpha (TNF-a), interleukin-6 (IL-6), and IL-10. LA-5 was among the four best inducers of TNF-a release inducing amounts significantly greater than those obtained with lipopolysaccharide as a control (32). 6.1.2.2 Specific Immune Responses In a study, mice fed conventional yogurt, yogurt plus LA-5, and BB-12 or unfermented milk without bacteria (control) were orally immunized with cholera toxin to mimic enteral infections. Higher concentrations of cholera toxin-specific antibodies were found in the feces and serum of LA-5, and BB-12 fed mice compared with the yogurt and milk group (33). 6.1.3

Other Health Effects

Health effects of LA-5 in humans seem to include inhibited growth of cancer breast cells (34). In patients with acute leukemia, administration of LA-5 and BB-12 during and after chemotherapy significantly delayed the occurrence of fever, on average from day 8 in the placebo group to day 12 in the probiotic group (35). Also, an improvement in lipid metabolism by reducing cholesterol has been shown both in humans (36) and rodents (37, 38) as well as in vitro (39).

444

6.1.4


Safety

In relation to the use of microorganisms as human probiotics, safety is clearly a major concern. Being a part of the normal human intestinal microbiota, Lactobacilli are generally considered safe, and millions of humans have consumed LA-5 without any reported negative side effects. 6.2 Lactobacillus acidophilus NCDO 1748

Rangne Fonden1 and Ulla Svensson2 1

Finnboda Kajv€ ag 15, Sweden Arla Foods, Sweden

2

Since the beginning of the former century L. acidophilus has been the original probiotic bacteria used in health studies (44, 48, 69, 74, 79). These early studies were probably been done with species belonging to the acidophilus group but not restricted to strains belonging to the present definition of L. acidophilus. The original type strain was lost and later a new strain was isolated and given the status of type strain (55, 63). The strain L. acidophilus NCDO 1748 (1748) is identical to ATCC 4356T, DSM 20079, JCM 5342 and is present in several strain collections given different numbers. 1748 was selected as the strain to be used in food products during 1970 due to its growth in milk and its survival through the GI (64, 70, 71). Human studies have shown that 1748 influences the gut microbiota and gut function in a favorable way (57). Similarly 1748 alone or as a strain in a mixture favorably balances bacterial flora during treatment with antibiotics (56, 58, 65, 67, 76). 1748 binds and immobilizes food mutagens both in vitro and in vivo and might thereby reduce their level in internal organs like kidney and liver (59, 60, 66, 68). 1748 was used for 25 years on its own or in TABLE 6.1

Identification and Safety of L. acidophilus NCDO 1748

Area

Data

Identification

Type strain isolated from human pharynx (55) Available at NCIMB, UK as strain 8690 (originally named NCDO1748, later NCFB 1748)

Safety Confirmation Antibiotic resistance Virulence Hospitalized persons Bacteraemia

Production of lactate isomer

Inherited antibiotic resistance of NCDO 1748 is in accordance with L. acidophilus group (46, 47). The virulence in a rabbit infective endocarditis model was negligible (43) Minor presence of L. acidophilus in isolates from hospitalized persons (45) 1748 not found in 44 persons suffering from bacteraemia caused by lactobacillus group including 4 infected with L. acidophilus (77) No D-lactate was produced when milk was fermented (41)

Lactobacillus acidophilus NCDO 1748

445

combinations with other probiotics in fermented milk products produced by a patented process from Arla Foods and in natural remedies from Semper (52, 53). 6.2.1

Origin and Safety

The ATCC strain 4356T was isolated from human pharynx (Table 6.1). The species L. acidophilus was seldom present in the clinical isolates, and the strain 1748 was not present in such isolates from Sweden during the time it was used in probiotic products (45, 77). 6.2.2

In Vitro and Animal Studies

1748 survives when exposed to low pH and/or bile acids as well as in vivo in humans (Tables 6.2 and 6.3) (51, 70). It binds several food mutagens and TABLE 6.2

In Vitro and Animal Studies on 1748

Area

Data

Survival, resistance to low pH and bile acids

Good survival when exposed to pH 2.0 or to a mixture of product/gastric juice at pH 1.4. 45% survived in a medium containing 0.3% bile for 3 h (51, 70). Survival confirmed in vivo (Table 6.3). Binding to surface layer protein of rat colonic mucin (62)

Adherance Micellaneous Antioxidative capacity

Binding of food mutagens

Uptake and distribution of food mutagen Trp-P-2 in mice Protect intestinal cells alone or in combination with S. thermophilus

Production of bacteriocins Production of antifungal metabolites Technological aspects/ performance in foods a

Results with 1748 þ Bifidobacterium longum.

The strain had the highest radical scavenging activity of 25 strains tested. Intact cells reduced the cytotoxicity of 4-nitroquinoline-N-oxide by half (61, 80) Almost complete binding of Trp-P-1 and Trp-P-2, less effective binding of PhIP, MeIQx, and IQ (66, 81) Uptake and distribution to kidney, liver, lung, and thymus in mice was reduceda (68) Limits adhesion, invasion, and physiological dysfunction induced by enteroinvasive E. coli and reversal of epithelial damage produced by cytokines (72, 73) Formation of Acidocin J1132 and Acidocin D20079 (50, 51, 78). Showing antifungal activity proven by agar-diffusion methods (49) Ferments milk enriched with yeast extract Good survival in fermented milks and in dried products (52, 53)

446


TABLE 6.3

Human Studies on 1748 Alone or Together with Other Probiotic Strains

Area

Data

Tolerance

NCDO 1748 has been well tolerated in all groups included in investigations, for example, healthy adultsa–c (57, 60, 64), elderlya (42), healthy adults given antibioticsa–c (58, 65, 67, 76), colon cancer patientsa (59), lactose intolerantsa (40) The survival has been analyzed as part of compliance in several of the human studies conducted. Immediate after consumption good survival, not isolated thereaftera,c (56, 64, 75, 76) Number of 1748 increaseda (57). Number of Lactobacillus generally increaseda (57, 71) Sustained/favorable balanced bacterial flora during antibiotic treatmenta–c (56, 58, 65, 67, 76) Stabilizes stool frequency in elderlya (42, 54) Increased tolerance to lactosea (40). Decreased uptake of mutagensa (60)

Survival in the gut

Influence on gut microbiota and balance

Influence on gut function and well being a

Results with 1748. Results with 1748 þ B. longum. c Results with1748 þ F19 þ BB-12. b

decreases their levels in internal organs and has a high antioxidative capacity (60, 61, 66, 68, 80, 81). Further it protects intestinal cells from deleterious effects of cytokines on epithelial function and protects the cells from negative effects of enteroinvasive E. coli (72, 73). Technologically 1748 could, as a single strain, be used to ferment milk enriched with a minute amount of yeast extract. It survives well and grows to the level of up to 2 109 g1 of fermented milk (52, 53). However, the product tastes a bit acrid, but on flavoring it is acceptable to most people. 6.2.3

Human Studies

1748 was well tolerated in all the investigated groups, and no side effects were reported during the 25 years of use even when daily intake was well above 1011 cfu. Further human studies proved that 1748 survived in the gut. The number of lactobacilli increased during the intake of 1748 and antibiotics (58). When taken together with bifidobacteria or with two complementary probiotics, it could counteract the negative impact of antibiotics on the normal GI flora (56, 65, 76). The ability of 1748 to bind mutagens in vitro and in animal studies was further proven in the studies of human volunteers (60). On ingestion of 1748 the mutagens formed during frying of meat were found be reduced in the urine and feces.

Lactobacillus acidophilus NCFM

447

6.3 Lactobacillus acidophilus NCFM

Arthur Ouwehand and Sampo Lahtinen Health & Nutrition, Danisco, Finland

Lactobacillus acidophilus NCFM was isolated from a human fecal sample in the early 1970s. The strain designation NCFM is derived from “North Carolina Food Microbiology,” the research laboratory at North Carolina State University (NCSU) where isolation took place (105). The strain is marketed by Danisco (Danisco Cultures Division, Paris). L. acidophilus NCFM is to date the only strain of this species for which the genome has been sequenced, annotated, and published (82). Genomic work has identified several regions important in probiotic functionality and supporting the role of L. acidophilus NCFM in maintaining or restoring gastrointestinal well being. This includes the genes involved in bacteriocin production, sugar and prebiotic metabolism (86), adherence to human cells, lactose metabolism, and tolerance to physiologically relevant stresses including acid and bile (83). Genomic reconstruction of metabolic pathways reflects the adaptation of L. acidophilus NCFM to the gastrointestinal environment. Furthermore, analysis of the L. acidophilus NCFM genome sequence has confirmed the absence of known transferable genetic elements related to antibiotic resistance (82). 6.3.1

L. acidophilus NCFM Basic Properties

In vitro studies have shown that L. acidophilus NCFM has the necessary prerequisites to survive gastrointestinal transit; resistance to bile, low pH, and digestive enzymes (89). Furthermore, L. acidophilus NCFM has been shown to adhere to human epithelial cell lines (96, 99) and human intestinal mucus (87). This adhesion property could be further improved by the addition of Ca2þ. By adhering to intestinal mucus and by coaggregation, L. acidophilus NCFM may also prevent the adhesion of certain pathogens (87, 88). Genome analysis of L. acidophilus NCFM has indicated the presence of several genes of potential importance to the adherence process, including mucus-binding proteins, fibrinonectin proteins, and others. Exopolysaccharides encoded by clusters of genes may also contribute to adherence capabilities (82). Oral adhesion and survival of L. acidophilus NCFM has also been investigated (97). Finally, L. acidophilus NCFM has been indicated to exert antimicrobial activity (84, 85). The ability of L. acidophilus NCFM to produce antimicrobial substances was confirmed by the genome sequence of the strain, where 12 putative genes were identified and implicated in the production and processing of antimicrobial substances (82, 90). 6.3.2 Survival of Intestinal Transit and Change in Intestinal Microbiota Composition and Activity Consumption of 1010 cfu of L. acidophilus NCFM by healthy adult volunteers caused an increase in the number of fecal lactobacilli during the intervention and in

448


particular L. acidophilus, which were not detectable prior to the intervention, became dominant (108), though no change in the levels of bifidobacteria and sulphide producing bacteria was observed (109). Recently, the survival of L. acidophilus NCFM through the gastrointestinal tract of humans was confirmed in a clinical trial, in which the strain in combination with lactitol also increased the levels of fecal Bifidobacterium levels (102). In a study with immune compromised mice experimentally infected with Candida albicans, prophylactic feeding with L. acidophilus NCFM significantly reduced the incidence of systemic candidiasis and prolonged the survival of the mice (111, 112). Moreover, prophlylactic administration of L. acidophilus NCFM has been shown to have a protective effect on colonic hyperplasia caused by Citrobacter rodentium in mice (110). In combination with four other probiotic strains, L. acidophilus NCFM has been shown to stabilize the intestinal microbiota in humans following antibiotic therapies (92), and in combination with soluble fiber and glutamine, it has been shown to improve diarrhea associated with antiretroviral therapies (98). In addition to changing composition of the intestinal microbiota, changes in the intestinal metabolic activity have been observed. Three human intervention trials showed a reduction in azoreductase and b-glucuronidase (93–95), and one showed a reduction in nitroreductase (94) when subjects consumed 109–1010 cfu L. acidophilus NCFM a day, added as a concentrate to milk. In animal studies, these enzyme activities have been related to intestinal tumor; the relevance for humans is however less clear. Also, in small bowel bacterial over growth, L. acidophilus NCFM has been shown to beneficially alter the metabolism of the intestinal microbiota by reducing the levels of dimethylamine and nitrosodimethylamine (91, 107). 6.3.3

Lactose Intolerance

Lactose maldigestion is a common state for most of adults of non-North-West European descent. An objective measure for lactose intolerance is the excretion of H2 in breath after consumption of lactose. Although L. acidophilus NCFM does not always show a reduction in breath H2, it has been shown to reduce lactose intolerance symptoms in children (100). Other mechanisms may therefore underlie this beneficial effect, such as relief of intestinal pain, as discussed below. 6.3.4

Relief of Intestinal Pain

One of the most recent findings on L. acidophilus NCFM is its ability to induce m-opioid and canabinoid receptors in the intestine of experimental animals (104). The relief of intestinal pain may have great implications in the area of, for example, irritable bowel syndrome (IBS) and infant colic. In animal model of IBS, L. acidophilus NCFM has been shown to be effective (104), but this requires further confirmation in humans.

Lactobacillus casei SHIROTA

6.3.5

449

Prevention of Common Respiratory Infections and Effects on Immunity

In a recent large-scale randomized controlled trial L. acidophilus NCFM, administered either as a single strain or in combination with Bifidobacterium lactis Bi-07, has been shown to reduce the incidence of symptoms of common respiratory tract infections such as fever, cough, and runny nose in children attending child-care centers (101). Symptom duration, absenteeism due to disease, and the use of antibiotics were also significantly reduced during the 6-month administration of probiotics. L. acidophilus NCFM is capable of beneficially modulating immune responses. In a combination with lactitol, L. acidophilus NCFM was shown to increase the levels of fecal PGE2 and spermidine levels in healthy elderly volunteers, suggesting reduced inflammation and enhanced cytoprotection in the intestine (102). Modulation of antibody responses to C. albicans has been demonstrated using a murine model (113). Recently, immunomodulatory effects of L. acidophilus NCFM on serum immunoglobulins were observed in healthy adults following oral vaccination (103). The observed improvement of immune responses in healthy volunteers may partly explain the efficacy of L. acidophilus NCFM in the prevention of common respiratory infections (101). 6.3.6

Application

L. acidophilus NCFM has been commercialized in supplements, fermented, and nonfermented foods, and has been shown to have excellent stability (106) and provides good flavor to fermented products. Furthermore, L. acidophilus NCFM is capable of utilizing fructooligosaccharides (86) and other prebiotic substances, providing opportunities for formulating synbiotic functional foods. 6.3.7

Conclusion

From the studies performed, it is clear that L. acidophilus NCFM’s best-documented health benefits mainly lie in the area of intestinal health and well being. Claims in the area of intestinal health have been submitted for the so-called Article 13 process in the European Union.

6.4 Lactobacillus casei SHIROTA

Mayumi Kiwaki and Koji Nomoto Yakult Central Institute for Microbiology Research, Tokyo, Japan

Reported characters of Lactobacillus casei Shirota associated with probiotic effects are summarized in the following tables.

450

6.4.1


Effects on Intestinal Environment

Human Studies Reported Effects/Type of Study Change in fecal microbiota by continuous ingestion of fermented milk Modulation of the composition and metabolic activity of the microbiota/randomized placebo-controlled trial Decrease of the urinary mutagenicity, possible relation to the change in microbiota/comparative study Suppression of the toxic fermentation metabolites/ randomized placebo-controlled crossover study Favorable effect on nitrogen–protein metabolism/ randomized placebo-controlled crossover study Decrease of the intestinal bacterial enzyme activity in feces/randomized crossover study

References (199) (187) (133) (123) (125) (124)

Animal Experiments Reported Effects/Administration Route/Animal Enhancement of the radical scavenging activity of milk/feeding of fermented milk/hamster Effect on cecal fermentation pattern depending on indigenous microbiota/oral administration/pig Mild effect on the metabolic activity in the intestinal mucosa/oral administration/rat

6.4.2

References (167) (173) (148)

Adhesive Property

Human Studies Reported Effects Survival in transit through the gastrointestinal tract after ingestion of the fermented milk

Reference (203)

Animal Experiments Reported Effects/Administration Route/Animal Low colonization potential by long average doubling times/oral administration/mouse

References (151)


451

In Vitro Experiments Reported Effects/Target Changes in adhesive abilities by different inactivation methods/human mucus Low adhesion, no change by pretreatments of the LcS/ human intestinal mucus glycoproteins Low adherence to mucus prepared from fecal samples/ human mucus Low number but high affinity adhesion, multiple binding mechanisms/human mucus, Caco-2 cells Estimation of two types of adhesins on the surface of LcS/human cells Isolation of biosurfactants containing several collagen-binding proteins/collagen Strongly positive binding of bovine fibrinogen and porcine fibronectin/animal ECM Promoting effects of PUFA on adhesion ability/Caco-2 cell

6.4.3

References (175) (196) (139) (152) (153) (138) (187) (145)

Intestinal Physiology

Human Studies Reported Effects/Type of Study Improvement of the intestinal function in a short bowel syndrome (SBS) patient by synbiotic therapy/Case Reports Beneficial effect on gastrointestinal symptoms of patients with chronic constipation/double-blind, placebo-controlled, randomized study

References (141)

(150)

Animal Experiments Reported Effects/Administration Route/Animal Activation of the large intestine motility response to feeding/feed of fermented milk/pig Increase of the number and the diversity of indigenous Lactobacilli/feed of fermented milk/pig Transition of LcS with maximum level at cecum 6 h after dosing/feed of fermented milk/pig Effect on gene expression in the ileal epithelial cells/oral administration/mouse

References (171) (170) (174) (184)

452

6.4.4


Immunomodulation

Human Studies Reported Effects/Type of Study No effects on the immune system by ingestion of fermented milk/randomized placebo-controlled trial Increase and maintenance of elevated activity by ingestion of fermented milk IL-12 may be responsible for enhancement of NK cell activity/placebo-controlled, crossover trial Positive effect on NK-cell activity by daily intake of LcS/controlled clinical trial

References (185) (165) (192) (191)

Animal Experiments Reported Effects/Administration Route/Animal Induction of cytokines and prolonging survival of Meth A-bearing mice/i.pl. administration/mouse Effective inhibition of IgE production in serum/oral feeding of heat-killed LcS/mouse Induction of TNF-a playing an important role in the antitumor effect/i.pl. injection/mouse Raising NK activity of blood mononuclear cells and splenocytes/feed on a diet/mouse Enhanced antigen-specific humoral and cellular Th1 cell-associated immunity/oral administration/rat Suppression of IgE responses and systemic anaphylaxis in a food allergy model/i.pl. injection/mouse Suppression of the humoral and cellular immune responses to C II and reduction of the development of CIA/oral administration/mouse Immunological modulations and prolongation of the lifespan of autoimmune disease model mouse/feeding and i.p. injection/mouse Regulation of the host immune response in the IDDM model, NOD mice/oral feeding/mouse Modification of the host immune responses in NIDDM model mice/oral administration/mouse Activation of systemic and local cellular immunity against influenza virus/oral administration/mouse Varying effects on the Th1 responses among the different model/oral administration/rodent Divergent immune effects induced by timing of administration/oral administration/rodent

References (158) (163) (202) (137) (128) (183) (146)

(164)

(160) (162) (136) (117) (129)

453


In Vitro Experiments Reported Effects/Target LTAs from LcS elicit strong TNF-a-inducing activities in macrophages/mouse cells Patterns of cytokine induction of LcS and Gram-negative probiotic strain/mouse cell line Induction of cytokines and augmentation of NK cell activity/human PBMNC Inhibition of antigen-induced IgE production through induction of IL-12/mouse splenocytes Activation of X-irr-Spl followed by IL-12 secretion and stimulation of IFN-g/mouse splenocytes Stimulation of macrophages to induce IL-12 by rigid cell wall structure/mouse peritoneal macrophages

6.4.5

References (156) (122) (182) (181) (147) (180)

Effects on Cancer

Human Studies Reported Effects/Type of Study Safe and effective prevention of recurrence of superficial bladder cancer by oral administration of BLP/randomized, controlled double-blind trial Habitual intake of LcS reduces the risk of bladder cancer/case-control study

References (116) (172)

Animal Experiments Reported Effects/Administration Route/Animal

References

Potent and safe therapeutic effects in the bladder tumors implantation model/intravesical instillation/mouse Inhibition of MC-induced tumorigenesis, modulation of the host immune response, enhancement of NK cell cytotoxicity/feed on a diet/mouse Preventive effect against chemically induced colon carcinogenesis/oral administration/rat Suppressive effects on the incidence of thymic lymphoma/i.p. administration/mouse Induction of TNF-a playing an important role in the antitumor effect/i.pl. injection/mouse

(190) (188, 189) (200) (198) (202)

In Vitro Experiments Reported Effects/Target

Reference

Induction of cytotoxic effects in bladder cancer cells primarily via necrosis/human cells

(178)

454

6.4.6


Prevention of Infectious Diseases

Animal Experiments Reported Effects/Administration Route/Animal

References

Protective activity on a novel mouse model of abdominal sepsis/i.p. pretreatment/mouse Enhancement of the local immune responses to STEC cells and Stxs leading to elimination of STEC from intestine/feeding of fermented milk/rabbit A heat-killed preparation of LcS exerted significant antimicrobial effects in a UTI model/intraurethrally administration/mouse Enhancement of host resistance against oral Listeria monocytogenes infection, increased cell-mediated immunity, enhancement of cell-mediated immunological memory/oral administration/rodent Enhancement of cellular immunity in the respiratory tract and protection against IFV infection/intranasal administration/mouse Activation of systemic and local cellular immunity, or immature immune system, amelioration of or protection against IFV infection/oral administration/mouse

(194) (168)

(114) (126, 127)

(135)

(136, 201)

In Vitro Experiments Reported Effects/Target Competition with, exclusion and displacement of pathogenic GI bacteria/human intestinal mucus glycoprotein and Caco-2 cell Bactericidal effect depending on its lactic acid production and pH reductive effect/STEC O157:H7 Inhibition of S. typhimurium adhesion to human intestinal mucus/human intestinal glycoproteins Decrease in the viability of Salmonella due to non-lactic acid molecule(s) in the CFCS/Salmonella enterica serovar typhimurium Antibacterial activity towards Salmonella solely due to the production of lactic acid/Salmonella enterica serovar typhimurium

6.4.7

References (154) (169) (195) (130) (155)

Prevention of Life Style Diseases

Human Studies Reported Effects/Type of Study Lex lowered the blood pressure and showed beneficial effects on glucose and lipid metabolism in patients with hypertension/double-blind, placebo-controlled study

Reference (166)


455

Animal Experiments Reported Effects/Administration Route/Animal Blood pressure-lowering effect of heat extract from LcS/oral administration/rat Purification of SG-1, the most effective antihypertensive compounds in Lex/oral administration/rat Antihypertensive effect of SG-1 resulted from an enhancement of PGI2 biosynthesis and decrease in PR/oral administration/mouse Effective reduction of the onset of AXN-induced diabetes/feeding or oral administration/mouse Effective inhibition of the onset of diabetes in an IDDM model/oral feeding of heat-killed cell/mouse Significant decrease in plasma glucose level in an NIDDM model/feeding or oral administration/mouse Decrease in serum cholesterol levels by feeding of the cell wall components/oral administration/rat Suppression of the plasma triglyceride level without lowering the plasma cholesterol concentration/feeding of fermented milk/hamster

6.4.8

References (132) (177) (131) (159) (160) (162) (121) (149)

Clinical Application

Human Studies Reported Effects/Type of Study Reduction of postoperative infections in biliary cancer patients by synbiotics administration/randomized controlled trial Beneficial effect on gastrointestinal symptoms of patients with chronic constipation/double-blind, placebo-controlled, randomized study Improvement of intestinal flora and increase of SCFA in short bowel patients with refractory enterocolitis/synbiotic therapy Non-significant trend towards a suppressive effect on H. pylori by frequent consumption of a fermented milk drink/randomized controlled intervention study Increase in a frequency of eradication of H. pylori by combination with traditional triple treatment/clinical comparative randomized study Improvement of spasticity and urinary symptoms in patients with HTLV-1 associated of HAM/TSP by oral administration/uncontrolled preliminary trial Delay on the occurrence of allergic symptoms induced by JCP/randomized double-blind, placebo-controlled study Reconstruction of microflora by synbiotic therapy in a infant with MASA enterocolitis after vancomycin treatment/Case Reports Beneficial effect on intestinal function of a pediatric patient with LTEC by synbiotic therapy/Case Reports Improvement of the intestinal function in a girl with SBS by synbiotics therapy/Case Reports Prompt and dramatic improvement in sodium balance in a child with SBS/Case Reports

References (144) (150) (143) (120)

(176) (161) (193) (140) (142) (141) (119)

456


Animal Experiments Reported Effects/Administration Route/Animal Reduction of H. pylori colonization, a significant decline in gastric mucosal inflammation/administration in the water/mouse Improvement in murine chronic IBD, reduction of IL-6 synthesis by LI-LPMC/feed on a diet/mouse No prevention of the ulcerative colitis induction by DSS, improvement of the clinical parameters/feeding via intragastric tube/mouse

References (179) (157) (134)

In Vitro Experiments Reported Effects/Target

References

Reduction of the number of bacteria and yeasts in oropharyngeal biofilms on voice prostheses after perfusion of fermented milk or suspension of LcS/biofilm bacteria

(118, 197)

6.4.9

Safety Assessment

Human Studies Reported Effects/Type of Study Clinical safety assessment by bacteriologic surveillance suggesting that the use of LcS as a probiotic in enterally fed CIC is safe/randomized controlled trial

Reference (186)

Animal Experiments Reported Effects/Administration Route/Animal No infectivity in a rabbit IE model/intravenous injection/rabbit Aggravation of EAE observed in Lewis rats/oral administration/rodent Significant increase in the duration of clinical symptoms of EAE and exacerbated lung inflammation by early administration during lactation/oral administration/rodent

Abbreviations AXN BCG BLP C II CFCS CIA CIC DSS

Alloxan Bacillus Calmette-Guerin Lactobacillus casei preparation Type II collagen Cell-free culture supernatants Type II collagen-induced arthritis Critically ill children Dextran sodium sulphate

References (115) (117) (129)

Lactobacillus gasseri OLL2716 (LG21)

EAE ECM GI HAM/TSP HTLV-1 i.p. i.pl. IBD IDDM IE IFN IFV Ig IL JCP LcS Lex LI-LPMC LLNA LTAs LTEC MASA MC NIDDM NK NOD PBMNC PR PUFA SG-1 SCFA STEC Stxs TNF UTI X-irr-Spl

457

Experimental autoimmune encephalomyelitis Extracellular matrix Gastrointestinal HTLV-1-associated myelopathy/tropical spastic paraparesis Human T-cell lymphotropic virus type-1 intraperioneal Intrapleural Inflammatory bowel disease Insulin-dependent diabetes mellitus Infective endocarditis Interferon Influenza virus Immunoglobulin Interleukin Japanese cedar pollen Lactobacillus casei strain Shirota Extract of autologous Lactobacillus casei cell lysate Large intestinal lamina propria mononuclear cells Local Lymph Node Assay Lipoteichoic acids laryngotracheo-esophageal cleft methicillin-resistant Staphylococcus aureus 3-methylcholanthrene Non-insulin-dependent diabetes mellitus Natural killer Nonobese diabetic Peripheral blood mononuclear cells Peripheral vascular resistance Polyunsaturated fatty acids Polysaccharide-glycopeptide complex from LcS Short chain fatty acids Shiga toxin-producing Escherichia coli Shiga toxins Tumor necrosis factor Urinary tract infection X-ray-irradiated splenocytes

6.5 Lactobacillus gasseri OLL2716 (LG21)

Katsunori Kimura Food Science Institute, Division of Research and Development, Meiji Dairies Corporation, Japan

The evidence of a relationship between Helicobacter pylori and gastric diseases has gradually become clear since Warren and Marshall succeeded in cultivating this

458


bacterium in 1982. Since the infection rate of H. pylori is very high, about 50% in Japanese, it is difficult to eradicate H. pylori in all the infected people. The eradication therapy using antibiotics is often accompanied by side effects and is not always successful because of antibiotic-resistant strains. Moreover, the number of antibioticresistant strains has recently been increasing (208, 210). Probiotics have been proposed as safe and simple alternatives to antibiotic therapy for H. pylori infection (204, 207). In order to select a strain that exhibited excellent anti-H. pylori activities, we screened 203 Latobacillus strains in in vitro assays and animal studies and selected Lactobacillus gasseri OLL2716 (LG21) as the most suitable strain for use as a probiotic for H. pylori infection. We examined the efficacy of LG21 against H. pylori infection in humans. 6.5.1

Helicobacter pylori

H. pylori is a spiral Gram-negative bacterium with some unipolar flagella. This bacterium displays strong urease activity, and thus can catalyze urea in stomach to ammonia and carbon dioxide. Because of this ammonia production, H. pylori can survive strong acidic conditions. H. pylori inhabits the human stomach and can cause chronic inflammation and ulcers in the stomach and duodenum. H. pylori has also been identified as a risk factor for stomach cancer (213). 6.5.2

Selection of a Probiotic for H. pylori Infection

We selected Lactobacillus gasseri OLL2716 (LG21), Lactobacillus gasseri No. 6 and Lactobacillus salivarius WB1004 by screening 203 Lactobacillus strains for in vitro anti-H. pylori abilities such as resistance to gastric juice, proliferation under acidic conditions, adherence to cultured gastric epithelial cells, and suppression of H. pylori during cofermentation. Following these in vitro experiments, the effects of administration of the selected three Lactobacillus strains on H. pylori-infected mice were examined. In a study using H. pylori-infected mice, orally administered LG21 and L. salivarius WB1004 eradicated H. pylori in mice, and the anti-H. pylori IgG levels of the LG21 administered mice were found to be the lowest (209, Fig. 6.1). Therefore LG21 was selected as the most suitable strain for use as a probiotic for H. pylori infection. LG21 is a Gram-positive rod, which was isolated from a healthy human (Fig. 6.2). LG21 was also found to act as a probiotic for clarithromycin-resistant H. pylori infection in mice (214). 6.5.3

Effects of LG21 on H. pylori Infection in Humans

The effects of yogurt containing LG21 on H. pylori infection in humans were examined (211). Thirty-one subjects infected with H. pylori ingested 90 g of normal yogurt containing no LG21 twice daily for 8 weeks. This 8-week period was followed

6 5 4 3 2 1

ND

ND

0 control

FIGURE 6.1

WB1004

No.6

LG21

Anti-H. pylori antibodies [absorbance:492nm]

Number of H. pylori (Log10cfu/g tissue)

Lactobacillus gasseri OLL2716 (LG21)

459

0.8 0.7 0.6 0.5 0.4 0.3 0.2 0.1 0 control

WB1004

No.6

LG21

Effects of administration of LG21 on H. pylori infected mice 8 weeks, n ¼ 5.

by a 1-week period without yogurt ingestion. This in turn was followed by an 8-week period during which the subjects ingested 90 g of yogurt containing 109 cfu of LG21 twice daily. The urea breath test and assays of serum pepsinogen I/II ratios were performed to measure the population of H. pylori and to evaluate the degree of mucosal inflammation in the stomach at three points, respectively: prior to ingestion of yogurt, after the first 8-week period, and after the second 8-week period. In addition gastric biopsy specimens were taken from six subjects for quantitative culture both before and after ingestion of LG21 yogurt. The D13 C value for the urea breath test did not significantly change after ingestion of normal yogurt, but did significantly decrease following ingestion of LG21 yogurt (Fig. 6.3). The serum pepsinogen I/II ratio did not significantly change after ingestion of normal yogurt, but did significantly increase following ingestion of LG21 yogurt (Fig. 6.4). The number of H. pylori in the gastric

FIGURE 6.2

Lactobacillus gasseri OLL2716 (LG21).

460


NS 45

p74% of solids Powder, >95% lactulose

MLC-A Duphalac Cephulac

Nyuka-Origo LS-40L Nyuka-Origo LS-55L Nyuka-Origo LS-55P Pet-Oligo L55 Pet-Oligo P55 Newka-Oligo LS-35 Newka-Oligo LS-55L Newka-Oligo LS-55P

Syrup containing 72% (w/v) solids Lactosucrose 42% of solids Syrup containing 75% (w/v) solids Lactosucrose 55% of solids Powder, 55% lactosucrose Syrup containing 75% (w/v) solids Lactosucrose 57% of solids Powder, 45% lactosucrose Syrup containing 72% (w/v) solids Lactosucrose 35% of solids Syrup containing 75% (w/v) solids Lactosucrose 55% of solids Powder, 55% lactosucrose

LACTY

Lactitol powder 96%

Lactitol Finlac DC

Milled and crystalline powders Compressible form for tablets

PRODUCTION OF PREBIOTICS

TABLE 7.4

543

(Continued)

Company Names and Addresses

Product Names

Transfructosylation Fructooligosaccharides Meiji Seika Kaisha, Japan; Meioligo P www.meiji.co.jp Meioligo G Beghin-Meiji Industries, France; www.beghin-say.fr Golden Technologies Co., GTC Nutrition, USA; www.nutraflora.com Cheil Foods and Chemicals, C.P.O Box 1155, Seoul, Korea

Actilight P Actilight G Actisucre NutraFlora scFOS

Oligo-sugar (syrup) Oligo-sugar (powder)

Inulin Fructooligosaccharides and Inulin Beneo-ORAFTI, Belgium; Orafti L60 www.beneo.orafti.com Orafti L85 Orafti L95 Orafti P95 Orafti Synergy1

Cosucra SA, Belgium; www.cosucra.com

Sensus C.V.,The Netherlands; www.sensus.nl Isomaltooligosaccharides Showa Sangyo Co., Japan; www.showa-sangyo.co.jp

Orafti ST Orafti GR Orafti HP Orafti HP-Gel Fibrulose F90 and F97 Fibruline standard Fibruline instant Fibruline long chain Frutafit –inulin

Isomalto-500 Isomalto-900 Isomalto-900P

Product Description Powder, 95% oligosaccharides Syrup containing 75% (w/v) solids Oligosaccharides 55% of solids Powder, 95% oligosaccharides Syrup containing 75% (w/v) solids Oligosaccharides 55% of solids Powder, 95% oligosaccharides

Syrup containing 70% (w/v) solids Oligosaccharides 60% of solids Powder, 23% oligosaccharides (animal feed) Syrup containing 75% (w/v) solids Oligosaccharides >60% of solids Syrup containing 75% (w/v) solids Oligosaccharides >85% of solids Syrup containing 75% (w/v) solids Oligosaccharides >95% of solids Powder, >95% oligosaccharides Powder, mix of oligofructose and inulin Powder inulin >90% Granulated powder – inulin >90% Powder–inulin >99.5% Instant powder–inulin >99.5% Fructooligosaccharides Inulins

White powder from chicory plants

Syrup containing 75% (w/v) solids Oligosaccharides > 50% of solids Syrup containing 75% (w/v) syrup Oligosaccharides >85% of solids Powder, >85% oligosaccharides (continued)

544

PREBIOTICS

TABLE 7.4

(Continued)

Company Names and Addresses

Product Names

Nihon Shokuhin Kako Co., (Japan Maize Products), Japan; www.nisshoku.co.jp

Biotose #50

Hayashibara Shoji Inc., Japan; www.hayashibara.co.jp

Panorup

Panorich

Product Description Syrup containing 75% (w/v) solids Oligosaccharides > 50% of solids Syrup containing 75% (w/v) solids Oligosaccharides 50% of solids including 25% panose Syrup containing 74% (w/v) solids Oligosaccharides 50% of solids including 25% panose

Soybean-oligosaccharides The Calpis Food Industry, Co. Japan; www.calpis.net

Soya-oligo

Syrup containing 75% (w/v) solids Soybean oligosaccharides 35% of solids

Xylooligosaccharides Suntory Ltd, Japan; www. suntory.com

Xylo-oligo 70

Syrup containing 75% (w/v) solids Oligosaccharides 70% of solids Powder, 20% oligosaccharides Powder, 35% oligosaccharides Powder, 95% oligosaccharides

Xylo-oligo 20P Xylo-oligo 35P Xylo-oligo 95P Resistant Starches Penford Australia Ltd, Australia; www.penford.com

National Chemical & Starch Company, USA; www.nationalstarch.com

Hi-Maize Culture-Pro

Hylon VII Novelose 330 Novelose 240

High amylose maize starches Modified resistant starches with different prebiotic properties also available High amylase (70%) corn starch (a RS2 type granular starch) From maize; a RS3 type(nongranular, retrograded starch) Higher dietary fiber type of resistant starch

FOS produced by the controlled hydrolysis of inulin contain a wider range of b-1 ! 2 fructooligosaccharide sizes (dp 2–9), relatively few of which possess a terminal glucose residue. Even different b-galactosidases used in the production of GOS will produce oligosaccharide mixtures with different proportions of b-1 ! 4 and b-1 ! 6 linkages. Hence, there can be some diversity between the structures of oligosaccharides produced by different manufacturers. The precise impact of these differences in their health effects remains to be determined. Some differences have been observed in the ability of lactobacilli and bifidobacteria to use oligosaccharides of different degrees of polymerization (100, 101), which has also translated to different bifidogenic potencies in vivo (41, 51).

545

FIGURE 7.2 Commercial fructooligosaccharide production via transfructosylation of sucrose. Following the enzymatic reaction, the reaction mixture contains 50–60% oligosaccharides. Chromatographic processes are used to remove monosaccharides and unreacted sucrose to produce higher purity oligosaccharides.

546

PREBIOTICS

7.6 PREBIOTIC MECHANISMS The molecular structure of the prebiotic can be expected to determine physiological effects and which microbial species are able to utilize it as a carbon and energy source in the bowel. However, despite the diversity in molecular sizes, sugar compositions, and structural linkages within the range of prebiotic carbohydrates, it is the bifidobacteria that are almost universally observed to respond. How prebiotics promote the relatively specific proliferation of bifidobacteria within the intestinal microbiota remains speculative, but the following points provide some insights. . . .

. .

Bifidobacteria possess the metabolic machinery to utilize a wide variety of oligosaccharides and complex carbohydrates as carbon and energy sources (102). Bifidobacteria grow well on many NDOs in comparison to putrefactive or potentially pathogenic bacterial species in the gut (76, 103–105). Although other intestinal genera (e.g. lactobacilli (100, 106–108), bacteriodes (109), and eubacteria (110)) can grow in vitro using prebiotic carbohydrates, bifidobacteria appear to grow more efficiently. Bifidobacteria are tolerant to the resulting production of short chain fatty acids (SCFA) and acidification of the intestinal environment. Bifidobacteria generally do not hydrolyze NDOs extracellularly, but possess permeases to internalize these substrates before hydrolyzing and metabolizing them (111, 112). This presumably minimizes the availability of released simple sugars for cross-feeding by other intestinal bacteria.

7.7 MODULATING THE INTESTINAL MICROBIOTA IN INFANTS 7.7.1

Breast Milk

The composition of the human intestinal microbiota changes naturally with age, and in early infancy the microbiota is believed to be particularly important in correct functioning of the gut and maturation of the immune system. Bifidobacteria colonize the human intestinal tract during or soon after birth and in breast-fed infants they eventually dominate the microbiota (113). The numerical dominance of bifidobacteria is induced by bifidogenic components in breast milk, including oligosaccharides (113, 114). Indeed, human milk oligosaccharides (HMOs) are the original prebiotics. The concentration of HMOs in breast milk (5–12 g/L) is about 100 times than that found in cow’s milk (0.03–0.06 g/L) (115, 116) representing the third largest solid component behind lactose and fat (117). The fact that mothers direct so much energy toward components of breast milk that are not directly metabolized by the infant, but rather selectively modulate the composition of the microbiota, shows evolutionarily just how important the infant gut microbiota is to well-being.

MODULATING THE INTESTINAL MICROBIOTA IN INFANTS

7.7.2

547

Infant Milk Formulas

In contrast to breast-fed infants, infants fed traditional cow’s milk-based formulas develop a more mixed intestinal microbiota, with lower counts of bifidobacteria and higher counts of clostridia and enterococci (118). Formula-fed infants have also been observed to have higher levels of fecal ammonia and other potentially harmful bacterial products (119, 120). The bifidogenic effect of HMO can be emulated using oligosaccharides such as GOS and FOS. GOS share some structural similarities with the backbone of HMOs, although HMOs are considerably more complex. Over 200 different HMO structures have been identified. They are based on the combinations of glucose, galactose, sialic acid, fucose and/or N-acetylglucosamine, with varied sizes and linkages accounting for the considerable variety (115). In recent years, a number of studies have investigated the effect of infant formula containing 8 g/L of a mixture of 9:1 GOS:FOS designed to mimic the molecular size distribution of HMOs (121). Table 7.5 shows formulae supplemented with the GOS:FOS can mimic many of the physiological impacts of HMOs. Although the bifidogenic effect of HMOs can be emulated using FOS and GOS, there is increasing evidence for roles of HMOs outside their bifidogenic impact in the gut. These include blocking adhesion of pathogens to the intestinal mucosa (131–133) and roles in developing cognition (134). Hence, N-acetylneuraminic acid derivatives or sialyl-lactose are also commonly added to infant milk formulae. The complexity of HMOs has thwarted attempts to synthesize their full range of structures commercially, although specific oligosaccharides have been synthesized using chemical and biotechnological approaches (135–138). There is a ready market in infant milk formulas

TABLE 7.5 Infant Formulae Containing Prebiotics Mimic Many of the Impacts of Breast Milk on the Infant Intestinal Microbiota Traditional cow’s milk-based infant formula

Cow’s milk-based infant formula supplemented with 8 g/L of a 9:1 mixture of GOS/FOS

Contains little or no nondigestible oligosaccharides (115) Stimulates a diverse, adult-like intestinal microbiota (118) Adult-like Bifidobacterium and Lactobacillus species composition (123, 124) Adult-like composition of SCFA in stools high in butyrate and propionate and higher pH (121, 125–127) Reduced stool frequency and firmer stool consistency (125, 128–130) Lower levels of protective secretory IgA in the gut (127)

Contains nondigestible oligosaccharides in similar quantity to human breast milk (116) Stimulates an intestinal microbiota dominated by bifidobacteria (121, 122) Bifidobacterium and Lactobacillus species composition similar to breast-fed infants (123, 124) Breast-fed infant-like composition of SCFA high in acetate and more acidic stools (121, 125–127)

Breast-fed infant-like, higher stool frequency and softer consistency (125, 128–130) Increased levels of protective secretory IgA in the gut (127)

548

PREBIOTICS

for oligosaccharides that more closely replicate all of the properties of HMOs, and research to synthesize them will no doubt continue. 7.8 MODULATING THE INTESTINAL MICROBIOTA IN ADULTS Following weaning, the composition of the colonic microbiota becomes increasingly complex. In adulthood, the microbiota consists of more than 500 different species, though is dominated by 30–40 of them, and its composition becomes quite stable (1). Bifidobacteria remain numerically important, though their proportion of total microbes declines from 60 to 80% in breast-fed infants to 1–5% in adults. In the feces of healthy adults, bifidobacteria are found in numbers generally in the order of 108–1010 cells/g (31, 34, 139–141). While these figures represent the typical Bifidobacterium cell density, a proportion of healthy adults harbor considerably lower numbers of Bifidobacteria in their gut (by several orders of magnitude) without any discernable adverse effects (31, 142–144). It is yet to be determined how the total number of bifidobacteria within a stable microbiota influences the long-term health of the human host. 7.8.1

Effects at the Genus Level

Feeding prebiotics to adults typically induces 10–100-fold increases in the size of the intestinal Bifidobacterium population during the feeding period (12). However, a range of factors may influence the magnitude of any increase in Bifidobacterium numbers, the most important being the initial size of the population within the intestinal tract. In individuals colonized with an already large population of bifidobacteria (in the order of 108 cfu/g in feces) prebiotic consumption appears not to increase Bifidobacterium numbers further (58, 145). Lactobacilli have often been noted to proliferate upon feeding various prebiotics, particularly in feeding studies with lactulose and galactooligosaccharides. The rise in beneficial bacterial populations during prebiotic feeding has often been shown to be accompanied by concomitant reductions in the numbers of putrefactive organisms such as clostridia and Bacteriodes spp. and Enterobacteriaceae (14, 52, 56, 57, 61, 83). The changes in population dynamics appear to persist only while the prebiotics are being consumed. The bacterial populations at the genus level tend to revert to prefeeding levels over a period of days once prebiotic consumption ceases (49, 60, 73). 7.8.2

Effects at the Species Level

B. adolescentis, B. catenulatum/pseudocatenulatum, B. bifidum, and B. longum are the most frequently reported Bifidobacterium species in the intestines of adults, with considerable variation between individuals (31, 142, 146–148). To date, no clear rationale for promoting one species of Bifidobacterium over others has

HEALTH EFFECTS AND APPLICATIONS OF PREBIOTICS

549

emerged. Indeed, it may be quite difficult to achieve major shifts within the population dynamic of bifidobacteria at the species level even if this was desirable. Studies that monitored the species composition of bifidobacteria during and after prebiotic feeding using GOS (21, 149, 150), inulin (48), and raffinose (80) have shown that the prebiotics did not substantially alter the relative proportions of Bifidobacterium species present. The species composition within intestinal bifidobacteria has been shown to remain fairly stable over many months in adults (27, 28, 30, 31, 139) suggesting that day-to-day fluctuations in normal diets have little impact on the species dynamic. 7.8.3

Altering the Physiology of the Microbiota

Physiological changes to bacterial metabolism rather than phylogenic changes to microbiota composition may be more important for many health effects. Examples include increased production of SCFA or vitamins that benefit the health of the colonic epithelium, or synthesis of antagonistic metabolites that augment colonization resistance against pathogens. Tannock et al. (29) used molecular techniques to show that feeding low levels of GOS or FOS could induce changes in relative gene expression with no discernable changes in population dynamics. The fermentation of different prebiotics by the consortia of gut bacteria can yield different profiles of SCFA. Generally, small, rapidly fermented prebiotics yield more acetate and lactate, while more slowly fermentable prebiotics tend to yield butyrate as a major end product (101, 151–155). 7.9 MODIFYING THE INTESTINAL MICROBIOTA IN THE ELDERLY Early studies using culture methods showed that Bifidobacterium levels substantially decreased as a proportion of the total fecal microbiota in the elderly Japanese, while the numbers of putrefactive bacteria such as clostridia increased (155). This suggests that prebiotics may benefit the elderly by restoring the Bifidobacterium populations while reducing the levels of deleterious bacteria. More recent studies using molecular techniques have confirmed that some elderly subjects do indeed have reduced levels of bifidobacteria, but this is not generally the case (156–158). It remains to be seen if increasing Bifidobacterium levels in elderly subjects can lead to improved health. 7.10 HEALTH EFFECTS AND APPLICATIONS OF PREBIOTICS Prebiotics have physicochemical and organoleptic properties that make them useful food ingredients. For example, NDOs are sweet and are used as low-cariogenic and low-calorific sugar substitutes, while polysaccharides such as inulin are used as fat replacers. Their indigestibility and subsequent reduced impact on glucose and insulin

550

PREBIOTICS

responses also make them suitable for diabetics. In terms of food technology, NDOs supply a number of valuable physicochemical functionalities. They can be used to increase viscosity, reduce Malliard reactions, alter water retention, depress freezing points, and suppress crystal formation (159). Hence, they are used commercially in a wide variety of foods and beverages. A number of largely prophylactic health targets have been proposed for prebiotics. As might be expected, these overlap considerably with the targets of probiotic interventions. Some effects have therapeutic value for specific disorders while others are potentially beneficial to the population at large. Hence, prebiotics have found applications both as pharmaceuticals and as functional food ingredients. 7.10.1

Laxatives

Lactulose is widely used as a pharmaceutical to treat constipation. It has proven efficacy in a number of placebo-controlled trials at doses between 10 and 20 g/day (160, 161) even in patients with chronic constipation. The effect is not caused by modifications to the composition of the intestinal microbiota. Rather, since it is a relatively small molecule that is not digested or absorbed, lactulose has an osmotic effect, trapping fluid, accelerating transit in the small bowel, and increasing ileocecal flow. Its rapid fermentation to SCFA and hydrogen also contributes to this effect and induces peristalsis (162). A number of other NDOs, such as inulin has been shown to mildly improve stool frequency and consistency in adults (163–167) although their applications are targeted towards functional foods rather than pharmaceutical applications. 7.10.2

Hepatic Encephalopathy

Lactulose (and lactitol) are also front-line therapeutic agents for the treatment of hepatic encephalopathy (HE). This neuropsychiatric condition results from liver dysfunction caused by cirrhosis or hepatitis. It includes a spectrum of symptoms ranging from subtle changes in cognition and personality to lethargy, stupor, and coma (168). A dysfunctional liver is unable to clear ammonia from the blood stream, which then accumulates to levels toxic to the central nervous system. The ammonia is produced by the intestinal microbiota as an end product of protein metabolism, and ammonia readily crosses the intestinal epithelium to enter circulation. Lactulose and lactitol act by limiting both ammonia production by the microbiota and the absorption of ammonia from the intestinal lumen (168, 169). Acidification of the colonic lumen resulting from SCFA production inhibits urease positive and deaminating bacteria (implicated in intestinal ammonia production) and importantly leads to the protonation of ammonia to ammonium ions in the intestinal lumen. Ammonium ions cannot readily cross the intestinal epithelium, and so the drop in pH effectively traps ammonia in the lumen. Lactulose and lactitol have similar efficacy, although lactitol is more palatable and produces more rapid results with fewer side effects (168). However, to be effective lactulose and lactitol are delivered in high doses (30–60 g/day). This of course has a large laxative effect, causing significant discomfort. Therefore, there is an


551

interest in using larger NDOs and soluble fibers that ferment rapidly, but with less osmotic effect in the gut. 7.10.3

Primary Prevention of Allergy in Infants

There is accumulating evidence that early colonization of the intestinal tract by an appropriate intestinal microbiota is important for the healthy maturation of the immune system, including appropriate programming of oral tolerance to dietary antigens (170, 171). Additionally, differences in certain bacterial populations within the intestinal tract have been noted between allergic and nonallergic infants (172). These include differences within the genus Bifidobacterium, which is found in lower numbers in the feces of allergic infants (173–179) and with a more adult-like species composition dominated by B. adolescentis (180, 181) rather than the usual species associated with the infant intestine such as B. bifidum, B. breve, and B. longum (¼ B. infantis) (142, 182). Hence, dietary interventions to augment the intestinal microbiota of infants have been explored as a means of decreasing allergic disease. In allergies, the immune response at the T cell level is skewed towards T helper type 2 cells (Th2) that signal the production of allergenic antibodies of the immunoglobulin E (IgE) class. It is believed that allergies can be prevented by inducing a counterbalancing T helper type 1 (Th1) cell response, and/or by the induction of regulatory T cells (T reg) that produce cytokines such as interleukin-10 (IL-10) and transforming growth factor-beta (TGF- b) that are involved in tolerance and suppress inflammation. Studies in animals demonstrated that feeding probiotics could redress Th1/Th2 imbalances, induce regulatory T cell activity, and reduce the development of allergy (183–185). In humans, a number of randomized controlled trials have shown a preventative effect of probiotic feeding on the development and severity of atopic dermatitis in infants (177, 186–190) although not all probiotic strains and trials have proven beneficial (191–195). Positive effects from using probiotics stimulated interest in determining if similar effects could be achieved with prebiotics. A number of animal feeding studies with NDOs have shown that prebiotics can induce Th1 immune responses, re-balance Th2biased immune responses and suppress allergenic IgE synthesis (Table 7.6). Primary prevention of atopic dermatitis in infants genetically at risk of atopic disease has now been reported in randomized controlled trials using a GOS:FOS mixture and a synbiotic combination including GOS (Table 1.6). These results indicate that prebiotics may be able to replicate the benefits seen for probiotics in allergy prevention. 7.10.4

Amelioration of Inflammatory Bowel Disease

Inflammatory bowel disease (IBD) describes a group of chronic, severe and relapsing inflammatory conditions of the gut that includes Crohn’s disease, ulcerative colitis, and pouchitis. The precise etiology of IBD remains unknown. However, there is accumulating evidence that a genetic predisposition to develop an overzealous inflammatory immune response to components of the intestinal microbiota is responsible (203). The drugs that have been developed to manage IBD have mostly targeted

552

PREBIOTICS

TABLE 7.6 Prebiotic Immunomodulation on Preventing the Development of Allergies Prebiotics

Models

Effects

Raffinose

Sensitized mice

(196)

Alginate oligosaccharides

Sensitized mice

Isomaltooligosaccharides Fructooligosaccharides

Mice Sensitized mice

Pectin-oligosaccharide and GOS:FOS mixture GOS;FOS mixture

Mice vaccination model Human infants at risk of atopy (n ¼ 206) Human infants at risk of atopy (n ¼ 925)

Stimulation of Th1 cells, reduced Th2 cell activity, suppressed IgE production to allergen Stimulation of Th1 cells, reduced Th2 cell activity, suppressed IgE production to allergen Stimulation of Th1 immunity Trend to reduce Th2 cell numbers in the gut; reduced mast cell numbers and reduced allergy symptoms Enhanced Th1 response; reduced Th2 response Significant reduction in atopic dermatitis Significant reduction in atopic dermatitis

(202)

Synbiotic including four probiotic strains and GOS

References

(197)

(198) (199)

(200) (201)

suppression of the host immune response and all are associated with significant side effects when used for long periods (204). Since the microbiota is the likely source of the inflammatory stimulus, modification of the intestinal microbiota using antibiotics, probiotics, and prebiotics have all been proposed and trialed as approaches to treat IBD. However, as no specific microbial groups or antigens have been confirmed as causatives, these approaches have been empirical rather than targeted. Elimination of specific bacterial antigens, immunomodulation, and trophic effects of SCFA on the intestinal epithelium have all been proposed as mechanisms by which prebiotics could alleviate IBD. The size of the intestinal Bifidobacterium population has been shown to be relatively small in subjects afflicted with IBD (205–207). However, cause and effect links between disease and a diminished intestinal Bifidobacterium population remain to be established. Prebiotic and synbiotic interventions have ameliorated colitis in different rodent models of IBD, although not all studies have demonstrated benefit (Table 7.7). Studies in both animal models and human subjects have shown that prebiotic-induced stimulation of Bifidobacterium numbers has been associated with downregulation of inflammatory markers in intestinal mucosa (208–210) and evidence of increased immune regulation (208, 211). However, direct evidence that a change in the microbial


TABLE 7.7

Recent Prebiotic Feeding Studies Using Animal Models of IBD

Prebiotics

Models

Effects

FOS

TNBS1 rats

Amelioration of colitis Increased SCFA and LAB in the intestine Amelioration of colitis Reduction in inflammatory markers in intestinal mucosa Increased numbers of lactobacilli and bifidobacteria and SCFA production No decrease in colitis score No significant reduction in colitis Resistant starch treatment was effective in the same study Significant reduction in colitis and faster mucosal recovery Significant amelioration of colitis Significant increase in numbers of bifidobacteria

TNBS rats

DSS2 rats DSS rats

DSS rats Inulin in synbiotic combination

FOS þ inulin (Synergy 1)

Lactulose

HLA-B27-b2microglobulin transgenic rats HLA-B27-b2microglobulin transgenic rats

DSS rats TNBS rats

GOS

TNBS rats

Resistant starch

DSS rats

1 2

553

TNBS-Trinitrobenzene sulfuric acid DSS-Dextran sodium sulfate

Amelioration of colitis Reduction in inflammatory markers in intestinal mucosa Increase in markers of immune regulation Increased numbers of lactobacilli and bifidobacteria Dose-dependant amelioration of colitis Decreased colonic inflammation and inflammatory cytokines Increased numbers of bifidobacteria and lactobacilli Increased colonic levels of bifidobacteria, but no attenuation of inflammation Significant amelioration of colitis Increased luminal SCFA concentrations FOS treatment was ineffective in the same study

References (212)

(210)

(213) (214)

(215) (203)

(208)

(216) (217)

(218)

(214)

554

PREBIOTICS

TABLE 7.8 Human StudiesUsing Prebiotic or Synbiotic TreatmentstoAmeliorate IBD

Pouchitis

Ulcerative colitis

Study Design

Result

Small, open label study n ¼ 10 with active disease Synbiotic combination of Lactobacillus rhamnosus GG and FOS Small, randomized, double-blind, crossover study n ¼ 20 with active disease Inulin

Complete clinical and endoscopic remission

(219)

Reduction in mucosal inflammation, accompanied by a reduced concentration of Bacteroides fragilis, increased butyrate concentrations and lowered pH, but no effect on the numbers of lactobacilli or bifidobacteria. Trend toward reduced inflammation Improved regeneration of epithelial tissue. A decrease in mucosal proinflammatory cytokines was associated with an increase in the numbers of mucosal-associated bifidobacteria Significant reduction in clinical activity and mucosal inflammation Increased numbers of fecal bifidobacteria and increased fecal butyrate concentration Significant reduction in clinical disease score Increased number of both fecal and mucosa-associated bifidobacteria in patients entering remission Enhanced immunoregulatory response (increased proportion of IL-10-positive mucosal dendritic cells)

(220)

Randomized controlled trial n ¼ 18 with active disease Synbiotic combination of Synergy 1 (FOS þ inulin)

Open labeled, controlled trial n ¼ 18 with active disease Fermented barley feed (rich in arabinoxylan) Crohn’s disease

Open label trial n ¼ 10 with moderately active disease FOS

References

(207, 209)

(221, 222)

(211)

antigen population within the microbiota leads to reduced inflammation with increased immune regulation remains to be established. Only a few pilot human studies have been reported using prebiotics or synbiotics to treat IBD (Table 7.8). The results of these trials suggest that prebiotics have at least

555


some potential to induce remission in patients with active IBD. The use of prebiotics to extend or maintain remission in IBD has been scantly explored, but studies reporting promising results using probiotics (see review by Hedin et al. (204)) indicate that the maintenance of remission would be a worthy target for prebiotics. Overall, there are enough encouraging indications that prebiotics could be beneficial in the treatment of IBD to warrant further exploration of efficacy and mechanisms in large, randomized, controlled trials. 7.10.5

Prevention of Infections

Studies in which animals have been challenged with enteric pathogens have indicated that prebiotics have some potential in preventing intestinal infections (Table 7.9). In addition to direct antagonism of pathogens, a number of animal studies have indicated that prebiotics can enhance protective immune responses (223). These include stimulation of secretory immunoglobulin A (sIgA) production in the gut (198), improved humoral antibody responses (224) and enhanced Th1-dependent immune responses (198, 200). Prebiotic oligosaccharides may provide protection against enteric infections through competitive inhibition of pathogen adherence to the mucosa. Many intestinal pathogens, such as Escherichia coli, Salmonellae and Campylobacters utilize oligosaccharide receptor sites in the gut for attachment (225). NDOs can act as structural mimics of the pathogen binding sites and act as soluble decoys. Human milk oligosaccharides act in this way to block the initial binding of a range of pathogens to inhibit colonization (225–227). In vitro experiments using epithelial cell culture models (227, 228) have shown that GOS and lactulose have the ability to interfere with the adhesion of enteropathogenic E. coli. The efficacy of prebiotics in preventing infections in human studies has been mixed. Lactulose consumption at high dose (up to 60 g/day) is effective in eliminating salmonella from the intestinal tract of chronic human carriers and it is used as a pharmaceutical for this purpose in some countries (232). Several small human trials TABLE 7.9 Ingestion

Animal Pathogen Challenge Studies Showing Benefits from Prebiotic

Prebiotics

Models

Results

Lactulose

Rats with obstructive jaundice

(229)

Lactulose

Rats challenged with the invasive pathogen Salmonella enteriditis Puppies challenged with Salmonella typhimurium

Significantly reduced cecal overgrowth and translocation of Escherichia coli Significantly reduced translocation of the pathogen Significant attenuation of infection symptoms including loss of appetite and enterocyte sloughing

(231)

FOS and inulin

References

(230)

556

PREBIOTICS

have indicated that prebiotics or synbiotics can prevent infections in some specific circumstances (Table 7.10). Prebiotics have so far generally failed to demonstrate antiinfective effects in trials of healthy subjects likely to be exposed to a diverse range of intestinal pathogens (e.g. traveler’s diarrhea) or for antibiotic-associated diarrhea. Overall, the evidence to date suggests that prebiotics have the capacity to prevent intestinal infections in some specific cases, particularly for acid-sensitive pathogens that infect the large bowel. However, prebiotics do not represent “silver bullets” that are effective against all intestinal pathogens. Further research is required to determine which prebiotics are effective against which pathogens, at what doses, for which populations, and by what mechanisms. 7.10.6

Mineral Absorption

As for nondigestible, fermentable carbohydrates in general, a number of prebiotics have been shown to increase mineral absorption. The precise mechanisms of prebioticmediated improvements in mineral uptake remain unclear, but fermentative activities of the microbiota are believed to be involved (239, 240). Bifidogenic effects, although evident, are probably not relevant. Calcium and magnesium are the main minerals for which uptake is improved. In rats, increased calcium uptake has led to improved bone mineralization for animals fed GOS (241), FOS (242–245), lactulose (246), and resistant starch (247, 248). A number of small, randomized, and controlled human studies have confirmed the beneficial impact of prebiotic consumption on mineral absorption, particularly for calcium. Positive results have been reported for fructans (recently reviewed by Frank (249)), other NDOs (239), and resistant starch (154). Increased calcium absorption stimulated by prebiotics has further been demonstrated to improve markers of bone health in humans (250, 251). Under normal circumstances dietary calcium is predominately absorbed in the small intestine with little calcium absorbed in the colon (252). However, prebiotic fermentation is believed to extend calcium uptake into the colon (43, 249). Sustainable fermentation in the gut appears to be important. Animal and human studies comparing prebiotics of differing chain lengths, fermentation patterns, and doses have shown that higher doses and more persistent fermentation profiles are more effective (42, 242, 253–256). The encouraging results seen in animal and human studies suggest that there is good potential for prebiotics to improve calcium and magnesium absorption from the gut and to improve bone health. Further research is warranted to investigate links between long-term prebiotic consumption and improved bone density in humans at risk of developing osteoporosis. 7.10.7

Prevention of Colorectal Cancer

Due to the difficulties in conducting long-term preventative studies in humans, there is little epidemiological data available for the use of pro- or prebiotics in cancer prevention. Evidence of benefits is largely limited to in vitro and animal studies,

557

Synbiotic 2000 (synbiotic combination of several probiotics and prebiotics)

Lactitol

Randomized controlled trial n ¼ 62 patients with severe acute pancreatitis

Randomized controlled trial. n ¼ 65 critically ill trauma patients

Significantly lower incidence of SIRS, organ failure and number of patients recovering with complications

(238)

(237)

(64)

(236)

No significant reduction in the prevalence of diarrhea

Significantly reduced levels of plasma endotoxin Significantly increased numbers of fecal bifidobacteria and lactobacilli and reduced numbers of Clostridium perfringens Significantly reduced rates of infections, systemic inflammatory response syndrome (SIRS), severe sepsis and mortality

(235)

(234)

(233)

References

Nonsignificant (p ¼ 0.08) trend to reduce episodes of traveler’s diarrhea

Significant reduction in the number of infectious diseases requiring antibiotic treatment, and the incidence of diarrhea, vomiting, and fever Failed to reduce the incidence of diarrhea, Clostridium difficile infection, or hospital stays

Small (n ¼ 20) randomized, controlled trial of young children in day care

FOS/inulin

Randomized, controlled trial of elderly subjects (n ¼ 435) administered broad-spectrum antibiotics Randomized controlled trial of 244 healthy volunteers travelling to destinations with medium to high risk of developing infective diarrhea Two randomized controlled trials of Peruvian infants living in low socioeconomic areas, n ¼ 282 and n ¼ 289 Placebo-controlled study n ¼ 60 patients with chronic viral hepatitis prone to endotoxemia

Results

Study Designs

Prebiotics

TABLE 7.10 Anti-Infective Outcomes in Human Studies with Prebiotics or Synbiotics

558

PREBIOTICS

TABLE 7.11

Impacts of Prebiotics on Improving Risk-Factors of Colorectal Cancer

Beneficial Effects of Prebiotics Fermentation of prebiotics to SCFA (particularly butyrate) Induces colonocyte differentiation and apoptosis Butyrate stimulated by larger fermentable carbohydrates such as inulin and resistant starch that may also provide SCFA production at the requited site of action in the distal colon Reduce mutagenic enzyme activities (e.g. b-glucuronidase and azoreductase) and bacterial metabolites (e.g. secondary bile acids, phenols, and indoles) that are purportedly associated with colon cancer risk Examples include studies with: . Lactulose . GOS . Resistant starch . Lactosucrose . Inulin . Not all prebiotic feeding studies have shown improvements in these parameters.

References (257–259) (153, 154, 260, 261)

(56, 59, 61) (262) (92, 263–266) (87) (267) (57, 58, 89, 268)

which have shown that prebiotics have the capacity to reduce purported risk factors for colon cancer in the colonic environment (Table 7.11). There are also numerous studies reporting protection by prebiotics against the development of preneoplastic lesions and/or tumors in rodent models of colon carcinogenesis (Table 7.12). Overall, the TABLE 7.12 Studies

Protective Effects of Prebiotics in Carcinogen Challenge Animal

Beneficial Effects of Prebiotics Protection against the development of preneoplastic lesions and/or tumors in rodent models of colon carcinogenesis Examples include: . FOS and inulin . Lactulose . XOS . Resistant starch Stimulation of anticancer immune activity Studies with different molecular sized fructan prebiotics reported increased protection with the larger, more slowly fermented prebiotics A number of studies comparing interventions with probiotics, prebiotics, and synbiotics have shown the synbiotic combination to be the most effective. These studies have used varying combination of pro- and prebiotics, and the exact nature of the synergies that lead to improved cancer markers remain speculative

References

(269) (270, 271) (272) (273, 274) (275, 276) (46, 278)

(96, 271, 276, 278– 280)

FUNCTIONAL FOODS FOR ANIMALS

559

capacity of prebiotics to significantly contribute to a reduced incidence of colorectal cancer in humans remains unproven. However, the results of preliminary human and animal experiments provide sufficient encouragement to maintain the impetus for continued research into the protective effects of prebiotics. 7.10.8

Reduction in Serum Lipid Concentrations

Numerous animal and human studies have focused on the effects of prebiotics on serum concentrations of cholesterol and triacylglycerides. While convincing beneficial results have often been obtained in animal studies, the results of trials in humans have been somewhat mixed, although no deleterious effects have been reported. Overall, the most convincing evidence is for inulin fructans, which demonstrate mainly a reduction in triglyceridaemia and only a relatively slight decrease in cholesterolaemia, and mostly in hypertriglyceridaemic conditions (42). Positive results have been observed in feeding studies using lactulose or lactitol (281–283) and resistance starch (reviewed by Nugent (154)). The mechanisms have been speculated to be regulation of host de novo lipogenesis via SCFA (particularly acetate) absorbed from the gut (284), or reduced intestinal fat absorption (282). Changes to the bacterial composition of the intestinal tract do not appear to be important. 7.10.9

Use in Weight Management and Improving Insulin Sensitivity

Since NDOs are sweet and not digested, they have a low calorific value and are used as low energy, low glycaemic index sweeteners that are also suitable for individuals with diabetes. Preliminary data also suggests that SCFA production resulting from prebiotic fermentation (and in particular acetate) could improve insulin sensitivity (281, 285, 286). The potential of prebiotics, and in particular small, rapidly fermented NDOs in the management of metabolic disorders linked to insulin resistance warrants further study. 7.11 FUNCTIONAL FOODS FOR ANIMALS Prebiotics have been trialed for use in both farm animal feeds and for companion animals. The advantage of feeding oligosaccharides in dogs and cats is the reduction of odor and improvement in volume and consistency of feces (287). With respect to farm animals, prebiotics have been studied for their potential to replace antibiotics in maintaining high feed conversion efficiencies, particularly in poultry and pork, and also to suppress methane production with ruminants (288–291). Alternatives to antibiotic use in animal feeds are urgently sought, and there has been considerable interest in the use of both prebiotics and probiotics to aid production. Although they have shown some promise in preliminary studies (292–294), further research is needed into their application within an overall management strategy in order to match the performance of antibiotics.

560

PREBIOTICS

TABLE 7.13

Safety of Prebiotics References

.

.

.

.

.

.

Nondigestible carbohydrates are consumed as part of the normal daily diet, as they are natural components of most plants Lactulose, short-chain oligosaccharides, inulin, resistant starch, and dietary fiber are not toxic, even at high doses Unsupplemented intakes of FOS and inulin are between 1 and 10 g/day from normal diets in Europe and the United States Recommended effective doses of prebiotic oligosaccharides in adults usually range from 10 to 15 g/day With the shorter chain oligosaccharides, intakes exceeding 15 g/day in adults can lead to flatulence, abdominal discomfort, and osmotic diarrhea at excessive doses Excessive consumption of rapidly fermented, acidogenic prebiotics may cause mucosal irritation

(296)

(295)

(43)

(43, 297–299) (43, 297–299)

(300–302)

7.12 SAFETY OF PREBIOTICS Most prebiotics can be found naturally in various foods. For example, most NDOs are natural components of many common foods including honey, milk, and various fruits and vegetables (295, 296) although usually in low concentrations. It is well established that lactulose, short-chain oligosaccharides, inulin, resistant starch, and dietary fiber are not toxic, even at high doses (Table 7.13). 7.13 REGULATION OF PREBIOTICS The regulatory regimes for nondigestible carbohydrates have been under active review in many countries in recent years. A marked development since the year 2000 has been the inclusion of most NDOs in the category “dietary fiber.” This has allowed recognition of these products as having some health benefits on product labels. Prior recognition in a regulatory sense had been restricted to Japan, who for many years has regulated the functional food sector with the FOSHU (Foods for Specified Health Use) system. The use of GOS and FOS as ingredients in infant milk formulas has been the subject of intensive regulatory inquiry and its acceptance varies among countries. Revised Codex standards were released in November 2006 (Codex ALINORM 07/30/26). Readers are referred to the Codex website for current standards (CODEX STAN 72–1981; and 156–1987). The website address is www.codexalimentarius.net.

CONCLUSION

561

7.14 CONCLUSION .

.

.

.

. . .

. .

.

.

.

It is clear from the volume of the accumulated evidences from human and animal studies using both culture and culture-independent methods that the consumption of prebiotics can modulate the composition of the intestinal microbiota. Bifidobacteria remain the population that is most often stimulated, although a number of prebiotics have also been shown to promote the proliferation of lactobacilli too. The fructans, FOS and inulin, and the lactose derivatives, GOS and lactulose, have the largest number of studies showing prebiotic effects. However, a range of other NDOs and dietary fibers have emerging evidence of prebiotic action. The success of prebiotics in replicating the bifidogenic effect of human milk oligosaccharides is a good example of where prebiotics can be applied with a clearly targeted objective for modulation of the composition and activity of the intestinal microbiota. In healthy adults, an imperative to maintain a numerically large population of bifidobacteria and lactobacilli has not been clearly demonstrated. Diminished or altered populations of intestinal bifidobacteria have been observed in IBD and atopy, but cause/effect links remain to be demonstrated. Prebiotics exert beneficial effects not only by manipulating the composition of the microbiota, but also by modulating its metabolic activity. It is clear that the production of SCFA and lowering luminal pH are important mechanisms for a number of potential health benefits. The most convincing evidence accumulated so far is for laxative effects, control of hepatic encephalopathy, and increased mineral absorption from the gut. There is preliminary evidence from randomized controlled trials for primary prevention of atopic eczema in infants; amelioration of IBD inflammation; prevention of infections; and control of serum lipids. The profile of SCFA produced varies with different prebiotics and the intestinal site and persistence of fermentation will clearly be important in determining which prebiotics are the most effect for specific health targets. We are just at the beginning of understanding how fermentable dietary fibers affect the composition and activity of the intestinal microbiota. In future, the distinction between current prebiotics and other fermentable fibers may prove somewhat arbitrary and artificial. What is likely to prove important is the choice of appropriate fermentable substrate(s) for the maintenance of health in specific populations. This may be highly bifidogenic NDOs in infants, larger fermentable fibers in adults, or indeed combinations of these as is already being explored. We are still grappling with the question “what is normal?” in terms of the composition and activities of the intestinal microbiota in different age groups and populations and in health and disease. Fundamental research into the

562

.

PREBIOTICS

composition and activities of the intestinal microbiota to determine which bacterial groups are important in health and disease remains an important prerequisite to developing targeted strategies to manipulate the intestinal microbiota using prebiotics to benefit the host. While acknowledging that the science of manipulating the intestinal microbiota to achieve improved health is still very much in its infancy, progress is being made, and strategies that may lead to tangible health benefits in specific populations are emerging.

REFERENCES 1. McCartney AL and Gibson GR. The normal microbiota of the human gastrointestinal tract: history of analysis, succession, and dietary influences In: Ouwehand AC and Vaughan EE, editors. Gastrointestinal Microbiology. Taylor and Francis, New York, 2006, pp. 51–73. 2. Bourlioux P, Koletzko B, Guarner F, and Braesco V. The intestine and its microflora are partners for the protection of the host: report on the Danone Symposium “The Intelligent Intestine” held in Paris, June 14, 2002. Am. J. Clin. Nutr. 2003; 78: 675–683. 3. Topping DL and Clifton PM. Short-chain fatty acids and human colonic function: roles of resistant starch and nonstarch polysaccharides. Physiol. Rev. 2001; 81: 1031–1064. 4. Blum S and Schiffrin EJ. Intestinal microflora and homeostasis of the mucosal immune response: implications for probiotic bacteria?. Curr Iss. Intest. Microbiol. 2003; 4: 53–60. 5. Tlaskalova-Hogenova H, Stepankova R, Hudcovic T, Tuckova L, Cukrowska B, Lodinova-Zadnkova R, Kozakova H, Rossmann P, Bartova J, Sokol D, Funda DP, Borovska D, Rehakova Z, Sinkora J, Hofman J, Drastich P, and Kokesova A. Commensal bacteria (normal microflora), mucosal immunity and chronic inflammatory and autoimmune diseases. Immunol. Lett. 2004; 93: 97–108. 6. Cummings JH, Macfarlane GT, and Macfarlane S. Intestinal bacteria and ulcerative colitis. Curr. Iss. Intesti. Microbiol. 2003; 4: 9–20. 7. Marteau P, Seksik P, and Shanahan F. Manipulation of the bacterial flora in inflammatory bowel disease. Best Pract. Res.: Clin. Gastroenterol. 2003; 17: 47–61. 8. Saunier K and Dore J. Gastrointestinal tract and the elderly: functional foods, gut microflora and healthy ageing. Digest. Liver Dis. 2002; 34(Suppl.) S19–S24. 9. Guarner F and Malagelada JR. Gut flora in health and disease. Lancet 2003; 361: 512– 519. 10. Crittenden R. An Update on Probiotic Bifidobacteria. In: Salminen S, von Wright A and Ouwerhand A. editors. Lactic Acid Bacteria: Microbiological and Functional Aspects. Marcel Dekker, New York, 2004, pp. 125–157. 11. Salminen S, Gorbach S, Lee YK, and Benno Y. Human Studies on Probiotics: What is Scientifically Proven Today? In: Salminen S, von Wright A and Ouwerhand A, editors Lactic Acid Bacteria: Microbiological and Functional Aspects. Marcel Dekker, New York, 2004, pp. 515–530. 12. Crittenden RG, Prebiotics. In: Tannock GW,edtitor. Probiotics: A Critical review. Horizon Scientific Press, Wymondham, United Kingdom, 1999, pp. 141–156.

REFERENCES

563

13. Boehm G and Stahl B. Oligosaccharides. In: Mattila-Sandholm and Saarela M, editors. Functional Dairy Products, Woodhead Publishing, CRC Press, England, 2003, pp. 203–243. 14. Gibson GR and Roberfroid MB. Dietary modulation of the human colonic microbiota introducing the concept of prebiotics. J. Nutr. 1995; 125: 1401–1412. 15. Tissier H. Recherches sur la flore intestinale des nourrissons (etat normal et pathologique). Thesis. Paris, France: University of Paris; 1900 [In French]. 16. Tissier H. Traitement des infections intestinales par la methode de la flore bacterienne de l’intestin. Crit. Rev. Soc. Biol. 1906; 60: 359–361 [In French]. 17. Gyorgy P. Norris RF, and Rose CS. Bifidus factor I. A variant of Lactobacillus bifidus requiring a special growth factor. Arch. Biochem. Biophys. 1954; 48: 193–201. 18. Petuely F. Bifidusflora bei flaschenkindern durch bifidogene substanzen (Bifidusfaktor). Z. Kinderheilkunde 1957; 79: 174–179 [In German]. 19. Yazawa K, Imai K, and Tamura Z. Oligosaccharides and polysaccharides specifically utilizable by bifidobacteria. Chem. Pharm. Bull. (Tokyo) 1978; 26: 3306–3311. 20. Yazawa K and Tamura Z. Search for sugar sources for selective increase of bifidobacteria. Bifidobact. Microflora 1982; 1: 34–44. 21. Satokari RM, Vaughan EE, Akkermans ADL, Saarela M, and de Vos WM. Polymerase chain reaction and denaturing gradient gel electrophoresis monitoring of fecal Bifidobacterium populations in a prebiotic and probiotic feeding trial. Syst. Appl. Microbiol. 2001; 24: 227–231. 22. Mattila-Sandholm T, Blum S, Collins JK, Crittenden R, de Vos W, Dunne C, Fonden R, Grenov B, Isolauri E, Kiely B, Marteau P, Morelli L, Ouwehand A, Reniero R, Saarela M, Salminen S, Saxelin M, Schiffrin E, Shanahan F, Vaughan E, and von Wright A. Probiotics: towards demonstrating efficacy. Trends Food Sci. Technol. 1999; 10: 393–399. 23. von Wright A, Vilpponen-Salmela T, Llopis MP, Collins K, Kiely B, Shanahan F, and Dunne C. The survival and colonic adhesion of Bifidobacterium infantis in patients with ulcerative colitis. Int. Dairy J. 2002; 12: 197–200. 24. Shimakawa Y, Matsubara S, Yuki N, Ikeda M, and Ishikawa F. Evaluation of Bifidobacterium breve strain Yakult-fermented soymilk as a probiotic food. Int. J. Food Microbiol. 2003; 81: 131–136. 25. Fujiwara S, Seto Y, Kimura A, and Hashiba H. Intestinal transit of an orally administered streptomycin-rifampicin-resistant variant of Bifidobacterium longum SBT2928: its longterm survival and effect on the intestinal microflora and metabolism. J. Appl. Micrbiol. 2001; 90: 43–52. 26. Brigidi P, Swennen E, Vitali B, Rossi M, and Matteuzzi D. PCR detection of Bifidobacterium strains and Streptococcus thermophilus in feces of human subjects after oral bacteriotherapy and yogurt consumption. Int. J. Food Microbiol. 2003; 81: 203–209. 27. Zoetendal EG, Akkermans AD, and de Vos WM. Temperature gradient gel electrophoresis analysis of 16S rRNA from human fecal samples reveals stable and host-specific communities of active bacteria. Appl. Environ. Microbiol. 1998; 64: 3854–3859. 28. Tannock GW. A fresh look at faeces. Microbiol. Aust. 2003; 24: 34–35. 29. Tannock GW. Munro K, Bibiloni R, Simon MA, Hargreaves P, Gopal P, Harmsen H, and Welling G. Impact of consumption of oligosaccharide-containing biscuits on the fecal microbiota of humans. Appl. Environ. Microbiol. 2004; 70: 2129–2136. 30. Requena T, Burton J, Matsuki T, Munro K, Simon MA, Tanaka R, Watanabe K, and Tannock GW. Identification, detection, and enumeration of human Bifidobacterium

564

31.

32.

33.

34. 35.

36.

37.

38.

39.

40.

41.

42. 43.

44. 45.

PREBIOTICS

species by PCR targeting the transaldolase gene. Appl. Environ. Microbiol. 2002; 68: 2420–2427. Satokari RM, Vaughan EE, Akkermans ADL, Saarela M, and de Vos WM. Bifidobacterial diversity in human feces detected by genus-specific PCR and denaturing gradient gel electrophoresis. Appl. Environ. Microbiol. 2001; 67: 504–513. McCartney AL, Wenzhi W, and Tannock GW. Molecular analysis of the composition of the bifidobacterial and lactobacillus microflora of humans. Appl. Environ. Microbiol. 1996; 62: 4608–4613. Kimura K, McCartney AL, McConnell MA, and Tannock GW. Analysis of fecal populations of bifidobacteria and lactobacilli and investigation of the immunological responses of their human hosts to the predominant strains. Appl. Environ. Microbiol. 1997; 63: 3394–3398. Mangin I, Bouhnik Y, Bisetti N, and Decaris B. Molecular monitoring of human intestinal Bifidobacterium strain diversity. Res. Microbiol. 1999; 150: 343–350. Chen H-L, Fan Y-H, Chen M-E, and Chan Y. Unhydrolyzed and hydrolyzed konjac glucomannans modulated cecal and fecal microflora in Balb/c mice. Nutrition 2005; 21: 1059–1064. Vulevic J, Rastall RA, and Gibson GR. Developing a quantitative approach for determining the in vitro prebiotic potential of dietary oligosaccharides. FEMS Microbiol. Lett. 2004; 236: 153–159. Chung C-H, and Day DF. Glucooligosaccharides from Leuconostoc mesenteroides B-742 (ATCC 13146): A potential prebiotic. J. Ind. Microbiol. Biotechnol. 2002; 29: 196–199. Mandalari G, Nueno Palop C, Tuohy K, Gibson GR, Bennett RN, Waldron KW, Bisignano G, Narbad A, and Faulds CB. In vitro evaluation of the prebiotic activity of a pectic oligosaccharide-rich extract enzymatically derived from bergamot peel. Appl. Microbiol. Biotechnol. 2007; 73: 1173–1179. Hu B, Gong Q, Wang Y, Ma Y, Li J, and Yu W. Prebiotic effects of neoagarooligosaccharides prepared by enzymatic hydrolysis of agarose. Anaerobe 2006; 12: 260–266. Okubo T, Ishihara N, Takahashi H, Fujisawa T, Kim M, Yamamoto T, and Mitsuoka T. Effects of partially hydrolyzed guar gum intake on human intestinal microflora and its metabolism. Biosci. Biotechnol. Biochem. 1994; 58: 1364–1369. Van Loo J. Inulin-type fructans as prebiotics. In: Gibson GR and Rastall RA, editors. Prebiotics: Development and Application. John Wiley and Sons, Chichester, UK, 2006, pp. 57–100. Roberfroid MB. Introducing inulin-type fructans. Br. J. Nutr. 2005; 93 (Suppl. 1): S13–S25. van Loo J, Cummings J, Delzenne N, Englyst H, Franck A, Hopkins M, Kok N, Macfarlane G, Newton D, Quigley M, Roberfroid M, van Vliet T, and van den Heuvel E. Functional food properties of nondigestible oligosaccharides: a consensus report from the ENDO project (DGXII AIRII-CT94-1095). Br J. Nutr. 1999; 81: 121–132. Kolida S, Tuohy K, and Gibson GR. Prebiotic effects of inulin and oligofructose. Br. J. Nutr. 2002; 87(Suppl. 2): S193–S197. Taper HS and Roberfroid MB. Inulin/oligofructose and anticancer therapy. Br. J. Nutr. 2002; 87(Suppl. 2): S283–S286.

REFERENCES

565

46. Pool-Zobel B, van Loo J, Rowland I, and Roberfroid MB. Experimental evidences on the potential of prebiotic fructans to reduce the risk of colon cancer. Br. J. Nutr. 2002; 87 (Suppl. 2): S273–S281. 47. Buddington KK, Donahoo JB, and Buddington RK. Dietary oligofructose and inulin protect mice from enteric and systemic pathogens and tumor inducers. J. Nutr. 2002; 132: 472–477. 48. Harmsen HJM, Raangs GC, Franks AH, Wildeboer-Veloo ACM, and Welling GW. The effect of the prebiotic inulin and the probiotic Bifidobacterium longum on the fecal microflora of healthy volunteers measured by FISH and DGGE. Microb. Ecol. Health Dis. 2002; 14: 211–219. 49. Bouhnik Y, Raskine L, Simoneau G, Paineau D, and Bornet F. The capacity of shortchain fructo-oligosaccharides to stimulate faecal bifidobacteria: a dose-response relationship study in healthy humans. J. Nutr. 2006; 5: 8. 50. Langlands SJ, Hopkins MJ, Coleman N, and Cummings JH. Prebiotic carbohydrates modify the mucosa associated microflora of the human large bowel. Gut 2004; 53: 1610–1616. 51. Suzuki N, Aiba Y, Takeda H, Fukumori Y, and Koga Y. Superiority of 1-kestose, the smallest fructo-oligosaccharide, to a synthetic mixture of fructo-oligosaccharides in the selective stimulating activity on Bifidobacteria. Biosci. Microflora 2006; 25: 109–116. 52. Roberfroid MB, Van Loo JAE, and Gibson GR. The bifidogenic nature of Chicory inulin and its hydrolysis products. J. Nutr. 1998; 128: 11–19. 53. Ben X-M, Zhou X-Y, Zhao W-H, Yu W-L, Pan W, Zhang W-L, Wu S-M, Beusekom CM, and van Schaafsma A. Growth and development of term infants fed with milk with long-chain polyunsaturated fatty acid supplementation. Chin. Med. J. 2004; 117: 1268– 1270. 54. Boehm G, Lidestri M, Casetta P, Jelinek J, Negretti F, Stahl B, and Marini A. Supplementation of a bovine milk formula with an oligosaccharide mixture increases counts of faecal bifidobacteria in preterm infants. Arch. Dis. Childhood 2002; 86: F178–F181. 55. Rastall RA. Galacto-oligosaccharides as prebiotics. In: Gibson GR and Rastall RA, editors. Prebiotics: Development and Application. John Wiley & Sons, Chichester, England, 2006, pp. 101–110. 56. Ballongue J, Schumann C, and Quignon P. Effects of lactulose and lactitol on colonic microflora and enzymatic activity. Scand. J. Gastroenterol. 1997; 32 (Suppl. 222): 41–44. 57. Tuohy KM, Ziemer CJ, Klinder A, Knobel Y, Pool-Zobel BL, and Gibson GR. A human volunteer study to determine the prebiotic effects of lactulose powder on human colonic microbiota. Microbial. Ecol. Health Dis. 2002; 14: 165–173. 58. Bouhnik Y, Attar A, Joly FA, Riottot M, Dyard F, and Flourie B. Lactulose ingestion increases faecal bifidobacterial counts: a randomised double-blind study in healthy humans. Eur. J. Clin. Nutr. 2004; 58: 462–466. 59. De Preter V, Vanhoutte T, Huys G, Swings J, Rutgeerts P, and Verbeke K. Effect of lactulose and Saccharomyces boulardii administration on the colonic urea-nitrogen metabolism and the bifidobacteria concentration in healthy human subjects. Aliment. Pharmacol. Ther. 2006; 23: 963–974. 60. Vanhoutte T, De Preter V, De Brandt E, Verbeke K, Swings J, and Huys G. Molecular monitoring of the fecal microbiota of healthy human subjects during administration of lactulose and Saccharomyces boulardii. Appl. Environ. Microbiol. 2006; 72: 5990–5997.

566

PREBIOTICS

61. Terada A, Hara H, Katoaka M, and and Mitsuoka T. Effect of lactulose on the composition and metabolic activity of human faecal flora. Microbial. Ecol. Health Dis. 1992; 5: 43–50. 62. Bouhnik Y, Raskine L, Simoneau G, Vicaut E, Neut C, Flourie B, Brouns F, and Bornet FR. The capacity of nondigestible carbohydrates to stimulate fecal bifidobacteria in healthy humans: a double-blind, randomized, placebo-controlled, parallel-group, doseresponse relation study. Am. J. Clin. Nutr. 2004; 80: 1658–1664. 63. Kummel KF and Brokx S. Lactitol as a functional prebiotic. Cer. Foods World 2001; 46: 424–429. 64. Chen C, Li L, Wu Z, Chen H, and Fu S. Effects of lactitol on intestinal microflora and plasma endotoxin in patients with chronic viral hepatitis. J. Infect. 2007; 54: 98–102. 65. Okazaki M, Fujikawa S, and Matsumomo N. Effect of xylooligosaccharide on the growth of bifidobacteria. Bifidobact. Microflora 1990; 9: 77–86. 66. Yamada H, Itoh K, Morishita Y, and Taniguchi H. Structure and properties of oligosaccharides from wheat bran. Cer. Foods World 1993; 38: 490–492. 67. Jaskari J, Kontula P, Siitonen A, Jousimies-Somer H, Mattila-Sandholm T, and Poutanen K, Oat b-glucan and xylan hydrolysates as selective substrates for Bifidobacterium and Lactobacillus strains. Appl. Microbiol. Biotechnol. 1998; 49: 175–181. 68. van Laere KM, Hartemink R, Bosveld M, Schols HA, and Voragen AG. Fermentation of plant cell wall derived polysaccharides and their corresponding oligosaccharides by intestinal bacteria. J. Agric. Food Chem. 2000; 48: 1644–1652. 69. Rycroft CE, Jones MR, Gibson GR, and Rastall RA. A comparative in vitro evaluation of the fermentation properties of prebiotic oligosaccharides. J. Appl. Microbiol. 2001; 91: 878–887. 70. Crittenden R, Karppinen S, Ojanen S, Tenkanen M, Fagerstr€ om R, M€att€ o J, Saarela M, Mattila-Sandholm T, and Poutanen K. In vitro fermentation of cereal dietary fibre carbohydrates by probiotic and intestinal bacteria. J. Sci. Food Agric. 2002; 82: 1–9. 71. Al-Tamimi MAHM, Palframan RJ, Cooper JM, Gibson GR, and Rastall RA. In vitro fermentation of sugar beet arabinan and arabino-oligosaccharides by the human gut microflora. J. Appl. Microbiol. 2006; 100: 407–414. 72. Campbell JM, Fahey GC Jr, and Wolf BW. Selected indigestible oligosaccharides affect large bowel mass, cecal and fecal short-chain fatty acids, pH and microflora in rats. J. Nutr. 1997; 127: 130–136. 73. Santos A, San Mauro M, and Marquina Diaz D. Prebiotics and their long-term influence on the microbial populations of the mouse bowel. Food Microbiol. 2006; 23: 498–503. 74. Oku Tand Nakamura S. Comparison of digestibility and breath hydrogen gas excretion of fructo-oligosaccharide, galactosyl-sucrose, and isomalto-oligosaccharide in healthy human subjects. Eur. J. Clin. Nutr. 2003; 57: 1150–1156. 75. Kohmoto T, Tsuji K, Kaneko T, Shiota M, Fukui F, Takaku H, Nakagawa Y, Ichikawa T, and Kobayashi S. Metabolism of 13C-isomaltooligosaccharides in healthy men. Biosci. Biotechnol. Biochem. 1992; 56: 937–940. 76. Kohmoto T, Fukui F, Takaku H, Machida Y, Arai M, and Mitsuoka T. Effect of isomaltooligosaccharides on human facal flora. Bifidobact. Microflora 1998; 7: 61–69. 77. Kohmoto T, Fukui F, Takaku H, and Mitsuoka T. Dose-response test of isomaltooligosaccharides for increasing fecal bifidobacteria. Agric. Biol. Chem. 1991; 55: 2157– 2159.

REFERENCES

567

78. Kaneko T, Kohmoto T, Kikuchi H, Shiota M, Yatake T, Iino H, and Tsuji K. Effects of isomaltoologosaccharides intake on defecation and intestinal environment in healthy volunteers. J. Home Econ. Japan 1993; 44: 245–254 [In Japanese]. 79. Kaneko T, Kohmoto T, Kikuchi H, Shiota M, Iino H, and Mitsuoka T. Effects of isomaltooligosaccharides with different degrees of polymerisation on human fecal bifidobacteria. Biosci. Biotechnol. Biochem. 1994; 58: 2288–2290. 80. Dinoto A, Marques TM, Sakamoto K, Fukiya S, Watanabe J, Ito S, and Yokota A. Population dynamics of Bifidobacterium species in human feces during raffinose administration monitored by fluorescence in situ hybridization-flow cytometry. Appl. Environ. Microbiol. 2006; 72: 7739–7747. 81. Hayakawa K, Mizutani J, Wada K, Masai T, Yoshihara I, and Mitsuoka T. Effects of soybean oligosaccharides on human faecal microflora. Microbial. Ecol. Health Dis. 1990; 3: 293–303. 82. Wada K, Watabe J, Mizutani J, Tomoda M, Suzuki H, and Saitoh Y. Effects of soybean oligosaccharides in a beverage on human fecal flora and metabolites. J. Agric. Chem. Soc. Japan 1992; 66: 127–135. 83. Benno Y, Endo K, Shiragami N, Sayama K, and Mitsuoka T. Effects of raffinose intake on human fecal microflora. Bifido‘a. 1987; 6: 59–63. 84. Hara T, Ikeda N, Hatsumi K, Watabe J, Iino H, and Mitsuoka T. Effects of small amount ingestion of soybean oligosaccharides on bowel habits and fecal flora of volunteers. Japanese J. Nutr. 1997; 55: 79–84. 85. Fujita K, Hara K, Sakai S, Miyake T, Yamashita M, Tsunstomi Y, and Mitsuoka T. Effects of 4-b-D-galactosylsucrose (lactosucrose) on intestinal flora and its digestibility in humans. J. Japanese Soc. Starch Sci. 1991; 38: 249–255. 86. Yoneyama M, Mandai T, Aga H, Fujii K, Sakai S, and Katayama Y. Effects of 4-b-Dgalactosylsucrose (lactosucrose) intake on intestinal flora in healthy humans. J. Japanese Soc. Nutr. Food Sci. 1992; 45: 101–107. 87. Hara H, Li S-T, Sasaki M, Maruyama T, Terada A, Ogata Y, Fujita K, Ishigami H, Hara K, Fujimori I, and Mitsuoka T. Effective dose of lactosucrose on fecal flora and fecal metabolites of humans. Bifidobact Microflora 1994; 13: 51–63. 88. Ohkusa T, Ozaki Y, Sato C, Mikuni K, and Ikeda H. Long-term ingestion of lactosucrose increases Bifidobacterium sp. in human fecal flora. Digestion 1994; 56: 415–420. 89. Kleessen B, Stoof G, Proll J, Schmiedl D, Noack J, and Blaut M. Feeding resistant starch affects fecal and cecal microflora and short-chain fatty acids in rats. J. Anim. Sci. 1997; 75: 2453–2462. 90. Brown IL, Wang X, Topping DL, Playne MJ, and Conway PL. High amylose maize starch as a versatile prebiotic for use with probiotic bacteria. Food Aust. 1998; 50: 603–610. 91. Wang X, Brown IL, Evans AJ, and Conway PL. The protective effects of high amylose maize (amylomaize) starch granules on the survival of Bifidobacterium spp. in the mouse intestinal tract. J. Appl. Microbiol. 1999; 87: 631–639. 92. Silvi S, Rumney CJ, Cresci A, and Rowland IR. Resistant starch modifies gut microflora and microbial metabolism in human flora-associated rats inoculated with faeces from Italian and UK donors. J. Appl. Microbiol. 1999; 86: 521–530. 93. Bielecka M, Biedrzycka E, Majkowska A, Juskiewicz J, and Wroblewska M. Effect of non-digestible oligosaccharides on gut microecosystem in rats. Food Res. Int. 2002; 35: 139–144.

568

PREBIOTICS

94. Wang X, Brown IL, Khaled D, Mahoney MC, Evans AJ, and Conway PL. Manipulation of colonic bacteria and volatile fatty acid production by dietary high amylose maize (amylomaize) starch granules. J. Appl. Microbiol. 2002; 93: 390–397. 95. Le Blay G, Michel C, Blottiere H, and Cherbut C. Raw potato starch and short-chain fructo-oligosaccharides affect the composition and metabolic activity of rat intestinal microbiota differently depending on the caecocolonic segment involved. J. Appl. Microbiol. 2003; 94: 312–320. 96. Le Leu RK, Brown IL, Hu Y, Bird AR, Jackson M, Esterman A, and Young GP. A Synbiotic combination of resistant starch and Bifidobacterium lactis facilitates apoptotic deletion of carcinogen-damaged cells in rat colon. J. Nutr. 2005; 135: 996–1001. 97. Bird AR, Vuaran M, Brown I, and Topping DL. Two high-amylose maize starches with different amounts of resistant starch vary in their effects on fermentation, tissue and digesta mass accretion, and bacterial populations in the large bowel of pigs. Br. J. Nutr. 2007; 97: 134–144. 98. Oikarinen S, Heinonen S, Karppinen S, M€att€o J, Adlecreutz H, Poutanen K, and Mutanen M. Plasma enterolactone or intestinal Bifidobacterium levels do not explain adenoma formation in multiple intestinal neoplasia (Min) mice fed with two different types of rye-bran fractions. Br. J. Nutr. 2003; 90: 119–125. 99. Kanauchi O, Fujiyama Y, Mitsuyama K, Araki Y, Ishii T, Nakamura T, Hitomi Y, Agata K, Saiki T, Andoh A, Toyonaga A, and Bamba T. Increased growth of Bifidobacterium and Eubacterium by germinated barley foodstuff, accompanied by enhanced butyrate production in healthy volunteers. Int. J. Mol. Med. 1999; 3: 175–179. 100. Saulnier DMA, Molenaar D, de Vos WM, Gibson GR, and Kolida S. Identification of prebiotic fructooligosaccharide metabolism in Lactobacillus plantarum WCFS1 through microarrays. Appl. Environ. Microbiol. 2007; 73: 1753–1765. 101. Van de Wiele T, Boon N, Possemiers S, Jacobs H, and Verstraete W. Inulin-type fructans of longer degree of polymerization exert more pronounced in vitro prebiotic effects. J. Appl. Microbiol. 2007; 102: 452–460. 102. Schell MA, Karmirantzou M, Snel B, Vilanova D, Berger B, Pessi G, Zwahlen MC, Desiere F, Bork P, Delley M, Pridmore RD, and Arigoni F. The genome sequence of Bifidobacterium longum reflects its adaptation to the human gastrointestinal tract. Proc. Nat. Acad. Sci. USA 2002; 99: 14422–14427. 103. Okazaki M, Fujikawa S, and Matsumoto N. Effect of xylo-oligosaccharide on the growth of bifidobacteria. Bifidobact. Microflora 1990; 9: 77–86. 104. Gibson GR and Wang X. Bifidogenic properties of different types of fructo-oligosacharides. Food Microbiol. 1994; 11: 491–498. 105. Wang X and Gibson GR. Effects of the in vitro fermentation of oligofructose and inulin by bacteria growing in the human large intestine. J. Appl. Bacteriol. 1993; 75: 373–380. 106. Goh Y-J, Zhang C, Benson AK, Schlegel V, Lee J-H, and Hutkins RW. Identification of a putative operon involved in fructo-oligosaccharide utilization by Lactobacillus paracasei. Appl. Environ. Microbiol. 2006; 72: 7518–7530. 107. Barrangou R, Altermann E, Hutkins R, Cano R, and Klaenhammer TR. Functional and comparative genomic analyses of an operon involved in Fructooligosaccharide utilization by Lactobacillus acidophilus. Proc. Nat. Acad. Sci. USA 2003; 100: 8957–8962. 108. Kaplan H and Hutkins RW. Metabolism of fructooligosaccharides by Lactobacillus paracasei 1195. Appl. Environ. Microbiol. 2003; 69: 2217–2222.

REFERENCES

569

109. Van der Meulen R, Makras L, Verbrugghe K, Adriany T, and De Vuyst L. In vitro kinetic analysis of oligofructose consumption by bacteroides and Bifidobacterium spp. indicates different degradation mechanisms. Appl. Environ. Microbiol. 2006; 72: 1006–1012. 110. Manderson K, Pinart M, Tuohy KM, Grace WE, Hotchkiss AT, Widmer W, Yadhav MP, Gibson GR, and Rastall RA. In vitro determination of prebiotic properties of oligosaccharides derived from an orange juice manufacturing by-product stream. Appl. Environ. Microbiol. 2005; 71: 8383–8389. 111. Ryan SM, Fitzgerald GF, and van Sinderen Douwe. Transcriptional regulation and characterization of a novel beta-fructofuranosidase-encoding gene from Bifidobacterium breve UCC2003. Appl. Environ. Microbiol. 2005; 71: 3475–3482. 112. Parche S, Amon J, Jankovic I, Rezzonico E, Beleut M, Barutcu H, Schendel I, Eddy MP, Burkovski A, Arigoni F, and Titgemeyer F. Sugar transport systems of Bifidobacterium longum NCC2705. J. Mol. Microbiol. Biotechnol. 2007; 12: 9–19. 113. Harmsen HJM, Wildeboer-Veloo ACM, Raangs CG, Wagendorp AA, Klijn N, Bindels JG, and Welling GW. Analysis of intestinal flora development in breast-fed and formulafed infants by using molecular identification and detection methods. J. Pediatr. Gastroenterol. Nutr. 2000; 30: 61–67. 114. Mountzouris KC, McCartney AL, and Gibson GR. Intestinal microflora of human infants and current trends for its nutritional modulation. Br. J. Nutr. 2002; 87: 405–420. 115. Kunz C, Rudloff S, Baier W, Klein N, and Strobel S. Oligosaccharides in human milk: structural, functional, and metabolic aspects. Annu. Rev. Nutr. 2000; 20: 699–722. 116. Boehm G and Stahl B. Oligosaccharides from milk. J. Nutr. 137 (Suppl.) 2007; 847S–849S. 117. Prentice AM and Prentice A. Evolutionary and environmental influences on human lactation. Proc. Nutr. Soc. 1995; 54: 391–400. 118. Adlerberth I. Establishment of a normal intestinal microflora in the newborn infant. In: Probiotics, other nutritional factors and intestinal microflora. Eds. Hansen LA and Yolken RH. Nestle Nutrition Workshop Series, Vol 42, Nestec Ltd, Vevey. Lippincott-Raven, Philadelphia. pp. 63–78, 1999 119. Heavey PM, Savage SA, Parrett A, Cecchini C, Edwards CA, and Rowland IR. Proteindegradation products and bacterial enzyme activities in faeces of breast-fed and formulafed infants. Br. J. Nutr. 2003; 89: 509–515. 120. Edwards CA and Parrett AM. Intestinal flora during the first months of life: new perspectives. Br. J. Nutr. 2002; 88 (Suppl. 1): S11–S18. 121. Knol J, Boehm G, Lidestri M, Negretti F, Jelinek J, Agosti M, Stahl B, Marini A, and Mosca F. Increase of faecal bifidobacteria due to dietary oligosaccharides induces a reduction of clinically relevant pathogen germs in the faeces of formula-fed preterm infants. Acta Paediatrica 2005; 94: 31–33. 122. Rinne MM, Gueimonde M, Kalliom€aki M, Hoppu U, Salminen SJ, and Isolauri E. Similar bifidogenic effects of prebiotic-supplemented partially hydrolyzed infant formula and breastfeeding on infant gut microbiota. FEMS Immunol. Med. Microbiol. 2005; 43: 59–65. 123. Haarman M and Knol J. Quantitative real-time PCR assays to identify and quantify fecal Bifidobacterium species in infants receiving a prebiotic infant formula. Appl. Environ. Microbiol. 2005; 71: 2318–2324. 124. Haarman M and Knol J. Quantitative real-time PCR analysis of fecal Lactobacillus species in infants receiving a prebiotic infant formula. Appl. Environ. Microbiol. 2006; 72: 2359–2365.

570

PREBIOTICS

125. Boehm G, Stahl B, Jelinek J, Knol J, Miniello V, and Moro GE. Prebiotic carbohydrates in human milk and formulas. Acta Paediatr. 2005; 94 (Suppl.): 18–21. 126. Fanaro S, Boehm G, Garssen J, Knol J, Mosca F, Stahl B, and Vigi V. Galactooligosaccharides and long-chain fructo-oligosaccharides as prebiotics in infant formulas: a review. Acta Paediatr. 2005; 94: 22–26. 127. Bakker-Zierikzee AM, Alles MS, Knol J, Kok FJ, Tolboom JJM, and Bindels JG. Effects of infant formula containing a mixture of galacto- and fructo-oligosaccharides or viable Bifidobacterium animalis on the intestinal microflora during the first 4 months of life. Br J. Nutr. 2005; 94: 783–790. 128. Bruzzese E, Volpicelli M, Squaglia M, Tartaglione A, and Guarino A. Impact of prebiotics on human health. Digest. Liver Dis. 2006; 38 (Suppl. 2): S283–S287. 129. Ziegler E, Vanderhoof JA, Petschow B, Mitmesser SH, Stolz SI, Harris CL, and Berseth CL. Term infants fed formula supplemented with selected blends of prebiotics grow normally and have soft stools similar to those reported for breast-fed infants. J. Pediatr. Gastroenterol. Nutr. 2007; 44: 359–364. 130. Colome G, Sierra C, Blasco J, Garcia MV, Valverde E, and Sanchez E. Intestinal permeability in different feedings in infancy. Acta Paediatric. 2007; 96: 69–72. 131. Newburg DS. Human milk glycoconjugates that inhibit pathogens. Curr. Medicinal Chem. 1999; 6: 117–127. 132. Martin-Sosa S, Martin MJ, and Hueso P. The sialylated fraction of milk oligosaccharides is partially responsible for binding to enterotoxigenic and uropathogenic Escherichia coli human strains. J. Nutr. 2002; 132: 3067–3072. 133. Morrow AL, Ruiz-Palacios GM, Altaye M, Jiang X, Guerrero ML, Meinzen-Derr JK, Farkas T, Chaturvedi P, Pickering LK, and Newburg DS. Human milk oligosaccharides are associated with protection against diarrhea in breast-fed infants. J. Pediatr. 2004; 145: 297–303. 134. Wang B and Brand-Miller J. The role and potential of sialic acid in human nutrition. Eur. J. Clin. Nutr. 2003; 57: 1351–1369. 135. Vincent SJ, Faber EJ, Neeser J-R, Stingele F, and Kamerling JP. Structure and properties of the exopolysaccharide produced by Streptococcus macedonicus Sc136. Glycobiology 2001; 11: 131–139. 136. Rencurosi A, Poletti L, Guerrini M, Russo G, and Lay L. Human milk oligosaccharides: an enzymatic protection step simplifies the synthesis of 30 - and 60 -O-sialyllactose and their analogues. Carbohydrate Res. 2002; 337: 473–483. 137. La Ferla B, Prosperi D, Lay L, Russo G, and Panza L. Synthesis of building blocks of human milk oligosaccharides. Fucosylated derivatives of the lacto- and neolacto-series. Carbohydrate Res. 2002; 337: 1333–1342. 138. Dumon C, Samain E, and Priem B. Assessment of the two Helicobacter pylori alpha-1,3fucosyltransferase ortholog genes for the large-scale synthesis of LewisX human milk oligosaccharides by metabolically engineered Escherichia coli. Biotechnol. Progr. 2004; 20: 412–419. 139. Vaughan EE, de Vries MC, Zoetendal EG, Ben-Amor K, Akkermans ADL, and de Vos WM. The intestinal LABs. Antonie van Leeuwenhoek. Int. J. Gen. Mol. Microbiol. 2002; 82: 341–352. 140. Tannock GW. Analysis of the intestinal microflora using molecular methods. Eur. J. Clin. Nutr. 2002; 56(Suppl. 4): S44–S49.

REFERENCES

571

141. Tannock GW. The bifidobacterial and lactobacillus microflora of humans. Clin. Rev. Allergy Immunol. 2002; 22: 231–253. 142. Matsuki T, Watanabe K, Tanaka R, Fukuda M, and Oyaizu H. Distribution of bifidobacterial species in human intestinal microflora examined with 16S rRNA-genetargeted species-specific primers. Appl. Environ. Microbiol. 1999; 65: 4506–4512. 143. Matsuki T, Watanabe K, Fujimoto J, Miyamoto Y, Takada T, Matsumoto K, Oyaizu H, and Tanaka R. Development of 16S rRNA-gene-targeted group-specific primers for the detection and identification of predominant bacteria in human feces. Appl. Environ. Micrbiol. 2002; 68: 5445–5451. 144. Hayashi H, Sakamoto M, and Benno Y. Phylogenetic analysis of the human gut microbiota using 16S rDNA clone libraries and strictly anaerobic culture-based methods. Microbiol. Immunol. 2002; 46: 535–548. 145. Rao AV. Dose-response effects of inulin and oligofructose on intestinal bifidogenesis effects. J. Nutr. 1999; 129(Suppl. 7): 1442–1445. 146. Requena T, Burton J, Matsuki T, Munro K, Simon MA, Tanaka R, Watanabe K, and Tannock GW. Identification, detection, and enumeration of human Bifidobacterium species by PCR targeting the transaldolase gene. Appl. Environ. Microbiol 2002; 68: 2420–2427. 147. Saito T, Kato S, Maeda T, Suzuki S, Iijima S, and Kobayashi T. Overproduction of thermostable b-galactosidase in Escherichia coli, its purification and molecular structure. J. Ferment. Bioeng. 1992; 74: 12–16. 148. Ventura M, Elli M, Reniero R, and Zink R. Molecular microbial analysis of Bifidobacterium isolates from different environments by the species-specific amplified ribosomal DNA restriction analysis (ARDRA). FEMS Microbiol. Ecol. 2001; 36: 113– 121. 149. Alander M, M€att€o J, Kneifel W, Johansson M, Kogler B, Crittenden R, MattilaSandholm T, Saarela M. Effect of galacto-oligosaccharide supplementation on human faecal microflora and on survival and persistence of Bifidobacterium lactis Bb-12 in the gastrointestinal tract. Int. Dairy J. 2001; 11: 817–825. 150. Malinen E, M€att€o J, Salmitie M, Alander M, Saarela M, and Palva A. PCR-ELISA - II: Analysis of Bifidobacterium populations in human faecal samples from a consumption trial with Bifidobacterium lactis Bb-12 and a galacto-oligosaccharide preparation. Syst. Appl. Microbiol. 2002; 25: 249–258. 151. Loh G, Eberhard M, Brunner RM, Hennig U, Kuhla S, Kleessen B, and Metges CC. Inulin alters the intestinal microbiota and short-chain fatty acid concentrations in growing pigs regardless of their basal diet. J. Nutr. 2006; 136: 1198–1202. 152. Mountzouris KC, Balaskas C F F, Tuohy K M, Gibson G R, and Fegeros K. Profiling of composition and metabolic activities of the colonic microflora of growing pigs fed diets supplemented with prebiotic oligosaccharides. Anaerobe 2006; 12(4): 178–185. 153. Rossi M, Corradini C, Amaretti A, Nicolini M, Pompei A, Zanoni S, and Matteuzzi D. Fermentation of fructooligosaccharides and inulin by bifidobacteria: a comparative study of pure and fecal cultures. Appl. Environ. Microbiol. 2005; 71: 6150–6158. 154. Nugent AP. Health properties of resistant starch. Nutr. Bull. 2005; 30: 27–54. 155. Mitsuoka T. Recent trends in research on intestinal flora. Bifidobact. Microflora 1982; 1: 3–24.

572

PREBIOTICS

156. Hopkins MJ, Sharp R, and Macfarlane GT. Age and disease related changes in intestinal bacterial populations assessed by cell culture, 16S rRNA abundance, and community cellular fatty acid profiles. Gut 2001; 48: 198–205. 157. Canzi E, Casiraghi MC, Zanchi R, Gandolfi R, Ferrari A, Brighenti F, Bosia R, Crippa A, Maestri P, Vesely R, and Salvadori BB. Yogurt in the diet of the elderly: a preliminary investigation into its effect on the gut ecosystem and lipid metabolism. Lait 2002; 82: 713–723. 158. Silvi S, Verdenelli MC, Orpianesi C, and Cresci A. EU project Crownalife: functional foods, gut microflora and healthy ageing - Isolation and identification of Lactobacillus and Bifidobacterium strains from faecal samples of elderly subjects for a possible probiotic use in functional foods. J. Food Eng. 2003; 56: 195–200. 159. Crittenden RG and Playne MJ. Production, properties and applications of food-grade oligosaccharides. Trends Food Sci. Technol. 1996; 7: 353–361. 160. Fernandez-Ba~nares F. Nutritional care of the patient with constipation. Clin. Gastroenterol. 2006; 20: 575–587. 161. Quah HM, Ooi BS, Seow-Choen F, Sng KK, and Ho KS. Prospective randomized crossover trial comparing fibre with lactulose in the treatment of idiopathic chronic constipation. Tech. Coloproctol 2006; 10: 111–114. 162. Jou€et P, Sabate J-M, Cuillerier E, Coffin B, Lemann M, Jian R, and Flourie B. Low-dose lactulose produces a tonic contraction in the human colon. Neurogastroenterol. Motil. 2006; 18: 45–52. 163. Gibson GR, Beatty ER, Wang X, and Cummings JH. Selective stimulation of bifidobacteria in the human colon by oligofructose and inulin. Gastroenteroogy 1995; 108: 975–982. 164. Castiglia-Delavaud C, Verdier E, Besle JM, Vernet J, Boirie Y, Beaufrere B, de Baynast R, and Vermorel M. Net energy value of non-starch polysaccharide isolates (sugarbeet fibre and commercial inulin) and their impact on nutrient digestive utilization in healthy human subjects. Br. J. Nutr. 1998; 80: 343–352. 165. Chen H-L, Lu Y-H, Lin J-J, Ko L-Y. Effects of fructooligosaccharide on bowel function and indicators of nutritional status in constipated elderly men. Nutr. Res. 2000; 20: 1725– 1733. 166. Chen H-L, Lu Y-H, Lin J-J, Ko L-Y. Effects of isomalto-oligosaccharides on bowel functions and indicators of nutritional status in constipated elderly men. J. Am. Coll. Nutr. 2001; 20: 44–49. 167. Tateyama I, Hashii K, Johno I, Iino T, Hirai K, Suwa Y, and Kiso Y. Effect of xylooligosaccharide intake on severe constipation in pregnant women. J. Nutr. Sci. Vitaminol. 2005; 51: 445–448. 168. Dbouk N and McGuire BM. Hepatic encephalopathy: a review of its pathophysiology and treatment. Curr. Treatment Opt. Gastroenterol. 2006; 9: 464–474. 169. Bongaerts G, Severijnen R, and Timmerman H. Effect of antibiotics, prebiotics and probiotics in treatment for hepatic encephalopathy. Med. Hypotheses 2005; 64: 64–68. 170. Bj€orksten B. Effects of intestinal microflora and the environment on the development of asthma and allergy. Springer Semin. Immunopathol. 2004; 25: 257–270. 171. Sudo N, Aiba Y, Oyama N, Yu XN, Matsunaga M, Koga Y, and Kubo C. Dietary nucleic acid and intestinal microbiota synergistically promote a shift in the Th1/Th2 balance toward Th1-skewed immunity. Int. Arch. Allergy Immunol. 2004; 135: 132–135.

REFERENCES

573

172. Ouwehand AC. Antiallergic effects of probiotics. J. Nutr. 2007; 137 (Suppl.): 7S. 173. Bj€orksten B, Naaber P, Sepp E, and Mikelsaar M. The intestinal microflora in allergic Estonian and Swedish 2-year old children. Clin. Exp. Allergy 1999; 29: 342–346. 174. Bj€orksten B, Sepp E, Julge K, Voor T, and Mikelsaar M. Allergy development and the intestinal microflora during the first year of life. J. Allergy Clin. Immunol. 2001; 108: 516–520. 175. B€ottcher M, Sandin A, Norin E, Midtvedt T, and Bj€ orksten B. Microflora associated characteristics in faeces from allergic and non-allergic children. Clin. Exp. Allergy 2000; 30: 590–596. 176. Gr€onlund MM, Arvilommi H, Kero P, Lehtonen OP, and Isolauri E. Importance of intestinal colonisation in the maturation of humoral immunity in early infancy: a prospective follow up study of healthy infants aged 0–6 months. Arch. Dis. Child 2000; 83: F186–F192. 177. Kalliom€aki M, Kirjavainen P, Eerola E, Kero P, Salminen S, and Isolauri E. Distinct patterns of neonatal gut microflora in infants in whom atopy was and was not developing. J. Allergy Clin. Immunol. 2001; 107: 129–134. 178. Kirjavainen PV, Apostolou E, Arvola T, Salminen SJ, Gibson GR, and Isolauri E. Characterizing the composition of intestinal microflora as a prospective treatment target in infant allergic disease. FEMS Immunol. Med. Microbiol. 2001; 32: 1–7. 179. Kirjavainen PV, Arvola T, Salminen SJ, and Isolauri E. Aberrant composition of gut microbiota of allergic infants: a target of bifidobacterial therapy at weaning?. Gut 2002; 51: 51–55. 180. He F, Ouwehand AC, Isolauri E, Hashimoto H, Benno Y, and Salminen S. Comparison of mucosal adhesion and species identification of bifidobacteria isolated from healthy and allergic infants. FEMS Immunol. Med. Microbiol. 2001; 30: 43–47. 181. Ouwehand AC, Isolauri E, He F, Hashimoto H, Benno Y, and Salminen S. Differences in Bifidobacterium flora composition in allergic and healthy infants. J. Allergy Clin. Immunol. 2001; 108: 144–145. 182. Mackie RI, Sghir A, and Gaskins HR. Developmental microbial ecology of the neonatal gastrointestinal tract. Am. J. Clin. Nutr. 1999; 69: 1035S–1045S. 183. Sashihara T, Sueki N, and Ikegami S. An analysis of the effectiveness of heatkilled lactic acid bacteria in alleviating allergic diseases. J. Dairy Sci. 2006; 89: 2846–2855. 184. Takahashi N, Kitazawa H, Shimosato T, Iwabuchi N, Xiao JZ, Iwatsuki K, Kokubo S, and Saito T. An immunostimulatory DNA sequence from a probiotic strain of Bifidobacterium longum inhibits IgE production in vitro. FEMS Immunol. Med. Microbiol. 2006; 46: 461–469. 185. Sawada J, Morita H, Tanaka A, Salminen S, He F, and Matsuda H. Ingestion of heattreated Lactobacillus rhamnosus GG prevents development of atopic dermatitis in NC/ Nga mice. Clin. Exp. Allergy 2007; 37: 296–303. 186. Isolauri E, Arvola T, Sutas Y, Moilanen E, and Salminen S. Probiotics in the management of atopic eczema. Clin. Exp. Allergy 2000; 30: 1604–1610. 187. Kalliomaki M, Salminen S, Arvilommi H, Kero P, and Isolauri E. Probiotics in primary prevention of atopic disease: a randomised placebo-controlled trial. Lancet 2001; 357: 1076–1079.

574

PREBIOTICS

188. Kalliomaki M, Salminen S, Poussa T, Arvilommi H, and Isolauri E. Probiotics and prevention of atopic disease: 4-year follow-up of a randomised placebo-controlled trial. Lancet 2003; 361: 1869–1871. 189. Viljanen M, Savilahti E, Haahtela T, Juntunen-Backman K, Korpela R, Poussa T, Tuure T, and Kuitunen M. Probiotics in the treatment of atopic eczema/dermatitis syndrome in infants: a double-blind placebo-controlled trial. Allergy 2005; 60: 494–500. 190. Weston S, Halbert A, Richmond P, and Prescott SL. Effects of probiotics on atopic dermatitis: a randomised controlled trial. Arch. Dis. Child 2005; 90: 892–897. 191. Taylor AL, Hale J, Wiltschut J, Lehmann H, Dunstan JA, and Prescott SL. Effects of probiotic supplementation for the first 6 months of life on allergen- and vaccine-specific immune responses. Clin. Exp. Allergy 2006; 36: 1227–1235. 192. Taylor AL, Dunstan JA, and Prescott SL. Probiotic supplementation for the first 6 months of life fails to reduce the risk of atopic dermatitis and increases the risk of allergen sensitization in high-risk children: a randomized controlled trial. J. Allergy Clin. Immunol. 2007; 119: 184–191. 193. Brouwer ML, Wolt-Plompen SA, Dubois AE, van der HS, Jansen DF, Hoijer MA, Kauffman HF, and Duiverman EJ. No effects of probiotics on atopic dermatitis in infancy: a randomized placebo-controlled trial. Clin. Exp. Allergy 2006; 36: 899–906. 194. F€olster-Holst R, M€uller F, Schnopp N, Abeck D, Kreiselmaier I, Lenz T, von R€ uden U, Schrezenmeir J, Christophers E, and Weichenthal M. Prospective, randomized controlled trial on Lactobacillus rhamnosus in infants with moderate to severe atopic dermatitis. Br. J. Dermatol. 2006; 155: 1256–1261. 195. Moreira A, Kekkonen R, Korpela R, Delgado L, and Haahtela T. Allergy in marathon runners and effect of Lactobacillus GG supplementation on allergic inflammatory markers. Respir. Med. 2007; 101: 1123–1131. 196. Nagura T, Hachimura S, Hashiguchi M, Ueda Y, Kanno T, Kikuchi H, Sayama K, and Kaminogawa s. Suppressive effect of dietary raffinose on T-helper 2 cell-mediated immunity. Br. J. Nutr. 2002; 88: 421–427. 197. Yoshida T, Hirano A, Wada H, Takahashi K, and Hattori M. Alginic acid oligosaccharide suppresses Th2 development and IgE production by inducing IL-12 production. Int. Arch. Allergy Immunol. 2004; 133: 239–247. 198. Mizubuchi H, Yajima T, Aoi N, Tomita T, and Yoshikai Y. Isomalto-oligosaccharides polarize Th1-like responses in intestinal and systemic immunity in mice. J. Nutr. 2005; 135: 2857–2861. 199. Fujitani S, Ueno K, Kamiya T, Tsukahara T, Ishihara K, Kitabayashi T, and Itabashi K. Increased number of CCR4-positive cells in the duodenum of ovalbumin-induced food allergy model NC/jic mice and antiallergic activity of fructooligosaccharides. Allergol. Int. 2007; 56: 131–138. 200. Vos AP, Haarman M, van Ginkel J-WH, Knol J, Garssen J, Stahl B, Boehm G, and M’Rabet L. Dietary supplementation of neutral and acidic oligosaccharides enhances Th1dependent vaccination responses in mice. Pediatr. Allergy Immunol. 2007; 18: 304–312. 201. Moro G, Arslanoglu S, Stahl B, Jelinek J, Wahn U, and Boehm G. A mixture of prebiotic oligosaccharides reduces the incidence of atopic dermatitis during the first six months of age. Arch. Dis. Child 2006; 91: 814–819. 202. Kukkonen K, Savilahti E, Haahtela T, Juntunen-Backman K, Korpela R, Poussa T, Tuure T, and Kuitunen M. Probiotics and prebiotic galacto-oligosaccharides in the

REFERENCES

203.

204. 205.

206.

207. 208.

209.

210.

211.

212.

213.

214.

215. 216.

575

prevention of allergic diseases: a randomized, double-blind, placebo-controlled trial. J. Allergy Clin. Immunol. 2007; 119: 192–198. Schultz M, Timmer A, Herfarth H, Sartor RB, Vanderhoof JA, and Rath HC. Lactobacillus GG in inducing and maintaining remission of Crohn’s disease. BMC Gastroenterol. 2004; 15: 5. Hedin C, Whelan K, and Lindsay JO. Evidence for the use of probiotics and prebiotics in inflammatory bowel disease: a review of clinical trials. Proc. Nutr. Soc. 2007; 66: 307–315. Linskens RK, Huijsdens XW, Savelkoul PHM, Vandenbroucke-Grauls CMJE, Meuwissen SMG. The bacterial flora in inflammatory bowel disease: Current insights in pathogenesis and the influence of antibiotics and probiotics. Scand. J. Gastroenterol. 2001; 36: S29–S40. Favier C, Neut C, Mizon C, Cortot A, Colombel JF, and Mizon J. Fecal beta-Dgalactosidase production and bifidobacteria are decreased in Crohn’s disease. Digest. Dis. Sci. 1997; 42: 817–822. Macfarlane S, Furrie E, Kennedy A, Cummings JH, and Macfarlane GT. Mucosal bacteria in ulcerative colitis. Br. J. Nutr. 2005; 93(Suppl. 1): S67–S72. Hoentjen F, Welling GW, Harmsen HJM, Zhang X, Snart J, Tannock GW, Lien K, Churchill TA, Lupicki M, and Dieleman LA. Reduction of colitis by prebiotics in HLAB27 transgenic rats is associated with microflora changes and immunomodulation. Inflamm. Bowel Dis. 2005; 11: 977–985. Furrie E, Macfarlane S, Kennedy A, Cummings JH, Walsh SV, O’Neil DA, Macfarlane GT. Synbiotic therapy (Bifidobacterium longum/Synergy 1) initiates resolution of inflammation in patients with active ulcerative colitis: a randomised controlled pilot trial. Gut 2005; 54: 242–249. Lara-Villoslada F, de Haro O, Camuesco D, Comalada M, Velasco J, Zarzuelo A, Xaus J, and Galvez J. Short-chain fructooligosaccharides, in spite of being fermented in the upper part of the large intestine, have anti-inflammatory activity in the TNBS model of colitis. Eur. J. Nutr. 2006; 45: 418–425. Lindsay JO, Whelan K, Stagg AJ, Gobin P, Al-Hassi HO, Rayment N, Kamm MA, Knight SC, and Forbes A. Clinical, microbiological, and immunological effects of fructooligosaccharide in patients with Crohn’s disease. Gut 2006; 55: 348–355. Cherbut C, Michel C, and Lecannu G. The prebiotic characteristics of fructooligosaccharides are necessary for reduction of TNBS-induced colitis in rats. J. Nutr. 2003; 133: 21–27. Geier MS, Butler RN, Giffard PM, and Howarth GS. Prebiotic and synbiotic fructooligosaccharide administration fails to reduce the severity of experimental colitis in rats. Dis. Colon Rectum 2007; 50: 1061–1069. Moreau NM, Martin LJ, Toquet CS, Laboisse CL, Nguyen PG, Siliart BS, Dumon HJ, and Champ MMJ. Restoration of the integrity of rat caeco-colonic mucosa by resistant starch, but not by fructo-oligosaccharides, in dextran sulfate sodium-induced experimental colitis. Br. J. Nutr. 2003; 90: 75–85. Winkler J, Butler R, and Symonds E. Fructo-oligosaccharide reduces inflammation in a dextran sodium sulphate mouse model of colitis. Digest. Dis. Sci. 2007; 52: 52–58. Rumi G, Tsubouchi R, Okayama M, Kato S, M ozsik G, and Takeuchi K. Protective effect of lactulose on dextran sulfate sodium-induced colonic inflammation in rats. Digest. Dis. Sci. 2004; 49: 1466–1472.

576

PREBIOTICS

217. Camuesco D, Peran L, Comalada M, Nieto A, Di Stasi LC, Rodriguez-Cabezas ME, Concha A, Zarzuelo A, and Galvez J. Preventative effects of lactulose in the trinitrobenzenesulphonic acid model of rat colitis. Inflamm. Bowel Dis. 2005; 11: 265–271. 218. Holma R, Juvonen P, Asmawi MZ, Vapaatalo H, and Korpela R. Galacto-oligosaccharides stimulate the growth of bifidobacteria but fail to attenuate inflammation in experimental colitis in rats. Scand. J. Gastroenterol. 2002; 37: 1042–1047. 219. Friedman G and George J. Treatment of refractory ‘pouchitis’ with prebiotic and probiotic therapy. Gastroenterology 2000; 118: G4167. 220. Welters CFM, Heineman E, Thunnissen BJM, Van den Bogaard AEJM, Soeters PB, and Baeten CGMI. Effect of dietary inulin supplementation on inflammation of pouch mucosa in patients with an ileal pouch-anal anastomosis. Dis. Colon Rectum 2002; 45: 621–627. 221. Kanauchi O, Suga T, Tochihara M, Hibi T, Naganuma M, Homma T, Asakura H, Nakano H, Takahama K, Fujiyama Y, Andoh A, Shimoyama T, Hida N, Haruma K, Koga H, Mitsuyama K, Sata M, Fukuda M, Kojima A, and Bamba T. Treatment of ulcerative colitis by feeding with germinated barley foodstuff: first report of a multicenter open control trial. J. Gastroenterol. 2002; 37(Suppl. 14): 67–72. 222. Bamba T, Kanauchi O, Andoh A, and Fujiyama Y. A new prebiotic from germinated barley for nutraceutical treatment of ulcerative colitis. J. Gastroenterol. Hepatol. 2002; 17: 818–824. 223. Fukasawa T, Murashima K, Matsumoto I, Hosono A, Ohara H, Nojiri C, Koga J, Kubota H, Kanegae M, Kaminogawa S, Abe K, and Kono T. Identification of marker genes for intestinal immunomodulating effect of a fructooligosaccharide by DNA microarray analysis. J. Agric. Food Chem. 2007; 55: 3174–3179. 224. Adogony V, Respondek F, Biourge V, Rudeaux F, Delaval J, Bind J-L, Salmon H. Effects of dietary scFOS on immunoglobulins in colostrums and milk of bitches. J. Anim. Physiol. Anim. Nutr. 2007; 91: 169–174. 225. Gibson GR, McCartney AL, and Rastall RA. Prebiotics and resistance to gastrointestinal infections. Br. J. Nutr. 2005; 93: 31–34. 226. Kunz C and Rudloff S. Biological functions of oligosaccharides in human milk. Acta Paediatr. 1993; 82: 903–912. 227. Shoaf K, Mulvey GL, Armstrong GD, and Hutkins RW. Prebiotic galactooligosaccharides reduce adherence of enteropathogenic Escherichia coli to tissue culture cells. Infect. Immun. 2006; 74: 6920–6928. 228. Tzortzis G, Goulas AK, and Gibson GR. Synthesis of prebiotic galactooligosaccharides using whole cells of a novel strain, Bifidobacterium bifidum NCIMB 41171. Appl. Microbiol. Biotechnol. 2005; 68: 412–416. € 229. Ozaslan C, T€urk¸capar AG, Kesenci M, Karayal¸cin K, Yerdel MA, Bengisun S, and T€or€uner A. Effect of lactulose on bacterial translocation. Eur. J. Surg. 1997; 163: 463–467. 230. Bovee-Oudenhoven IMJ, Termont DMSL, Heidt PJ, and Van der Meer R. Increasing the intestinal resistance of rats to the invasive pathogen Salmonella enteritidis: additive effects of dietary lactulose and calcium. Gut 1997; 40: 497–504. 231. Apanavicius CJ, Powell KL, Vester BM, Karr-Lilienthal LK, Pope LL, Fastinger ND, Wallig MA, Tappenden KA, and Swanson K. Fructan supplementation and infection affect food intake, fever, and epithelial sloughing from salmonella challenge in weanling puppies. J. Nutr. 2007; 137: 1923–1930.

REFERENCES

577

232. Schumann C. Medical, nutritional and technological properties of lactulose. An update. Eur. J. Nutr. 2002; 41(Suppl. 1): 17–25. 233. Waligora-Dupriet AJ, Campeotto F, Nicolis I, Bonet A, Soulaines P, Dupont C, and Butel MJ. Effect of oligofructose supplementation on gut microflora and well-being in young children attending a day care. Int. J. Food Microbiol. 2007; 113: 108–113. 234. Lewis S, Burmeister S, Cohen S, Brazier J, and Awasthi A. Failure of dietary oligofructose to prevent antibiotic-associated diarrhoea. Aliment. Pharmacol. Ther. 2005; 21: 469–477. 235. Cummings JH, Christie S, and Cole TJ. A study of fructo oligosaccharides in the prevention of travellers’ diarrhea. Aliment. Pharmacol. Ther. 2001; 15: 1139–1145. 236. Duggan C, Penny ME, Hibberd P, Gil A, Huapaya A, Cooper A, Coletta F, Emenhiser C, and Kleinman RE. Oligofructose-supplemented infant cereal: 2 randomized, blinded, community-based trials in Peruvian infants. Am. J. Clin. Nutr. 2003; 77: 937–942. 237. Kotzampassi K, Giamarellos-Bourboulis EJ, Voudouris A, Kazamias P, and Eleftheriadis E. Benefits of a synbiotic formula (Synbiotic 2000Forte) in critically Ill trauma patients: early results of a randomized controlled trial. World J. Surg. 2006; 30: 1848–1855. 238. Olah A, Belagyi T, Poto L, Romics L, and Bengmark S. Synbiotic control of inflammation and infection in severe acute pancreatitis: a prospective, randomized, double blind study. Hepato-gastroenterology 2007; 54: 590–594. 239. Scholz-Ahrens KE, Ade P, Marten B, Weber P, Timm W, Açil Y, Gl€ uer C-C, Schrezenmeir J. Prebiotics, probiotics, and synbiotics affect mineral absorption, bone mineral content, and bone structure. J. Nutr. 2007; 137: 838S–846S. 240. Morohashi T. The effect on bone of stimulated intestinal mineral absorption following fructooligosaccharide consumption in rats. Biosci. Microflora 2002; 21: 21–25. 241. Chonan O, Matsumoto K, and Watanuki M. Effect of galacto-oligosaccharides on calcium absorption and preventing bone loss in ovariectomized rats. Biosci. Biotechnol. Biochem. 1995; 59: 236–239. 242. Coudray C, Demigne C, and Rayssiguier Y. Effects of dietary fibers on magnesium absorption in animals and humans. J. Nutr. 2003; 133: 1–4. 243. Taguchi A, Ohta A, Abe M, Baba S, Ohtsuki M, Takizawa T, Yuda Y, and Adachi T. The influence of fructo-oligosaccharides on the bone of model rats with ovariectomized osteoporosis. Sci. Rep. Meiji Seika Kaisha 1995; 33: 37–44. 244. Ohta A, Osakabe N, Yamada K, Saito Y, and Hidaka H. The influence of fructooligosaccharides and various other oligosaccharides on the absorption of Ca, Mg and P in rats. J. Japanese Soc. Nutr. Food Sci. 1993; 46: 123–129. 245. Devareddy L, Khalil DA, Korlagunta K, Hooshmand S, Bellmer DD, and Arjmandi BH. The effects of fructo-oligosaccharides in combination with soy protein on bone in osteopenic ovariectomized rats. Menopause 2006; 13: 692–699. 246. Mizota T. Lactulose as a growth promoting factor for Bifidobacterium and its physiological aspects. Bull. Int. Dairy Fed. 1996; 313: 43–48. 247. Lopez HW, Levrat-Verny M-A, Coudray C, Besson C, Krespine V, Messager A, Demigne C, and Remesy C. Class 2 Resistant starches lower plasma and liver lipids and improve mineral retention in rats. J. Nutr. 2001; 131: 1283–1289. 248. Younes H, Demigne C, and Remesy C. Acidic fermentation in the caecum increases absorption of calcium and magnesium in the large intestine of the rat. Br. J. Nutr. 1996; 75: 301–314.

578

PREBIOTICS

249. Frank A. Oligofructose-enriched inulin stimulates calcium absorption and bone mineralisation. Br. Nutr. Foundation Nutr. Bull. 2006; 31: 341–345. 250. Holloway L, Moynihan S, Abrams SA, Kent K, Hsu AR, and Friedlander AL. Effects of oligofructose-enriched inulin on intestinal absorption of calcium and magnesium and bone turnover markers in postmenopausal women. Br. J. Nutr. 2007; 97: 365–372. 251. Abrams SA, Griffin IJ, Hawthorne KM, Liang L, Gunn SK, Darlington G, and Ellis KJ. A combination of prebiotic short- and long-chain inulin-type fructans enhances calcium absorption and bone mineralization in young adolescents. Am. J. Clin. Nutr. 2005; 82: 471–476. 252. Hillman LS, Tack E, Covell DG, Vieira NE, and Yergey AL. Measurement of true calcium absorption in premature infants using intravenous 46 Ca and oral 44 Ca. Pediatr. Res. 1988; 23: 589–594. 253. Van den Heuvel EG, Muijs T, van Dokkum W, and Schaafsma G. Lactulose stimulates calcium absorption in postmenopausal women. J. Bone Mineral Res. 1999; 14: 1211– 1216. 254. Younes H, Coudray C, Bellanger J, Demigne C, Rayssiguier Y, and Remesy C. Effects of two fermentable carbohydrates (inulin and resistant starch) and their combination on calcium and magnesium balance in rats. Br. J. Nutr. 2001; 86: 479–485. 255. Kruger MC, Brown KE, Collett G, Layton L, and Schollum LM. The effect of fructooligosaccharides with various degrees of polymerization on calcium bioavailability in the growing rat. Exp. Biol. Med. 2003; 228: 683–688. 256. Griffin IJ, Davila PM, and Abrams SA. Non-digestible oligosaccharides and calcium absorption in girls with adequate calcium intakes. Br. J. Nutr. 2002; 87(Suppl. 2): S187– S191. 257. Orchel A, Dzierewicz Z, Parfiniewicz B, Weglarz L, and Wilczok T. Butyrate-induced differentiation of colon cancer cells is PKC and JNK dependent. J. Digest. Dis. Sci. 2005; 50: 490–498. 258. Daly K, Shirazi-Beechey SP. Microarray analysis of butyrate regulated genes in colonic epithelial cells. DNA Cell. Biol. 2006; 25: 49–62. 259. Lupton Microbial degradation products influence colon cancer risk: the butyrate controvosy. J. Nutr. 2004; 134: 479–482. 260. Duncan SH, Louis P, and Flint HJ. Lactate-utilizing bacteria, isolated from human feces, that produce butyrate as a major fermentation product. Appl. Environ. Microbiol. 2004; 70: 5810–5817. 261. Morrison DJ, Mackay WG, Edwards CA, Preston T, Dodson B, and Weaver LT. Butyrate production from oligofructose fermentation by the human faecal flora: what is the contribution of extracellular acetate and lactate?. Br. J. Nutr. 2006; 96: 570–577. 262. Rowland IR and Tanaka R. The effects of transgalactosylated oligosaccharides on gut flora metabolism in rats associated with a human faecal microflora. J. Appl. Bacteriol. 1993; 74: 667–674. 263. Phillips J, Muir JG, Birkett A, Lu ZX, Jones GP, O’Dea K, Young GP. Effect of resistant starch on fecal bulk and fermentation-dependent events in humans. Am. J. Clin. Nutr. 1995; 62: 121–130. 264. Hylla S, Gostner A, Dusel G, Anger H, Bartram HP, Christl SU, Kasper H, and Scheppach W. Effects of resistant starch on the colon in healthy volunteers: possible implications for cancer prevention. Am. J. Clin. Nutr. 1998; 67: 136–142.

REFERENCES

579

265. Grubben MJ, van den Braak CC, Essenberg M, Olthof M, Tangerman A, Katan MB, and Nagengast FM. Effect of resistant starch on potential biomarkers for colonic cancer risk in patients with colonic adenomas: a controlled trial. Digest. Dis. Sci. 2001; 46: 750–756. 266. Jacobasch G, Dongowski G, Schmiedl D, M€uller-Schmehl K. Hydrothermal treatment of Novelose 330 results in high yield of resistant starch type 3 with beneficial prebiotic properties and decreased secondary bile acid formation in rats. Br. J. Nutr. 2006; 95: 1063–1074. 267. Bouhnik Y, Raskine L, Champion K, Andrieux C, Penven S, Jacobs H, and Simoneau G. Prolonged administration of low-dose inulin stimulates the growth of bifidobacteria in humans. Nutr. Res. 2007; 27: 187–193. 268. Bouhnik Y, Flourie B, Ouarne F, Riottot M, Bissetti N, Bornet F, and Rambaud JC. Effects of prolonged ingestion of fructo-oligosaccharides (FOS) on colonic bifidobacteria, faecal enzymes and bile acids in humans. Gastroenterology 1994; 106: A598. 269. Pool-Zobel BL. Inulin-type fructans and reduction in colon cancer risk: review of experimental and human data. Br. J. Nutr. 2005; 93(Suppl. 1): S73–S90. 270. Rowland IR, Bearne CA, Fischer R, Pool-Zobel BL. The effect of lactulose on DNA damage induced by DMH in the colon of human flora-associated rats. Nutr. Cancer 1996; 26: 37–47. 271. Challa A, Rao DR, Chawan CB, and Shackelford L. Bifidobacterium longum and lactulose suppress azoxymethane-induced colonic aberrant crypt foci in rats. Carcinogenesis 1997; 18: 517–521. 272. Hsu C-K, Liao J-W, Chung Y-C, Hsieh C-P, Chan Y-C. Xylooligosaccharides and fructooligosaccharides affect the intestinal microbiota and precancerous colonic lesion development in rats. J. Nutr. 2004; 134: 1523–1528. 273. Perrin P, Pierre F, Patry Y, Champ M, Berreur M, Pradal G, Bornet F, Meflah K, and Menanteau J. Only fibers promoting a stable butyrate producing colonic ecosystem decrease the rate of aberrant crypt foci in rats. Gut 2001; 48: 53–61. 274. Nakanishi S, Kataoka K, Kuwahara T, and Ohnishi Y. Effects of high amylose maize starch and Clostridium butyricum on metabolism in colonic microbiota and formation of azoxymethane-induced aberrant crypt foci in the rat colon. Microbiol. Immunol. 2003; 47: 951–958. 275. Watzl B, Girrbach S, and Roller M. Inulin, oligofructose and immunomodulation. Br. J. Nutr. 2005; 93(Suppl. 1): S49–S55. 276. Roller M, Pietro Femia A, Caderni G, Rechkemmer G, and Watzl B. Intestinal immunity of rats with colon cancer is modulated by oligofructose-enriched inulin combined with Lactobacillus rhamnosus and Bifidobacterium lactis. Br. J. Nutr. 2004; 92: 931–938. 277. Verghese M, Walker LT, Shackelford L, and Chawan CB. Inhibitory effects of nondigestible carbohydrates of different chain lengths on azoxymethane-induced aberrant crypt foci in Fisher 344 rats. Nutr. Res. 2005; 25: 859–868. 278. Rowland IR, Rumney CJ, Coutts JT, and Lievense LC. Effect of Bifidobacterium longum and inulin on gut bacterial metabolism and carcinogen-induced aberrant crypt foci in rats. Carcinogenesis 1998; 19: 281–285. 279. Gallaher DD and Khil j. The effect of synbiotics on colon carcinogenesis in rats. J. Nutr. 1999; 129: S1483–S1487. 280. Femia AP, Luceri C, Dolara P, Giannini A, Biggeri A, Salvadori M, Clune Y, Collins JK, Paglierani M, and Caderni G. Antitumorigenic activity of the prebiotic inulin enriched

580

281.

282.

283.

284. 285.

286.

287.

288.

289.

290.

291.

292. 293.

PREBIOTICS

with oligofructose in combination with the probiotics Lactobacillus rhamnosus and Bifidobacterium lactis on azoxymethane-induced colon carcinogenesis in rats. Carcinogenesis 2002; 23: 1953–1960. Ferchaud-Roucher V, Pouteau E, Piloquet H, Za€ır Y, and Krempf M. Colonic fermentation from lactulose inhibits lipolysis in overweight subjects. Am. J. Physiol. 2005; 289: E716–E720. Shimomura Y, Maeda K, Nagasaki M, Matsuo Y, Murakami T, Bajotto G, Sato J, Seino T, Kamiwaki T, and Suzuki M. Attenuated response of the serum triglyceride concentration to ingestion of a chocolate containing polydextrose and lactitol in place of sugar. Biosci. Biotechnol. Biochem. 2005; 69: 1819–1823. Vogt JA, Ishii-Schrade KB, Pencharz PB, Jones PJH, and Wolever TMS. Lrhamnose and lactulose decrease serum triacylglycerols and their rates of synthesis, but do not affect serum cholesterol concentrations in men. J. Nutr. 2006; 136: 2160– 2166. Williams CM and Jackson KG. Inulin and oligofructose: effects on lipid metabolism from human studies. Br. J. Nutr. 2002; 87(Suppl. 2): S261–S264. Brighenti F, Benini L, Del Rio D, Casiraghi C, Pellegrini N, Scazzina F, Jenkins DJA, and Vantini I. Colonic fermentation of indigestible carbohydrates contributes to the second-meal effect. Am. J. Clin. Nutr. 2006; 83: 817–822. Juskiewicz J, Klewicki R, and Zdunczyk Z. Consumption of galactosyl derivatives of polyols beneficially affects cecal fermentation and serum parameters in rats. Nutr. Res. 2006; 26: 531–536. Swanson KS and Fahey GC Jr. Prebiotic impacts on companion animals. In: Gibson GR and Rastall RA, editors. Prebiotics: Development and Application. John Wiley & Sons, Chichester, England, 2006, pp. 213–236. Mwenya B, Santoso B, Sar C, Gamo Y, Kobayashi T, Arai I, and Takahashi J. Effects of including beta1-4 galacto-oligosaccharides, lactic acid bacteria or yeast culture on methanogenesis as well as energy and nitrogen metabolism in sheep. Animal Feed Sci. Technol. 2004; 115: 313–326. Mwenya B, Zhou X, Santoso B, Sar C, Gamo Y, Kobayashi T, and Takahashi J. Effects of probiotic-vitacogen and beta1-4 galacto-oligosaccharides supplementation on methanogenesis and energy and nitrogen utilization in dairy cows. Asian-Australasian J. Anim. Sci. 2004; 17: 349–354. Sar C, Santoso B, Gamo Y, Kobayashi T, Shiozaki S, Kimura K, Mizukoshi H, Arai I, and Takahashi J. Effects of combination of nitrate with beta1-4 galacto-oligosaccharides and yeast (Candida kefyr) on methane emission from sheep. Asian-Australasian J. Anim. Sci. 2004; 17: 73–79. Santoso B, Mwenya B, Sar C, Gamo Y, Kobayashi T, Morikawa R, Kimura K, Mizukoshi H, and Takahashi J. Effects of supplementing galacto-oligosaccharides, Yucca schidigera or nisin on rumen methanogenesis, nitrogen and energy metabolism in sheep. Livestock Production Sci. 2004; 91: 209–217. Patterson JA and Burkholder KM. Application of prebiotics and probiotics in poultry production. Poultry Sci. 2003; 82: 627–631. Flickinger EA, Van Loo J, and Fahey GC Jr. Nutritional responses to the presence of inulin and oligofructose in the diets of domesticated animals: A review. Crit. Rev. Food Sci. Nutr. 2003; 43: 19–60.

REFERENCES

581

294. Shim SB, Verstegen MWA, Kim IH, Kwon OS, and Verdonk JMAJ. Effects of feeding antibiotic-free creep feed supplemented with oligofructose, probiotics or synbiotics to suckling piglets increases the preweaning weight gain and composition of intestinal microbiota. Arch. Animal Nutr. 2005; 59: 419–427. 295. Playne MJ and Crittenden R. Commercially available oligosaccharides. Bull. Int. Dairy Fed. 1996; 313: 10–22. 296. Moshfegh AJ, Friday JE, Goldman JP, and Chug Ahuja JK. Presence of inulin and oligofructose in the diets of Americans. J. Nutr. 1999; 129(Suppl. 7): S1407–S1411. 297. Smith PB. Safety of short-chain fructo-oligosaccharides and GRAS affirmation by the US FDA. Biosci. Microflora 2002; 21: 27–29. 298. Deguchi Y, Matsumoto K, Ito A, and Watanuki M. Effects of b 1-4 galactooligosaccharides administration on defaecation of healthy volunteers with a tendency to constipation. Japanese J. Nutr. 1997; 55: 13–22. 299. Saavedra JM and Tschernia A. Human studies with probiotics and prebiotics: clinical implications. Br. J. Nutr. 2002; 87(Suppl. 2): S241–S246. 300. Bovee-Oudenhoven IMJ, Ten Bruggencate SJM, Lettink-Wissink MLG, and van der Meer R. Dietary fructo-oligosaccharides and lactulose inhibit intestinal colonisation but stimulate translocation of Salmonella in rats. Gut 2003; 52: 1572–1578. 301. Ten Bruggencate SJM, Bovee-Oudenhoven IMJ, Lettink-Wissink MLG, and van der Meer R. Dietary fructo-oligosaccharides dose-dependently increase translocation of Salmonella in rats. J. Nutr. 2003; 133: 2313–2318. 302. Ten Bruggencate SJM, Bovee-Oudenhoven IMJ, Lettink-Wissink MLG, Katan MB, and van der Meer R. Dietary fructooligosaccharides affect intestinal barrier function in healthy men J. Nutr. 2006; 136: 70–74.

AUTHOR INDEX

Abelardo Margolles, 4, 6, 190 Allan Lim, 123, 321 Andrew W. Bruce, 30, 472 Arthur C. Ouwehand, 21, 23, 106, 377, 379, 382–384, 386, 389, 390, 447, 451, 469, 477, 551 Baltasar Mayo, 4, 37 Camilla Hoppe, 441, 480 Charlotte Nexmann Larsen, 38, 41, 441, 466, 480 Clara de los Reyes–Gavilan, 6, 25 Diana Donohue, 75, 83 Dorte Eskesen, 38, 41, 466, 480 Fred H Degnan, 111 Gregor Reid, 4, 20, 79, 83, 85, 90, 386, 388, 470–472 Hai–Meng Tan, 123, 321 Hirokazu Tsuji, 220, 539, 485

James J.C. Chin, 406, 408, 409 Jin–zhong Xiao, 306, 488, 490, 491 Jose M Saavedra, 111, 482, 485, 560 J.M. Laparra, 259, 260, 262 Kajsa Kajander, 258, 285, 385, 390, 469, 477–479 Katsunori Kimura, 14, 15, 21, 457 Koji Nomoto, 449, 485 M. Carmen Collado, 1, 6, 20, 23, 24, 38, 41, 257, 263, 382, 384–391, 397, 403, 404, 447, 478, 481 Maija Saxelin, 63, 67, 70, 92, 182, 462–465, 469, 470 Martin J. Playne, 62, 80, 560 Mayumi Kiwaki, 217, 226, 449 Miguel Gueimonde, 20, 21, 23–25, 36, 38, 41, 79, 94, 262, 382, 389, 400, 401 Mimi Tang, 395 Paivi Nurminen, 30, 473 Patricia Ruas–Madiedo, 4, 190, 390

Handbook of Probiotics and Prebiotics, Second Edition Edited by Yuan Kun Lee and Seppo Salminen Copyright Ó 2009 John Wiley & Sons, Inc.

583

584

AUTHOR INDEX

Rafael Frias, 79, 94, 263 Rangne Fonden, 444–446, 462–464, 473 Reetta Satokari, 7, 14, 16, 33, 400, 402, 548, 549 Riitta Korpela, 270, 271, 477 Ross Crittenden, 20, 58, 62–66, 68, 69, 462, 465, 535, 536, 539, 548, 550

Seppo Salminen, 3, 23, 35, 36, 59, 64, 81, 83, 84, 85, 90, 92, 257, 267, 384, 399, 469, 478, 480, 492, 536 Toni A Chapman, 43, 406, 410, 411, 415 Ulla Svensson, 63, 67, 70, 219, 444, 462–465 William Hung Chang Tien, 95, 205, 212, 216

Sampo Lahtinen, 41, 42, 106, 377, 382, 447, 473, 492–494 Satu Vesterlund, 81, 377, 391, 469

Yuan Kun Lee, 3, 52, 54, 57, 177, 180, 181, 267, 321, 322, 450, 451, 454

SUBJECT INDEX

7-keto-deoxycholic acid, 485 16s sequencing, 9, 10 Aberrant crypt foci (ACF), 486, 487 Absenteeism, reduction of, 449, 482 Acid, 6, 15, 29, 39, 40, 64, 66, 91, 98, 99, 180, 190, 191, 267, 268, 331, 341, 392, 398, 400, 415, 418, 441, 447, 454, 461, 471, 480, 485, 487, 489 effect on adhesion, 382, 480 tolerance, 64, 73, 180, 197, 480 Acquired immunity, 76, 409 Adhesion, 19–21, 23, 24, 56, 81, 181, 190, 222, 262, 263, 322, 348, 377–391, 418, 445, 447, 451, 454, 463, 464, 466, 469, 471, 477, 478, 480, 481, 492, 547 factors affecting, 382–383 to epithelial cells, 23, 377–378, 382–383, 386, 389 to human intestinal mucus, 23, 377–379, 384, 385, 389, 390, 454, 469, 478, 492 to oral cavity, 21, 388, 478 to fibronectin, 381

prevention of pathogen adhesion, 19–21, 24, 377, 383–386, 389, 391, 492 AFLP, 11, 13, 18 Aggregation, 384–386, 388 Agricultural Compounds and Veterinary Medicines Regulation (ACVM), 135 Allergic infants, 384, 402, 551 Allergy, 89, 91, 105, 302, 305, 307, 309, 310, 397, 452, 470, 479, 484, 490, 491, 551, 552 Amplified Ribosomal DNA Restriction Analysis (ARDRA), 571 Animal model, 5, 263–267, 397, 398, 448, 552, 553 Antagonistic, 22, 23, 385, 549 Antibiotic, 25, 38, 41, 54, 78, 81–86, 90, 91, 124, 181, 258, 276–279, 292, 321–323, 331, 385, 393, 408, 410, 415, 442, 446, 448, 449, 458, 462, 463, 467, 470, 472, 474, 481, 482, 489, 535–537, 552, 559 associated diarrhea, 54, 55, 57, 91, 258, 276, 279, 535, 537 growth promoter (AGP), 321, 322, 408, 415, 419, 420


585

586

SUBJECT INDEX

Antibiotic (Continued) resistance, 78, 83, 85, 86, 124, 181, 190, 415, 444, 463, 489 therapies, 86, 258, 385, 448, 458, 461 Antibody responses, 449, 479, 555 Antigenotoxic, 21, 24 Antimicrobial, 19–22, 24, 66, 84, 88, 181, 257, 263, 385, 391–395, 401, 408, 415, 418, 447, 454, 461, 473, 493, 537 against Escherichia coli, 27, 76, 493 against Helicobacter pylor, 76, 461, 493 against Salmonella, 24 against Staphylococcus aureus, 76, 493 resistant, 408, 415, 418, 537 Antioxidant, 66, 67, 124, 262, 445, 446, 463, 464 Antitumor, 93, 310, 468 Arthritis rheumatoides, 470 Aspergillus niger, 124, 126, 136 Aspergillus oryzae, 329, 337, 339, 341–343 Association of American Feed Control Authority (AAFCO), 123 Atopy, 35, 302, 561 Autistic children, 402 Australia, 125, 136, 138, 415, 544 Australian Pesticides and Veterinary Medicines Authority (APVMA), 125, 135 Autochthonous commensal, 408 Azoreductase, 448, 558 b-glucuronidase, 200, 448, 489, 558 Bacillus badius, 49, 126, 136 Bacillus cereus, 76, 200, 336, 338, 346 mutagenesis, 200 transposon, 200 Bacillus clausii, 277, 293, 295 Bacillus coagulans, 105, 124, 325 Bacillus lentus, 124, 126, 136 Bacillus licheniformis, 124, 126, 136, 336, 337 Bacillus pumilus, 124, 126, 136, 336 Bacillus subtilis, 124, 127, 136, 221, 322–324, 327, 328, 330, 336, 341, 342 vector, 212, 214 Bacillus toyoi, 127, 136, 337 Bacterial community profiling, 43, 44, 47, 48, 51, 402s

Bacteriocin, 190, 199, 226, 388, 392–394, 398, 415, 416, 442, 445 CH-5, 442 Bacteriodes amylophilus, 124, 127, 136 Bacteriodes capillosus, 124, 127, 136 Bacteriodes ruminocola, 124, 127, 136 Bacteriodes suis, 124, 127, 136 Bacteroides vulgatus, 29, 31, 32, 36, 388, 389 Bifidobacterium, 4–10, 13, 14, 19, 20, 22, 23, 25, 29–33, 35–41, 49, 50, 60, 62, 64, 70, 72, 75, 86, 123, 124, 127, 136, 200, 221, 262, 263, 281, 284, 293, 294, 303, 306, 350, 380, 387, 397, 399–401, 403, 405, 442, 448, 478, 485, 488, 489, 491–493, 536, 547–549, 551, 552 characterization, 4–6, 19, 24 identification, 4–18, 24 typing of, 5, 7, 9–12, 14, 24 Bifidobacterium adolescentis, 31, 101, 124, 127, 136, 212, 221, 402 M101-4, 268 vector, 212–221 Bifidobacterium angulatum, 7, 262 Bifidobacterium animalis, 7, 72, 86, 87, 108, 200, 221, 262, 284, 442, 473, 480 BB12, 41, 86, 90, 108, 442, 478, 480 DN-173010, 284 mutagenesis, 199 subsp, animalis, 7, 13, 14, 62–64, 66, 70–74, 86, 478 subsp. lactis, 7, 13, 14, 62–64, 66, 70–74, 86, 478 vector, 221 Bifidobacterium asteroids, 7, 8, 202, 221 plasmid, 202, 221 Bifidobacterium bifidum, 7, 39, 62, 63, 71, 72, 80, 88, 101, 124, 127, 136, 200, 202, 262, 268, 301, 329, 381, 400, 401, 548, 551 A234-4, 268 MF20/5, 301 mutagenesis, 199 plasmid, 200, 202 vector, 212–221 Bifidobacterium boum, 7, 8 Bifidobacterium breve, 7, 31, 58, 62, 63, 66, 71, 101, 200, 202, 221, 262, 267, 285, 286, 293, 306, 307, 399, 400, 401, 482, 486

SUBJECT INDEX

Bb99, 286, 293, 307, 320 I-53–8, 268 mutagenesis, 199 plasmid, 200, 202, 221 vector, 212–221 Yakult, 296, 485 Bifidobacterium catenulatum, 7, 31, 33, 202, 221, 548 plasmid, 202, 221, 222 Bifidobacterium choerinum, 7 Bifidobacterium coryneforme, 7 Bifidobacterium cuniculi, 7 Bifidobacterium dentium, 7, 9, 33, 221 vector, 221 Bifidobacteria fermented milk (BFM), 40, 487 Bifidobacteria fermented soya milk (FMS), 487 Bifidobacterium gallicum, 7 Bifidobacterium gallinarum, 7 Bifidobacterium indicum, 7 Bifidobacterium infantis, 31, 54, 62, 63, 66, 71, 88, 101, 124, 127, 136, 200, 221, 262, 267, 268, 273, 277, 280, 290, 291, 384, 400, 401, 551 I-10-5, 268 mutagenesis, 199 vector, 212–221 Bifidobacterium lactis, 20, 85, 90, 114, 277, 278, 298, 303, 310, 348, 379, 385, 398, 473, 474, 477 Bb-12, 90, 298, 303, 310, 348, 379, 385 Bi-07, 449 HN019 (DR10), 473–477 Bifidobacterium longum, 7, 8, 31, 62, 63, 66, 71, 72, 74, 103, 200, 202, 221, 262, 267, 268, 277, 280, 290, 291, 294, 301, 306, 314, 316, 378, 400, 401, 488–492, 494, 548, 551 913, 314 antiallergic activity, 490 BB536, 488, 489–491 BL2C, 491, 492, 494 BL46, 492, 494 effects on immunity and cancer, 490 improvement of intestinal environment, 489 M101-2, 268 mutagenesis, 199

587

plasmids, 200, 202, 221 safety, 103, 267, 488, 489, 492 SP07/0, 301 subsp. infantis, 7, 62, 63, 66, 71, 401, 551 subsp. longum, 7, 62, 63, 66, 71, 401, 551 subsp. suis, 7 vectors, 221 Bifidobacterium magnum, 7, 221 vector, 221 Bifidobacterium merycicum, 7 Bifidobacterium minimum, 7 Bifidobacterium pseudocatenulatum, 7, 33, 221 vector, 221 Bifidobacterium pseudolongum, 7, 33, 221 subsp. globosum, 7, 133, 202 subsp. pseudolongum, 60, 262 vector, 221 Bifidobacterium pseudomonas subsp. globosum, 202 plasmid, 202 Bifidobacterium psychraerophilum, 7 Bifidobacterium pullorum, 7 Bifidobacterium ruminantium, 7 Bifidobacterium saeculare, 7 Bifidobacterium scardovii, 7 Bifidobacterium subtile, 7 Bifidobacterium thermacidophilum, 7 subsp. thermoacidophilum, 7 subsp. porcinum, 7 Bifidobacterium thermophilum, 7, 49, 185, 336, 342 Biliary cancer, 296, 455, 487 Bile, 6, 19–22, 24, 25, 37, 38, 39, 52, 98, 180, 181, 184, 190, 191, 193, 200, 211, 262, 263, 268, 296, 313, 357, 382, 441, 445, 464, 466, 473, 480, 484, 489, 537 effect on adhesion, 382 tolerance to, 6, 20, 180, 183, 184, 190, 446, 465, 466 Biopsies, 6, 25, 290, 379, 380, 384, 398, 459–461, 464, 469 Bladder cancer, 182, 311, 313, 453 Blood mononuclear cells, 308, 452, 457, 479 Blood pressure, 454, 455 Bowel function, 108, 182 Caco-2, 23, 260–263, 378, 380–383, 451, 454, 478

588

SUBJECT INDEX

Calves, 126–128, 131, 134, 321, 331, 340–343 Campylobacter enteritis, 486 Campylobacter jejuni, 280, 322, 323, 348, 442 Cancer, 84, 105, 118, 182, 260, 292, 296, 310–313, 443, 446, 453, 455, 486, 487, 48, 490, 556, 558 Candida albicans, 87, 118, 448, 449, 484 Candida glabrata, 127 Candida pinolepessi, 127, 136 Candida utilis, 101, 127 Candidiasis, 448 Cannabinoid receptors, 448 Carbon dioxide, 393, 458 Cell line model, 259, 263 Cellular fatty acids, 29, 37 Cellular immunity, 89, 452, 454 Characterization, probiotics, 4–6, 19, 24 China, 100, 125, 136, 138 Cheese, 15, 21, 67, 70, 71, 95, 464, 469 Children, improvement of growth, 108 Cholesterol, 22, 104, 105, 221, 313–317, 323–327, 329, 334, 345, 455, 484–486, 559 liver, 104, 313, 317, 324, 326, 486 plasma, 313, 345, 455, 486 Claims, 76–79, 89, 90, 94, 99, 100, 103, 104, 106–111, 113, 115–122, 310, 350, 449, 477, 479 content, 116 benefit or efficacy, 116 health, 76, 79, 89, 94, 99, 106–110, 117–119, 121, 479 qualified health, 117, 119 structure or function, 117–121 Classification, probiotics, 4, 5, 7, 13–16 Clostridium butyricum, 127, 137, 277 MIYAIRI, 277 Clostridium cluster XIV, 403 Clostridium coccoides-Eubacterium rectale group, 32, 35 Clostridium perfringens, 321, 322, 348, 389, 557 Clostridium sporogenes phage, 127 Closridium tyrobutyricum phage, 127 Coaggregation, 35, 195, 200, 385, 386, 388, 447, 478 Coccidiostats, 125

Colic, infant, 448 Colicins, 415, 416, 418–420 Colibacillosis, 406–408, 414, 419 Collagen, 81, 381, 451, 456, 464 Colon carcinogenesis, 453, 558 Colonic epithelial cell, 261, 485, 535 Colonic hyperplasia, 448 Colonization, 15, 20, 21, 23, 87, 98, 181, 184, 262, 270, 298, 309, 310, 345, 377–380, 384–386, 388, 389, 391, 395, 398–401, 403–407, 409, 420, 450, 456, 462, 469, 482, 486, 549, 551, 553 Competition, 24, 54–56, 385, 389, 409, 417, 454 Competitive exclusion, 23, 321, 322, 408, 409 Confectionary, 74 Conjugated bile salt hydrolase, 200, 489 Cough, 449 Critically ill children (CIC), 456 Crohn’s disease, 36, 76, 93, 287, 288, 470, 473, 551, 554 Cystic fibrosis, 76, 470 Cytokines, 88, 89, 93, 259, 308, 378, 397, 398, 443, 445, 446, 452, 453, 468, 483, 490, 493, 551, 553, 554 Cytoprotection, 449 Cytotoxic activity, 474 Digestive enzymes, 52, 98, 102, 382, 441, 447, 473, 480 effect on adhesion, 382 tolerance to, 447 Dimethylamine, 448 Deconjugate bile salts, 21, 24, 489 Decrease cholesterol, 24 Denaturing Gradient Gel Electrophoresis (DGGE), 11–13, 16, 27, 30, 32–34, 42, 43, 51, 290, 402 Denaturing /Thermal Gradient Gel Electrophoresis (DGGE/TGGE), 33, 43 Denaturing High Performance Liquid Chromatography, 33 Dendritic cells, 89, 396, 399, 554 Dental caries, 270 Deoxycholic acid, 485 Department of Livestock Development, Thailand, 125 Desserts, 72 Designer lactic acid bacteria, 415

SUBJECT INDEX

Diabetes, 76, 84, 88, 259, 455, 457, 484, 550, 559 Diarrhea, 52, 53, 54, 90, 258, 281, 466, 481 antibiotic-associated, 54, 55, 181, 258, 276 Colibacillosis, 406, 407, 414 Clostridium difficile-associated, 279 infants at risk, 402, 434, 552 radiation-induced, 279, 280, 361 Rotavirus, 53, 258, 272, 385, 398 tube-fed patients, 281, 362 Dietary Supplement Health and Education Act, USA (DSHEA), 115 Digestibility enhancer, 125 Digestive juices, tolerance, 180–181 Displacement, 321, 389, 391 Dysentery, 477 Ear infections, 477 Effective dosage, 52, 53, 55 acute (Rotavirus) diarrhea, 53, 272 antibiotic-associated diarrhea, 54. 55, 57, 82 181, 258, 276, 385 Helicobacter pyroli, 58 Egg quality, 323 Elderly, 23, 32, 34, 36, 90, 91, 152, 492, 493 normal, 60, 77, 82, 86, 87, 89, 103, 556 with constipation, 284, 404 with diarrhea, 279, 404, 414, 467 ELISA, 13, 124 Encapsulation, 65, 68, 69 Endogenous microbiota, 382 Enteric Microbial Community Profiling (EMCoP), 43, 47, 51 Enterobacterial Repetitive Intergenic Consensus Sequence-PCR (ERIC-PCR), 13 Enterobacter sakazakii, 24 Enterococcus cremoris, 127 Enterococcus diacetylactis, 127 Enterococcus durans, 221 vector, 212, 214, 215, 216 Enterococcus faecalis, 18, 75 homologous recombination, 198, 199, 222, 224 plasmid insertion, 226 transposable element insertion, 226 vector, 212, 214, 215, 216 Enterococcus faecium, 80, 322, 350 M-74, 314

589

mutangenesis, 190–201 plasmid, 38, 83, 206–211 SF68, 277, 329, 337, 347 vector, 212, 214, 215, 216 Enterococcus mundtii, 129 Enteropathogen, 23, 391, 407, 409 Enteropathogenic Escherichia coli (EPEC), 407, 409, 484 Epithelial cells, 451, 458, 463, 469, 535 Epithelia model, 259–267 Escherichia coli, 24, 33, 36, 48, 76, 389, 406 extraintestinal pathogenic, 409 H10407, 262 JPN15, 262 O6:K5:H1, 289 serogroup, 407, 411 Eubiosis, 321 European Food Safety Authority (EFSA), 5, 125 European Parlement, 106, 123 European Union (EU), 91, 123, 135, 449 Exopolysaccharides ERIC-PCR, 390, 447 Experimental autoimmune encephalomyelitis (EAE), 88 Extracellular matrix (ECM), 457 Fecal microbiota, 31, 33, 34, 35, 36, 406 Feed, 14, 15, 50 additives, 114, 123 conversion ratio, 321, 408 Fermented foods, 14, 63, 69 78, 83 Fermented milk, 38, 58, 60, 64, 69, 92, 99, 263, 269, 450 Fever, 82, 83, 443, 449 Fibrinogen, 81 Fibronectin, 228, 451, 464 Fimbriae, 407, 411, 418, 419 Fimbrial adhesions, 407, 409 Fluorescence in situ hybridization (FISH), 30, 35 Food and Agricultural Materials Inspection Centre (FAMIC), Japan, 125 Food and Drug Administration (FDA), USA, 97, 101, 103, 111, 118, 135 Food Safety Authority of Ireland, 110 Food Standards Agency (UK), 110 Freeze-dried probiotics, 65, 66 Fructose-6-phosphate phosphoketolase (F6PPK) 9, 201

590

SUBJECT INDEX

Fructooligosaccharides (FOS) 108, 405, 449 Fusobacterium prausnitzii, 31, 403 Galactooligosaccharides (GOS), 296, 307, 320 Gastrointestinal, 296, 307, 320 diseases, 4, 7, 31, 52, 76, 82, 88 environnent, 447 model, 5, 23, 47, 89, 93, 259, 260, 261, 263, 264 survival during, 59, 64, 179 symptom, 83, 88, 90, 94, 96, 257, 258, 259, 266 transit, 4, 9, 19, 60, 403 Gene expression, in gut, 470 Gene signatures, 51, 408, 411, 412, 413 Generally recognized as safe (GRAS), 112, 135, 485 Genome, 13, 18, 19, 34, 356, 42 plasticity, 410 Genotoxicity, 124 Generally Recognized as Safe (GRAS), 112, 135, 485 Glucose metabolism, 394 Gut, 23, 30, 31, 33, 35, 36, 77, 87, 123, 259 associated lymphoid tissue, 23, 395, 404, 443 flora stabilizers, 125 immune system, 7, 23, 24, 75, 87, 90, 94 microbiota, 4, 6, 25, 27, 28, 29, 30, 31, 32, 33, 34, 35 permeability, 27, 35, 260 transit, 4, 9, 19, 60, 63 Health benefits, 59, 60, 69, 75, 76 Healthy microbiota, 399, 404, 405 Heavy metals, binding of, 493 Helicobacter pylori, 7, 76, 258, 292 Histomonostats, 125 Host immunity, 409 HOWARU, 473 Rhamnosus, 18, 54, 62, 84, 92 Bifido, 4, 5, 6, 7, 29, 31, 32, 33, 35, 63 HT29, 260, 261, 262 HT-29-MTX, 378 HTB-37, 23, 260 Human T-cell lymphotropic virus type-1 (HTLV-1), 457 Hybridization probes, 31 Hydrogen peroxide, 231, 392, 398

Hydrophobic grid membrane filtration (HGMF), 412, 413 Hydrophobicity, 386, 388 Ice cream, 60, 67, 72 Identification, 4, 5, 6, 9, 13, 14 Bifidobacterium, 5, 6, 7, 8, 9, 13, 31, 492 Lactobacillus, 4, 5, 14, 15, 16 Infectious diseases, 454, 483 Immunoglobulin, 259, 449, 490 A (IgA), 468, 483 E (IgE), 551 G (IgG), 319–320, 458, 468 M (IgM), 319, 468 Immunological memory, 454 Immunomodulation, 15, 59, 89, 552 Indigenous lactobacilli, 451 Indonesia, 104 Infant formula, 60, 90, 114, 485 Inflammation, 287, 292, 298, 554 Inflammatory bowel disease (IBD), 287, 535 Inflammatory diseases, 442, 481 Influenza virus (IFV), 490 Inhibition, 15, 24, 339 Innate immunity, 434 Insulin-dependent diabetes mellitus (IDDM), 452, 455, 457 Interferon-gamma (INF-g), 468 Interleukin, 396, 443 4 (IL-4), 396 6 (IL-6), 443 8 (IL-8), 508 12 (IL-12), 396 Intestinal, 3, 4, 6, 23, 25, 33, 42 bacterial enzyme activity, 450 barrier, 19, 65, 66 epithelial cell, 23, 56, 377 metabolic activity, 42, 258, 383, 474 microbiota, 4, 6, 29 mucus, 19, 23, 24, 81, 378 Intergenic spacer (IGS), 12, 44 Internal transcribed spacer (ITS), 44 Irritable bowel syndrome (IBS), 258, 448 Isolation, 6, 25, 43, 82 bifidobacteria, 5, 6, 9, 13, 33, 36 enterococci, 25, 52, 84, 403 lactobacilli, 5, 6, 14, 18, 64, 66 streptococci, 270, 395 yeast, 4, 52, 95, 394, 407

SUBJECT INDEX

Japan, 96, 99, 105, 125, 136, 488, 560 Joint Health Claims Initiative (UK), 106 Juice, 19, 73, 180 Korea, 102–103, 125, 136 Kinetic Inhibition Microtiter Assay (KIMA), 416 Kluyveromyces marxianus, 129 Kluyveromyces marxianus-fragilis, 129 Knock-outs, 265 Labeling, 8, 94, 98, 109, 116, 118 Lactina, 322, 329 Lactic acid, 14, 79, 91, 191, 195, 392 Lactitol, 448, 449, 550, 557 Lactobacillus, 4, 7, 10, 20–22, 33, 61, 81–92, 339–340, 386, 397–398, 547 characterization, 4–5 identification, 4–6, 10–11, 18, 444, 462–463 mutagenesis, 190–200 plasmid, 203–206 typings, 5, 8, 10–11, 18 Lactobacillus acidophilus, 62, 66, 80, 101, 129, 137, 203, 293, 441, 444, 447 145, 314 antibiotic-associate diarrhea, 276 CH 5, 86, 180–181 DDS Plus, 316 DNA fragment replacement, 224 homologous recombination, 198–199, 222, 224 L-1, 316 LA-1, 316 LAVRI-A1, 309 La5, 222, 298, 343 LB, 293, 383 NCDO 1748, 444, 446 NCFM, 447–449 NCIMB 8690, 180–181 plasmid, 38, 83, 202–210 SBT2062, 268 vector, 212–221 Lactobacillus agilis, 381 Lactobacillus amyloliticus, 129 Lactobacillus amylovorans, 129 Lactobacillus amylovorus, 142, 201 mutagenesis, 190–200 Lactobacillus bifidus, 137

591

Lactobacillus brevis, 124, 325, 381 DNA fragment replacement, 224 homologous recombination, 198–199, 222, 224 plasmid, 203 vector, 212–221 Lactobacillus bucheri, 124, 129, 137 Lactobacillus bulgaricus, 54, 101, 113 Lactobacillus casei, 82, 101, 203, 449–456 DN-114001, 301 GG, 390–391 homologous recombination, 198–199, 222–224 NCIMB 8822, 179–181 NCIMB 11970, 179–181 plasmid, 203 recombination, 222–228 Shirota, 41, 88, 89, 179–181, 283, 296, 311, 345, 449 subsp. alactosus, 221 transposable element, 255 vector, 212–221 Lactobacillus cellobiosus, 129, 137 Lactobacillus collinoides, 129 Lactobacillus crispatus, 50, 352, 380 vector, 212–221 Lactobacillus curvatus, 129, 137 vectors, 212–221 Lactobacillus delbrueckii, 101, 203, 442 100-18, 268 100-21, 268 mutagenesis, 190–200 NCIMB 11778, 181 plasmid, 203 subsp. bulgaricus (also Lactobacillus bulgaricus), 39, 70, 101, 181, 203, 345 subsp. lactis, 221 vectors, 212–221 Lactobacillus farciminis, 130 Lactobacillus fareiminis, 124, 130 Lactobacillus fermentum, 204, 221 100-20, 268 104-R, 381, 383 DNA fragment replacement, 224 KLD, 280 homologous recombination, 198–199, 222–224 PCC, 306, 317 plasmid, 204

592

SUBJECT INDEX

Lactobacillus fermentum (Continued) recombination, 222–228 vector, 212–221 VRI-033 PCC, 306 Lactobacillus fructosus, 221 Vector, 212–221 Lactobacillus gasseri, 221, 457–459 DNA fragment replacement, 224 F71, 263 homologous recombination, 198–199, 222–224 L1, 206 LG21, 457–462 mutagenesis, 190–200 PA16/8, 301 plasmid, 202–211 vector, 212–221 Lactobacillus helveticus, 204, 221 DNA fragment replacement, 224 homologous recombination, 198–199, 222–224 plasmid, 204 transposable element insertion, 226 vector, 212–221 Lactobacillus hilgardii, 221 plasmid, 204 Lactobacillus jensenii, 221 vector, 212–221 Lactobacillus johnsonii, 221 DNA fragment replacement, 224 homologous recombination, 198–199, 222–224 La1, 41, 381 plasmid, 204 vector, 212–221 Lactobacillus lactis, 114, 201 Bb-12, 480–485 DNA fragment replacement, 224 homologous recombination, 198–199, 222–224 mutagenesis, 190–200 plasmid, 206 subsp. cremoris, 207 subsp. lactis, 200 subsp. lactis biovar diacetylactis, 132, 208 vector, 212–221 Lactobacillus mucosa, 49 Lactobacillus murinus, Lactobacillus paracasei, 67–68, 462, 466

BA3, 263 F76, 263 NCIMB 8001, 180–181 NCIMB 9709, 180–181 NCIMB 9713, 180–181 plasmid, 204 subsp. paracasei F19, 462–465 vector, 212–221 Lactobacillus paraplantarum, 221 plasmid, 205 vector, 212–221 Lactobacillus pentosus, 221 Lactobacillus plantarum, 205 299v, 41, 283, 298, 384 DNA fragment replacement, 224 homologous recombination, 198–199, 222, 224 mutagenesis, 190–200 plasmid, 205 recombination, 222–228 transposable element, 226 vector, 212–221 Lactobacillus reuteri, 49, 350, 394, 399, 470 100-23, 206, 268, 381 DSM12246, 305 plasmid, 206 RC-14, 470–471 vector, 212–221 Lactobacillus rhamnosus, 81, 101, 397, 469–475 19070-2, 305 GR-1, 470–471 antibiotic-associated diarrhea, 54, 82, 276 GG, 60, 397, 469 HN001 (DR20), 473–475 LC705, 293–294, 390, 478, 480 mutagenesis, 190–200 NCIMB 6375, 180–181 plasmid, 190–200 vector, 212–221 Lactobacillus sake, 223–226 homologous recombination, 198–199, 222, 224 plasmid, 190–200 transposable element insertion, 226 Lactobacillus sakei, 206 DNA fragment replacement, 224

SUBJECT INDEX

homologous recombination, 198–199, 222–224 mutagenesis, 190–200 plasmid, 206 vector, 212–221 Lactobacillus salivarius, 33, 206 subsp. salivarius, 206 plasmid, 206 vector, 212–221 Lactobacillus sanfranciscensis, 221 vectors, 212–221 Lactose, 194, 211, 222–228, 258, 268–270, 344, 443, 446–448 Intolerance, 443, 448 Maldigestion, 268–269 Lantibiotics, 393, 415 laryngotracheo-esophageal cleft (LTEC), 457, 487 Legal Status, in Asia, 95–105 China, 100, 125, 136–138 Japan, 488, 542–544 Korean, 103Malaysia, 103, 139 Taiwan, 103, 104 Thailand, 104, 125, 136–138 Legislation, 106, 108, 110 Leuconostoc citreum, 209 plasmids, 209 vectors, 212–221 Leuconostoc mesenteroides, 124, 132, 137, 209 mutagenesis, 190–200 plasmid, 209 subsp. mesenteroides, 209 vector, 212–221 Leuconostoc oeno, 132 Leuconostoc pseudo-mesenteroides, 132, 137 Lignans, 382 Lipoteichoic acids (LTAs), 381, 457 Listeria monocytogenes, 394, 454 LS174T, 260 Macrophage, 182, 443, 483, 490 Maintenance, 75, 177–186, 405 bifidobacteria, 5, 9, 13, 14 enterococci, 177–178 lactobacilli, 177–178 streptococci, 177–178 yeast, 177–178

593

Malaysia, 103, 139 Mammary carcinogenesis, 486 Manufacturing criteria 179 Market size, 96 Maternal fecal microbiota, 406 Meat, 62, 179, 321, 446 Metabolism, 18, 64, 67, 72, 261, 266, 331, 381, 549 carbohydrates, 64, 331 lactose, 268, 448 prebiotics, 405, 536, 550, metagenomic, 36 Metaproteomic, 30 Methicillin-resistant Staphylococcus aureus (MRSA), 430, 457 Microarray, 12, 14 Microbial, 4, 43, 47, 55, 265, 395, 409, 466 analysis, 9, 14, 16, 33, 48 diversity, 6, 47 Microbiota, 42, 258, 331, 383, 384, 395, 399, 400, 402, 403, 405, 492, 552, 562 assessment, 25–33, 37 elderly, 34, 36, 404, 492, 493, 549 infancy, 87, 401–405, 546, 547 Microcystin-LR, 493 Microecology, 310 Microencapsulation, 68, 69 Minerals, 67, 107, 124 effect on adhesion, 382 improvement of nutritional status, 107, 124 Ministry of Agriculture, People’s Republic of China, 176 Ministry of Health (Belgium, The Netherlands), 110 Monostrain, 390 Mosaicism, 410 MUC5AC mucin gene, 261 Mucosa, 23 Mucus, 377, 378, 385 glycoprotein, 450–455 Multilocus enzyme electrophoresis (MLEE), 409 Multilocus sequence syping (MLST), 13 Multiple strains, 10, 75 Multispecies, 88, 91, 477 Mutagen binding, 310, 445, 446 Mutagenicity, 124

594

SUBJECT INDEX

Mycotoxins, 382 binding of, 382 effect on adhesion, 382 Natural killer (NK)-cell, 474–476 Necrosis, 91 New Dietary Ingredient (NDI) USA, 114 New Zealand, 69, 135 New Zealand Food authority, 69 Nisin, 393 Nitroreductase, 448 Nitrosodimethylamine, 448 Non-insulin-dependent diabetes mellitus (NIDDM), 457 Nonfermented foods, 69 Nonlantibiotics, 393, 418 heat-stable, 393, 418 heat-labile, 393, 418 Nonobese diabetic (NOD), 457 Nonviable probiotics, 380, 383 Oligonucleotide, 34 Operational Taxonomic Units, 16, 49 (m-)Opioid receptors, 448 Oral infection, 270 Organic acid, 64 Oropharyngeal biofilms, 456 Overage, 59 Pediocuceus, 132, 138 plasmid, 132–138 vector, 132–138 Pediococcus cerevisiae, 124, 133 Pediococcus damnosu, 208–211 Plasmid, 208–211 Pediococcus parvulus, 209 plasmid, 209 Pediococcus pentosaceus, 209 plasmid, 209 vector, 209 Peripheral blood mononuclear cells (PBMNC), 308 Pets, 339 PCR, 13, 30, 31, 35, 38 PCR-DGGE, 33 PCR-TGGE, 32 PFGE, 14 Phagocytic activity, 468 Phenotyping, 10

Philippines, 104, 139 Pigs, 47, 323, 407 Phylogenetic diversity, 44 Phylogenetic typing, 18, 44, 410, 415 Phylogeny, 409 Polydextrose, 108 Polyunsaturated fatty acids (PUFA), 457 Population virulence gene signatures, 412, 414, 417, 418 Postoperative infection, 299 Pouchitis, 287 Prebiotics, 3–123, 536–560 Principal Coordinate Analysis (PCO), 411 Probiosis, 419 Probiotics, 3–123, 536–560 antagonistic properties, 19–24 bioefficacy, 417 definition, 408 mechanism of action, 408, 409 persistence, 469, 561 product classification, 111 tracking of, 16 Proprionibacterium freudenreichii, 285 subsp. shemanii JS, 285 Proprionibacterium globosum, 133, 138 Proprionibacterium shermanii, 133, 138, 285, 306, 307, 320 Protozoa, 331 Pulsed Field Gel Electrophoresis (PFGE), 13, 29 qPCR, 402 Qualified Presumption of Safety, 5, 492 Rabbits, 339, 345, 346 Radical scavenging, 445, 450 Random Amplification of Polymorphic DNA (RAPD), 13 Real-Time PCR, 35, 36 Registration process, 97, 98 Regulations, 79, 94, 95, 99, 100, 103, 112, 119, 182 REP-PCR, 11–13 Resected colonic tissue, 377, 384 Respiratory tract infections, 299, 449 Reuterin, 394, 471 Reverse transcriptase quantitative PCR, 36 Rhodospeudomonas palustris, 133, 138 Ribosomal database, 17, 44

SUBJECT INDEX

rRNA-stable isotope probing, 37 Ribotyping, 11, 14, 18, 402 Rotavirus, 53–54, 267, 272–274, 319, 384, 398, 399, 482, digestion, 268, 443 microbiota, 258, 470 rumen, 331 Ruminal acidosis, 331 Ruminants, 331, 339, 559 Saccharomyces boulardii, 54, 57, 275, 278–279, 281, 293 Saccharomyces cerevisiae, 101 Safety, 4–5, 18, 75–83, 85–98, 103–105, 110–111, 113–115, 119–120, 122–125, 182–183, 444–445, 456, 462–463, 468, 472, 474, 485, 488, 492, 560 Salmonella enterica serovar typhimurium, 454, 486 SL1344, 262 SAMP1/Yit SAMP1/Yit, 487 Screening, probiotics, 4–20, 60 Selection, probiotics, 4–20, 178–184, 399, 458 Serum cholesterol, 313, 324–325, 329, 334, 455, 491 Serum pepsinogen, 459, 460 Shelf life, 63, 74, 98, 104, 179, 183 Shiga toxin-producing Escherichia coli (STEC), 407, 457, 488 Shiga toxins (Stxs), 407, 409, 457 Shigella, 281, 385, 442, 481 Short bowel syndrome (SBS), 487 Short chain fatty acid (SCFA), 313, 457, 487, 537 Single stranded site conformational polymorphism (SSCP), 43 Source of microbiota, 400–401 Soybean. 102, 324, 539, 540, 544 Spray-dried probiotics, 60 SSU rRNA, 402 Standing Committee on the Food and Animal Health, 125 Streptococcus, 221 vector, 212–221 Staphylococcus aureus, 76, 221, 394, 402, 471, 493 Streptococcus gordonii, 201, 221

595

mutagenesis, 190–200 vector, 212–221 Streptococcus intermedius, 134, 138 Streptococcus mutans, 221 vector, 212–221 Streptococcus pneumoniae, 322–321 Streptococcus salivarus, 138, 209 antibiotic-associated diarrhea, 54–58, 276 DNA fragment replacement, 224–228 homologous recombination, 198–199, 222, 224 mutagenesis, 190–200 NCIMB 10387, 180–181 plasmid, 209–210 subsp. thermophilus (also S. thermophilus), 138, 180vectors, 212–221 Streptococcus thermophilus, 54–55, 101, 210, 383 Stress proteins, 63 Survival, probiotics, 6, 19–22, 58–75, 336, 445–452, 463–466, 474, 478, 480 effect of food ingredients, effect of freeze-thawing, effect of oxygen, effect of pH, effect of sheer, effect of temperature, effect of water activity, inter-species differences, strain-to-strain differences, SW-116, 260 SW-480, 260 Swedish Nutrition Foundation, 106, 110, 479 Swine, 323, 408, 410–414 Synbiotics, 67, 322, 339, 455, 487, 536, 557–558, T helper cells, 88, 397–398, 551 (Th1), 88–89, 396–399 (Th2), 89, 395–399, 551 T regulatory cells, 396–398 TAP-PCR, 12, 18 Taxonomy, probiotics, 7–8 Terminal Restriction Fragment Length Polymorphism (T-RFLP), 27, 30, 33–34, 43–48, 51–52

596

SUBJECT INDEX

Temperature Gradient Gel Electrophoresis (TGGE), 11–13, 27, 32–33, 42–43 Terminal Labeled Restriction Fragments (TRF), 43–51 Terminal Restriction Fragment Length Polymorphism (TRFLP) Tetragenococcus halophila, 211 plasmid, 211 Thailand, 104, 125, 136, 138, 302 Thymic lymphoma, 453 Toxins, 124, 407, 418, 468, 492, 494 Transepithelial Electrical Resistance (TER), 261, 406 Transgalactosylated oligosaccharides (TOS), 486, 488, 542 Transgenic animal, 265 Translocation, 82, 298, 463, 555 Traveler’s diarrhea, 280–281, 385, 442, 470, 481, 557 Triglyceride, plasma, 314–317, 455 Tumor necrosis factor-alpha (TGF-a), 443 Ulcerative colitis, 288–291, 470 United States, 95, 111–124, 408, 415 Urease, 192–194

Urinary tract infection (UTI), 457, 472 Urogenital infection, 258 Vaccination, 419, 468, 552 Vaginal infection, 98 Vellionella, 403 Very low birth weight (VLBW), 488 Viability, probiotics, 38, 52, 59, 60–67, 69, 71–74, 98, 101, 179 Vietnam, 104, 139 Virulence, 83, 84, 407, 411, 412, 414, 418–420, 444 factors, 81, 24, 410 genes, 83–84, 410, 411, 412, 418–420 Voedings centrum, 106 Wheezing infants, 402 X-ray-irradiated splenocytes (X-irr-Spl), 457 Yersinia pseudotuberculosis, 262 YPIII pYV, 262 Yogurt, 64, 70, 80 Zootechnical additives, 123, 125

Handbook of Probiotics and Prebiotics, 2nd edition

Prebiotics and probiotics science and technology

Handbook of Prebiotics

Handbook of Prebiotics

Handbook of Prebiotics

Handbook of Prebiotics and Probiotics Ingredients: Health Benefits and Food Applications

Bioactive Foods in Promoting Health: Probiotics and Prebiotics

Handbook of Composites, 2nd Edition

Handbook of Thromboprophylaxis, 2nd Edition

FreeBSD Handbook (2nd Edition)

Linux Administration Handbook (2nd Edition)

Adhesives Technology Handbook, 2nd Edition

Universal Design Handbook, 2nd Edition

Food Processing Handbook, 2nd Edition

Sustainable Forestry Handbook, 2nd Edition

Probiotics and Health Claims

VBA Developer's Handbook, 2nd Edition

Handbook of Nuclear Chemistry, 2nd Edition

Handbook of Small Animal Gastroenterology 2nd Edition

Handbook of Industrial Engineering, 2nd Edition

Handbook of Psychotherapy Case Formulation, 2nd Edition

Handbook of Physical Measurements, 2nd edition

Handbook of Solid Waste Management, 2nd Edition

Handbook of International Law, 2nd Edition

Handbook of Lipoprotein Testing, 2nd Edition

Handbook of Women's Health, 2nd edition

Handbook of Applied Cognition 2nd Edition

Handbook of Equine Anaesthesia 2nd Edition

Physical Properties of Polymers Handbook, 2nd edition

Handbook of Veterinary Obstetrics 2nd Edition

Handbook of Probiotics and Prebiotics, 2nd edition

Prebiotics and probiotics science and technology

Handbook of Prebiotics

Handbook of Prebiotics

Handbook of Prebiotics

Handbook of Prebiotics and Probiotics Ingredients: Health Benefits and Food Applications

Bioactive Foods in Promoting Health: Probiotics and Prebiotics

Handbook of Composites, 2nd Edition

Handbook of Thromboprophylaxis, 2nd Edition

FreeBSD Handbook (2nd Edition)

Linux Administration Handbook (2nd Edition)

Adhesives Technology Handbook, 2nd Edition

Universal Design Handbook, 2nd Edition

Food Processing Handbook, 2nd Edition

Sustainable Forestry Handbook, 2nd Edition

Probiotics and Health Claims

VBA Developer's Handbook, 2nd Edition

Handbook of Nuclear Chemistry, 2nd Edition

Handbook of Small Animal Gastroenterology 2nd Edition

Handbook of Industrial Engineering, 2nd Edition

Handbook of Psychotherapy Case Formulation, 2nd Edition

Handbook of Physical Measurements, 2nd edition

Handbook of Solid Waste Management, 2nd Edition

Handbook of International Law, 2nd Edition

Handbook of Lipoprotein Testing, 2nd Edition

Handbook of Women's Health, 2nd edition

Handbook of Applied Cognition 2nd Edition

Handbook of Equine Anaesthesia 2nd Edition

Physical Properties of Polymers Handbook, 2nd edition

Handbook of Veterinary Obstetrics 2nd Edition

Recommend Documents